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Motto of the book:
You cannot hope to build a better world without improving the individuals. To that end 
each of us must work for his own improvement and at the same time share a general 
responsibility for all humanity, our particular duty being to aid those to whom we think 
we can be most useful.
—Maria Sklodowska‐Curie
Huge progress has been made in recent years in modern medicine owing to, inter 
alia, the development of molecular biology. Better understanding of the nature of the 
disease is a continuous challenge to look for more effective forms of diagnostics and 
therapy resulting in the improvement of the quality of life of our patients.
The model example of such progress is “somatostatin story”. Somatostatin isola-
tion over 40 years ago not only resulted in the Nobel Prize for its discoverers but has 
also greatly impacted the current clinical practice. The hormone, which at beginning 
was known only as regulating factor, has now become a potent drug and imaging 
medium. It has changed the fate of many acromegalic patients and has been applied 
in other oncological and non‐oncological diseases.
Somatostatin was the first peptide to be obtained by bacterial recombination. 
Although its first therapeutic administration took place before the exact mechanisms 
of its action were elucidated, it was the discovery of somatostatin receptors and their 
subtypes, which gave rise to interdisciplinary research leading to the use of somato-
statin analogues in routine clinical practice.
The development of radiolabeled somatostatins has to some degree defined the 
development of nuclear medicine over the past 20 years. During this journey, much 
has been learned about the nature of cancer with particular reference to those tumors 
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originating from neuroendocrine tissue. What has been unique about this process is 
the key role played by nuclear medicine scientists both clinical and preclinical. Initial 
work was supported by industry with imaging agents such as In‐111 pentetreotide 
and Tc‐99m depreotide becoming licensed products. However, for the past 10 years, 
every new advance has been led by academia, and not industry. Nuclear medicine has 
been able to care for the patient is a holistic way, imaging for diagnosis, staging and 
re‐staging, and treatment to palliate symptoms and extend life. To aid in this nuclear 
medicine, physicians have interacted with a wide range of clinicians and built multi-
disciplinary clinics, a pattern followed in other cancer types.
The nuclear medicine community continues to innovate using radiolabeled 
somatostatin analogues: developing Lu‐177 as a therapeutic isotope offering efficacy 
with reduced toxicity, using Ga‐68 DOTATATE in imaging which differentiated thy-
roid cancer, and the administrating Y‐90 DOTATOC intra‐arterially for treating gli-
omas. All these innovations  depended on the imagination, careful science, and 
dedication of a range of scientists and clinicians around the world.
The best examples of somatostatin research importance in clinical practice are 
neuroendocrine tumors, particularly originating from the gastroenteropancreatic 
system. Whilst it is true that neuroendocrine tumors are rare. The slow progression of 
many tumors has resulted in a prevalence that is much higher than the incidence and 
at any time 10% of patients visiting gastroenterological oncology clinics may have 
neuroendocrine tumors. Firstly, somatostatin and its analogues were applied to con-
trol the clinical symptoms in syndromic patients, particularly carcinoid ones. Then 
somatostatin receptor scintigraphy in its various forms became the imaging of choice 
in gastroenteropancreatic neuroendocrine tumor (GEP‐NET) patients. Development 
of radioguided surgery improved the surgical outcomes. The diagnostic application 
of the radiolabeled somatostatin analogues led to the therapeutic approach with 
In-111, replaced by 90‐Y and 177‐Lu labeled compounds. Those centers worldwide 
that offer radio‐peptide therapy for neuroendocrine tumors have together treated 
more patients than the centers that use licensed radiolabeled products to treat much 
more common lymphomas. But the last word has not been said yet. Locoregional 
therapies for liver metastases with alpha‐particles emitting isotopes are being tested. 
Although the direct cytostatic effect of “old” non‐labeled somatostatin analogues in 
neuroendocrine tumors has been confirmed, the new ones seem to be even more 
promising. Currently there are attempts to organize and unify the GEP‐NET 
classification to establish important prognostic factors, which would allow the 
 prediction of the disease outcome with a great probability, and to choose optimal 
diagnostic and therapeutic options for each individual patient. Those methods have 
still not been  optimized and remain a huge challenge in this field of oncology.
The book presented to you is a compendium of current knowledge on the use of 
somatostatin analogues in diagnostics and therapy, and it also shows the directions of 
further research in this field. The authors of the book chapters are experts of various 
scientific disciplines involved in work on somatostatin analogues as well as well‐
known authorities interested in management of patients with different neoplasms, 
especially neuroendocrine tumors. The book has been greatly supported by, among 
xiv PREFACE
others, people actively working in the European Neuroendocrine Tumor Society 
(ENETs) and those who managed COST Actions (European Cooperation in the field 
of Scientific and  Technical Research) devoted to the development of targeted therapy 
based on radiolabeled somatostatin compounds. Last but not least involved has been 
the International Research group in Immuno‐Scintigraphy and Therapy (IRIST) and 
the editors of this book have all been or are Presidents of IRIST. This group has been 
intimately involved in the development of radiolabeled somatostatins for diagnosis 
and therapy and as such, is ideally placed to share this knowledge with a wider med-
ical audience.
We should believe the words said by Orioson Swett Marden: There is no medicine 
like hope, no incentive so great and no tonic so powerful as expectations of something 
better than tomorrow, and that every day of our work helps our patients. Hence, there 
still is a field for development of research to find out the new compounds with 
superior efficacy to current treatments, or labeled molecules to be used in imaging 
diagnostics.
We hope that this book will become a guide for all those who deal with the issue 
presented herein.
Alicja Hubalewska‐Dydejczyk, Alberto Signore,
Marion de Jong, Rudi A. Dierckx, 
John Buscombe, and Christophe Van de Wiele
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AbbreviAtions
FDA the Food and Drug Administration
GIF growth hormone‐inhibiting factor
PET positron emission tomography
SPECT single photon emission computed tomography
SRIF somatotropin release‐inhibiting factor
Now, here, you can see, it takes all the running you can do, to keep in the same place. 
If you want to get somewhere else, you must run at least twice as fast as that!
Lewis Carroll, Through the Looking Glass
The beginning of the second half of the twentieth century, the great era of discovery 
of factors regulating anterior pituitary hormones synthesis and release, resulted also 
in isolation and characterization of somatostatin. The history started with search for 
growth hormone‐releasing factor. In 1968, Krulich and colleagues noted that extracts 
from different parts of rat hypothalamus either stimulated or inhibited release of 
pituitary growth hormone [1]. The inhibiting substance was named growth hormone‐
inhibiting factor (GIF). The group of Roger Guillemin developed highly sensitive 
assay for rat growth hormone, which enabled the confirmation of negative linear 
somAtostAtin: the history 
of Discovery
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Hubalewska‐Dydejczyk
Department of Endocrinology with Nuclear Medicine Unit, Medical College,  
Jagiellonian University, Krakow, Poland
1
2 SoMAToSTATIn: THE HISToRy oF DISCovERy
relationship between the production of the growth hormone by anterior pituitary cell 
culture and amount of hypothalamic extract added [2]. About 500,000 sheep 
 hypothalami later Brazeau and Guillemin isolated the substance responsible for 
inhibiting effect—somatotropin release‐inhibiting factor—SRIF. The structure of 
14‐aminoacid peptide was then sequenced, the sequence of the residues confirmed, 
and the molecule was resynthesized. The synthetic molecule inhibiting properties 
were confirmed in both in vivo and in vitro experiments. The result of the discovery 
was paper published in Science in 1973 [3]. Roger Guillemin renamed the hor-
mone—since 1973 it has been known as the somatostatin [4]. The new hormone was 
extracted also from hypothalami of other species.
Those times were also regarded the gut hormones era. In 1969, Hellman and 
Lernmark announced the inhibiting effect of extract from alfa-1 cells of pigeon pancreas 
on insulin secretion from pancreatic islets derived from obese, hyperglycemic mice [5]. 
In 1974, group of C. Gale from Seattle noticed the lowering of fasting insulin and glu-
cagon levels in baboons as well as tampering of arginine‐stimulated insulin release by 
somatostatin—directly and in dose‐dependent manner [6]. This finding was confirmed 
also in other animal models and humans shortly after. As the hypothalamic somatostatin 
seemed to act locally, the search for local, pancreatic source of the hormone started. The 
antibodies against somatostatin proved to be useful tool. The presence of somatostatin 
in delta (D) cells of the pancreas (formerly alfa‐1 cells) was proved by immunofluores-
cence [7, 8]. In 1979, somatostatin was isolated from the pigeon pancreas, and next from 
other species [9]. The somatostatin‐reactive cells were also found in gastrointestinal 
mucosa, and then in other tissues, including tumors. Concurrently, the multiple groups 
worked on the somatostatin action and its pan‐inhibiting properties were gradually char-
acterized. In 1977, Roger Guillemin and Andrew Schally were awarded the nobel Prize 
in medicine and physiology for their work on somatostatin and other regulating 
hormones. of interest, somatostatin‐like peptides were also discovered in plants [10].
other somatostatin forms, somatostatin‐28 particularly, and somatostatin  precursor—
preprosomatostatin—were characterized in late 1970s/early 1980s. Human cDnA 
coding preprosomatostatin was isolated and cloned in 1982 [11, 12].
The possible pathological implications and potential therapeutic use of somato-
statin were postulated early in the somatostatin discovery era. The clinical descrip-
tion of somatostatin‐producing pancreatic tumor in human came from Larsson and 
colleagues in 1977 [13]. Somatostatin administration to block the growth hormone 
secretion in acromegalic patients was reported as early as in 1974 [14]. The potency 
of the hormone to block carcinoid flush was also observed in late 1970s and early 
1980s [15, 16]. Somatostatin was the first human peptide to be produced by bacterial 
recombination. In 1977 Itakura, Riggs and Boyer group synthesized gene for somato-
statin‐14, fused it with Escherichia coli beta‐galactosidase gene on the plasmid and 
transformed the E. coli bacteria with chimeric plasmid DnA. As the result, they 
obtained the functional human polypeptide [17]. The synthesis of recombinant 
human somatostatin led to the commercial human recombinant insulin production.
Although it was possible to produce somatostatin in large quantities, the short half‐life 
of the hormone was one of the reasons why the native hormone was not feasible for rou-
tine clinical practice. The search for more stable yet functional hormone analogue started 
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in 1974. The search was focused on the peptide analogues. The somatostatin receptor 
agonists were first to be used in clinical practice. In 1980–1982, octapeptide SMS 201–
995 was synthetized and proved to be more resistant to degradation and more potent than 
native hormone in inhibiting growth hormone synthesis [18]. The drug, currently known 
as octreotide, was the first Food and Drug Administration (FDA)‐approved somatostatin 
analogue. It was followed by other analogues, such as lanreotide (BIM 23014), and by 
the long‐acting formulas. High selective affinity of octreotide and lanreotide for somato-
statin receptor type 2 (lesser to the receptor types 3 and 5) was one of the triggers for 
further research. In 2005 vapreotide (RC160), somatostatin analogue with additional 
affinity to receptor type 4, was initially accepted for treatment of acute oesophageal vari-
ceal bleeding and granted the orphan drug status in 2008 in the United States (although 
final FDA approval has not been granted). Lately, promising results of large phase III 
studies on “universal” multitargeted somatostatin analogue, cyclohexapeptide SoM‐230 
pasireotide, in acromegaly and Cushing’s disease, have been published [19, 20]. The drug 
has been granted the European Medicines Agency and the FDA approval for pituitary 
adrenocorticotropic hormone (ACTH)‐producing adenomas treatment. The research on 
first nonpeptide receptor subtype selective agonists was published in 1998; however, 
none of tested compounds have been introduced to clinical practice [21]. The studies on 
somatostatin receptors antagonists have been conducted since 1990s.
The other areas for research were somatostatin receptors. The high affinity‐binding 
sites for somatostatin were found on pancreatic cells and in brain surface by group of 
J.C. Reubi in 1981–1982. The different pharmacological properties of the receptors 
were noted early. At the beginning two types of somatostatin receptors, with high and 
low affinity for octreotide, were characterized [22, 23]. In 1990s, all five subtypes of 
somatostatin receptors were cloned and their function was discovered. The other 
important step was the discovery of the somatostatin receptors overexpression in tumor 
cells, particularly of neuroendocrine origin [24]. This led to the first successful trials on 
diagnostic use of radioisotope‐labeled hormones. The iodinated octreotide was used in 
localization of the neuroendocrine tumors in 1989–1990 [25, 26]. The Iodine-123 was 
replaced by the Indium‐111, and later on by the Technetium 99 m [27–29]. The first 
Gallium‐68 labeled somatostatin analogues for positron emission tomography (PET) 
studies were proposed in 1993 [30]. Feasibility of labeled somatostatin receptor 
 antagonist for single photon emission computed tomography (SPECT) or PET tumor 
imaging has been reported in 2011 [31]. Together with diagnostics, the concept of 
therapeutic use radioisotope labeled somatostatin analogues has evolved. The first pep-
tides for therapy were those labeled with Indium‐111 [32]. In 1997, the yttrium‐90 
labeled analogues, followed by Lutetium‐177 labeled ones, were introduced in pallia-
tive treatment of neuroendocrine disseminated tumors [33, 34].
The co‐expression of somatostatin and dopamine receptors, as well as discovery 
of receptor heterodimerization, led to the search for chimeric somatostatin‐dopamine 
molecules, dopastatins [35]. other area of recent research is cortistatin, a member of 
somatostatin peptides family, with somatostatin receptors affinity but also with dis-
tinct properties [36].
Summing up the multicenter research on somatostatin led to the discovery of the 
hormone probably second only to the insulin in its clinical use.
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IGF‐I insulin‐like growth factor I
IP3 inositol 1,4,5‐triphosphate
JNK c‐Jun NH(2)‐terminal kinase
MAPK mitogen‐activated protein kinase
mTOR mammalian target of rapamycin
NOS nitric oxide synthase
PI3K phosphatidyl inositol 3‐kinase
PIP2 phosphatidylinositol 4,5‐bisphosphate
PKC protein kinase C
PLA phospholipase A
PLC phospholipase C
PTP protein tyrosine phosphatase
Raf rapidly accelerated fibrosarcoma
Rb retinoblastoma
SH2 src homology 2
SHP SH2‐containing phosphatase
Sos son of sevenless
Src Rous sarcoma oncogene cellular homolog
SSTR somatostatin receptors
TNFR1 tumor necrosis factor receptor 1
TSC2 tumor sclerosis complex 2
TSP‐1 thrombospondin‐1
introduction
Somatostatin mediates its action upon binding to somatostatin receptors (SSTR) which 
belong to the seven‐transmembrane domain, G‐protein‐coupled receptors (GPCRs) 
superfamily and are mainly coupled to the Gi protein and therefore inhibit adenylate 
cyclase and cAMP accumulation [1]. There are five somatostatin receptors SSTR1‐5. 
The genes encoding human SSTR1‐5 are located in chromosome 14q13, 17q24, 
22q13.1, 20p11.2 and 16p13.3. The gene encoding for SSTR2 has an intron and the 
transcribed mRNA can be spliced to encode SSTR2A and B isoforms [2]. SSTR5 also 
exists as truncated isoforms with four or five transmembrane domains (sst5TDM4 and 
sst5TDM5; [3]) generated by cryptic splice sites in the coding sequence and the 3′ 
untranslated region of the SSTR5 gene. All SSTR are Gi coupled and inhibit adenylate 
cyclase. However, as it will be described more extensively later, they also trigger several 
signaling cascades that may be pertussis toxin (i.e., Gi) dependent or independent.
secretion
Somatostatin was initially identified as a hypothalamic peptide able to inhibit growth hor­
mone (GH) secretion from the pituitary [4]. Two biological forms of somatostatin exist, 
somatostatin‐14 and ‐28, which are derived from a 92 aminoacid pro‐somatostatin 
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precursor [5, 6]. Somatostatin is a neurotransmitter and can be regarded as a secretory 
pan‐inhibitor; it suppresses GH, prolactin, thyroid‐stimulating hormone [7, 8] and 
adrenocorticotropic hormone (ACTH) [9] secretion from the anterior pituitary; cholecys­
tokinin, gastrin, secretin, vasoactive intestinal peptide, motilin, gastric inhibitory poly­
peptide from the gastrointestinal track (GI); glucagon, insulin, and pancreatic polypeptide 
from the endocrine pancreas [10]; triiodothyronine, thyroxin, and calcitonin from the 
thyroid; and renin and aldosterone from the kidney and the adrenals [11]. In addition to 
its endocrine action, it also suppresses exocrine secretion (e.g., gastric acid from intestinal 
mucosa, bicarbonate, and digestive enzymes from exocrine pancreas). In the GI, it also 
inhibits bile flow from the gallbladder, bowel motility and gastric emptying, smooth 
muscle contraction and nutrient absorption from the intestine. Somatostatin also inhibits 
cytokine and growth factors production from immune and various tumor cells.
Somatostatin suppresses GH and TSH through SSTR2 and SSTR5, and pro­
lactin predominantly through SSTR5 [12, 13]. GH secretion is also inhibited by 
SSTR1 [14]. Sstr2 knockout mice have elevated ACTH levels, indicating a 
regulatory role for SSTR2 [15]. Both SSTR2 and SSTR5 decrease ACTH syn­
thesis [16], with SSTR5 displaying a more potent suppressive action on ACTH 
release [17]. Insulin secretion is primarily inhibited by SSTR5, while glucagon 
secretion is primarily inhibited by SSTR2 [18]. Gastric acid and pancreatic amy­
lase release is inhibited by SSTR2 and SSTR4, while other GI hormones are 
inhibited by SSTR1, 2, and 5 [19, 20].
Somatostatin exerts its antisecretory action mainly by inhibiting exocytosis. This 
is mediated by its inhibitory action on adenylate cyclase and subsequent decrease in 
cyclic adenosine monophosphate (cAMP) production [21–24]. The effect is pertussis 
toxin‐dependent indicating the involvement of the Gi protein [25]. In addition to 
cAMP suppression, somatostatin activates potassium (K+) channels (delayed recti­
fying, inward rectifying and ATP sensitive) and induces membrane hyperpolarization 
that inhibits depolarization‐induced Ca2+ influx via voltage‐sensitive Ca2+ channels. 
This reduces intracellular Ca2+ and inhibits exocytosis [26–30]. The inhibitory action 
of somatostatin on Ca2+ is mediated through the Gi and Go protein subtypes [31, 32]. 
In addition, an alternative pathway involving a cGMP‐dependent protein kinase was 
identified behind the inhibitory action of somatostatin on neuronal calcium channels 
[33]. All SSTRs, except SSTR3, couple to voltage‐gated K+ channels, but SSTR2 and 
4 are more potent in increasing K+ currents [34]. SSTR1, 2, 4 and 5 couple to N‐ and 
L‐type voltage‐sensitive Ca2+ channels indicating a direct effect [35–38]. In addition, 
somatostatin has a distal to secondary messengers effect on exocytosis by activating 
the Ca2+‐dependent phosphatase calcineurin [39, 40].
Regarding the effect of somatostatin on hormone transcription, initial studies did 
not find changes in GH mRNA levels after somatostatin administration, supporting the 
hypothesis that somatostatin suppresses GH secretion by blocking exocytosis rather 
than transcription [41–43]. However, studies in vitro and in tumors from patients with 
acromegaly who were preoperatively treated with somatostatin analogs revealed 
reduced GH transcript levels after somatostatin treatment [44–47]. Somatostatin sup­
pressed GH‐releasing hormone‐induced GH promoter activity in a pertussis toxin‐
sensitive manner [48]. SSTR2 overexpression in human somatotropinomas and 
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prolactinomas in primary cell cultures suppressed GH and PRL transcripts, indicating 
a role for this receptor in somatostatin’s suppressive action on GH [49]. Interestingly, 
somatostatin was shown to stimulate GH secretion at low doses (below 10−13 M), an 
effect that was mediated by SSTR5 [50, 51]. By contrast, SSTR5 agonists suppress 
PRL secretion, but not transcription in vitro [52]. Somatostatin analogs suppress POMC 
promoter activity, an effect that is abolished by SSTR2 knockdown [53].
AntiProliferAtive signAling
Somatostatin limits cell growth through cytostatic or apoptotic mechanisms depend­
ing on the SSTR [54, 55]. One of the first described mechanisms behind the antipro­
liferative action of SSTR was the inhibitory action on growth factor receptor signaling 
[56–58]. Protein tyrosine phosphatases (PTPs) were shown to play a central role in 
this process by de‐phosphorylating the growth factor bound tyrosine kinase receptors 
[59]. PTP activity was found to be increased after somatostatin treatment in many cell 
systems [60–63] and in human tumors in primary cell culture [64, 65]. PTP were 
shown to be activated by Gαi [59] and Gαi/o [66]. SSTR associate with the cytosolic 
src homology 2 (SH2) domain containing PTP, SHP‐1 (PTP1C) and SHP‐2 (PTP1D), 
and the membrane anchored PTPη (DEP1) [67–74]. Through PTPs, somatostatin 
blocks cell cycle progression by arresting cells at the G1/S (SSTR1, 2, 4 and 5) or the 
G2/M (SSTR3) boundary [75, 76]. In addition, SSTR2 and SSTR3 were shown to 
induce apoptosis [77–79]. SSTRs also induce acidification, which results in apoptosis 
via a SHP‐1‐dependent mechanism [80], while SSTR1, 3 and 4 inhibit the Na+/H+ 
exchanger NHE1, leading to increased intracellular acidification [81, 82]. Finally, 
SSTR1, 2, 3 and 5 block nitric oxide synthase (NOS), revealing an additional regula­
tion point in the antiproliferative action of somatostatin [83, 84].
SSTR have common and individual signaling aspects, which are covered in more 
detail further (Fig. 2.1).
sstr1
SSTR1 couples to Gαi3 and Gαi1/2 [85–87] and inhibits adenylate cyclase when 
overexpressed in Chinese hamster ovarian (CHO) cells [88]. SSTR1 also increases 
PTP activity [60, 69, 89]. In fact, it uses SHP‐2 to activate the serine/threonine 
mitogen‐activated protein kinase (MAPK) concomitantly with its antiproliferative 
action in these cells [64]. The MAPK pathway usually mediates the mitogenic action 
of growth factors, cytokines and hormones. However, depending on the cell system 
and extracellular milieu, the MAPK pathway can also halt cell growth in order to 
promote cell differentiation. Typically, the pathway starts with activation of the tyro­
sine kinase domain of the growth factor receptors and the association through special 
adaptors to Sos which enhances the GTP‐binding activity of the GTP‐ase Ras. GTP‐
bound activated Ras associate with, brings to the membrane and activates the Raf 
family of kinases (A‐Raf, B‐Raf, and c‐Raf/Raf‐1). Raf kinases (MAPK kinase 
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kinases) phosphorylate and activate the MAPK kinases MEK1/2 which then phos­
phorylate and activate the p44 and p42 MAPK. Raf‐1 can also be activated by the src 
family of tyrosine kinases. SSTR1 activated SHP‐2 dephosphorylates c‐src at an 
inhibitory site (Tyr529) which enables its phosphorylation at the stimulatory Tyr418. 
This enables c‐src to phosphorylate and activate Raf‐1, which in turn phosphorylates 
and activates MEK/MAPK leading to upregulation of the cell cycle inhibitor p21/
Cip1. This pathway is inhibited by the Gi inhibitor pertussis toxin and is mediated by 
the βγ subunits of the Gi protein. It also involves an active phosphatidyl inositol 3 
kinase (PI3K) although the exact mechanism is not clear [64].
Somatostatin treatment induces a long‐lasting PTP activity that cannot be 
explained by the rapidly activated SHP‐2. This PTP is the membrane anchored PTPη, 
which was described as a tumor suppressor in several tumor types [90, 91]. The 
importance of PTPη in mediating the antiproliferative action of SSTR1 was demon­
strated in the PC CI3 clonal thyroid cells, which loose their ability to respond to 
somatostatin after oncogene‐induced cellular transformation that suppresses PTPη; 
re‐introducing PTPη restores their response to the antiproliferative action of somato­
statin [73]. SSTR1 inhibits MAPK through PTPη in glioma and neuroblastoma cells 
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figure 2.1 Schematic presentation of the main signaling cascades of the five SSTRs. All 
SSTRs are coupled to Gi, inhibit adenylate cyclase and lower cAMP. SSTR1, 2, and 3 trans­
duce their antiproliferative action by stimulating one or more PTP which in turn affects the 
mitogenic MAPK and the survival PI3K pathways. By contrast, SSTR5 mediates its antipro­
liferative action through PTP‐independent pathways. Open arrowheads: stimulatory effect; 
blunt arrowheads: inhibitory effect; interrupted lines: indirect effect.
SSTR2 11
[92]. SSTR1 activates Jak2, in a pertussis toxin‐sensitive manner, which then 
 phosphorylates and activates SHP‐2 leading to c‐src dephosphorylation and activation, 
and eventually to PTPη phosphorylation [93].
sstr2
SSTR2 is the best‐studied mediator of somatostatin’s antiproliferative action. In fact, 
SSTR2 is considered as a tumor suppressor in pancreatic cancer since its expression 
is lost in these tumors [94, 95].
SSTR2A and B inhibit adenylate cyclase, and this effect was found to depend 
on the G protein subunits available in each cell type [86, 96, 97]. In pituitary 
tumor GH4C1 cells, the ability of SSTR2A to inhibit adenylate cyclase and sub­
sequently cAMP production resulted in decreased protein kinase A (PKA) 
activity [98]. The antiproliferative action of SSTR2 also begins with PTP 
activation. The PTP associated with SSTR2 is the cytosolic SH2 domain con­
taining SHP‐1, which associates with the receptor constitutively through Gαi3 
[70–89]. Somatostatin treatment leads to SHP‐1 dissociation from the receptor 
and activation resulting in the dephosphorylation of tyrosine kinase receptors 
(e.g., insulin receptor) and its substrates (e.g., insulin receptor substrate‐1, IRS‐1) 
[99]. Another mechanism leading to SHP‐1 activation is through SHP‐2, which 
also associates with SSTR2 [100]. upon receptor activation, the βγ subunits of 
the Gi proteins activate src, probably by binding src to β‐arrestin, which then 
phosphorylates SHP‐2 and subsequently activates SHP‐1 [101]. Finally, SSTR2 
activates SHP‐1 through the α subunit of the Gi protein and the receptor‐bound 
tyrosine kinase JAK2 and inhibits fibroblast growth factor (FGF)‐2 isoform of 
210 amino acids (HMW FGF‐2)‐induced pancreatic tumor cell growth [102]. 
This was a novel finding since JAK2 is traditionally considered to associate with 
the cytokine receptor family.
SSTR2 was shown to inhibit growth factor induced MAPK phosphorylation and 
activation [103, 104], but also to activate MAPK, which together with the activated 
p38‐MAPK leads to decreased cell proliferation [105]. In this setting, the SSTR2‐
induced MAPK activation was mediated by Ras and B‐Raf, but also by Rap1 that is 
another member of the Ras subfamily of small GTP‐ases [106]. SSTR2 also activates 
the survival PI3K signaling, in a mechanism involving Gβγ and SHP‐2 [106, 107]. 
By contrast, activation of overexpressed or endogenous SSTR2 inhibits the PI3K 
pathway in tumor cell systems [108, 109]. SSTR2 binds directly p85 and this is a 
unique feature of SSTR2 not shared by another member of the SSTR family. SSTR2 
activation disrupts its association with p85 by associating filamin A, resulting in 
PI3K inhibition [110]. In pituitary tumor cells, p85 physically associates with SHP‐1 
and SSTR2 activation with octreotide leads to decreased p85 tyrosine phosphoryla­
tion, which was SHP‐1 dependent. Although the effect of octreotide was pertussis 
toxin sensitive, indicating involvement of the Gi, it was not depending on Gβγ show­
ing that Gi‐linked GPCR could interact with and inhibit PI3K through the Gi α‐sub­
unit. This way SSTR2 inhibits the serine/threonine kinase Akt that mediates the 
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antiapoptotic and cell survival effects of several growth factors. This is done in part 
by phosphorylating and subsequently inhibiting glycogen synthase kinase‐3 (GSK3β) 
which halts cell cycle progression. Cell cycle progression starts with the activation of 
D‐type cyclins and their associated cyclin‐dependent kinases Cdk4 and 6 [111]. The 
G1 to S transition is primarily governed by cyclin E and its associated kinase Cdk2, 
which hyperphosphorylates retinoblastoma (Rb) [112]. Phosphorylated Rb dissoci­
ates from E2F transcription factors resulting in the transcription of genes that will 
bring the cell to the S phase of the cell cycle [113]. Cyclin/CDK complexes are 
inhibited by cyclin kinase inhibitors such as p21/Cip1 and p27/Kip1. p27/Kip1 is the 
primary regulator of cyclin E/CDK2 complex, since by sequestering Cdk2 it prevents 
the complex formation. GSK3β phosphorylates and marks for proteolytic degrada­
tion the cyclins E and D1 and activates p27/Kip1. SSTR2 upregulates p21/Cip1 after 
stimulating both ERK1/2 and p38‐MAPK [105] and p27/Kip1 in a mechanism 
involving SHP‐1 [72, 83].
Although p27/Kip1 is an important downstream target of somatostatin’s antip­
roliferative signaling, cells like the rat pituitary tumor GH3 that do not express 
p27/Kip1 also respond to SSTR2 activation by decreasing cell proliferation [114]. 
In these cells, SSTR2 was shown to induce the expression of the tumor suppressor 
Zac1, in a mechanism involving Gαi, SHP‐1, GSK3β, and the Zac1 activator p53 
[109]. Zac1 (gene name Plagl1) is a zinc finger protein able to induce apoptosis 
and cell cycle arrest that is frequently downregulated/lost in several solid cancers 
[115]. RNA interference experiments in pituitary tumor cells revealed that Zac1 is 
essential for octreotide’s antiproliferative action. A retrospective immunohisto­
chemical analysis on archival paraffin embedded tumoral tissue from acromegalic 
patients treated with somatostatin analogs pre‐operatively revealed a strong 
positive correlation between treatment response and ZAC1 immunoreactivity, with 
strong ZAC1 immunoreactivity positively correlating with IGF‐I normalization 
and tumor shrinkage after treatment [116]. Interestingly, in GH3 cells ZAC1 gene 
expression was suppressed after knocking down the aryl hydrocarbon receptor 
interacting protein (AIP), which is triggered by octreotide treatment [117]. The 
gene encoding for AIP was found to have germline mutations in patients with 
familial and sporadic acromegaly and AIP mutations predict an unfavorable 
response to somatostatin analogs [118, 119].
In addition to its action on cell cycle proteins, GSK3β also activates the tumor 
suppressor tuberin (TSC2), which inhibits the mammalian target of rapamycin 
(mTOR) controlling cap‐dependent translation and subsequently cell growth in terms 
of cell size rather than cell proliferation. SSTR2 by inhibiting Akt decreased GSK3β 
phosphorylation and increased its activity leading to decreased phosphorylation of 
the mTOR effectors p70/S6K and 4E‐BP1 [120]. Suppression of the mTOR pathway 
may explain the observations reporting tumor shrinkage in acromegalic patients 
treated with SSTR2 agonists not due to apoptosis but rather due to decrease in cell 
volume [121, 122].
There is increasing evidence that SSTR2 is not only cytostatic but also able to 
induce apoptosis by upregulating the death receptor 4 (DR4) and tumor necrosis 
factor receptor 1 (TNFR1) and downregulating the antiapoptotic Bcl2 [123].
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sstr3
SSTR3 inhibits adenylate cyclase activity in a pertussis toxin sensitive pathway by 
coupling to Gαi1 [96]. Similar to SSTR1 and 2, SSTR3 is also able to activate a PTP; 
overexpressed SSTR3 was found to activate SHP‐2 and subsequently inactivate 
Raf‐1 [63, 71]. Nevertheless, SSTR3 was initially described as the only SSTR able to 
induce apoptosis, since its activation in cells selectively expressing SSTR3 led to 
apoptosis but not to cell cycle arrest [77, 124]. This effect is mediated by upregulat­
ing p53 and the proapoptotic protein Bax. In addition, an involvement of SHP‐1 and 
activated caspase 8 was described in the somatostatin‐induced cell acidification and 
apoptosis in SSTR3‐expressing cells [80, 125]. SSTR3 is also characterized by a 
unique antiproliferative action in endothelial cells, constituting it as the primary apo­
ptotic and antiangiogenic SSTR [126, 127].
sstr4
This receptor type is the less studied in the family. The original studies failed to dem­
onstrate a coupling of SSTR4 to Gi and adenylate cyclase; but eventually, it was 
shown to suppress cAMP production similar to the other members of the family 
[128]. Furthermore, SSTR4 was found to activate MAPK in a pertussis toxin sensitive 
manner by activating phospholipase A (PLA)‐2 and arachidonate production. In fact, 
this is the only SSTR that is reported to stimulate cell proliferation. SSTR4 is also 
coupled to K+ channels (delayed rectifier) leading to decreased Ca2+ influx. SSTR4 
displays an unusually long lasting effect and is hypothesized to mediate the antiepi­
leptic properties of somatostatin [129, 130]. Interestingly, this receptor was also 
shown to mediate the anti‐inflammatory properties of somatostatin [131].
sstr5
SSTR5, together with SSTR2, is the main SSTR inhibiting hormone release. SSTR5 
(initially termed “SSTR4”) was cloned as an adenylate cyclase coupled SSTR with 
high affinity to somatostatin‐28 [132]. Similar to the other SSTRs it is able to inhibit 
adenylate cyclase in a pertussis toxin sensitive mechanism. SSTR5 induces K+ 
leading to cell hyperpolarization which subsequently closes the L‐type voltage‐
sensitive Ca2+ channels resulting in decreased Ca2+ influx [133]. SSTR5 also affects 
phospholipase C (PLC) in a mechanism only partially involving Gi and requiring the 
Gαq [134]. PLC cleaves phosphatidylinositol 4,5‐bisphosphate (PIP2) into diacyl 
glycerol (DAG) and inositol 1,4,5‐triphosphate (IP3), which gets released into the 
cytosol where it binds to Ca2+ channels and increases Ca2+ influx into the cytosol. 
DAG is membrane bound and together with Ca2+ functions in recruiting and acti­
vating protein kinase C (PKC). Overexpressed SSTR5 was reported to increase IP3 
and subsequent Ca2+ increase [135]. By contrast, it was found to inhibit cholecysto­
kinin (CCK)‐induced Ca2+ influx by inhibiting PLC and IP3 generation [89]. Contrary 
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to what is the case for the other SSTRs, no PTP is required for SSTR5 antiproliferative 
effect [89]. Instead, SSTR5 acts by inhibiting CCK‐induced cyclic GMP (cGMP), 
which can activate specific kinases (G kinases) able to upregulate c‐fos and subse­
quently cell proliferation [136]. In this model, SSTR5 by decreasing cGMP inhibits 
MAPK. In addition, SSTR5 activation in human pancreatic carcinoid cells increases 
the receptor association with the src‐like tyrosine kinase p60src, which phosphory­
lates and inactivates neuronal nitric oxide synthase (nNOS), and therefore suppresses 
tumor cell proliferation [137]. These data show that SSTR5 employs completely dif­
ferent cascades to induce its antiproliferative effect compared to the other SSTR.
indirect AntiProliferAtive Action of sstrs
SSTR do not abolish the mitogenic action of growth factors only by inhibiting their 
signaling cascades, but also by downregulating the synthesis of the growth factors 
themselves. The founding example of somatostatin‐induced growth factor downreg­
ulation is IGF‐I, which is primarily regulated by GH. Somatostatin analogs used in 
the treatment of acromegaly decrease circulating IGF‐I levels by inhibiting GH syn­
thesis. In addition a direct action on hepatocyte IGF‐I production was shown with the 
activation of hepatic SSTR2 and 3 inhibiting GH‐induced IGF‐I by dephosphorylat­
ing STAT5b, an important transcription factor for IGF‐I promoter activation, in a 
pertussis toxin sensitive mechanism involving a PTP [138].
The ability of SSTRs to suppress growth factor synthesis is also responsible for 
their antiangiogenic action. Angiogenesis is regulated by the vascular endothelial 
growth factor (VEGF), which drives the development of new vessels under the trigger 
of hypoxia in the growing tumor. Somatostatin treatment in an in vivo model of 
Kaposi sarcoma inhibited tumor growth despite the complete lack of SSTR in these 
cells, an effect that was attributed to the antiangiogenic action of somatostatin [127]. 
SSTR1 is highly expressed in vessels where it inhibits endothelial proliferation, 
migration and neovascularization [139, 140]. Endothelial SSTR3 downregulates 
VEGF and endothelial NOS (eNOS) transcription [126]. The ability of SSTR3 to 
decrease eNOS activity is also shared by SSTR1 and SSTR2 [84, 126]. More recently, 
SSTR2 activation was found to block angiogenesis by upregulating the secretion of 
antiangiogenic factor thrombospondin‐1 (TSP‐1) from pancreatic cancer cells bring­
ing another twist in the antiangiogenic action of somatostatin [141].
orgAn sPecific distribution
All SSTR are expressed in the brain: SSTR1 in the cortex, hippocampus, hypo­
thalamus, midbrain, and cerebellum; SSTR2 in the cortex, basal ganglia, and 
hypo thalamus; SSTR3 in the cortex, hypothalamus (arcuate and ventromedial 
nuclei), and basal ganglia; SSTR5 (and SSTR4 in less extent) in the hypothalamus 
in the arcuate/ventromedial and arcuate/median eminence, respectively; and 
SSTR4 mainly in the hippocampus [142]. SSTR2 and SSTR5 are the main 
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receptors found in the adenohypophysis with SSTR1 and SSTR3 being expressed 
at lower levels [143]. All SSTRs are found in parts of the GI and the spleen [144]. 
SSTR1 is expressed in jejunum and stomach and SSTR2 in kidney [145]. In 
the pancreas, alpha cells express mainly SSTR2, beta cells SSTR1 and SSTR5, 
and delta cells SSTR5. The adrenals express SSTR2 and SSTR5. In the immune 
system, lymphocytes express SSTR3 and thymus SSTR1, SSTR2, and SSTR3. 
Liver expresses SSTR1 and SSTR2. SSTR4 is present in the lung, pancreas, and 
heart. It has to be considered that most of these data were obtained by in situ 
hybridization and autoradiography techniques. The development of specific 
SSTR  antibodies will enable a thorough mapping of SSTR expression in 
normal tissues.
conclusion
SSTR expression pattern and complex signaling is what makes somatostatin such an 
extraordinary neurotransmitter and hormone. Their ability to trigger common but also 
unique pathways fine‐tune somatostatin’s action depending on the cell type, receptor 
types expressed, and physiological circumstances. The potent inhibitory action of 
SSTR on cellular processes as diverse as secretion, proliferation, and apoptosis is 
what makes somatostatin an invaluable target for drug development.
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AbbreviAtions
RT‐PCR reverse transcriptase‐polymerase chain reaction
SSTR somatostatin receptors
Premise
Somatostatin (SS) is an acidic polypeptide, originally described by Krulich and 
coworkers [1] in hypothalamic extracts, that exerts several biological functions 
through the interaction with specific transmembrane receptors, the somatostatin 
receptor (SSTR) family. The physiological and pharmacological properties, as well 
as the distribution in normal cells and tissues, of SSTR have been described previ-
ously in this book. The present chapter will discuss the different methods used to 
localize SSTR at the tissue level and the data available on the distribution of SSTR in 
human tumors, with special reference to neuroendocrine ones, and other diseases. 
These informations will be crucial to understand the role in the clinical practice of 
targeting SSTR with specific analogues, both in terms of developing diagnostic tools 
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and of manipulating SSTR signaling as a therapeutic strategy, that will be discussed 
extensively in the following sections of this book.
methods to identify sstr in tissues
Before discussing the current knowledge on SSTR expression in tumors and other 
pathologies, a short reappraisal of the different methods available and reported to 
determine SSTR at the tissue level is mandatory to critically consider the expression 
data currently available.
Several methods have been used to determine the expression of SSTR in 
tissue samples. All of them have intrinsically limitations and advantages, and 
therefore, the most powerful data have been generated by the combination of 
two or more of them. A comparison of the three most relevant methods is repre-
sented in Table 3.1.
SSTR tissue localization had originally been demonstrated by means of binding 
assays of radiolabeled SS analogues [2–4]. however, this method that has the unique 
property of tracing the presence of “functionally active” receptors is affected by a 
scarce reproducibility, is applicable to high‐quality frozen material only, and does 
not recognize the SSTR subtype expressed, unless using highly subtype‐specific 
analogues [5].
Since the cloning of the five genes, between 1992 and 1994, several studies detected 
the specific mRnA expression of SSTR in normal tissue and tumors by means of 
alternative techniques such as the northern blot [6], in situ hybridization [7, 8], or 
tAble 3.1 comparison between different methods of tissue identification of sstr
Method Pros Cons Applicability
gene expression (PCR) •	 Sensitive
•	 Identifies SSTR 
subtypes





•	 needs frozen material
Low
Autoradiography •	 Tissue localization
•	 Identifies 
“functional” SSTR
•	 does not identify 
SSTR subtype
•	 Scarce reproducibility
•	 needs frozen material
Very low
Immunohistochemistry •	 Tissue localization
•	 Cost effective
Applicable to archival 
tissues (including 
biopsies)
•	 Identifies SSTR 
subtypes
•	 needs standardization
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reverse transcriptase‐polymerase chain reaction (RT‐PCR), either qualitative or 
quantitative [9–11]. however, in general terms, mRnA expression from tissue extracts 
is variably affected by signals determined by SSTR‐expressing cells different from 
those that represent the target, and the quality of the tissue sample is again a relevant 
clue for obtaining adequate results.
In parallel with mRnA determination, several groups aimed at the development of 
SSTR‐specific antibodies. The vast majority of them are polyclonal antisera and have 
been determined either against the n‐ or the C‐terminus of the protein [12–17]. Most 
of these antibodies are working nicely on paraffin‐embedded tissue, are raised against 
all or most of SSTR receptor subtypes (although with variable reliability), are com-
mercially available, and, therefore, allowed extensive investigations on large archival 
case series. Moreover, some monoclonal antibodies have also been developed, with 
special reference to SSTR subtype 2A [18–21], although not commercially available 
yet at the time of this manuscript preparation.
Besides research purposes, the advantages of immunohistochemical SSTR detec-
tion in the clinical practice include a high cost/benefit ratio, high reproducibility in 
pathology laboratories worldwide, possibility of tissue localization of tumor cells, 
recognition of the different SSTR subtypes, and, last but not least, applicability on 
retrospective archival material. In addition, immunohistochemical methods may be 
applied to preoperative fine‐needle aspiration of cytological or biopsy material [22], 
allowing SSTR demonstration in inoperable tumors or offering specific information 
to diagnostic or therapeutic decisions before surgery (Fig. 3.1). Several studies have 
also documented that immunohistochemistry correlates with other methods in a 
(a) (b)
figure 3.1 SSTR type 2A determination in a cellblock preparation from a liver metastasis 
of a well‐differentiated neuroendocrine carcinoma of unknown primary. (a) hematoxylin and 
eosin; (b) immunoperoxidase; (a and b) original magnification 400×. (See insert for color rep-
resentation of the figure.)
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significant proportion of cases, with only minor discrepancies [10, 13, 18, 21–23]. 
however, a major caveat of immunohistochemistry for SSTR, with special reference 
to its use as a diagnostic tool, is represented by the lack of standardization, although 
some scoring systems have been proposed [24, 25]. In general terms, a fine 
membranous staining is considered the most specific [26], although a cytoplasmic 
staining may be a result of receptor internalization, especially in the case of tumors 
 coexpressing both SSTR and their natural ligand or in the cases of patients treated 
with SS analogues [27].
sstr exPression in humAn mAlignAncies
A range of different tumors overexpress SSTR, as compared to nontransformed cells. 
The underlying stimuli that induce this overexpression as well as the functional 
meaning for the biology of tumor cells have not been conclusively explained. It is 
possible that the upregulation of SSTR serves as homeostatic growth inhibitory auto-
crine/paracrine response to the deregulated tumor cell proliferation [28]. nevertheless, 
with all the limitations related to the complexity of the role of SSTR in cancer 
biology, it can be asserted that SSTR and their intracellular signaling pathways 
should generally be considered as tumor suppressive.
sstr exPression in neuroendocrine neoPlAsms
neuroendocrine neoplasms originate from a normal cell population that is physio-
logically a target of SS, thus expressing SSTR. Therefore, the generally high level of 
SSTR expression in these groups of tumors is not surprising.
A tentative list of all data on SSTR‐positive neuroendocrine neoplasms would 
greatly fail to be comprehensive. Wide literature data (see for review [29–32]) show 
that SSTR are highly expressed in pituitary adenomas; neuroendocrine tumors of 
the  pancreas, gastrointestinal tract, and lung; paragangliomas/pheochromocytomas; 
Merkel cell carcinomas; neuroblastomas; and medullary thyroid carcinomas. hundreds 
of such tumors have been analyzed by means of various techniques, including binding 
assays, immunohistochemistry, and mRnA analysis. A wide heterogeneity in SSTR 
subtype expression in the different tumor types, in different cases of the same tumor 
type, and even in different cell populations within individual lesions has been reported. 
Such high heterogeneity of SSTR distribution partially explains some discrepancies 
in the clinical features and response to SS analogue therapy observed in neuroendocrine 
tumors from various sites. According to such literature data, in most cases, individual 
tumors coexpress different SSTR subtypes, SSTR type 2 being the most frequently 
represented in all locations, followed by types 3, 5, and 1. Subtype 4 is generally poorly 
expressed. higher SSTR expression is generally observed in “well‐differentiated” 
tumors although a considerable proportion of positive cases might be observed also in 
poorly differentiated—highly aggressive—lesions, such as small cell lung cancer [33]. 
Although poorly elucidated from a biological point of view, hormonal secretion by the 
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tumor is also associated with different patterns of expression of SSTR subtypes, such 
as in the case of pancreatic insulin‐producing tumors that show a low SSTR type 2 
expression [34].
Apart from detailing a prevalence of expression, SSTR determination at the tissue level 
is potentially a complementary approach to better define the diagnostic and therapeutic 
strategies in patients affected by neuroendocrine tumors. A recent literature focused on the 
comparison between SSTR tissue determination (mainly by means of immunohistochem-
istry) and in vivo imaging using different SS analogue‐based methodologies [24, 25, 
35–37], with in general a good correlation. In a previous paper by our group, a relatively 
high correlation was observed with the response to SS analogue treatment [24]. Moreover, 
some studies claimed a prognostic value of SSTR type 2 determination in neuroendocrine 
tumors of the gastrointestinal tract and pancreas [38–40].
Future studies are therefore needed to validate SSTR testing as a relevant marker 
of clinical usefulness in neuroendocrine neoplasms.
sstr exPression in nonneuroendocrine mAlignAncies
A wide spectrum of solid or hematological malignancies has been demonstrated to 
variably express SSTR [41, 42]. A variety of carcinomas showed in vivo and tissue 
localization‐based evidence of SSTR expression: such tumors include, among 
others, cancers from the breast [43–45], lung [18, 22], kidney [45], pancreatobili-
ary tract [46], stomach [47], liver [48], colorectum [49], ovary [50], thyroid follic-
ular cells [51], and prostate [52–55] (Fig. 3.2). Unpublished data from our group 
onto cell lines (Table 3.2) are consistent with what was reported on tissues earlier. 
In some cases, an antiproliferative activity of SS analogues could be demonstrated 
figure 3.2 SSTR type 2A clonal expression in prostatic adenocarcinoma (immunoperoxi-
dase; original magnification 400×). (See insert for color representation of the figure.)
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in vitro in hormone independent prostate cancer models [56]. SSTR subtypes have 
also been detected in meningiomas, medulloblastomas, and gliomas, in soft tissue 
sarcomas, and in malignant melanomas; this distribution correlated with either 
scintigraphic imaging or in vitro tests on SS analogue response [57–59]. Promising 
clinical applications of SS analogues have also been reported in lymphohemato-
logical malignancies [60] and in thymomas [61].
sstr in nonneoPlAstic diseAses
There is strong evidence that selected nontumoral lesion may also express SSTR. For 
instance, active granulomas in sarcoidosis express SSTR on epithelioid cells [62], 
whereas inactive or successfully treated fibrosing granulomas devoid of epithelioid 
cells lack SSTR. Inflamed joints in active rheumatoid arthritis express SSTR, prefer-
entially located in the proliferating synovial vessel [63].
Furthermore, inflammatory bowel disease is characterized by an overexpression of 
SSTR in the vascular system [64] of the altered parts of the gastrointestinal tract. 
Concerning SSTR presence and possible applications of SS analogues in nonneoplas-
tic diseases, SS actions in modulating the immunological response and angiogenesis 
together with the high density of expression of SSTR (viz., type 1 and 2) in the retina 
represent the baseline of very promising applications for therapy in various retinal 
diseases, from macular edema or macular degeneration to thyrotoxic orbitopathy, ret-
inal ischemic damage, and proliferative diabetic retinopathy [65, 66].
unmet clues
despite the wide body of evidence on the presence and function of SSTR in several 
neoplastic and nonneoplastic human diseases, several issues still deserve further 
investigation and elucidation.
tAble 3.2 sstr expression at mrnA level in nonneuroendocrine cell linesa
Cell line derivation SSTR mRnA expressed
MonoMAC Monoblastic leukemia 4
MCF7 Breast cancer 2, 5
T47d Breast cancer, apocrine 2, 5
MdAMB231 Breast cancer 2, 4
CALU‐1 Lung cancer, squamous 3
KATo III gastric cancer 1, 2, 5
hT29 Colon cancer 1, 2, 5
h716 Colon cancer (with neuroendocrine 
features)
1, 2, 3, 5
Mog UVW glioblastoma 2
a Volante, M., unpublished.
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The correct methodology for SSTR determination that could be applied in the 
clinical practice is not well established, so far. Immunohistochemistry seems the 
most promising but is still limited by the scarce availability of reliable and clinically 
validated reagents (mostly related to SSTR subtype 2), as well as by the lack of stan-
dardization in the interpretation. Moreover, novel molecules with a wider spectrum 
of affinity to different SSTR subtypes than those currently available [67] claim a 
reinterpretation of the data available with a better understanding of coexpression 
modalities of the different SSTR subtypes, also taking into consideration the capa-
bility of different subtype to form functionally active homo‐ or heterodimers that 
modify significantly the activation of intracellular signaling pathways also due to 
altered agonist‐induced desensitization [68]. Moreover, the SS/SSTR axis is more 
complex, due to both other peptides with selective affinity to SSTR such as cor-
tistatin [31] and due to the capability of SSTR to heterodimerize with other receptors 
such as dopamine receptors [69]. In this respect, recent studies claim that the coex-
pression of SSTR and dopamine receptors (type 2) might open to novel therapeutic 
strategies with chimeric molecules [70–72].
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AbbreviAtions
NET neuroendocrine tumor
SRS somatostatin receptor scintigraphy
SST somatostatin
SSTR somatostatin receptor
Nuclear medicine has always been a powerful tool for the study of biological functions 
and, more recently, for the molecular and histological characterization of tissues under 
physiological and pathological conditions. The growing knowledge of the biology of 
normal and pathological tissues leads to the discovery of several biologically active 
peptides that mediate their function by binding to external membrane‐bound receptors 
with high affinity. This property made peptide/receptor complex a potential target to 
be used for molecular characterization of tissues in vivo.
Peptides have good characteristics as radiopharmaceuticals: they are small in size 
and have a fast renal clearance and easily penetrate into tissues with consequent low 
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background blood pool activity after few minutes from injection. They can be 
synthetic or of natural human recombinant origin and do not usually elicit allergic 
reactions.
Somatostatin (SST) is a peptide with a broad distribution in the nervous system 
and acts as a neurotransmitter in several organs, having a wide range of mainly 
inhibiting effects, such as the suppression of growth hormone release, as well as the 
inhibition of pancreatic and gastrointestinal hormone release [1, 2]. five SST receptor 
(SSTR) subtypes have been cloned, of which SSTR1 and SSTR4 are grouped into 
one family and SSTR2, SSTR3, and SSTR5 into another. They all are g‐protein‐ 
coupled receptors located at the cell membrane [3], which recognize the ligand and 
generate a transmembrane signal. The resulting hormone–receptor complexes have 
the ability to be internalized. once internalized, these vesicles fuse with lysosomes, 
resulting in hormone degradation or receptor recycling [4]. SSTR2 appears to be the 
most frequently represented receptor subtype over the surface of neuroendocrine 
tumor (NET) cells [5] and activated lymphocytes providing the molecular basis for 
many clinical applications of radiolabeled SST analogues [6]. Toward the end of the 
1980s, the in vivo demonstration of SSTRs on the surface of some tumors raised 
interest in receptor imaging [7], and indeed, the peptide receptor overexpression on 
tumors cells, as compared to normal tissues [8, 9], constituted the basis for molecular 
imaging of these tumors.
both natural SST‐14 and SST‐28 bind with high affinity to all five SSTRs but 
have a short plasma half‐life (~3 min) owing to rapid enzymatic degradation by 
endogenous peptidases. first attempts to label recombinant SST‐28 were made 
by Signore and coworkers at the “Sapienza” University of Rome, italy, in 1982. 
The SST was labeled with 123i and used for imaging pituitary tumors. 
Unfortunately, the plasma half‐life of this hormone was extremely rapid, thus 
not allowing good imaging with the available technology. in an early study by 
Amartey et al. [10], SST was labeled with 99mTc. As could be expected in view 
of its short half‐life, no specific accumulation in receptor‐rich tissue was 
observed. in the following years, the availability of SSTR analogues with a 
longer half‐life (of 1.5–2 h) and preserved receptor binding has allowed 
significant improvements for diagnosis and therapy of NET. furthermore, SST 
analogues have no major side effects, and their use is very safe, particularly 
when used as radiopharmaceuticals [11].
molecular imaging by radiolabeled SST analogue highlights the presence of path-
ological tissues overexpressing SSTR. it can be used to characterize lesions with 
respect to the expression of SSTR, to contribute to differential diagnosis, for staging 
diseases by detecting or excluding sites of metastases, and for grading the disease 
since in NET the loss of the expression of SSTR is a sign of dedifferentiation and has 
a poor prognostic value.
Somatostatin receptor scintigraphy (SRS), however, is not disease specific but 
receptor specific, and to be able to interpret the results of the scan, one needs to 
understand the underlying tumor biology. A negative scan may indicate absence of 
tumor, tumor regression, or tumor dedifferentiation. correlation with anatomical 
imaging is always mandatory.
REfERENcES 33
The application of 111in‐labeled octreotide analogue to target SSTRs on tumor 
cells still represents a paradigm in the field of peptide radiopharmaceuticals. The 
SST analogue 111in‐labeled octreotide (octreoScan) was officially introduced in 
1994, and its use to visualize various SSTR‐positive tumors and tissues is widely 
accepted. many tumors (most of them neuroendocrine related) may express a 
combination of the five receptor subtypes (SSTR1–SSTR5) in different percentages 
[12, 13].
Since that time, a very large “panel” of tumors and diseases were studied by 
octreoScan scintigraphy, and extensive clinical studies have been performed mainly 
in NET [14–20] but also in other tumors like brain tumors [21], melanomas [22], and 
lung [23] and breast [24] cancer. in order to overcome the limitations of the use of 
octreoScan like the high cost of 111in (a cyclotron‐produced radionuclide) and the 
nonoptimal physical features of this radioisotope, many SST analogues have been 
labeled with 99mTc. depreotide, a synthetically produced ten‐amino‐acid peptide with 
affinity for SSTR2, SSTR3, and SSTR5, has been labeled with 99mTc [25] and suc-
cessfully used to characterize malignancy in solitary pulmonary nodules [26]. 
Another interesting peptide is vapreotide, which binds SSTR2 and SSTR5 with high 
affinity and moderately to SSTR3 and SSTR4 and has been used in animals [27]. 
Another promising radiopharmaceutical, the 99mTc‐hYNic‐tyr(3)‐octreotide, has 
been labeled and successfully used in humans [28–31].
A further evolution in the field of SST analogues is represented by the development 
of macrocyclic chelators that exhibit the property to bind also beta particle emitters 
like 90Y and 177lu. These chelators include doTA, doTAoc, doTAToc, doTAVAP, 
doTATATE, and lanreotide doTAlAN. These radiolabeled compounds including 
these chelators seem to show favorable binding and biodistribution characteristics 
with high uptake and retention in target organs, thus being promising candidates for 
peptide receptor radionuclide therapy. it is well known that at least one of the first 
generation of 90Y‐labeled octreotide analogues, 90Y‐doTAToc, has real therapeutic 
activity in the treatment of NET, which have proved resistant to other forms of 
treatment [32, 33].
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PET positron emission tomography
SPECT single‐photon emission computed tomography
SPN solitary pulmonary nodule
SRS somatostatin receptor scintigraphy
Sst somatostatin receptor
rAdiophArmAceuticAls for srs‐spect
The development of radiolabeled peptides for successful receptor targeting requires 
consideration of several factors, such as the accumulation in the target and nontarget 
tissues, the clearance from the body, the excretory pathway, and the in vivo stability 
of the radiopeptide. The radiolabeled peptides that successfully went through all 
tests, including toxicological studies, and with well‐established preparation method 
may enter clinical studies in humans. The issues related to the peptide‐based radio­
pharmaceutical design and their development have been well described in several 
excellent reviews [1–3].
Particularly for the well‐characterized somatostatin receptors, the design of a pep­
tide and its synthetic pathway was possible in order to produce metabolically stabi­
lized peptide analogues, which preserved most of the biological activity of the 
original molecule and high affinity for the corresponding receptor. They could be 
labeled with various radionuclides for both diagnosis and therapy, while the choice 
of radiolabeling approach depended on the radionuclide properties and characteris­
tics of the chelator. As a common feature, it is required that the labeling protocols 
allow very high labeling yield, radiochemical purity, and specific activity and the 
peptide retains the affinity for the receptor.
There are certain protocols established for in vitro characterization of radioligand 
affinity for the receptors expressed on the tumor cell membrane, their internalization 
rate, dissociation from the tumor cells, etc., which are helpful in selecting the most 
promising radiopeptides during preclinical investigations. Biodistribution and 
imaging techniques are used with suitable animal models to evaluate in vivo the phar­
macological behavior and pharmacokinetics of the radiopeptides. However, it is a 
long way from the design of a new peptide until its use in the clinic, both due to the 
radiopharmaceutical development and to the regulatory constraints. As a result, from 
a large number of newly developed radiopeptides, only very few found their way into 
routine clinical application.
Historically, the development of agents used for imaging of somatostatin 
receptors reflected the above considerations and followed the increasing 
knowledge of the role of somatostatin and its analogues in the diagnosis and 
treatment of tumors. It has been shown that sst‐expressing tumors can be treated 
with somatostatin or synthetic analogues to either reduce hypersecretion of 
hormones or inhibit tumor growth [4]. However, because somatostatin undergoes 
rapid in vivo enzymatic degradation, somatostatin analogues that are more resis­
tant to in vivo degradation have been developed [5–9]. The molecule was 
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modified in various ways resulting in improved biological characteristics, but 
mostly in increased affinity for sst
2
 and to some extent for sst
5
. Introduction of 
d‐amino acids and shortening of the molecule to the bioactive core sequence 
resulted in eight amino acid‐containing somatostatin analogues such as octreo­
tide (OC) (Sandostatin, SMS 201‐995), lanreotide (BIM23014), and vapreotide 
(RC‐160). Lanreotide and OC are widely used for the symptomatic treatment of 
neuroendocrine‐active tumors, such as growth hormone‐producing pituitary ade­
nomas and gastroenteropancreatic tumors [10].
Nowadays, new somatostatin‐based agents labeled with gamma emitters found 
their way to the clinic offering improved imaging characteristics. Three radiophar­
maceuticals for somatostatin receptor scintigraphy (SRS)‐SPECT, which were 
granted marketing authorization, are briefly discussed.
111in‐pentetreotide
The evidence of the overexpression of somatostatin receptors by primary and 
metastatic malignant disease, mainly of neuroendocrine origin, has prompted a 
worldwide search for radiolabeled somatostatin analogues for use in SRS [4, 
11]. First, the successful visualization of somatostatin receptor‐positive neo­
plastic lesions with a radioiodinated synthetic somatostatin analogue (123I‐Tyr3‐
octreotide) was reported [12–14]. Soon, an improved octreotide‐based 
radioligand labeled with indium‐111 was introduced [15, 16]. Both radiolabeled 
octreotide derivatives, 123I‐Tyr3‐octreotide and 111In‐DTPA‐D‐Phe1‐octreotide, 
were shown to be very useful in detecting small neuroendocrine tumors and 
metastases not detected by conventional means and for identifying tumors that 
respond to therapeutic doses of “cold” octreotide. The limitations of 123I‐Tyr3‐
octreotide, however, were the high cost of 123I, the short half‐life, and the unfa­
vorable clearance via bile ducts, which did not allow imaging of tumors in the 
abdominal region. The improved imaging properties of 111In‐DTPA‐D‐Phe1‐
octreotide, the first somatostatin analogue developed for indirect labeling with 
111In, resulted in its wider application in medical diagnosis [4, 17]. This imaging 
agent was developed by Mallinckrodt Medical, Inc., in conjunction with the 
University Hospital of Rotterdam in the Netherlands and Sandoz Pharma Ltd., 
Basel, Switzerland. It has undergone clinical trials in Europe and in the United 
States and has been granted marketing authorization (111In‐pentetreotide, 
OctreoScan®) (see Fig. 4.1.1).
SRS with 111In‐DTPA‐D‐Phe1‐octreotide became a “gold standard” in the localiza­
tion, staging, and therapy follow‐up in patients with neuroendocrine tumors. Though 
a very powerful noninvasive imaging technique, the application of 111In‐DTPA‐D‐
Phe1‐octreotide in diagnostic oncology is restricted by the increased cost and limited 
availability of the cyclotron‐produced 111In and its suboptimal nuclear characteristics, 
such as a long half‐life (T
1/2
 = 67 h) and the two medium‐energy photons (171 keV, 
245 keV), which lead to a poor image resolution and a high radiation dose to the 
patient.
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99mtc‐depreotide
Two new somatostatin analogues, 99mTc‐P587 and 99mTc‐P829, were synthesized 
and evaluated preclinically in comparison to 111In‐DTPA‐octreotide [18]. Both 
P587 (with the sequence of –Gly‐Gly‐Cys‐ as a triamide‐thiol chelator) and 
P829 (with the monoamine, bisamide, and monothiol chelating sequence of –(β‐
Dap)‐Lys‐Cys‐ appended to the homocysteine side chain) were labeled with 
99mTc by ligand exchange from 99mTc‐glucoheptonate with specific activity 
higher than 2.2 TBq/mmol. Tumor/blood and tumor/muscle ratios at 90 min 
post  injection to Lewis rats bearing CA20948 rat pancreatic tumors were 6 and 
33  for 99mTc‐P587, 21 and 68 for 99mTc‐P829, and 22 and 64 for 111In‐DTPA‐
octreotide. In addition, the uptake of labeled peptides was shown to be specific 
and saturable (diminished up to 80–90% by increasing doses of coinjected par­
ent peptide up to the dose of 4 mg/kg). 99mTc‐P829 has been selected for clinical 
studies due to its high tumor uptake and low gastrointestinal uptake. It has been 
studied in patients with various tumors and showed good results in the 





































figure 4.1.1 Structure of 111In‐DTPA‐D‐Phe1‐octreotide.
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cell lung cancer [19]. The agent was approved for human use (99mTc‐depreotide, 
NeoSpect; GE Healthcare: Amersham Health). Its chemical structure is pre­
sented in Figure 4.1.2.
In patients with endocrine tumors, the detection rate using 99mTc‐depreotide 
scintigraphy was lower than that of 111In‐pentetreotide scintigraphy, which 
appeared to be more sensitive, especially for liver metastases, because of high 
liver uptake of 99mTc‐depreotide [20]. Currently, the product registration is 
discontinued.
99mtc‐eddA/hynic‐tyr3‐octreotide
The first report on the diagnostic usefulness of 99mTc‐tricine/HYNIC‐Tyr3‐octreotide 
(TOC) [99mTc‐HYNIC‐TOC] compared to 111In‐pentetreotide was published in 2000 [21]. 
Further tracer development resulted in the new radiopharmaceutical 99mTc‐EDDA/
HYNIC‐TOC that was then compared to 111In‐pentetreotide in various neuroendo­
crine tumors and confirmed the superior imaging features of 99mTc‐labeled tracer [22]. 
Figure 4.1.3 shows the structure of this complex.
In the process of clinical validation of the 99mTc‐EDDA/HYNIC‐TOC kit 
(Tektrotyd, POLATOM, Poland), the first results showing its diagnostic efficacy 
were obtained in collaboration within the European Cooperation in Science and 
Technology (COST) and International Atomic Energy Agency (IAEA) programs. A 
pilot study showed that 99mTc‐EDDA/HYNIC‐TOC can be effectively utilized for 
the diagnosis of neuroendocrine tumors and that it is useful in imaging of primary 
tumors and metastatic lesions [23]. In the course of further investigations, the 
attention was focused on the good imaging features of this agent in detecting non‐
small cell lung cancer [24–28]. In a direct comparison, it has been shown that 99mTc‐
EDDA/HYNIC‐TOC is equivalent to 99mTc‐depreotide in the detection of SPN [29]. 
Currently, the tracer is granted marketing authorization in some European 
countries.

















figure 4.1.3 Structure of 99mTc‐EDDA/HYNIC‐Tyr3‐octreotide.
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rAdiolAbeling of peptides for srs‐spect
Only a few radionuclides are available, which can be used for radiolabeling of 
peptides for scintigraphy. Their physical properties are summarized in Table 4.1.1. 
Depending on the chemical properties of the radioactive element, the strategies for 
peptide radiolabeling can be developed.
Iodine‐123 is a useful gamma emitter for SPECT with ligands such as metaiodo­
benzylguanidine (MIBG). Small peptides can be radioiodinated by electrophilic 
substitution of an aromatic proton by electrophilic radioiodine (*I−), and this reaction 
can take place at an amino acid residue of the peptide, which contains aromatic rings, 
for example, tyrosine or histidine. To enable iodination with 123I, octreotide was mod­
ified by replacing Phe3 in the amino acid chain by Tyr3 and further electrophilic reac­
tion on the hydroxyl group present in the aromatic ring of tyrosine and evaluated for 
imaging of neuroendocrine tumors [12–14]. The labeling of the peptide with iodine 
radioisotopes via electrophilic substitution makes the obtained bond susceptible to in 
vivo enzymatic attack resulting in their reduced stability, which is a limitation of this 
method. Another approach for iodination is the acylation reactions via prelabeled 
prosthetic groups; however, the attachment of a bulky prosthetic group in a small 
peptide often significantly influences the binding affinity for the receptor and the in 
vivo pharmacokinetics of the labeled peptide [2].
111In, 67Ga, and 99mTc are radiometals and to incorporate a radiometal into the 
peptide structure, a chelator is required. Usually, the bifunctional metal chelating 
agent (BCA) is coupled with the peptide, and the radionuclide is coordinated to the 
peptide–chelator compound. It is important that the chelator is at sufficient distance 
from the binding sites of the peptide to avoid adverse interaction of these two 
entities. This may necessitate the addition of a spacer between them to separate the 
active regions of both components. During the conjugation process, the chelator 
reacts with a free terminal amine group of the peptide. Therefore, the chelator must 
have carboxylic acid groups for this reaction. A wide range of suitable chelators 
ready for coupling with peptides are available [30–32].The choice on an appropriate 
chelator for a given radiometal is crucial both for the efficiency of radiometallation 
and for the in vivo performance of the radiometallated peptide. 111In‐pentetreotide 
has only moderate binding affinity to the sst
2
, and acyclic diethylenetriaminepenta­
acetic acid (DTPA) is not a suitable chelator for β‐emitters, such as 90Y and 177Lu. 
For these radiometals, DTPA has been replaced by 1,4,7,10‐tetraazacyclododec­
ane‐1,4,710‐tetraacetic acid (DOTA), which forms thermodynamically and 
tAble 4.1.1 physical properties of radionuclides used in srs‐spect
Radionuclide Half‐life γ‐Energy (keV) Decay mode Production mode
123I 13.2 h 159 (83%) EC Cyclotron
67Ga 78.3 h 93 (10%), 185 (24%), 
296 (22%)
EC Cyclotron
99mTc 6.02 h 141 (89%) IT Generator
111In 2.83 days 171 (88%), 247 (94%) EC (100) Auger Cyclotron
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kinetically stable complexes with +3 cations of radiometals. This was of high 
importance, since patients with disseminated neoplasms and positive result after 
SRS were referred for therapy with another somatostatin analogue labeled with β‐
emitter, such as 90Y or 177Lu [33, 34]. DOTA can be used for radiolabeling with 
111In and also with 67/68Ga. Earlier chelator modifications designed to stably bind 
gallium radioisotopes were based on desferrioxamine (DFO) conjugated to octreo­
tide via a succinyl linker to form a stable conjugate (DFO‐β‐succinyl‐DPhe1‐octreo­
tide). Although this ligand demonstrated specific binding in vivo, its receptor affinity 
was found reduced [35, 36].
It has been shown that not only the amino acid sequence but also the radiolabel­
ing method affects the biological behavior of radiopeptides due to the small 
number of sites available for labeling and the likelihood of modifying amino acid 
residues that are essential for biological activity. Due to the high potency of many pep­
tides and, on the other hand, the low tissue concentration of their receptors, 
specific activity is often critical [37, 38]. This is more relevant to therapeutic than 
diagnostic applications of radiolabeled peptides, where usually the administered 
dose of peptide is lower. In addition, the radiolabeled BCA–peptide conjugate must 
be thermodynamically stable and kinetically inert to survive physiological 
conditions.
From the point of view of SRS‐SPECT technique, 99mTc‐labeled sst‐binding radio­
tracers were of main interest. 99mTc is called a “perfect radioisotope,” because of its 
very low radiotoxicity (group IV of radiotoxicity; k = 0.001; k‐estimate reduction of 
biologic effect of radiation with the use of radioisotopes of the same activity), short 
physical half‐life (T
1/2
 = 6.02 h), and optimum radiation energy for detection by 
gamma camera (141 keV). 111In belongs to group III of radiotoxicity (k = 0.01). It has 
a longer physical half‐life (T
1/2
 = 67 h) and two energy photons (171 keV with abun­
dance 90% and 245 keV with abundance 94%) requiring the use of medium‐energy 
all‐purpose collimators (MEAP), a 3‐day examination protocol, and eventually 
resulting in images of inferior spatial resolution. Most importantly, patient’s and staff’s 
exposure to radiation is considerably smaller when using 99mTc‐labeled compounds. 
The wide availability and cost‐effectiveness of 99mTc are of major importance for 
routine clinical applications. As a consequence, the search for a 99mTc‐based somato­
statin analogue has been intense [39, 40].
99mTc can be easily obtained from 99Mo/99mTc generators, in the chemical form of 
pertechnetate ion 99mTcO
4
–, Tc(VII), and needs to be reduced to a lower oxidation 
state to be effectively bound to biomolecules. The rich redox chemistry of 99mTc 
makes it difficult to control the oxidation state and solution stability of 99mTc chelates, 
but on the other hand, it provides opportunities to modify the structures and prop­
erties of technetium complexes by the choice of chelators.
The main strategies for labeling peptides with radionuclides are generally similar 
to those used for labeling proteins [41, 42]. The direct labeling approach used for 
labeling antibodies after converting the cysteine disulfide bridges into free thiols by a 
reducing agent, which in turn are free to bind 99mTc in a very efficient way, can’t be 
used for 99mTc labeling of somatostatin analogues. The forming 99mTc complexes are 
unstable, and there is poor control on the labeling site [43]. For small disulfide 
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bond‐containing peptides, these bonds are often critical for biological function, and 
even slight alterations in the ring structure can result in dramatic alterations in 
biological activity. The reducing agent (usually stannous ion) used in 99mTc labeling 
can reduce (open) the disulfide bond with consequent considerable loss of receptor‐
binding affinity [44].
Therefore, usually, the indirect labeling approach is the method of choice whereby 
the BCA is attached to the peptide to form a BCA–peptide conjugate and the conjugate 
is then labeled with the radiometal. In the case of 99mTc, the labeling proceeds either 
directly by reduction of 99mTcO
4
− or indirectly by ligand exchange via an intermediate 
99mTc complex (such as 99mTc‐glucoheptonate, 99mTc‐diphosphonate, or 99mTc‐tricine). 
In general, this approach is easy to carry out and has a well‐defined chemistry.
The attractiveness of the indirect approach was growing after the solid‐phase 
peptide synthesis was introduced in the development of peptide‐based ligands. 
The technique consists of two major steps: first, the peptide chain with protected 
amino acid lateral chains is assembled on a polymeric support (resin), and sec­
ond, the peptide is released from the resin, yielding the crude product. During pep­
tide synthesis, functional groups not involved in peptide bond formation need to 
be reversibly protected to prevent unwanted side reactions. Side‐chain protecting 
groups are either fully retained, partially removed, or completely removed, 
depending on the requirements for further workup and derivatization. Compared 
to synthesis in solution, solid‐phase peptide synthesis has major advantages: first, 
the ease of reagent removal and purification of the intermediate peptides by simple 
washing of the resin and, second, its high yield. For the somatostatin analogues, 
the introduction of the chelator by simple elongation of the octapeptide is the 
main advantage [45].
As a result, over the past few years, several somatostatin analogues have emerged 
carrying a variety of chelators utilized for efficient 99mTc labeling of biomolecules 
including small peptides [46]. Examples of such ligands are presented in Figure 4.1.4. 











 diaminedithiols [18, 47–49], propylene amine oxime [50], or open‐













) core. Another labeling 
approach is based on organometallic 99mTc carbonyl complexes, which are character­
ized by high stability and can be formed in high specific activity due to the d6 electron 







+, which exchanges water molecules with mono‐, di‐, and triden­
tate chelators to form stable complexes. The easy access to the [99mTc(CO)
3
]+ core has 







(M = 99mTc and 188Re) by direct reduction of 99mTc‐pertechnetate with sodium boro­
hydride in aqueous solution. Usually, histidine is of particular interest as the labeling 
site, since it is a natural amino acid, or Nα‐His moiety [54]. However, many of these 
analogues did not find practical application due to complicated labeling procedures 
and/or unfavorable pharmacokinetics.
The new quality in the investigation of possibilities for 99mTc labeling of small 
peptides was found in the application of HYNIC core with N‐hydroxysuccinimidyl 
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hydrazinonicotinamide (NHS‐HYNIC, HYNIC) as a BCA precursor [55]. It has 
initially been developed for radiolabeling of polyclonal immunoglobulin [56] and 
was then recommended for preparation of hydrazino‐modified proteins and synthesis 
of 99mTc–protein conjugates [57] and chemotactic peptides [58].
Initially, tricine (N‐[tris(hydroxymethyl)methyl]glycine) was used as coligand for 
99mTc in the HYNIC core [59]. It was assumed that the 99mTc species is coordinated by 
two tricine molecules and the terminal N‐atom of the hydrazine group of HYNIC in 
the resulting 99mTc‐HYNIC–protein complex [60]. Detailed HPLC analysis indicated 

















































figure  4.1.4 Selected chelators used in the indirect 99mTc labeling of somatostatin 
analogues for SRS‐SPECT.
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reaction time, and pH. Replacement of tricine by other coligands such as ethylenedi­
amine‐N,N′‐diacetic acid (EDDA) resulted in more stable complexes and lower 
number of isomers [61, 62]. Study of potential structures by LC‐MS confirmed that 
HYNIC may function as a monodentate or a bidentate chelator [63, 64]. Therefore, 
99mTc labeling is performed in the presence of one or more coligands, which saturate 
the hexacoordinate coordination sphere of the Tc(V) core with donor groups such as 
amine, carboxylate, or hydroxyl [40]. The HYNIC core has become one of the most 
popular and effective BCA used for 99mTc labeling of somatostatin analogues.
The coligands studied for 99mTc labeling of somatostatin analogues were EDDA, 
tricine, nicotinic acid, and combinations thereof. Changing the coligand can signifi­
cantly affect the lipophilicity of the complex and allows to modify its biodistribution. 
Several studies have been published on the 99mTc labeling of octreotide via HYNIC 
in combination with different coligands [65, 66].99mTc‐HYNIC‐TOC after labeling 
with 99mTc using tricine and EDDA as coligands retained its receptor affinity as deter­
mined in vitro in rat brain cortex membranes and showed favorable biodistribution 
in vivo in tumor‐bearing animals [67, 68]. In animal models, the tracer accumulation 
ratio in the tumor compared to the kidneys and liver was higher than in the case of 
111In‐DTPA‐octreotide [69].
Kits for 99mtc‐lAbeled somAtostAtin AnAlogues
There are considerable advantages of having the somatostatin analogues delivered to 
the hospital in the form of dry kits allowing their labeling with 99mTc directly before 
administration to the patient. The kits offer high and reproducible labeling yields 
combined with the long shelf life. They contain all chemical components, including 
the reducing agent, the ligand‐functionalized peptide, as well as potential supporting 
ligands, buffers, and other excipients, in lyophilized form, and the labeling reaction 
is initiated by adding the generator eluate (99mTcO
4
− in saline) to the kit vial.
The direct 99mTc labeling of HYNIC‐derivatized peptides in presence of EDDA 
resulted in low labeling yields [49, 60, 70] unsuitable for a routine clinical use, while 
the labeling yield in presence of tricine (N‐[tris(hydroxymethyl)methyl]glycine) as 
coligand was very high at room temperature and could be achieved in a short time. 
To overcome these limitations, the single‐step and two‐step kit approaches were 
developed [71], both demanding incubation at elevated temperature. Based on the 
labeling approach utilizing ligand exchange from tricine to EDDA at the elevated 
temperature with almost quantitative yields in a short time [61], the kit formulation 
has been developed after optimization of pH of freeze‐drying solution and the content 
of stannous chloride. Mannitol as the bulking agent was added to improve the features 
of freeze‐dried pellet and ensure rapid dissolution of all reagents in the labeling 
process [72]. Manufacturing conditions leading to the optimized freeze‐dried 
composition of a kit for 99mTc‐EDDA/HYNIC‐TOC radiopharmaceutical were also 
described [73], leading to the radiopharmaceutical of good imaging properties.
Similarly to other kits for 99mTc radiopharmaceuticals, it is generally assumed 
that the peptide‐based radiopharmaceutical can be obtained in the 99mTc labeling 
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procedure lasting 30–60 min. Most of the labeling reactions are performed at 
80–100°C (with the exception of N
4
‐derivatized peptides that are labeled at room 
temperature). The radiolabeled product is sterile and can be administered to patients 
without any further purification steps. The administration of the radiopharmaceutical 
should not induce pharmacologic effects.
modificAtions of octreotide for spect‐srs
The pharmacophore of octreotide consists of the sequence ‐Phe‐(D)Trp‐Lys‐Thr‐ 
(see Fig.  4.1.5), which is forced into a β‐turn conformation by a disulfide bridge 
formed between the two cysteinyl residues close to the N‐ and C‐terminus, respectively, 
thus mimicking the spatial disposition of the corresponding amino acids in native 
somatostatin‐14. In order to maintain high sst‐binding affinity, the pharmacophore of 
an sst ligand needs to be conformationally constrained [74].
Also, the presence of the ε‐amino group of Lys5 is a prerequisite for the biological 
activity and especially for receptor recognition. Hence, modification of one of the 
phenylalanine residues through replacement by tyrosine or derivatization of the α‐
amino group of (D)‐Phe1 was the most reasonable approach. The hydroxy group 
present in tyrosine allows an electrophilic reaction of the aromatic ring with iodine 
isotopes, while coupling of an appropriate chelator at the N‐terminus allows stable 
binding of certain metallic radionuclides.
Modifications of the amino acid sequence of octreotide analogues, that is, the 
replacement of Phe3 by Tyr3 that was useful for radioiodination, appeared to also 
improve sst
2
 affinity, while the C‐terminal substitution of Thr(ol) by Thr resulted in a 
further improvement of sst
2
 affinity, to a higher rate of internalization, and to a higher 
tumor uptake in animal models [11]. The preclinical comparison of 111In‐ and 99mTc‐
labeled somatostatin analogues—OC, TOC, and [Tyr3, Thr8]‐octreotide (TATE) with 
either DOTA or HYNIC as chelators [71]—showed that all of them were character­
ized by specific internalization in AR42J rat pancreatic tumor cells known to express 
the rat sst
2
 [75]. However, there was distinct tendency of increasing internalization 
rates from OC through TOC to TATE, which was also clearly reflected in the tumor 
uptake in AR42J tumor‐bearing rats. Uptake in the experimental tumor and in the 
















figure 4.1.5 The amino acid sequence of native somatostatin‐(14) and octreotide.
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pancreas correlated well with the rate of internalization determined in vitro. Based on 
these results, the authors concluded that radioligands based on TATE are superior for 
in vivo sst
2
‐tumor targeting to those based on TOC and octreotide, respectively. 
Consequently, it was assumed that the higher hydrophilicity and the higher tumor‐to‐
liver ratio of 99mTc‐EDDA/HYNIC‐TATE compared to 99mTc‐EDDA/HYNIC‐TOC 
may consequently lead to improved sensitivity in the detection of liver metastases. 
This assumption, however, was not confirmed in human study comparing 111In‐
DOTA‐TOC and 111In‐DOTA‐TATE. Both tracers showed the expected high specific 
uptake in somatostatin receptor‐positive tissue although better visualization of some 
liver metastases was found with 111In‐DOTA‐TOC and a significantly higher mean 
absorbed dose to the liver was found for 111In‐DOTA‐TATE [76].
The final verification of the diagnostic efficacy of 99mTc‐EDDA/HYNIC‐TOC and 
99mTc‐EDDA/HYNIC‐TATE was performed by direct comparison of SRS using both 
tracers in the uniform group of 12 patients with confirmed GEP‐NET [77]. Both 
99mTc‐EDDA/HYNIC‐TOC and 99mTc‐EDDA/HYNIC‐TATE were found to be useful 
radiopharmaceuticals for SRS‐SPECT, in neuroendocrine tumors, especially those 
expressing sst
2
. Similar number of metastatic lesions was detected using either agent; 
85% correlation was found when analyzing each of metastases individually. The 
uptake of 99mTc‐HYNIC‐TOC in the liver was higher than in the case of 99mTc‐
HYNIC‐TATE, but the ratio of uptake in the lesion to background was comparable. 
No significant differences were observed in the uptake of these agents in the tumors 
and in the kidneys.
Promising preclinical results were obtained also with the 99mTc‐Demotate series 
(e.g., [99mTc‐N
4
0, Tyr3]octreotate, 99mTc‐Demotate 1) [78, 79] or with [99mTc‐
N
4
0‐1,Asp0,Tyr3]octreotate, 99mTc‐Demotate 2, during a preclinical comparison with 
[111In]DOTA‐TATE in the detection of sst
2
‐positive tumors [80]. 99mTc‐labeled octreo­
tide analogues have been developed and clinically evaluated for SRS‐SPECT imaging, 
such as HYNIC‐TOC [81], HYNIC‐TATE [82–84], and 99mTc‐Demotate 1 [85, 86].
developments in srs‐spect trAcers
All of the so far mentioned analogues have high affinity for sst
2
. The search for other 
somatostatin‐based peptides having affinity for a broader range of somatostatin 
receptor subtypes, which might target a broader spectrum of tumors but also have a 
higher net tumor uptake, has been continued [87]. Several new compounds have been 






. These new compounds were 
modified at position 3 of octapeptide, the best of them containing the unnatural 
amino acids 1‐naphthyl‐alanine 111In‐DOTA‐NOC (1‐NaI3‐octreotide) [88, 89], 111In‐
DOTANOC‐ATE (1‐NaI3‐Thr8‐octreotide), benzothienyl‐alanine (DOTA‐BOC) 
and 111In‐DOTABOC‐ATE (Bz‐Thi3‐Thr8‐octreotide); however, their applications 
were limited [90]. Modification of the physical properties of somatostatin analogues 







, such as AM3 (DOTA‐)Tyr‐cyclo(DAB‐Arg‐cyclo(Cys‐Phe‐d‐Trp‐Lys‐Thr‐
Cys)). These molecules show fast background clearance and high tumor‐to‐nontumor 
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ratios are soon obtained; therefore, they look ideal for imaging with short‐lived 
radionuclides such as 68Ga [91]. Pansomatostatin radiopeptides with high‐affinity 
binding for all five receptor subtypes have also been developed. The first such 
peptide, KE108 (Tyr‐cyclo(DAB‐Arg‐Phe‐Phe‐d‐Trp‐Lys‐Thr‐Phe)), was modified 
by replacing Tyr as a prosthetic group for iodination NH
2
‐terminally [92] by DOTA, 
resulting in the analogue KE88 [93]. 111In‐KE88 was able to bind with high affinity 




) but was efficiently internalized only in sst
3
‐
expressing cells. The sst
3
‐expressing tumors had a high and persistent tumor uptake, 
whereas the sst
2
‐expressing tumors showed low uptake and fast washout in vivo. 
It did not appear to offer multisubtype imaging properties, since the in vitro internal­
ization and in vivo uptake in sst
2
 tumors were very low, compared to sst3 tumors.
Presented studies have been based on the development of radiolabeled somato­
statin agonists, assuming that the internalization of the receptor after radioligand 
binding is critical for efficient retention of the tracer in tumor cells, allowing for effi­
cient imaging and therapy. The molecular–pharmacologic investigations showed that 
efficient internalization is usually provided by agonists [94]. Recent developments 
have indicated that receptor antagonists may be as good or even better than agonists 
for such purposes. A recent study showed that high‐affinity somatostatin receptor 
antagonists that poorly internalize into tumor cells can, in terms of in vivo uptake in 
animal tumors, perform equally good or better than corresponding agonists, which 





 selective analogues, suggesting that this observation may be valid for more than 
just one particular G‐protein‐coupled receptor. The study demonstrated that the sst 
antagonists are preferable for in vivo tumor targeting [95]. The first clinical evalu­
ation of SRS with an antagonist confirmed the preclinical data, as it showed higher 







) compared to the agonist 111In‐DTPA0‐octreotide and 
improved tumor‐to‐background ratios, in particular tumor‐to‐kidney [96].
clinicAl utility of srs‐spect in neuroendocrine tumors
In vivo imaging of various tumors that overexpress somatostatin receptors, especially 
of neuroendocrine origin, using radiolabeled somatostatin analogs has become an 
accepted clinical tool in oncology [97]. Since its introduction, many applications of 
111In‐pentetreotide have been reported. It has been successfully used in patients to 
visualize somatostatin receptor‐positive tumors, sometimes identifying metastases 
that were not detected by conventional methods [16, 98].
The sensitivity and specificity of the 111In‐pentetreotide SRS‐SPECT in the diag­
nosis of intestinal neuroendocrine tumors, including primary foci and metastatic 
lesions, were assessed as 71–96% and 76–95%, respectively [99–101]. On the basis 
of the 162 SRS studies with gastric carcinoid in a course of MEN‐1 syndrome, the 
sensitivity of 75%, specificity of 95%, and negative predictive value of 97% were 
calculated in positive gastric SRS localization using 111In‐OctreoScan [102]. The 
potential value of SRS in identifying patients with gastric carcinoids in this study 
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was supported by the analysis of value of clinical and laboratory characteristics in 
such patients. Except for the presence of MEN‐1, no characteristics were helpful in 
identifying which patients might have gastric carcinoid. Therefore, the availability of 
SRS was assessed as very important in the treatment of patients with hypergastrin­
emic states and other diseases with an increased incidence of gastric carcinoids.
SRS allows the localization of distant metastases that are not visualized by other 
structural diagnostic methods revealing the superiority of SRS over CT or MRI in 
NET staging. SRS‐SPECT with the use of 99mTc‐labeled somatostatin analogues is 
very helpful in GEP‐NET for staging, for primary focus and recurrent disease detec­
tion, and for therapy follow‐up (Fig. 4.1.6).
Superimposed CT/MRI scans and scintigraphy images with fusion image tech­
niques or the use of SPECT/CT hybrid devices provide optimal imaging. These 
techniques enable a precise anatomical localization of the lesion visible in SRS and 
improve sensitivity in differentiating lesions with physiological and pathological 
accumulation of the tracer. The combined anatomical–functional imaging with 
SPECT/CT and additional visual correlation to high‐end CT has a high diagnostic 
accuracy and significantly improves tumor localization and characterization in 
patients with NET [103].
In comparison to 111In‐labeled agents, 99mTc‐labeled radiopharmaceuticals show 
many advantages. In the group of 41 patients with somatostatin receptor‐positive 
tumors, also higher sensitivity of 99mTc‐EDDA/HYNIC‐TOC in neuroendocrine 
tumor detection than that of the 111In‐pentetreotide (65.9 vs. 51.2%) was found [104]. 
More focal lesions were detected, especially small liver and lymph node metastases 
(105 vs. 91 lesions). The authors concluded that 99mTc‐EDDA/HYNIC‐TOC com­
bines the advantages of favorable pharmacokinetics, higher spatial resolution, lower 
radiation dose, and improved availability of 99mTc with a simplified imaging procedure 
figure  4.1.6 Anterior chest images obtained 3 h after administration of 370 MBq of 
99mTc‐HYNIC‐TOC in a patient with metastatic medullary thyroid cancer. Before therapy (left 
panel) and after one cycle of therapy with 90Y‐DOTA‐TOC (right panel) showing partial 
necrosis of some metastases and complete disappearance of others.
REFERENCES 49
and could replace 111In‐OctreoScan for routine SRS. 99mTc‐labeled somatostatin 
 analogues are particularly helpful in detecting small tumors or tumors bearing a low 
density of somatostatin receptors.
Parisella and Signore [105] evaluated the use of 99mTc‐EDDA/HYNIC‐TOC in 
neuroendocrine tumors and concluded that SRS with 99mTc‐EDDA/HYNIC‐TOC is 
highly indicated for in vivo histological characterization of known NET lesions, pre­
viously identified by other imaging modalities or biopsy, to plan appropriate therapy 
especially for patients with inoperable disease.
Scintigraphy using 99mTc‐EDDA/HYNIC‐TOC was proved to be useful in the 
diagnostic of metastatic medullary thyroid cancer (MTC); however, it’s important to 
note that sst2 expression is downregulated with the advancement of MTC. The 
method appeared to be more efficient than other radioisotope or radiologic techniques 
taking into account the number of detected metastatic foci of MTC [106]. In a signifi­
cantly larger group of MTC patients, the sensitivity was 74.1%, therefore better than 
in the case of other diagnostic modalities [107–110].
conclusions
SRS using SPECT radiopharmaceuticals opened a new era in the field of molecular 
imaging. When these new tracers were developed, they changed the approach to 
diagnosis and treatment of neuroendocrine tumors. In these days, however, the avail­
ability of 68Ga‐labeled sst‐affine analogues for PET imaging improved significantly 
diagnostic sensitivity, and when available, they now represent the best option.
Not all nuclear medicine centers, however, have access to PET facilities and 68Ga‐
labeled peptides, and therefore, SRS‐SPECT remains a suitable and economical 
alternative, particularly when used for the molecular characterization of known 
lesions (larger than 1 cm), for differential diagnosis, and for therapy decision making 
but not for the detection of unknown sites of disease.
The use of SRS‐SPECT for the study of inflammatory diseases is still an option, 
especially for the study of the state of activity of the disease and to early evaluation 
of therapy efficacy.
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APUD amine precursor uptake and decarboxylation
BBQ‐MIT Bad Berka Molecular Imaging Tool
CNL cognition network language
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MRI magnetic resonance imaging
MTD molecular tumor diameter
MTV molecular tumor volume
NET neuroendocrine tumor
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PET positron emission tomography
pNETs pancreatic NETs
PRRT peptide receptor radionuclide therapy
SI‐NETs small intestinal (ileum/jejunum/duodenum) NETs
SMS somatostatin
SSTR somatostatin receptor
SUV standardized uptake value
SUV T/S SUVmax tumor‐to‐spleen ratio
TACE transarterial chemoembolization
USG ultrasonography
WHO World Health Organization
introduction
Neuroendocrine tumors (NETs) are heterogeneous group of tumors originating 
from pluripotent stem cells or differentiated neuroendocrine cells. The hallmark of 
NETs is the expression of somatostatin receptors (SSTRs), which forms the ratio-
nale for the use of radiolabeled somatostatin (SMS) analogues for imaging and 
therapy. Another unique feature is their endocrine metabolism, that is, decarboxylation 
of amine precursors, hence previously referred to as amine precursor uptake and 
decarboxylation (APUD)‐omas. NETs occur predominantly in the lungs and the 
gastroenteropancreatic system (GEP). Taking into account the complex and diverse 
histology of NETs and to allow optimal prognostic stratification, a new system of 
classification was devised in 2010 by the WHO (Table 4.2.1) [1].
The heterogeneous nature, the indolent course, and the possibility of multiple 
and variable anatomic site of primary make it difficult to evaluate patients with 
NETs. The clinical manifestations due to the secretion of a wide range of biogenic 
amines typify NETs. However, they do not provide adequate information to allow 
the clinician to decide upon a treatment regime, which therefore requires imaging. 
tAble 4.2.1 WHo 2010 classification of net with corresponding values for mitoses 
per 10 high‐power fields (Hpf) and proliferation rate (as Ki‐67/Mib‐1 index in %), 
determining the grade (g) of net






Mixed adenoneuroendocrine carcinoma 
(MANEC)
Hyperplastic and preneoplastic lesion
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Computed tomography (CT) scans, magnetic resonance imaging (MRI), and endoscopic 
ultrasonography (USG) (EUS) are the morphological imaging modalities in the 
diagnostics of NETs. However, these do not give the functional status of the tumor, 
which is often essential for defining the prognosis, as molecular changes precede 
the morphologic changes. One of the biggest disadvantages of USG is its operator 
dependency. It also fails to differentiate liver metastases of NETs from other type of 
liver metastases. Hypervascularity, one of the most common features of NET liver 
metastases, can be very well documented using Doppler techniques and contrast‐
enhanced USG. However, these hypervascular solitary lesions may be misdiagnosed 
as hemangiomas. A combination of functional and morphological imaging often 
helps in initial diagnosis and staging, deciding upon the treatment regime, and mon-
itoring therapy response [2–4].
The discovery of overexpression of SSTRs for peptide hormones in NETs, more 
than two decades ago, has revolutionized the role of nuclear medicine in the diag-
nosis and therapy of NETs [5, 6]. This was indeed paralleled by the development of 
various radiopharmaceuticals targeting these tumor‐related receptors, as well as 
various metabolic pathways peculiar to the NET cells [7].
Over the past two decades, 111In‐DTPA‐octreotide scintigraphy has been the fore-
most functional imaging in the diagnostics of NETs [3, 8].
More recently, molecular imaging using diverse positron emission tomography 
(PET) radiopharmaceuticals has gained popularity in the diagnostic workup of 
patients with NET [9–11]. In addition, the amalgamation of PET with CT (PET/CT) 
enables fast and high‐resolution functional imaging with more accurate anatomical 
localization.
With the ever‐growing list of PET tracers currently being employed for the 
imaging of NETs, it is essential to first describe their respective molecular targets so 
as to understand and compare the results of this wide range of PET radiopharmaceu-
ticals (Table 4.2.2). The potential molecular events/targets that can be currently tar-
geted by PET‐based radiopharmaceuticals are:
a) SSTR expression
b) Serotonin production pathway
c) Biogenic amine storage
d) Catecholamine transport
e) Glucose metabolism
f) Miscellaneous peptide receptor expression
sMs AnAlogues for pet/ct iMAging
SMS is a cyclic peptide hormone with primary action of inhibition of hormone 
secretion and modulation of neurotransmission and cell proliferation through 
specific membrane‐bound G‐protein‐coupled receptors. These SSTRs, which are 
also normally expressed in different organs such as the pituitary, thyroid, adrenals, 
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spleen (activated lymphocytes), kidneys, and gastrointestinal tract in different quan-
tities, have generated immense clinical interest due to their expression on various 
tumor types. This offers the potential of labeling SMS and its analogues with differ-
ent radionuclides for imaging and also for therapy. The advantages of small peptides 
are better pharmacokinetic characteristics and no (or very low) antigenicity as 
compared to antibodies, making them nearly ideal ligands for receptor‐based radio-
nuclide imaging.
The basis of peptide receptor imaging using radiolabeled SMS is the overexpres-
sion in NETs of SSTRs [5]. There are five different types of SSTR proteins, which 
have been cloned (SSTRs 1 through 5); SSTR2 consists of two subtypes, SSTR2A 
and SSTR2B. Though most of the tumors predominantly express SSTR2, it has been 
demonstrated that SSTR1, SSTR3, SSTR4, and SSTR5 are also expressed on many 
tAble 4.2.2 diagnostic pet radiopharmaceuticals for net
Radiopharmaceutical Receptor/metabolic target Indication and comments
18f‐fDG Glycolytic pathway All NETs. Observation of flip‐flop 
mechanism with SMS‐R PET
68Ga‐DOTANOC Somatostatin receptor 
(pansomatostatin, high 
affinity for SSTR2, SSTR3, 
and SSTR5)
All SSTR +ve NETs
68Ga‐DOTATOC Somatostatin receptor (high 
affinity for SSTR2)
68Ga‐DOTATATE Somatostatin receptor (highest 
affinity for SSTR2)
11C‐5‐HTP Serotonin production pathway All serotonin‐producing NETs
11C‐DOPA Dopamine production pathway Pheochromocytoma, 
paraganglioma, neuroblastoma; 
short half‐life, cost of 
production, and difficulty 
in obtaining 11C major  
obstacle
18f‐DOPA Dopamine production pathway Pheochromocytoma, 
paraganglioma, neuroblastoma, 
glomus tumor
18f‐fDA Catecholamine precursor Pheochromocytoma, 
paraganglioma, neuroblastoma
64Cu‐TETA‐octretoide Somatostatin receptor All SSTR +ve NETs
18f‐fP‐Gluc‐TOCA Somatostatin receptor All SSTR +ve NETs
11C‐Ephidrine Catecholamine transporter Pheochromocytoma, 
neuroblastoma, study of the 
sympathetic nervous system
11C‐Hydroxyephidrine Catecholamine transporter Pheochromocytoma, 
neuroblastoma, study of the 
sympathetic nervous system
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tumors with varying percentage of expression [12]. The prevalence of expression 
of SSTRs by NET of midgut origin was found to be maximum for SSTR2 (95%), 
followed by SSTR1 (80%) and SSTR5 (75%).
111In‐DTPA‐D‐Phe1‐octreotide (111In‐pentetreotide; OctreoScan, Mallinckrodt, 
Inc., St. Louis, Missouri) was the first radiolabeled SMS analogue to be approved for 
scintigraphy of NETs and has been shown to be well suited for the scintigraphic 
localization of primary and metastatic NET [13, 14]. 99mTc (technetium) has also 
been labeled with SMS analogues to enable conventional nuclear medicine imaging 
[15–18]. 99mTc‐EDDA/HYNIC‐TOC has been demonstrated to be promising for the 
detection of SSTR‐positive tumors and metastases [19].
DOTA‐d‐Phe1‐Tyr3‐octreotide (DOTATOC) and DOTA‐d‐Phe1‐Tyr3‐Thr8‐ 
octreotide (DOTATATE) have a very high affinity for the SSTR2, low or negligible 
affinity for SSTR3 and SSTR5, and no significant affinity for SSTR1 and SSTR4 
[20, 21]. The development of this next generation of SMS analogues opened the 
prospect for convenient radiolabeling with 68Ga for PET imaging [22]. DOTA‐1‐NaI3‐
octreotide (DOTANOC) was developed by amino acid exchange at position 3 of 
octreotide as a pansomatostatin analogue, covering a broader spectrum of SSTRs. 
This compound has not only a higher affinity to SSTR3 and SSTR5 but also binds 
more avidly to SSTR2 [23].
fourth‐generation analogues to be have been studied preclinically are (DOTA‐1‐
NaI3, Thr8)‐octreotide (DOTA‐NOC‐ATE) and (DOTA‐BzThi3, Thr8)‐octreotide 
(DOTA‐BOC‐ATE) [24]. They have been shown to have very high affinity for 
SSTR2, SSTR3, and SSTR5 and intermediate high affinity to SSTR4. SSTR antago-
nists [NH(2)‐CO‐c(DCys‐Phe‐Tyr‐DAgl(8)(Me,2‐naphthoyl)‐Lys‐Thr‐Phe‐Cys)‐
OH (SST(3)‐ODN‐8) and (SST(2)‐ANT)] have also been labeled with 111In, and their 
superiority over SSTR agonists (in murine models) for in vivo targeting of SSTR2‐ 
and SSTR3‐rich tumors has resulted in the shift in paradigm, and they are now being 
contemplated for use in tumor diagnosis [25]. Recently, the SSTR antagonist 111In‐
DOTA‐BASS has been demonstrated to have a favorable human biodistribution in 
five patients with metastatic thyroid carcinoma or neuroendocrine neoplasms [26].
sstr pet/ct using 68ga
68Ga is a diagnostic trivalent radiometal and is feasible for labeling with SMS ana-
logues (DOTATOC, DOTATATE, or DOTANOC) with the help of chelator DOTA 
[27]. 68Ga is prepared from a TiO
2
‐based 68Ge/68Ga generator system, which has a 
half‐life of 288 days [28]. A GMP‐compliant, fully automated click‐and‐start cassette‐
based synthesis system with easy handling is now available (EZAG, Berlin, Germany) 
for the daily routine production of 68Ga‐labeled radiopharmaceuticals. Postprocessing 
of 68Ge/68Ga radionuclide generators using cation exchange resin provides chemi-
cally and radiochemically pure 68Ga (97 ± 2%) within a few minutes, ready for on‐site 
labeling with high overall product yields.
The most consequential feature of PET/CT is its ability to quantify the disease at a 
molecular level. In addition, superior resolution gives it a distinct edge over SPECT/CT 
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using gamma‐emitting radionuclides like Tc‐99m. The recent tremendous increase 
in  the number of diagnostic imaging studies with 68Ga has indeed demonstrated 
its potential to become the Tc‐99m for PET/CT. Apart from detection of primary 
and metastatic disease (staging), assessment of molecular response to therapy, and 
long‐term follow‐up, PET/CT using 68Ga‐labeled SMS analogues like DOTATOC, 
DOTATATE, and DOTANOC (SSTR PET/CT) also helps to select patients who are 
likely to benefit from peptide receptor radionuclide therapy (PRRT) using the same 
analogue labeled with a beta emitter like 177Lu or 90Y. The successful use of 68Ga and 
177Lu/90Y, respectively, for diagnosis and radionuclide therapy using the same peptide 
targeting SSTRs, has demonstrated that THERANOSTICS of neuroendocrine neo-
plasms is already a fact today and not a fiction.
iMAging protocol
The guidelines for 68Ga‐SSTR PET/CT have been outlined [29]. Sandostatin LAR 
injections must be stopped 3–4 weeks prior to the scan, and subcutaneous (s.c.) 
treatment with octreotide should be stopped at least 1 day before. However, there are 
some centers that do not recommend stopping Sandostatin injection before imaging. 
Care is taken for proper hydration of the patient. Just prior to the acquisition, the 
patient should be requested to void. Use of oral contrast media is recommended. The 
maximum tumor activity is reached within 70 ± 20 min after injection. PET/CT acqui-
sition should start at 45–90 min (depending upon the radiolabeled analogues) after 
intravenous injection of approximately 120 MBq of the radiolabeled peptides. In 
order to increase renal elimination and to reduce radiation exposure to the urinary 
bladder, furosemide may be given at the time of injection of 68Ga‐DOTANOC. In 
order to use the full potential of the modern PET/CT cameras equipped with 
multislice CT, a three‐phase CT should be performed.
diAgnosis, stAging, And restAging
In a recent study in normal human tissues, expression of SSTR2 at the level of mRNA 
was found to correlate with the SUVmax obtained from 68Ga‐DOTATOC PET/CT 
[30]. Another recent study provided for the first time the proof of concept of the 
utility of SSTR PET/CT for quantification of the SSTR density on tumor cells: a 
close correlation between maximum SUV and immunohistochemical scores used for 
the quantitative assessment of the density of subtypes of SSTR in NET tissue [31]. 
This underlines the crucial role of molecular imaging of the SSTR expression by 
PET/CT using 68Ga.
68Ga‐DOTATOC has been demonstrated to be superior to 111In‐octreotide SPECT 
(CT was taken as the reference for comparison) in detecting upper abdominal metas-
tases more than 10 years ago [22]. In a recent study, 68Ga‐DOTATOC PET/CT was 
proven to be superior to 111In‐octreotide in the detection of NET metastases in the 
lung and skeletal system and similar for the detection of NET metastases in the liver 
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and brain [32]. On a patient basis, the accuracy of 68Ga‐DOTATOC PET (96%) was 
found to be significantly higher than that of CT (75%) and 111In‐DOTATOC SPECT 
(58%) [33]. In 32/88 patients, 68Ga‐DOTATOC PET was not only able to detect 
more lesions than SPECT and CT but also was true positive where SPECT results 
were false negative. It was observed that for the staging of patients, PET was better 
than CT or SPECT as it could pick up more lesions in the lymph node (LN), in the 
liver, and in the bone. In addition, in comparison to the 111In‐octreotide scan, 68Ga‐
DOTATOC PET has been established to be superior especially in detecting small 
tumors or tumors bearing only a low density of SSTRs [34]. In patients with equiv-
ocal or negative OctreoScan, 68Ga‐DOTATATE PET/CT detected additional lesions 
and changed the management [35]. Of the 51 patients included in the study, 47 
showed evidence of disease on cross‐sectional imaging or biochemically. 68Ga‐
DOTATATE PET was found to be positive in 41 of these 47 patients (87.2%), detect-
ing 168 of the 226 lesions (74.3%) that were identified with cross‐sectional imaging. 
68Ga‐DOTATATE PET also identified significantly more lesions than 111In‐DTPA‐
octreotide scintigraphy (P < 0.001) and changed management in 36 patients (70.6%), 
who were subsequently deemed suitable for peptide receptor‐targeted therapy. 68Ga‐
DOTATOC was also shown to perform better than CT or SRS for the early detection 
of skeletal metastases of NETs [36]. In a larger subgroup of patients (n = 90) with 
pathologically confirmed NET, a comparison of 68Ga‐DOTANOC PET/CT with 
conventional imaging (CI) CT and EUS showed the superiority of PET/CT over CI 
[37]. Considering PET/CT and CI concordant cases (47/90 [52.2%]), PET findings 
affected the therapeutic management in 17 of 47 (36.2%) patients. Although PET 
did not result in modification of disease stage, 68Ga‐DOTANOC detected a higher 
lesion number in most patients. PET resulted in a modification of stage in 12 patients 
(28.6%) and affected the treatment plan in 32 patients (76.2%). 68Ga‐DOTANOC 
PET/CT thus affected either stage or therapy in 50 of 90 (55.5%) patients. The most 
frequent impact was the initiation or continuance of PPRT, followed by the initia-
tion or continuance of SMS analogue medical treatment and referral to surgery. Of 
importance is that PET could avoid unnecessary surgery in 6 patients and excluded 
from treatment with SMS analogues two patients with NET lesions that did not 
express SSTRs. Due to the broader range of SSTR expression, 68Ga‐DOTANOC is 
an excellent tracer for imaging SSTR‐positive tumors, which in addition, due to the 
high target to nontarget ratios, allows the detection of very small lesions, especially 
of LN and bone metastases [38]. PET using 68Ga‐DOTATOC has been found to be 
superior to 18f‐fDG PET in the detection of NETs, imaging 57/63 lesions in 15 
patients, as compared with only 43/63 on fDG PET [39]. In malignant neural crest 
tumors (pheochromocytoma, paraganglioma, and medullary thyroid cancer), a 
direct comparison with 123I‐MIBG study showed the superiority of the 68Ga‐
DOTATATE PET/CT in terms of sensitivity [40]. In a study in pulmonary endocrine 
tumors, 68Ga‐DOTATATE was shown to have a definite incremental value over 
18f‐fDG for typical bronchial carcinoids than in atypical carcinoids and higher 
grades of tumors [41]. Also, due to the probability of development of concomitant 
NETs, SSTR PET/CT with 68Ga could be useful in the detection and follow‐up 
of pulmonary NETs [42]. Indeed, 68Ga‐SSTR PET/CT provides a whole‐body 
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one‐stop‐shop approach to the identification and localization of NETs and their 
metastases (figs. 4.2.1 and 4.2.2).
68Ga‐DOTATOC PET/CT has been also found to be considerably cheaper than 
111In‐DTPA‐octreotide with respect to both material and personnel costs [43]. In 
clinical practice, apart from higher resolution and excellent quality of the images, the 
other advantages of PET imaging with the 68Ga‐labeled SMS analogues over 111In‐
DTPA0‐octreotide scintigraphy are easy availability of the 68Ga generator, relative 
short scanning time, and low radiation exposure to the patient [44]. Two recent studies 
have taken into account the comparison between the 68Ga‐labeled SMS analogues. A 
preliminary intraindividual study comparing 68Ga‐DOTANOC and 68Ga‐DOTATATE 
demonstrated that 68Ga‐DOTANOC localized more lesions in, especially, the liver and 
pancreas, due to its broader SSTR affinity profile [45]. Another study demonstrated 
comparable diagnostic accuracy of 68Ga‐DOTATATE and 68Ga‐DOTATOC for detec-





figure 4.2.1 68Ga‐DOTATATE PET/CT (maximum intensity projection image on extreme 
left) shows multiple primary neuroendocrine tumors in pancreatic tail with an SUVmax of 
15.4 (a); in both adrenals, massive enlargement and partial necrosis in the left adrenal with an 
SUVmax of 29.7 (b) and comparatively smaller and less dense SSTR expression in the right 
adrenal with an SUVmax of 10.3 (c); and right ovary with an SUVmax of 11.6 (d). There was 
also widespread metastasis in the liver, multiple abdominal/extra‐abdominal lymph nodes, and 
possibly the pituitary gland (SUVmax of 5.4) (a, b, c, d—images in transverse view; CT on the 
left and fused PET/CT on the right). (See insert for color representation of the figure.)
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Gluc‐Lys 18f fP‐TOCA is an 18f‐based radiopharmaceutical that targets SSTRs. 
In a preliminary comparative study, Gluc‐Lys 18f fP‐TOCA PET was found to be 
superior to 111In‐DTPA‐octreotide scan in the diagnosis of NETs. The results also 
suggested that the sensitivity and specificity of Gluc‐Lys 18f fP‐TOCA is comparable 
to the reported sensitivity and specificity of 68Ga‐DOTATOC PET findings in NETs 
[47]. 64Cu, with a half‐life of 12.7 hours, is another potential positron‐emitting radio-
nuclide for PET imaging [48]. The possibility of performing dosimetry for PRRT 
based upon 64Cu is one other possible advantage. In a preliminary study, 64Cu‐TETA‐
octreotide PET was found to have high sensitivity and favorable dosimetry and 
pharmacokinetics [49].
detection of unKnoWn priMAry tuMor
In a bicentric study, the role of 68Ga‐DOTANOC PET/CT in the detection of unknown 
primary NETs has been demonstrated (fig. 4.2.3) [50].
Overall, 59 patients (33 men and 26 women, aged 65 ± 9 years) with documented 
NETs and unknown primary were enrolled. PET/CT was performed after injection of 
approximately 100 MBq (46–260 MBq) of 68Ga‐DOTANOC. The SUVmax were 
calculated and compared with SUVmax in known pancreatic NETs (pNETs) and 
ileum/jejunum/duodenum NETs (SI‐NETs). The results of PET/CT were also corre-





figure 4.2.2 Identification of rare metastases of neuroendocrine tumors with high‐sensitivity 
on 68Ga‐SSTR PET/CT: not only were myocardial metastases, which were otherwise difficult to 
appreciate on CT (a), localized on 68Ga‐DOTA‐SSTR PET/CT (b) but also pericardial metas-
tases (c, CT; d, fused PET/CT). (See insert for color representation of the figure.)
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the site of the primary: ileum/jejunum (14), pancreas (16), rectum/colon (2), lungs 
(2), and paraganglioma (1). CT alone (on retrospective analyses) confirmed the find-
ings in 12 of 59 patients (20%). The mean SUVmax of previously unknown (cancer 
of unknown provenience (CUP)) pNETs and SI‐NETs were 18.6 ± 9.8 (range: 7.8–
34.8) and 9.1 ± 6.0 (range: 4.2—27.8), respectively. SUVmax in patients with previ-
ously known pNET and SI‐NET were 26.1 ± 14.5 (range: 8.7–42.4) and 11.3 ± 3.7 
(range: 5.6–17.9). The SUVmax of the unknown pNETs and SI‐NETs were signifi-
cantly lower (P < 0.05) as compared to the ones with known primary tumor sites; 
19% of the patients had high‐grade NET and 81% low‐grade NET. Based on 68Ga‐
DOTANOC receptor PET/CT, 6 of 59 patients were operated, and the primary was 
removed (4 pancreatic, 1 ileal, and 1 rectal tumor) resulting in a management change 
in approximately 10% of the patients. In the remaining 29 patients, because of the far 
advanced stage of the disease (due to distant metastases), the primary tumors were 
not operated. Additional histopathological sampling was available from one patient 





figure 4.2.3 In this case of CUP syndrome, 68Ga‐DOTATOC PET/CT (MIP image on 
extreme left) revealed somatostatin receptor‐positive primary tumor in the jejunum with 
SUVmax of 13.8 (a), along with multiple metastases in the liver (b), bone (c), and lymph nodes 
(d), and a metastasis in the left adrenal. (a, b, c, d—images in transverse view; CT on the left 
and fused PET/CT on the right.) (See insert for color representation of the figure.)
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PET/CT was found to be highly superior to 111In‐OctreoScan (39% detection rate for 
CUP according to the literature). It therefore has a major role to play in the 
management of patients with CUP‐NET.
tHerApy plAnning
Curative treatment of NETs usually requires the possibility of complete surgical 
resection of the primary tumor and perhaps regional LN metastases. However, effec-
tive palliative therapies are also available at all stages of the disease and can be 
applied even to advanced stage. Depending upon tumor stage, size, localization, and 
degree of differentiation, treatment protocols for NET are currently based upon the 
following therapeutic options:
1. Surgery
2. Immunological therapy (interferon)
3. Trans‐arterial chemoembolization
4. Chemotherapy
5. Therapy with SMS analogues
6. PRRT
7. Intra‐arterial PRRT
Among these, surgical resection and cold SMS analogues (intramuscular or s.c. 
octreotide) are most commonly used as the first line of treatment; chemotherapy is 
used as the last option. The recent years have seen the development of PRRT as a 
highly effective treatment option for metastasized progressive NET, and PRRT is now 
regarded as the third leg of treatment protocol. for effective management of patients 
with NET, receptor and metabolic PET/CT play a very important role. As indicators 
of prognosis and by directing the surgeons toward the site of primary tumor, PET/CT 
with 68Ga‐DOTA‐peptides and 18f‐fDG play an important role in the management of 
NETs. for the institution of “cold” SMS therapy as well as SSTR‐based radionuclide 
therapy, it is important to document the expression of SSTRs on the tumor cells. The 
therapy schedule (amount of administered radioactivity and timing) of PRRT using 
177Lu‐ or 90Y‐DOTATATE/DOTATOC is highly dependent on the semiquantitative/
visual interpretation of 68Ga‐DOTA‐peptide PET/CT. Although dosimetry still is the 
best way to “individualize” PRRT, in our own experience, semiquantitative (SUVmax) 
evaluation is a good measure of the degree of receptor expression and hence 
prediction of response. Intra‐arterial PRRT is also an exciting option specifically 
for localized and bulky liver metastases. Although partial hepatectomy and hepatic 
transplantation remains a possibility, at Zentralklinik Bad Berka, intra‐arterial PRRT 
has been found to be highly successful. The dosing of such treatment is also dependent 
on receptor expression, since size on CT and MRI is not a reliable parameter because 
of the possibility of presence of cystic degeneration.
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evAluAtion of tHerApy response And prognosis
PET/CT is increasingly being used for therapy monitoring of various tumors. Most 
of these response parameters are based on morphologic imaging. However off‐late, 
there has been upsurge in the use of molecular response criteria for the early and 
accurate detection of response to therapy. SUVmax has been correlated with the 
prognosis in several cancers. Despite the fact that several studies have been published 
regarding the prognostic factors of NETs, there are some cases in which available 
data are not sufficient to predict disease progression and to define a correct therapeutic 
approach. In a study involving 47 patients, the SUVmax of 68Ga‐DOTANOC was 
validated for its potential to predict prognoses [51]. SUVmax was significantly 
higher in patients with pNET and in those with well‐differentiated NET, which indi-
cated an elevated expression of SSTR2A. During the follow‐up, whereas disease was 
stable or presented a partial response in 25 patients, it progressed in 19 cases. The 
patients with stable disease or a partial response had SUVmax significantly higher 
than did those in the progressive disease group, with the best cutoff ranging from 
17.9 to 19.3. Univariate and multivariate analyses demonstrated significant positive 
prognostic factors to be well‐differentiated NET, a SUVmax of 19.3 or more, and a 
combined treatment with long‐acting SMS analogues and radiolabeled SMS 
analogues. This study thus showed that SUVmax correlated with the clinical and 
pathologic features of NETs and is also an accurate prognostic index.
The RECIST and World Health Organization (WHO) criteria for classifying 
tumor response work best with fast‐growing cancers and when the therapy for which 
the response is being assessed is cytotoxic and not cytostatic [52]. Treatment evalua-
tion of slow‐growing NETs based on size changes alone is far more difficult. Also, a 
high percentage of NETs are nonfunctional, and clinical response parameters are 
often insufficient. Biochemical markers, such as CgA and 5‐HIAA, may be mis-
leading too, owing to their poor sensitivity. Rather than using RECIST criteria alone 
when monitoring NET, combined imaging approach that takes into consideration 
both molecular response parameter (MORE) and morphological information pro-
vides a much better measure of early treatment response since molecular response 
precedes morphology [53].
The role of metabolic PET/CT in the assessment of response to therapy is limited, 
primarily because NETs are slow‐growing tumors and glucose metabolism does not 
necessarily increase in slow‐growing and well‐differentiated tumors. In addition, no 
definitive therapy that directly influences the glucose metabolism so as to be assessed 
by 18f‐fDG exists for these tumors. It had already been postulated that 18f‐fDG PET 
should be performed only if SSTR imaging is negative [54]. The main use of 18f‐
fDG PET in the diagnosis of NETs depends on the grade of differentiation and/or 
aggressiveness of NETs and has been proposed for comprehensive tumor assessment 
in intermediate‐ and high‐grade tumors [39, 55]. Intense metabolic activity, reflected 
on 18f‐fDG PET scans, can still be an important prognostic indicator, being related 
to an outgrowth of aggressive tumor clones, suggesting a poor prognosis. However, 
functional imaging with both 68Ga‐DOTATATE and 18f‐fDG has been shown to 
address different biological properties of the NET lesions in patients planned for PRRT 
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and has been proposed as for comprehensive tumor assessment in intermediate‐ and 
high‐grade tumors (fig. 4.2.4) [39, 55].
The finding of increased L‐DOPA decarboxylase activity in 80% of NETs has 
resulted in the use of this parameter as a marker of tumor activity [56]. 18f‐DOPA 
PET/CT has been shown to have a promising role in GEP‐NET patients with negative 
or inconclusive findings at conventional radiological imaging and 111In‐pentetreotide 
scintigraphy [57]. 18f‐DOPA may have a role in the evaluation of functionally active 
NETs, especially pancreatic tumors, and also pheochromocytoma, paraganglioma, 
medullary thyroid cancer, and neuroblastoma [9]. In comparison with 18f‐DOPA, 
(a) (b)
(c) (d)
figure 4.2.4 Nonfunctional, well‐differentiated neuroendocrine neoplasm of the pancreas 
head with hepatic and abdominal lymph node metastases and proliferation rate (Ki‐67) of 7%. 
18f‐fDG PET/CT (a, b) demonstrated no increased glucose metabolism in the metastases. 
68Ga‐DOTATOC PET/CT (c, d), on the other hand, demonstrated intense expression of 
somatostatin receptors. This mismatch is a sign of good prognosis and an indication for 
PRRT (a, c, MIP images; b, d, fused PET/CT images in transverse view, demonstrating 
hepatic metastases). (See insert for color representation of the figure.)
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68Ga‐labeled SMS analogues have been demonstrated to have a higher sensitivity for 
the identification of metastases as well as occult primary [58, 59].
In a preliminary study at the Zentralklinik Bad Berka, investigators selected 25 
subjects at random from a group of 505 patients with metastasized neuroendocrine 
cancer who were scheduled for treatment with PRRT (138 lesions) and compared 
pre‐ and posttreatment images acquired using 68Ga‐DOTANOC PET/CT (molec-
ular response), 18f‐fDG PET/CT (metabolic response), and contrast‐enhanced 
CT (morphological response) [60]. A response index was calculated for each lesion 
from PET images based on the pre‐ and posttreatment SUVmax. RECIST criteria 
were applied to the contrast‐enhanced CT data. All lesions were categorized 
as partial responders, stable disease, or progressive disease. No correlation was 
observed between any of the three modalities. for example, 68Ga‐DOTANOC PET 
classified 70.6% of the lesions as partial responders, while 18f‐fDG PET put 43.8% 
into this category and CT just 17.6%. The sensitivity and specificity of 68Ga‐
DOTANOC PET to predict response to radiopeptide therapy were calculated as 89 
and 71%, respectively. 68Ga‐DOTANOC PET/CT was found to be superior to 18f‐
fDG PET/CT and morphological imaging in early and better prediction of response 
to PRRT. furthermore, a matching pattern between receptor expression and glucose 
metabolism was observed to increase with the grade of NETs, and therefore in 
high‐grade NETs, a concurrence between the changes in glucose metabolism and 
SSTR expression, that is, on 18f‐fDG PET/CT and 68Ga‐DOTANOC PET/CT, 
respectively, after PRRT was noticed. Also, higher tumor remission rate was corre-
lated with a high‐baseline SUVmax on SSTR PET/CT. This finding is consistent 
with previous studies, and PRRT seems to be quite an effective therapy option for 
NET patients expressing adequate densities of SSTRs on the tumors (figs. 4.2.5 
and 4.2.6) [61].
In another recent study, 68Ga‐DOTATATE PET/CT was validated for its potential 
to predict response to PRRT at an early stage [62]. Thirty‐three consecutive patients 
(22 men and 11 women; mean age ±SD, 57.8 ± 12.1 years) were investigated at base-
line and again 3 months after initiation of the first cycle of PRRT. 68Ga‐DOTATATE 
receptor expression was assessed using 2 measures of standardized uptake value 
(SUV): SUVmax and tumor‐to‐spleen SUV ratio (SUV T/S). Percentage change in 
SUV scores after PRRT relative to baseline (SUV) was calculated. After completing 
1–3 cycles of PRRT, patients entered the follow‐up study for estimation of time to 
progression. According to the RECIST criteria, progression was defined on the basis 
of contrast‐enhanced CT. Clinical symptoms as well as the tumor markers chromo-
granin A and neuron‐specific enolase were also recorded during regular follow‐up 
visits. The 23 of 31 patients with decreased SUV T/S after the first PRRT cycle had 
longer progression‐free survival than did the 8 of 31 patients with stable or increased 
scores (median survival not reached vs. 6 months, P = 0.002). for the 18 of 33 patients 
showing a reduction in SUVmax, there was no significant difference in progression‐
free survival (median survival not reached vs. 14 months, P = 0.22). Multivariate 
regression analysis identified SUV T/S as the only independent predictor for tumor 
progression during follow‐up. In the 17 of 33 patients with clinical symptoms before 






figure 4.2.5 68Ga‐DOTATATE PET/CT (a, MIP image pretherapy; d, MIP image post-
therapy) demonstrated significant therapeutic response in the same patient (described in 
fig. 4.2.4) (partial response according to molecular imaging criteria) after PRRT with 2700 
MBq 90Y‐DOTATOC. Hepatic metastasis in segment S5 inferoventral segment of the liver (b, 
fused PET/CT image in transverse view pretherapy; e, fused PET/CT image in transverse view 
posttherapy) showed an SUV fall of 68% from 61.1 to 19.4 posttherapy. Preaortic lymph node 
metastasis (c, fused PET/CT image in transverse view pretherapy; f, fused PET/CT image in 
transverse view posttherapy) showed an SUV fall of 29% from 55.5 to 39.5 posttherapy. (See 
insert for color representation of the figure.)
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SUVmax did not (r = 0.42, P = 0.10). Changes in the tumor markers (chromogranin A 
and neuron‐specific enolase) did not predict SUV scores, clinical improvement, or 
time to progression. This study showed that decreased 68Ga‐DOTATATE uptake in 
tumors after the first cycle of PRRT predicted time to progression and correlated with 
an improvement in clinical symptoms among patients with well‐differentiated NETs; 
SUV T/S was superior to SUVmax for prediction of outcome. However, more data 
is needed to substantiate this observation. The other potential application of 
receptor and metabolic PET/CT would be in the assessment of response to transar-
terial chemoembolization (TACE), chemotherapy, and Sandostatin therapy (to predict 
relapse). Biochemical markers are not very good indicators for early and accurate 






figure 4.2.6 Neuroendocrine neoplasm of the pancreatic tail with hepatic and skeletal 
metastases: 68Ga‐DOTATATE PET/CT (pretherapy images—a, MIP; b, coronal PET/CT fused; 
c, transverse PET/CT fused) demonstrated excellent response in the liver metastases after two 
cycles of PRRT with a cumulative administered activity of 8000 MBq of 177Lu (posttherapy 
images—d, MIP; e, coronal PET/CT fused; f, transverse PET/CT fused). (See insert for color 
representation of the figure.).
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Receptor PET/CT using 68Ga‐labeled SMS analogues enables molecular imaging of 
NETs and their metastases with very high diagnostic sensitivity and specificity. It 
provides quantitative, reproducible data (SUV) that can be used for selecting patients 
for PRRT and evaluation of therapy response. Among other advantages are fast pro-
tocol (60–90 min), low radiation burden (10–12 mSv), flexibility in daily use, and 
lower cost than octreotide scintigraphy. As we move toward personalized medicine, 
the diagnostic information obtained from PET/CT must be improved, that is, by fast 
and routine quantification of lesions. The Bad Berka Molecular Imaging Tool (BBQ‐
MIT) has been developed based on the cognition network language (CNL), provided 
by Definiens AG (Munich, Germany). The BBQ‐MIT is an automatic, user‐
independent routine for segregation and quantification of neoplastic lesions in molec-
ular PET/CT DICOM sets. This prototype routine built on CNL for PET/CT images 
enables the automatic analysis of lesions, for example, by calculating SUV, molec-
ular tumor volume (MTV), molecular tumor diameter (MTD), molecular tumor 
index (SUV x MTD), whole‐body and organ tumor burden, and many other parame-
ters. It seems especially promising for shortening the analysis time for reading a PET 
scan with many tumor lesions, improving reproducibility, as well as increasing the 
sensitivity in lesion detection. The BBQ‐MIT is a definite step forward and should 
set a trend toward the fast and accurate analysis of serial PET/CT, allowing monitoring 
of tumor response and assessment of therapy effect early in the course of therapy, 
thus enabling effective personalized patient management.
references
[1] Anlauf, M.; Gerlach, P.; Raffel, A.; et al. Der Onkologe 2011, 17, 572–582.
[2] Bombardieri, E.; Maccauro, M.; de Deckere, E.; et al. Annals of Oncology 2001, 12, 
51–61.
[3] Rufini, V.; Calcagni, ML.; Baum, R. P. Seminars in Nuclear Medicine 2006, 36, 
228–247.
[4] Baum, R. P.; Kulkarni, H. R.; Carreras, C. Seminars in Nuclear Medicine 2012, 42, 
190–207.
[5] Reubi, J. C. Journal of Nuclear Medicine 1995, 36, 1825–1835.
[6] Koopmans, K. P.; Neels, O.N.; Kema, I. P.; et al. Critical Reviews in Oncology/
Hematology 2009, 71, 199–213.
[7] Carrasquillo, J. A.; Chen, C. C. Seminars in Oncology 2010, 37, 662–679.
[8] Kwekkeboom, D. J.; Krenning, E. P. Seminars in Nuclear Medicine 2002, 32, 84–91.
[9] Wahl, R. L., ed., Principles and Practice of PET and PET/CT. Wolters Kluwer/Lippincott 
Williams & Wilkins, Philadelphia; 2008.
[10] Ambrosini, V.; Tomassetti, P.; franchi, R.; et al. The Quarterly Journal of Nuclear 
Medicine and Molecular Imaging 2010, 54, 16–23.
[11] Miederer, M.; Weber, M. M.; fottner, C. Gastroenterology Clinics of North America 
2010, 39, 923–935.
72 MOLECULAR IMAGING Of SOMATOSTATIN RECEPTOR‐POSITIVE TUMORS
[12] Reubi, J.C.; Waser, B.; Schaer, J. C.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2001, 287, 836–846.
[13] Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.; et al. European Journal of Nuclear 
Medicine and Molecular Imaging 1993, 20, 716–731.
[14] Bombardieri, E.; Ambrosini, V.; Aktolun, C.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2010, 37, 1441–1448.
[15] Decristoforo, C.; Melendez‐Alafort, L.; Sosabowski, J. K.; et al. Journal of Nuclear 
Medicine 2000, 41, 1114–1119.
[16] Lebtahi, R.; Le Cloirec, J.; Houzard, C.; et al. Journal of Nuclear Medicine 2002, 43, 
889–895.
[17] Maina, T.; Nock, B.; Nikolopoulou, A.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2002, 29, 742–753.
[18] Storch, D.; Béhé, M.; Walter, M. A.; et al. Journal of Nuclear Medicine 2005, 46, 
1561–1569.
[19] Gabriel, M.; Muehllechner, P.; Decristoforo, C.; et al. The Quarterly Journal of Nuclear 
Medicine and Molecular Imaging 2005, 49, 237–244.
[20] De Jong, M.; Bakker, W. H.; Krenning, E. P.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 1997, 24, 368–371.
[21] forrer, f.; Uusijärvi, H.; Waldherr, C.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2004, 31, 1257–1262.
[22] Hofmann, M.; Maecke, H.; Borner, R.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2001, 28, 1751–1757.
[23] Wild, D.; Schmitt, J.S.; Ginj, M.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2003, 30, 1338–1347.
[24] Ginj, M.; Chen, J.; Walter, M. A.; et al. Clinical Cancer Research 2005, 11, 1136–1145.
[25] Ginj, M.; Zhang, H.; Waser, B.; et al. Proceedings of the National Academy of Sciences 
2006, 103, 16436–16441.
[26] Wild, D.; fani, M.; Behe, M.; et al. Journal of Nuclear Medicine 2011, 52, 1412–1417.
[27] Roesch, f.; Baum, R. P. Generator‐based PET radiopharmaceuticals for molecular 
imaging of tumors: on the way to THERANOSTICS. Dalton Transactions 2011, 40, 
6104–6111.
[28] Zhernosekov, K. P.; filosofov, D. V.; Baum, R. P.; et al. Journal of Nuclear Medicine 
2007, 48, 1741–1748.
[29] Virgolini, I.; Ambrosini, V.; Bomanji, J.B.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2010, 37, 2004–2010.
[30] Boy, C.; Heusner, T. A.; Poeppel, T. D.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2011, 38, 1224–1236.
[31] Kaemmerer, D.; Peter, L.; Lupp, A.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2011, 8, 1659–1668.
[32] Buchmann, I.; Henze, M.; Engelbrecht, S.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2007, 34, 1617–1626.
[33] Gabriel, M.; Decristoforo, C.; Kendler, D.; et al. Journal of Nuclear Medicine 2007, 48, 
508–518.
[34] Kowalski, J.; Henze, M.; Schuhmacher, J.; et al. Molecular Imaging and Biology 2003, 
5, 42–48.
REfERENCES 73
[35] Srirajaskanthan, R.; Kayani, I.; Quigley, A. M.; et al. Journal of Nuclear Medicine 2010, 
51, 875–882.
[36] Putzer, D.; Gabriel, M.; Henninger, B.; et al. Journal of Nuclear Medicine 2009, 50, 
1214–1221.
[37] Ambrosini, V.; Campana, D.; Bodei, L.; et al. Journal of Nuclear Medicine 2010, 51, 
669–673.
[38] Prasad, V.; Baum, R. P. The Quarterly Journal of Nuclear Medicine and Molecular 
Imaging 2010, 54, 61–67.
[39] Koukouraki, S.; Strauss, L. G.; Georgoulias, V.; et al. European Journal of Nuclear 
Medicine and Molecular Imaging 2006, 33, 1115–1122.
[40] Naji, M.; Zhao, C.; Welsh, S. J.; et al. Molecular Imaging and Biology 2011, 13, 
769–775.
[41] Kayani, I.; Conry, B. G.; Groves, A. M.; et al. Journal of Nuclear Medicine 2009, 50, 
1927–1932.
[42] Kaemmerer, D.; Khatib‐Chahidi, K.; Baum, R. P.; et al. Cancer Imaging 2011, 11, 
179–183.
[43] Schreiter, N. f.; Brenner, W.; Nogami, M.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2012, 39, 72–82.
[44] Krausz, Y.; freedman, N.; Rubinstein, R.; et al. Molecular Imaging and Biology 2011, 
13, 583–593.
[45] Wild, D.; Bomanji, B. J.; Reubi, J. C.; et al. European Journal of Nuclear Medicine and 
Molecular Imaging 2009, 36, S201.
[46] Poeppel, T. D.; Binse, I.; Petersenn, S.; et al. Journal of Nuclear Medicine 2011, 52, 
1864–1870.
[47] Meisetschläger, G.; Poethko, T.; Stahl, A.; et al. Journal of Nuclear Medicine 2006, 47, 
566–573.
[48] Hanaoka, H.; Tominaga, H.; Yamada, K.; et al. Annals of Nuclear Medicine 2009, 23, 559–567.
[49] Anderson, C. J.; Dehdashti, f.; Cutler, P. D.; et al. Journal of Nuclear Medicine 2001, 42, 
213–221.
[50] Prasad, V.; Ambrosini, V.; Hommann, M.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2010, 37, 67–77.
[51] Campana, D.; Ambrosini, V.; Pezzilli, R.; et al. Journal of Nuclear Medicine 2010, 51, 
353–359.
[52] Chalian, H.; Töre, H. G.; Horowitz, J. M.; et al. Radiographics 2011, 31, 2093–2105.
[53] Baum, R. P.; Prasad, V.; Hommann, M.; et al. Recent Results in Cancer Research 2008, 
170, 225–242.
[54] Adams, S.; Baum, R.; Rink, T.; et al. European Journal of Nuclear Medicine 1998, 25, 
79–83.
[55] Kayani, I.; Bomanji, J. B.; Groves, A.; et al. Cancer 2008, 112, 2447–2455.
[56] Eldrup, E.; Clausen, N.; Scherling, B.; et al. Scandinavian Journal of Clinical & Laboratory 
Investigation 2001, 61, 479–490.
[57] Ambrosini V, Tomassetti, P.; Rubello, D.; et al. Nuclear Medicine Communications 
2007, 28, 473–477.
[58] Ambrosini, V.; Tomassetti, P.; Castellucci, P.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2008, 35, 1431–1438.
74 MOLECULAR IMAGING Of SOMATOSTATIN RECEPTOR‐POSITIVE TUMORS
[59] Haug, A.; Auernhammer, C. J.; Wängler, B.; et al. European Journal of Nuclear Medicine 
and Molecular Imaging 2009, 36, 765–770.
[60] Oh, S.; Prasad, V.; Lee, D. S.; et al. International Journal of Molecular Imaging 2011, 
2011, 524130.
[61] Kwekkeboom, D. J.; Bakker, W. H.; Kooij, P. P.; et al. European Journal of Nuclear 
Medicine 2001, 28, 1319–1325.
[62] Haug, A. R.; Auernhammer, C. J.; Wängler, B.; et al. Journal of Nuclear Medicine 2010, 
51, 1349–1356.
Somatostatin Analogues: From Research to Clinical Practice, First Edition. Edited by  
Alicja Hubalewska-Dydejczyk, Alberto Signore, Marion de Jong, Rudi A. Dierckx,  
John Buscombe, and Christophe Van de Wiele. 
© 2015 John Wiley & Sons, Inc. Published 2015 by John Wiley & Sons, Inc. 
AbbreviAtions
11C‐5‐HTP β‐[11C]‐5‐hydroxy‐l‐tryptophan





AADC aromatic amino acid decarboxylase
other rAdiophArmAceuticAls 
for imAging gep‐net
Klaas Pieter Koopmans1, Rudi A. Dierckx2, Philip H. Elsinga2,  
Thera P. Links3, Ido P. Kema4, Helle-Brit Fiebrich5,  
Annemiek M.E. Walekamp5, Elisabeth G.E. de Vries5,  
and Adrienne H. Brouwers2
1Department of Radiology and Nuclear Medicine, Martini Hospital Groningen, 
Groningen, The Netherlands
2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, and 
University Medical Center of Groningen, Groningen, The Netherlands
3Department of Endocrinology, University of Groningen, and University Medical Center of 
Groningen, Groningen, The Netherlands
4Department of Laboratory Center, University of Groningen, and University Medical Center 
of Groningen, Groningen, The Netherlands
5Department of Medical Oncology, University of Groningen, and University Medical Center 
of Groningen, Groningen, The Netherlands
4.3
76 OTHER RADIOPHARMACEuTICALs FOR IMAGInG GEP‐nET
GEP gastroenteropancreatic
LAT system l large amino acid transporters
L‐DOPA l‐3,4 ‐dihydroxyphenylalanine
MIBG metaiodobenzylguanidine
MIP maximum intensity projection
nET neuroendocrine tumor
PET positron emission tomography
sRs somatostatin receptor scintigraphy with 111In‐octreotide
VMAT vesicular monoamine transporters
introduction
Gastroenteropancreatic neuroendocrine tumors (GEP‐nETs) are tumors that arise in 
the pancreas and gastrointestinal system and are derived from neuroendocrine cells.
In contrast to many other malignancies, well‐differentiated GEP‐nETs generally 
have a low glucose metabolism [1, 2]. 18F‐fluorodexyglucose (18F‐FDG) PET scanning 
has limited value for the primary staging of patients with well‐differentiated GEP‐nET, 
showing only moderately increased glucose uptake in primary tumors and also often 
missing metastases. Besides, these primary tumors can be very small in size, thus 
failing the detection limit of PET camera systems. Therefore, as a staging tool, 18F‐
FDG does not seem to have a place in staging the general GEP‐nET patient population 
[1, 3]. A few studies with small heterogeneous GEP‐nET tumor groups have shown 
that in patients with rapidly progressive disease, dedifferentiation of GEP‐nET tumors 
can lead to a higher cellular glucose metabolism in tumor cells. In these patients, 18F‐
FDG PET can be of benefit for tumor staging. The 18F‐FDG uptake in tumor lesions 
in these patients could possibly play a role in predicting outcome and in assessing 
therapy response [4]. 18F‐FDG PET can be of value when other malignancies are sus-
pected in patients with GEP‐nETs, since these patients experience a higher incidence 
of these malignancies compared to the general population [5]. However, data for this 
indication are scarce. Due to the limited applicability of 18F‐FDG PET in GEP‐nETs, 
this technique will not be discussed in depth.
In contrast to most tissues in the human body, GEP‐nETs often show increased 
synthesis and secretion of hormones and neurotransmitters. nontumorous neuroen-
docrine cells regulate a variety of body functions through paracrine stimulation with 
a large variety of hormones and neurotransmitters. serotonin, catecholamine, and 
histamine are examples of compounds that share specific steps in their biosynthesis 
and storage, such as decarboxylation prior to storage in granules [6]. In GEP‐nETs, 
especially the catecholamine and serotonin biosynthetic pathways are upregulated. 
Therefore, increased biosynthesis of these specific amines in GEP‐nETs enables 
imaging with specific amine precursors. In this chapter, imaging of cells that show 
increased production of catecholamine and/or serotonin will be discussed for GEP‐
nETs encompassing neuroendocrine tumors (nETs) from foregut origin (bronchus, 
lung, thymus, stomach, pancreas, and proximal duodenum), midgut nETs (from 
distal half of second part of the duodenum to the proximal two‐thirds of the transverse 
colon), and hindgut nETs (descending colon, sigmoid, and rectum).
CATECHOLAMInE PATHWAY 77
cAtecholAmine pAthwAy
Catecholamines act as neurotransmitters especially in the brain, or as hormones, for 
example, adrenaline when it is released from the adrenals, via α‐ and β‐adrenergic 
receptors located on vessels and internal organs.
In the catecholamine pathway, phenylalanine and intermediate products such as 
l‐3,4 ‐dihydroxyphenylalanine (L‐DOPA) are taken up via system l large amino acid 
transporters (LAT) (Fig. 4.3.1). After entering the cell, decarboxylation to dopamine 
takes place intracytoplasmatically via the enzyme aromatic amino acid decarbox-
ylase (AADC). Vesicular monoamine transporters (VMAT) then transport dopamine 
into intracellular storage vesicles. In these vesicles, dopamine can, dependent on 
the  activity of specific enzymes, be further metabolized to noradrenaline and 
adrenaline. The resulting end products dopamine, noradrenaline, and adrenaline 
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figure 4.3.1 Overview. In this figure, a schematic overview is presented on the uptake 
mechanisms of the main tracers used in GEP‐nET imaging. GEP‐nET, gastroenteropancreatic 
neuroendocrine tumor.
78 OTHER RADIOPHARMACEuTICALs FOR IMAGInG GEP‐nET
reuptake transporter systems, for example, dopamine and noradrenaline trans-
porters, can thereafter transport these hormones back into the cell.
Catecholamines can be metabolized mainly intracellularly but also extracellularly into 
various metabolites, which can be measured in plasma and urine as acid and basic cate-
cholamine metabolites, such as homovanillic acid (HVA), vanillylmandelic acid (VMA), 
and metanephrines. Increased LAT activity seems to play a role in nETs, where due to a 
high precursor turnover and high AADC activity, a high precursor need has to be satis-
fied. The exact mechanism for precursor uptake regulation is not yet clear though [6, 7].
For the catecholamine pathway, 6‐18F ‐l‐3,4‐dihydroxyphenylalanine (18F‐DOPA) 
and 6‐18F‐dopamine are available as tracers. since 6‐18F‐dopamine will be described 
extensively in Chapter 4.4.2, we will limit this chapter to 18F‐DOPA.
18F‐DOPA is most commonly produced via regioselective fluorodestannylation 
(electrophilic fluorination). Another possibility is nucleophilic fluorination, a multi-
step procedure that, although more time consuming, has the advantage of having 
readily available large quantities of no‐carrier‐added 18F‐fluoride [6, 8].
18F‐DOPA tracer has been developed and first studied in men at McMaster university, 
Hamilton, Canada, during the 1970s and 1980s [9]. It has since then first been used for 
the imaging of the dopaminergic system in the striatum in patients with Parkinson’s 
disease and related disorders. several years later, this tracer has been used as a whole‐
body imaging technique in patients with nETs (Fig. 4.3.2) [10, 11].
figure 4.3.2 18F‐DOPA PET/CT. Images of a 73‐year‐old female with a serotonin‐pro-
ducing metastasized well‐differentiated nET of the small bowel (carcinoid). On the left, a 
maximum intensity projection (MIP) image is depicted; in the middle, a coronal slice; and on 
the right, a coronal fusion slice of PET and low‐dose CT. Physiological uptake of 18F‐DOPA is 
visible in the striata and excretion via kidneys with physiological activity in the ureters 
and urinary bladder. Metastases are visible in the liver and mesenteric tissue/lymph nodes. 
18F‐DOPA, 6‐18F‐l‐3,4‐dihydroxyphenylalanine; PET/CT, positron emission tomography/
computed tomography. (See insert for color representation of the figure.)
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In most centers, patients are required to fast 2–6 h with amino acid‐free fluid 
intake before the 18F‐DOPA PET scan is performed [12, 13]. 18F‐DOPA doses used 
are either a fixed dose or a body weight‐dependent dose, up to 5 MBq/kg. scanning 
after injection of 18F‐DOPA PET scan is usually performed 60 min after tracer injec-
tion with or without suV quantification. scanning at other time points has not been 
proven to be advantageous [14].
The use of carbidopa as pretreatment is still in debate. When used, it is given as 
2 mg/kg body weight or a fixed dose (i.e., 100–200 mg) 1 h before tracer injection 
[15–17]. Carbidopa is a peripheral inhibitor of the enzyme AADC. It decreases the 
peripheral decarboxylation of 18F‐DOPA and also β‐[11C]‐5‐hydroxy‐l‐tryptophan 
(11C‐5‐HTP), a tracer of the serotonin pathway, thus reducing renal excretion and 
subsequently improving tracer uptake in metastatic carcinoid tumors most likely due 
to increased tracer availability in the circulation. This resulted in better image quality 
due to decreased streaky image reconstruction artifacts caused by high physiological 
excretion of the radiotracer via kidneys and urinary bladder and increasing suV 
values of tumor lesions [17]. Why carbidopa pretreatment results in a generally 
decreased tracer uptake in pancreatic tissue is not quite understood, but may be 
related to differences in AADC activity in nETs and differences in metabolic 
handling of these PET tracers by exocrine and endocrine pancreatic tissue [16]. 
Because of the likely strong similarities between 11C‐5‐HTP and 18F‐DOPA tracer 
handling in patients with gastrointestinal nETs, carbidopa pretreatment is also advo-
cated for 18F‐DOPA PET imaging in this patient group to improve image quality 
especially in the region of the kidneys and bladder and to improve lesion detectability 
via further increased suV values of lesions. Indeed, high accuracy rates for the 
detection of (metastatic) nETs have been reported by the institutes that do use carbi-
dopa pretreatment [18]. However, pancreatic islet cell tumors may be an exception to 
the rule [15]. This should be further investigated [16]. With carbidopa pretreatment, 
the estimated mean radiation dose is 1.9 msv per 100 MBq 18F‐DOPA [19].
A possible complication of administering catecholamines to patients with a large 
tumor load is the development of a carcinoid crisis. Thus far, the development of a 
carcinoid crisis after injection of 18F‐DOPA has only been described in one case and 
is possibly related to a lower specific activity of 18F‐DOPA tracer [20].
Results of 18F‐DOPA PET(/CT) imaging in patients with midgut well‐differenti-
ated nETs (carcinoids) and other GEP‐nETs, such as (non)functioning pancreatic 
nETs (islet cell tumors), have been described in the literature [6, 18, 21–23]. In these 
studies, most patients had proven (recurrent) disease, and 18F‐DOPA PET(/CT) has 
been compared with current anatomical imaging techniques, mostly CT and/or MRI, 
and other functional imaging techniques, such as somatostatin receptor scintigraphy 
(sRs) with 111In‐octreotide, 123/131I‐labeled metaiodobenzylguanidine (MIBG), and 
18F‐FDG PET, and more recently also with 68Ga‐labeled PET‐based variants of 
octreotide. Morphological imaging techniques seem to be complementary to the 
functional imaging techniques under study in these patient series. In carcinoids, 
patient‐based reported sensitivities for 18F‐DOPA PET(/CT) are (very) high, ranging 
from 65 to 100% [6, 18, 22, 23], and therefore, it seems to be an excellent staging 
method for this patient group [6, 23]. 11C‐5‐HTP PET, however, was better than 
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18F‐DOPA PET on a patient‐based analysis (sensitivity of 100% vs. 96%, respectively), 
whereas per‐lesion analysis showed the opposite (sensitivity of 78% for 11C‐5‐
HTP and 87% for 18F‐DOPA, respectively) in patients with carcinoids and islet 
cell tumors [22]. Another study of Fiebrich et al. showed that in patients with 
carcinoid tumors, 18F‐DOPA uptake, defined as total body tumor load, corre-
sponds well to the tumor markers of the serotonin and catecholamine pathway in 
the urine and plasma in carcinoid patients, thereby reflecting metabolic tumor 
activity [24].
The 68Ga‐labeled analogues of somatostatin performed better than 18F‐DOPA PET 
in two studies with mixed nET types. A partial explanation for this result can be that 
in patients with (non)functioning islet cell tumors, 18F‐DOPA PET does not seem to 
have a good detection rate for these tumors [13, 21, 22].
since the published results for 18F‐DOPA PET were mainly achieved in patients 
with proven nET, it can be expected that performance of 18F‐DOPA PET will be 
lower in clinically more difficult cases where diagnosis of a nET is suspected but has 
yet to be confirmed [6, 25]. This was addressed in a recent published study in which 
patients (n = 119) with only biochemical proof of the disease and various types of 
nETs were investigated [25]. In this study, the diagnostic accuracy of 18F‐DOPA 
PET/CT in patients who were entered for primary staging of abdominal nETs was 
88%, whereas the diagnostic accuracy for patients entered for restaging of abdominal 
nETs (n = 61) was 92%. specificity of 18F‐DOPA PET in this tumor type has not yet 
been studied, since most research has been performed in patients with proven nETs 
where it is unlikely that histological proof will be obtained [6]. Thus far, no studies 
have been published on the influence of 18F‐DOPA PET on therapeutic management 
or the prognostic value for early response monitoring with 18F‐DOPA PET. These are 
all areas in which more research is warranted.
There is a clear need for in‐depth comparison of the other recently emerging 
functional PET imaging techniques, especially the 68Ga‐labeled somatostatin ana-
logues in (subsets of) nETs with 18F‐DOPA PET. Advantages of 68Ga‐labeled 
somatostatin analogues are the relatively easy generator‐based synthesis and the pos-
sibility to evaluate whether peptide receptor radionuclide therapy (PRRT) for nETs 
can be considered. However, 18F‐DOPA PET may have a broader clinical applica-
bility, for example, for studying the dopaminergic system of the human brain, malig-
nant tumors that do not (usually) express somatostatin receptors [26], and 
nononcologic settings, such as infants with hyperinsulinism. since 18F‐DOPA is 
already commercially available in many countries, the increased availability may 
lead to a better understanding of the place of 18F‐DOPA PET in clinical decision 
making for nETs.
serotonin pAthwAy
serotonin is a monoamine neurotransmitter that is present in blood platelets and in 
the intestinal wall where it regulates contractions. In the brain, it acts as a neurotrans-
mitter and plays a role in feelings of well‐being.
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Both the serotonin and the catecholamine pathways share common transporter 
systems, the LAT and the VMAT systems. Also, in both pathways, the enzyme AADC 
plays a key role in the final step for the synthesis of a functional hormone, serotonin 
and dopamine, respectively.
In the serotonin pathway, the amino acid tryptophan and the intermediate product 
5‐HTP are precursors for serotonin after uptake via the LAT system. How uptake is 
regulated is still unclear. After decarboxylation via the enzyme AADC, serotonin is 
taken up via VMAT into storage vesicles from which it can be released extracellu-
larly (Fig. 4.3.1). serotonin is eventually metabolized to 5‐hydroxyindoleacetic acid 
(5‐HIAA), which is secreted in the urine. The serotonin pathway is overactive in 
many nETs, which makes this pathway a good candidate for imaging with PET 
tracers [6].
Thus far, only a carbon‐11‐labeled tracer has been developed for the serotonin 
pathway, β‐[11C]‐5‐HTP. This tracer was developed in uppsala, sweden, during 
the 1980s. It is a complex tracer to produce, demanding an on‐site cyclotron 
for  the production of the 11C isotope, which has a half‐life of only 20 min. The 
synthesis of 11C‐5‐HTP itself is rather complex since it requires two multienzyme 
steps [27, 28]. Only a few centers worldwide produce 11C‐5‐HTP. However, in 
experienced hands, quantities up to 1000 MBq can be reliably synthesized for 
(clinical) use. Image interpretation is mostly easy due to high tumor tracer uptake 
and low background uptake in normal tissues. Clinical results justify the use of 
this tracer [7].
In 1993, the first results with this tracer were published [29]. nowadays, 11C‐5‐
HTP PET scanning is typically performed 10–20 min after injection of 11C‐5‐HTP 
with carbidopa pretreatment, 2 mg/kg body weight or with a fixed dose of 200 mg, 1 h 
prior to injection (Fig. 4.3.3). In contrary to 18F‐DOPA, no adverse reactions have 
thus far been reported after intravenous administration of 11C‐5‐HTP.
For 11C‐5‐HTP PET scans, carbidopa proved to be essential in order to improve 
image quality. Without carbidopa pretreatment, scans showed streaky image recon-
struction artifacts due to high urinary tract 11C‐5‐HTP uptake and excretion. 
Theoretically, carbidopa decreases the peripheral decarboxylation of 11C‐5‐HTP to 
11C‐5‐HT (serotonin) and subsequent urinary excretion of serotonin metabolites. The 
effect of carbidopa was tested in patients with midgut carcinoids, who were scanned 
with and without carbidopa pretreatment 1 h prior to injection of 11C‐5‐HTP. It was 
found that oral pretreatment significantly reduced urinary radioactivity concentration 
from a mean suV of the pelvis of 155 ± 195 to 39 ± 14 sD. This led to an improved 
image quality in that area. Tumor uptake of 11C‐5‐HTP significantly increased, from 
11 ± 3 to 14 ± 3 sD. Interestingly, pancreatic uptake decreased slightly to an suV of 
4.4 ± 0.8 sD. In liver tissue, a small increase of 11C‐5‐HTP uptake was found, now 
reaching an suV of 3.6 ± 0.8 [17].
Due to the low number of centers using 11C‐5‐HTP PET, only few studies with a 
reasonable number of patients with GEP‐nETs have thus far been published. In the 
first published study with 11C‐5‐HTP PET, 18 patients with histopathologically veri-
fied nETs were included: midgut (n = 14), foregut (n = 1), and hindgut carcinoid 
(n = 1) and endocrine pancreatic tumors (n = 2) [30]. 11C‐5‐HTP PET without oral 
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carbidopa pretreatment was compared to CT. All 18 patients showed increased 11C‐5‐
HTP uptake in tumor tissue; interestingly, a patient with a hindgut carcinoid and a 
patient with nonfunctioning endocrine pancreatic tumor with normal urinary 5‐HIAA 
levels also showed increased tumor uptake. 11C‐5‐HTP PET detected more tumor 
lesions than CT in 10 patients and was equal in five patients (four midgut, one 
foregut), with missing data in three patients with midgut nET. In the 10 patients that 
were on treatment (interferon‐α ± octreotide, or somatostatin analogue only), a close 
correlation between the changes in 11C‐5‐HTP transport rate constant in the tumors 
and urinary 5‐HIAA was noted. It was therefore suggested that 11C‐5‐HTP PET may 
serve as a means to monitor therapy, although it is still unknown whether these PET 
findings under medication relate to changes in tumor metabolism or in changes in 
amine processing [30].
In another patient series, 38 patients were evaluated, again with a variety of nETs, 
consisting of midgut carcinoids (n = 13), lung carcinoids (n = 7), nonfunctioning 
endocrine pancreatic tumors (n = 5), and other nETs [30]. Whole‐body 11C‐5‐HTP 
PET imaging with oral carbidopa pretreatment was compared to both CT and the 
functional imaging technique sRs, which is often used in standard clinical care in 
nETs and more widely available than 11C‐5‐HTP PET. Whole‐body 11C‐5‐HTP PET 
scanning detected tumor lesions in 36 of 38 (95%) patients. In 84% of patients, sRs 
was positive, whereas CT was positive in 79%. More lesions were detected with 
figure 4.3.3 11C‐5‐HTP PET/CT. Images of a 62‐year‐old female with a gastrinoma. In 
contrary to 18F‐DOPA PET, the striata are not visualized. On the left, an MIP is depicted; in the 
middle, a coronal slice; and on the right, a coronal fusion slice of PET and low‐dose CT. 
Physiological excretion of 11C‐5‐HTP metabolites is via kidneys with physiological activity in the 
ureters and urinary bladder. Tumor is visible in the head of the pancreas and metastases in the liver. 
11C‐5‐HTP, β‐[11C]‐5‐hydroxy‐l‐tryptophan; 18F‐DOPA, 6‐18F‐l‐3,4‐dihydroxyphenylalanine; 
PET/CT, positron emission tomography/computed tomography. (See insert for color repre-
sentation of the figure.)
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11C‐5‐HTP PET in 22 of 38 (58%) patients compared to sRs and CT, whereas the 
imaging modalities showed equal numbers of lesions in 13 of 38 patients (34%). In 
three patients, sRs or CT showed more lesions than 11C‐5‐HTP PET. Patients with a 
nonfunctioning endocrine pancreatic tumor and a pancreatic carcinoma with some 
endocrine differentiation on immunohistochemistry were PET negative. A patient 
with metastasized thymus carcinoma only showed the primary tumor on 11C‐5‐HTP 
PET and sRs, while CT scan also detected metastases. From these patients, it was 
speculated that in the case of high proliferation rate and dedifferentiation of nETs, 
18F‐FDG PET is probably the imaging modality of choice. In the 17 patients who had 
their primary tumor still in situ, 11C‐5‐HTP PET was positive in 16, compared to sRs 
in 9 and CT in 8 patients. PET could detect surgically removed lesions as small as six 
mm. The main conclusion of this study was that PET imaging with 11C‐5‐HTP can be 
universally applied in nETs, also in patients without elevated 5‐HIAA excretion in 
urine, as long as the tumor is not highly proliferating and/or dedifferentiating [31].
In another study with 24 patients with carcinoid tumors and 23 patients with 
pancreatic islet cell tumors, 11C‐5‐HTP PET was compared to conventional imaging 
with CT and sRs and a 18F‐DOPA PET scan [22]. Whole‐body PET images with 
carbidopa pretreatment were recorded 10 min after intravenous injection of 11C‐5‐
HTP or 60 min after intravenous administration of 18F‐DOPA. The PET findings were 
compared, per patient and per lesion, with a composite reference standard derived from 
all available imaging data along with clinical and cytological/histological information. 
Results indicated that indeed 11C‐5‐HTP PET can be seen as a universal imaging agent 
for carcinoid and pancreatic islet cell tumor patients. It was the only imaging modality 
that was positive in all patients (100% sensitivity). Especially in islet cell tumor 
patients, more tumor‐positive patients and lesions were found with 11C‐5‐HTP 
(100 and 67%) compared to 18F‐DOPA (89 and 41%), sRs (78 and 46%), and CT 
(87 and 68%). In carcinoid patients, the per‐lesion analysis showed that 18F‐DOPA 
PET outperformed all other imaging techniques. Adding CT to both imaging tech-
niques resulted in a further improvement in sensitivity in a per‐lesion analysis, since 
both types of imaging techniques were complementary to each other. Therefore, for 
pancreatic islet cell tumor patients, 11C‐5‐HTP PET/CT was considered the optimal 
imaging technique, whereas for carcinoid patients, this was 18F‐DOPA PET/CT. 
Furthermore, it was stated that in carcinoid patients sRs scanning can be omitted 
without missing any lesions. However, in islet cell tumors in a minority of patients 
(8%), sRs performed better than both PET techniques and therefore remains of 
additional value.
A direct comparison between 11C‐5‐HTP, 18F‐DOPA, and the recently developed 
68Ga‐labeled somatostatin analogues for PET imaging in various subtypes of nETs 
would be much of interest.
since tracer availability is scarce due to the difficult tracer production, it will be 
even more important for this tracer to assess its place in staging and monitoring 
disease progression in GEP‐nETs. An easier to produce serotonin tracer analogue, 
preferably labeled with a PET isotope with a longer half‐life such as 18F, would be 
beneficial for increasing the understanding of the role of serotonin PET analogues in 
the imaging of GEP‐nETs.
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conclusion
In conclusion, 11C‐5‐HTP PET and18F‐DOPA PET are excellent functional imaging 
techniques for evaluating patients with (suspected) nETs. There is however only 
limited evidence for the use of 18F‐FDG PET in patients with GEP‐nETs. Thus far, 
the indications for 18F‐FDG PET seem limited to specific patients in which dediffer-
entiation of GEP‐nET tumors is suspected, the evaluation of secondary tumors, and 
possibly therapy monitoring.
Convincing data are available that show the benefits of 11C‐5‐HTP PET and18F‐
DOPA PET for staging patients with proven pancreatic islet cell tumors and carcinoids. 
More data is needed to determine the place of these tracers in therapy evaluation. For 
both tracers, the place in diagnostic workup in patients where only a suspicion of 
nET has risen has yet to be determined. For both tracers, the combination with CT 
further improves the detection rate of nET, which shows that performing PET scans 
with these tracers in PET/CT scanners is beneficial for patients. Also, a direct 
comparison in large homogeneous patient groups of these tracers with 68Ga‐labeled 
somatostatin analogues for PET imaging would be very useful to help the clinician 
determine when to use which technique.
The major drawbacks of both 11C‐5‐HTP PET and 18F‐DOPA PET are the difficult 
syntheses and therefore limited availability. However, the commercial availability of 
18F‐DOPA PET is increasing, which might lead to a better understanding of the place 
of this tracer in the clinic for patients with (suspected) nET. since the availability of 
11C ‐5‐HTP PET is very limited, the development of a 18F‐labeled serotonin precursor 
that performs at least equal to the 11C‐5‐HTP tracer would be very helpful.
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MANEC mixed adenoneuroendocrine cancer
MRI magnetic resonance imaging
NEN neuroendocrine neoplasm
NET neuroendocrine tumor
SRS somatostatin receptor scintigraphy
Sstr somatostatin receptor
VIP vasoactive intestinal peptide
WHO World Health Organization
Overexpression of somatostatin receptors on the cells of neuroendocrine tumors 
(NETs) gives the possibility of the specific diagnostic and therapeutic options. 
Somatostatin receptors are present in 80–100% of functioning and nonfunctioning 
neuroendocrine neoplasms (NENs) [1–3]. Though the distribution of somatostatin 
receptors in NETs is generally homogenous, there are differences in the incidence and 
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density of these receptors depending on the type of the tumor and the degree of tumor’s 
differentiation [1–3]. According to Reubi et al., pancreatic NENs such as gastrinomas 
express sstr2 in about 100%, sstr5 in 35%, sstr3 in 20%, and sstr1 in 10%; insulinomas 
express especially sstr2 but only in 70%, sstr1 in 60%, sstr3 in 35%, sstr5 in 15%, and 
sstr4 in about 3%; and jejunoileal NENs express sstr2 in about 95%, sstr1 in 50%, sstr5 
in 48%, sstr3 in 15%, and sstr4 in 3% [1]. Moreover, somatostatin receptor subtypes 
differ in their affinity for the radioligand, which also influences tumor detectability.
The current WHO 2010 classification system divides NENs by their mitotic index 
or Ki67 into NET g1 (with Ki67 ≤2%), NET g2 (Ki67 3–20%), and neuroendocrine 
cancer (NEC) with Ki67 over 20% [4, 5]. There are also mixed adenoneuroendocrine 
cancers (MANEC) distinguished [4, 5]. The sensitivity of standard somatostatin 
receptor scintigraphy (SRS) depending on the type of NET and the degree of its 
differentiation is presented in Table 4.4.1.
Sensitivity of SRS differs also between primary lesion and metastases. In some 
cases of NENs, liver metastases may appear isointense due to a similar degree of tracer 
accumulation by the normal hepatic tissue. Therefore, correlation with anatomic 
imaging and SPECT imaging may be helpful [3, 6]. Hybrid imaging results in more 
accurate characterization of foci showing elevated radiopharmaceutical uptake and a 
more precise anatomical localization. CT can be also used to generate attenuation maps 
to correct the SPECT imaging. The usefulness of this technology is especially visible 
in the abdominal lesions with sensitivity of 95% and specificity of 92% [3, 7].
tAble 4.4.1 sensitivity of standard srs depending on the type of neuroendocrine 
tumor and the degree of its differentiation
high sensitivity > 75%
1. gEP‐NEN
(a) NET g1 (according to WHO 2010) (excluding insulinoma)
– functioning endocrine tumors, that is, gastrinoma
– Nonfunctioning endocrine pancreatic tumors and jejunoileal NENs
(b) NET g2 (according to WHO 2010)
– functioning tumors of pancreatic and extrapancreatic origin (gastrinoma, 
VIPoma, glucagonoma, jejunoileal NETs)
– Nonfunctioning pancreatic tumors
2. Other endocrine tumors
– Paraganglioma
– Malignant pheochromocytoma
– Small cell lung cancer
intermediate sensitivity 40–75%
1. gEP‐NEN
(a) NET g1 (according to WHO 2010)
– Insulinoma
(b) NEC g3 (according to WHO 2010)
(c) MANEC (mixed adenoneuroendocrine cancer)
2. Other endocrine tumors
– Medullary thyroid cancer
– Differentiated thyroid cancer including Hurthle cell cancer
– Pheochromocytoma
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The advantage of SRS is that it can examine all body regions, whereas conventional 
imaging can only examine suspected areas. In normal scintigraphic imaging, the thy-
roid, spleen, liver, kidney, pituitary, and adrenal glands are visualized due to the sstr 
expression in those glands. The urinary bladder and bowel are usually visualized to var-
iable degrees. Uptake in the kidneys is mainly the consequence of the reabsorption of 
the radiolabeled peptide in the renal tubular cells after glomerular filtration. While inter-
preting results of SRS, it has to be taken into consideration that somatostatin receptors 
exist also on white body cells. This may lead to false‐positive results in cases of 
inflammation or infection and existing healing processes after surgical treatment. 
false‐positive uptake in SRS may be visible in radiation pneumonia, bacterial pneu-
monia, respiratory infections, accessory spleen, surgical scar tissue, nodular goiter, focal 
collection of stool, gallbladder, ventral hernia, cerebrovascular accident, concomitant 
granulomatous disease, urine contamination, and concomitant second primary tumor. 
The negative results may be connected with the lack of sstr on tumor cell membrane, sstr 
type, and sstr functional status. The receptor‐negative lesions may be poorly differenti-
ated and characterized by aggressive growth and poor prognosis.
Indications to SRS includes detection and localization of different types of NENs 
and their metastases, staging in patients with NEN, selection of patients with metastatic 
tumors and/or inoperable primary lesion for treatment with “cold” and radiolabeled 
somatostatin analogues, prediction of the effect of PRRT, and follow‐up of patients to 
evaluate potential recurrence [1, 8–10].
Sensitivity of different imaging modalities varies for locating specific NETs [10]. 
SRS specificity for detection of primary gastrointestinal NETs is 86–95% and is higher 
than for location of pancreatic gastrin‐/VIP‐/somatostatin‐secreting NETs (75%) and 
insulinomas (50–60%) [10]. for pancreatic NETs, the imaging modality with higher 
specificity is endoscopic ultrasound (EUS) (82–93%) [10]. Specificities of dual‐phase 
multidetector computed tomography (CT) and magnetic resonance imaging (MRI) in 
the case of pancreatic NENs are 57–94% and 74–94%, respectively [10]. In the case of 
gastrointestinal NENs, specificities of CT enteroclysis and MRI enteroclysis are 85 and 
86%, respectively [10]. for detection of neuroendocrine liver metastases, specificities 
of CT and MRI are 44–82% and 82–95%, respectively [10].
It is worth mentioning here that the assessment of somatostatin receptor expres-
sion is possible also with the use of positron emission tomography/computed tomog-
raphy (PET/CT) with different somatostatin analogues (DOTA‐NOC, DOTA‐TOC, 
DOTA‐TATE) labeled with 68ga [10, 11], and this imaging method is being increas-
ingly introduced into clinical practice.
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GLP‐1R glucagon‐like peptide type 1 receptors
g‐NENs gastric neuroendocrine neoplasms
IOUS intraoperative ultrasound
LCNEC large cell neuroendocrine cancers
MANEC mixed adenoneuroendocrine carcinoma
MEN‐1 multiple endocrine neoplasia type 1
MRI magnetic resonance imaging




NF‐NENs nonfunctioning neuroendocrine neoplasms
PET positron emission tomography
p‐NEN pancreatic neuroendocrine neoplasm
PRRT peptide receptor radionuclide therapy
RGS radio‐guided surgery
SCLC small cell lung cancer
SPECT single‐photon emission computed tomography
SRI somatostatin receptor imaging
SRS somatostatin receptor scintigraphy
sstr somatostatin receptors
THPVS transhepatic portal venous sampling
UGI upper gastrointestinal
USG ultrasound examination
VIP vasoactive intestinal peptide
ZES Zollinger–Ellison syndrome
gAstric neuroendocrine neoplAsms
Gastric neuroendocrine neoplasms (g‐NENs) are nowadays revealed more often 
due to expanding indications to upper gastrointestinal (UGI) endoscopy [1, 2]. 
Usually silent and benign, gastric NEN may, however, be aggressive and may 
sometimes mimic the course of gastric adenocarcinoma [1, 2]. The main cause of 
type 1 gastric NEN is achlorhydria secondary to autoimmune atrophic fundic gas-
tritis [1–5]. These neoplasms present usually as multiple (2–10) polyps, <1 cm in 
diameter in the gastric fundus with little risk of deep invasion of the gastric wall 
[5]. Type 2 gastric NENs are related to hypergastrinemia resulting from tumoral 
secretion from gastrinomas (Zollinger–Ellison syndrome), mostly in patients pre-
senting with multiple endocrine neoplasia type 1 (MEN‐1) [1–3]. These neo-
plasms present usually as small polyps (<1–2 cm), may involve the entire fundic 
mucosa, and are generally asymptomatic [1–3]. Type 3 neoplasms are usually 
solitary neuroendocrine cancers (NEC) G3 tumors, above 2 cm in diameter with 
infiltrative growth [1–4]. In type 3 pain, weight loss and iron‐deficiency anemia occur 
very often; also, distal metastases are observed in more than 50% of cases [1–4].
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The minimal biochemical tests in patients with type 1 and 2 g‐NENs include serum 
gastrin and chromogranin A (CgA), and in patients with type 3 tumors (especially in 
case of rare in this group well‐differentiated tumors) assessment of CgA level may be 
useful [1–3]. Moreover, in type 1 tumors, antiparietal cell and anti‐intrinsic factor 
autoantibodies as well as thyroid functional tests and thyroperoxidase antibodies 
should be assessed [2, 3].
g‐NENs are revealed by UGI endoscopy. Endoscopy and biopsy are usually 
sufficient for type 1 and small type 2 tumors [1]. Biopsy samples should be taken 
from antrum (2 biopsies) and fundus (4 biopsies) in addition to biopsies of the larg-
est polyps [1–5]. When the tumor size is above 1 cm, endoscopic ultrasonography 
(EUS) should be performed to assess regional lymph node involvement and for his-
tological confirmation by fine‐needle aspiration [1–5]. Computed tomography (CT) 
and magnetic resonance imaging (MRI) have limited value for small type 1 and 2 
tumors [1–5]. However, CT, MRI, and transabdominal ultrasonography have high 
sensitivity/specificity to detect liver metastases. Therefore, these imaging proce-
dures should be considered in case of larger tumors or tumors invasive in EUS [2]. 
While cells of the g‐NENs, as in the other cases of neuroendocrine tumors (NET), 
express all subtypes of somatostatin receptors (sstr), except sstr4, somatostatin 
receptor scintigraphy (SRS) is also useful diagnostic tool [1]. SRS is particularly 
recommended in patients with well‐differentiated tumors to search for liver, lymph 
node, and bone metastases [2, 4, 5]. In case of type 3 g‐NENs, which are usually 
more aggressive and poorly differentiated tumors (NEC G3), UGI endoscopy is not 
sufficient diagnostic tool [2, 4, 5]. In these tumors, use of EUS, CT, MRI, SRS, and/
or positron emission tomography (PET) should be considered to assess advancement 
of the disease; to detect lymph nodes, liver, or bone metastases; and also in case of 
disseminated tumors to qualify patients to peptide receptor radionuclide therapy 
(PRRT) [2, 4, 5].
Figures 4.4.1.1 and 4.4.1.2 present the use of different techniques, including SRS, 
in diagnosis (Fig. 4.4.1.1) and follow‐up (Fig. 4.4.1.2) in case of g‐NENs.
figure 4.4.1.1 Gastric neuroendocrine neoplasms (g‐NENs): diagnostic procedures and 
imaging (according to [2]). CT, computed tomography; EUS, endoscopic ultrasonography; 
MRI, magnetic resonance imaging; PET, positron emission tomography; SRS, somatostatin 
receptor scintigraphy; UGI, upper gastrointestinal; USG, ultrasound examination.
g-NEN type 1 and 2 g-NEN type 3
UGI endoscopy +
+ biopsy samples
<1 cm >1 cm
EUS (prior to endoscopic resection/surgery)
Invasive tumor and/or suspicion of metastases
USG/CT/MR/SRS/PET
EUS/USG/CT/MRI/SRS/PET
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duodenAl neuroendocrine neoplAsms
Duodenal neuroendocrine neoplasms (d‐NENs) are generally small, >75%, and have 
<2 cm in diameter [6]. Tumors are usually limited to the submucosa or mucosa, in 
which 40–60% are associated with regional lymph node metastases. Liver metastases 
occur in <10% of all patients with d‐NENs [7]. These tumors may produce hormones 
such as gastrin and somatostatin, which is associated with specific clinical syndromes. 
In some asymptomatic cases, hormone’s production (serotonin and calcitonin) is 
revealed by the immunohistochemical examination [7]. More than 90% of d‐NENs do 
not cause any clinical syndrome. Therefore, usually, tumor‐related symptoms such as 
pain, jaundice, nausea/vomiting, bleeding, anemia, diarrhea, duodenal obstruction, 
or the incidental discovery of the tumor (usually at UGI endoscopy) lead to diagnosis 
[6, 7]. Lesions are usually single; multiple tumors are only found in about 9% of 
cases. Multiple lesions should lead to a suspicion of MEN‐1, which occurs in 6 ± 2.5% 
of all patients with d‐NENs [6].
Similarly as in case of g‐NENs to assess the primary d‐NEN, UGI endoscopy with 
biopsy is the most sensitive modality [2, 7]. Endoscopic ultrasonography (EUS) 
examination is used for confirmation of the diagnosis and for staging of the disease 
[2, 7]. Gastrinomas may be primarily submucosal and may be therefore not revealed 
by both UGI endoscopy and EUS, which results in low detection rate (30–60%) for 
duodenal tumors causing Zollinger–Ellison syndrome (ZES), which was diagnosed 
by hormone assays [7]. In case of d‐NENs, SRS might play an important role not 
only in searching for lymph node, liver, and bone metastases but, different than in 
case of g‐NENs, also in detection of the primary tumor [2, 7–9]. The imaging 
methods (CT, MRI, ultrasound) are generally not useful in conventional diagnostic of 
the usually small primary duodenal tumors [2, 7, 8]. However, helical CT and MRI 
are used to fully assess disease extent and to reveal distant metastases [2, 7] although 
studies with gastrinomas suggest SRS may be more sensitive [7]. In patients with 
advanced disease, especially in suspicion of bone metastases (bone metastases are 
often present in patients with liver metastases), whole‐body SRS and MRI of the 
spinal column should be performed [7]. In diagnostic approach of d‐NENs, there is 
also a place for PET/CT imaging, which is one of the most sensitive examinations to 
assess small lesions (<1 cm) and metastases to the lymph nodes.
Type 1(not recurring cases) 
UGI endoscopy
every 24 months






follow-up as for gastric
adenocarcinoma
figure 4.4.1.2 Gastric neuroendocrine neoplasms (g‐NENs): follow‐up (according to [2]). 
CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomog-
raphy; SRS, somatostatin receptor scintigraphy; UGI, upper gastrointestinal; USG, ultrasound 
examination.
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SRS, among other imaging techniques, might be useful also in the follow‐up of 
d‐NENs (Fig. 4.4.1.3).
diAgnostic procedures in Zes
In case of patients with ZES, sensitive and specific diagnostic tools are needed to 
choose the proper treatment option. Tumor localization studies are necessary to 
localize the primary tumor, to determine whether the surgical resection is indicated, 
and to determine the extent of the disease and the presence of metastases [10, 11]. 
Tumor localization studies should be performed in all patients with biochemically 
established ZES. UGI endoscopy with inspection of the duodenum followed by a 
helical CT and SRS is recommended as initial study. If these studies are negative, EUS 
should be performed. EUS is particularly sensitive for pancreatic lesions, and its use 
in detection of small duodenal focuses is controversial [10–12]. If results of afore-
mentioned studies are negative, selective angiography with secretin stimulation and 
hepatic venous sampling should be considered [10, 11]. This is worth to emphasize 
that SRS plays an important role in diagnosis of primary tumor and metastatic lesions in 
case of gastrinomas. Prospective studies for primary gastrinomas show that conven-
tional imaging studies localize 10–40%, angiography 20–50%, and SRS 60–70% of the 
tumors [10–13]. The use of SRS changes management in 15–45% of patients [10, 13]. 
Prospective studies in metastatic gastrinoma show that CT and ultrasonography detect 
30–50% of patients with metastases, MRI and angiography 60–75%, and SRS 92% 
[13]. Promising are results of the use of PET/CT with 68Ga‐labeled somatostatin ana-
logues (SSA), 11C‐5‐hydroxytryptophan (5‐HTP) or 6‐[fluoride‐18]fluoro‐levodopa 
(18F‐DOPA), but the availability of this techniques is still limited [11].
pAncreAtic neuroendocrine neoplAsms
Pancreatic neuroendocrine neoplasms (p‐NENs) account for about 2–10% of all 
pancreatic tumors [14, 15]. p‐NENs can be divided into nonfunctioning and func-
tioning tumors. Nonfunctioning neoplasms (NF‐NENs) account for about 50% of 
all pancreatic NET, and most of them (60–100%) are classified as NET G1 and 
Complete endoscopic removal
Endoscopy/USG/CT/CgA




at 6 and 12 months than







figure  4.4.1.3 Figure  1.3 Duodenal neuroendocrine neoplasms (d‐NENs): follow‐up 
(according to [2]). CgA, chromogranin A; CT, computed tomography; EUS, endoscopic ultra-
sonography; SRS, somatostatin receptor scintigraphy; USG, ultrasound examination.
PANCREATIC NEUROENDOCRINE NEOPLASMS 95
G2 [14–16]. Nonfunctioning tumors are usually located in the head of the pan-
creas. Clinical presentation relates to the anatomic site of the lesion. Predominant 
symptoms can be abdominal pain, weight loss, and jaundice. These symptoms 
are similar as those found in other pancreatic tumors such as adenocarcinoma. 
The term “nonfunctioning” refers to the absence of clinical symptoms of hormonal 
hypersecretion, but these tumors may show immunohistochemical positivity for 
hormones, neuropeptides, or neurotransmitters [14, 15]. About 8% of patients with 
nonfunctioning p‐NENs have MEN‐1 syndrome, while the prevalence of NF‐NEN 
in MEN‐1 patients is about 55%. Functioning tumors will be discussed in the 
following text.
In diagnosis of p‐NEN, abdominal ultrasonography is usually the first‐step exam-
ination. But the sensitivity of ultrasonography in diagnosis of small lesions such as 
gastrinoma or insulinoma varies between 19 and 70% [14, 15]. However, the recent 
implementation of contrast‐enhanced ultrasonography (CEUS) has led to improve-
ment in the diagnostic capabilities of B‐mode sonography of the liver and pancreas 
[14, 17, 18]. Moreover, there is a correlation observed between CEUS enhancement 
pattern and the Ki‐67 index [14, 17, 18]. However, the standard imaging proce-
dures for p‐NENs are contrast‐enhanced helical CT or MRI and EUS in combination 
with SRS. These methods are used to detect the primary tumor and metastases. 
EUS provides high‐resolution images of structures within or just beyond the wall 
of the gastrointestinal wall and is very effective method for detection of NENs [14, 
15, 19]. The sensitivity of CT and MRI in localization of the primary tumor is 
about 75–79% [14, 15, 20]. In difficult situation, magnetic resonance tomography 
(MRT) can be used. The aforementioned techniques enable differentiation of the 
hypervascular pancreatic NET from hypovascular pancreatic adenocarcinoma 
(multidetector CT or MRT). CT and MRT are helpful in determination of the mean 
larger volume of the tumor and assessment of the presence of the cystic component 
and the lack of infiltration of peripancreatic fat and vessels in case of NET in 
comparison to the more aggressively growing adenocarcinoma [14, 15]. In patients 
with a high degree of clinical suspicion and negative noninvasive imaging like USG, 
CT, and/or MRI/MRT, further diagnostic investigations may include contrast‐enhanced 
USG, where sensitivity and specificity are 94 and 96%, respectively, or EUS with 
EUS‐guided fine‐needle aspiration cytology/biopsy (FNAC/B) with sensitivity of 
82–86% [14, 15].
Pancreatic NET show high expression of receptor subtypes 2, 3, and 5, while the 
expression of subtype 1 is usually intermediate. A lot of gastrinoma and gluca-
gonoma tumors express sstr subtype 2, while all somatostatinomas express subtype 
5 receptor. These facts enable use of SRS as important diagnostic tool to detect 
both primary tumor and metastases and should be performed prior to the treatment. 
SRS has a high sensitivity and specificity for p‐NENs, 90 and 80%, respectively 
[14, 21]. SRS can be used for the localization of the primary disease and for 
assessment of the extent of the disease [14, 15]. It is the most sensitive method for 
assessment of the presence of extrahepatic disease. SRS is an important diagnostic 
procedure when the demonstration of extrahepatic metastases is necessary for 
making therapeutic decision [14, 15]. Image‐fusion data combining CT and SRS 
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(single‐photon emission computed tomography (SPECT)) appears promising in 
helping to accurately locate residues and plan surgery and to detect lesions espe-
cially in the tail of the pancreas, in staging, and in qualification to PRRT. Following 
standard SRS procedure is recommended: a double‐ or triple‐head gamma camera 
and a medium‐energy, parallel‐hole collimator, peaks at 172 and 245 keV with the 
window of 20% [14, 15, 22]. At an acquisition time of 15 min and 4 hours (h) after 
injection, anterior and posterior abdominal views should be performed [14, 15, 22]. 
At 24 h after injection, anterior and posterior views of the upper abdomen, head, 
chest, and pelvis as well as left and right lateral, anterior, and posterior oblique 
views of the upper abdomen should be performed [14, 15, 22]. Whole‐body 
imaging should be performed with a scanning speed of 3 cm/min [14, 15, 22]. 
SPECT images should be acquired at 24 h after injection with a 6‐step rotation for 
360°/40–60 s [14, 15, 22]. Optional delayed images at 30–48 h after injection are 
recommended [14, 15, 22].
PET/CT with 68Ga‐labeled SSA is another sensitive diagnostic method, but its 
use is still limited (Fig. 4.4.1.4). In comparison to scintigraphy, PET has a two‐ to 
threefold higher spatial resolution and facilities quantification of tracer uptake 
[14, 23]. PET with the use of 5‐hydroxytryptophan (5‐HTP) or 18F‐DOPA has 
also shown promising results and may be an option for detection of small well‐
differentiated tumors [14, 24]. Standard PET with 18F‐glucose is not efficient in 
detecting well‐differentiated tumors, but can be helpful in the detection of aggressive 
poorly differentiated p‐NENs (NEC G3) [14]. NEC G3 of the pancreas is very rare 
tumors. Patients present with jaundice, weight loss, abdominal pain, and hepato-
megaly. Overproduction of the hormones is rare, but Cushing’s syndrome and 
carcinoid syndrome were reported in few cases. Histopathological features of 
pancreatic NEC G3 include small‐ to intermediate‐sized tumor cells growing dif-
fusely or in irregular nests, often with extensive necrosis and high mitotic rate 
[25, 26]. In diagnosis of these neoplasms, similarly as for well‐differentiated 
tumors, CT, MRI, or EUS with biopsy was used. Fluorodeoxyglucose positron 
emission tomography (FDG PET) may be useful in the diagnosis of the primary 
tumor and for staging [25, 26]. SRS is not recommended, but should be evaluated 
in the clinical setting.
Somatostatin receptor imaging (SRI), including SRS and/or PET/CT with the use 
of labeled SSA, is useful in the follow‐up of p‐NENs (Fig. 4.4.1.5).
functioning p‐nens
In contrast to NF‐NENs, where due to lack of specific symptoms, diagnosis is 
made usually in the advanced stage of the disease; in case of hormonally active 
pancreatic tumors, revealing of the small primary lesion might be a diagnostic 
challenge.
For both nonfunctioning and functioning p‐NENs, CgA is a tumor marker, and 





figure  4.4.1.4 PET/CT with radiolabeled somatostatin analogue (68Ga‐DOTATOC) in 
patient with disseminated pancreatic neuroendocrine tumor. Arrows indicate liver (a, b) and 
lymph node metastases (a, c). (See insert for color representation of the figure.)




(SRS or Ga-68 PET/CT) + CgA
at least once a year
CT/MRI + CgA
every 6 months
figure 4.4.1.5 Pancreatic neuroendocrine tumors: follow‐up (according to [14]). NET, 
neuroendocrine tumor; NEC, neuroendocrine cancer; CEUS, contrast‐enhanced ultrasound; 
EUS, endoscopic ultrasonography; CT, computed tomography; MRI, magnetic resonance 
imaging; SRI, somatostatin receptor imaging; SRS, somatostatin receptor scintigraphy; PET, 
positron emission tomography; CgA, chromogranin A.
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insulinomas are the most common functioning NET of the pancreas [11]. 
They are usually small, solitary tumors, and the majority of the insulinoma 
tumors have pancreatic localization [11, 27]. These small tumors might be difficult 
to localize radiologically. The best diagnostic methods to localize insulinoma are 
MRI, 3‐phase CT, and EUS. But usually more than one diagnostic tool has to be 
used.
In CT, insulinomas are usually hypervascular, and therefore, these tumors and 
their metastases are better visible in arterial phase. The sensitivity of CT for the 
detection of insulinomas ranges from 30 to 85%, depending on tumor size [28]. 
MRI shows sensitivity from 85 to 95% [28]. Compared to CT, MRI is superior in the 
detection of small lesions [28]. The enhancement pattern of these tumors on MRI 
depends primarily on their hypervascularity [28]. Small metastases and the primary 
tumor show homogeneous enhancement [28]. EUS is effective but invasive preoper-
ative procedure to localize insulinomas with sensitivity of 94% [11, 27]. The high 
spatial resolution of this technique allows the detection of very small lesions and 
their precise anatomical localization. It is easier to localize lesions in the head and 
body of the pancreas than in the tail, for lesions in the pancreatic tail, sensitivity is 
about 60% [27]. Other invasive investigations such as angiography combined with 
calcium stimulation and transhepatic portal venous sampling (THPVS) might be 
useful for insulinoma localization, when the noninvasive techniques have failed [11]. 
Angiography combines anatomic localization with functional information provided 
by THPVS, which can confirm angiographic abnormality as insulinomas [27]. The 
rate of false‐positive results is low; sensitivity ranges from 63 to 94%. Intraoperative 
localization techniques, which include careful palpation of the pancreas and the use of 
intraoperative ultrasound (IOUS), remain the most reliable way to localize insulino-
mas and to determine the correct surgical procedure [27]. Combination of palpation 
and IOUS enables detection of about 92% of tumors [28]. SRS might be less useful 
in localization of insulinomas, because these tumors have a low density of sstr and gen-
erally do not express the somatostatin subtype 2 and 5 cell‐surface receptor [11, 29]. 
In malignant insulinomas, the relative distribution of sstr subtypes is different than 
in benign tumors, and a higher rate of scan positivity with this technique can be 
expected [27, 30].
To detect tumors such as insulinoma, gastrinoma, or medullary thyroid cancer, in 
which cells express not only sstr but also glucagon‐like peptide type 1 receptors 
(GLP‐1R), a new radiopharmaceutical—labeled exendin‐4—might be used [31, 32]. 
Christ et al. showed the usefulness of 111In‐labeled GLP‐1R agonist 111In‐DOTA‐exen-
din‐4 in localizing insulinomas using SPECT with combination of CT images [33].
In our center, the first clinical study with the use of 99mTc‐labeled analogue of 
GLP‐1 to diagnose primary insulinoma was performed (Fig. 4.4.1.6). This method 
enabled detection of the primary insulinoma tumor, local recurrence, and metastases 
in cases in which other diagnostic methods have failed. We also detected medullary 
thyroid cancer and glucagonoma using this method.
PET/CT with the use of 68Ga‐labeled SSA or 11C‐5‐HTP might be considered in 
experienced centers in case of doubtful results of aforementioned methods [11].
Diagnostics of gastrinomas was discussed in the preceding text.
Similarly as in case of NF‐NENs to diagnose rare functioning tumors of the pan-
creas, such as glucagonoma, VIP‐oma, ACTH‐oma, and somatostatinoma, combined 
use of multidetector CT (or MRI) and SRS‐SPECT is always recommended [11, 34]. 
EUS and EUS‐guided fine‐needle aspiration may be useful in cases in which previ-
ously mentioned techniques are inconclusive [11, 34]. PET/CT methods are not 
 recommended on a routine basis; however, particularly 68Ga‐labeled SSA PET, if avail-
able, might be helpful in doubtful cases [11, 34]. glucagonomas are usually large 
tumors, and CT scanning is the imaging modality of choice for the detection of these 
neoplasms. SRS is helpful in confirming the diagnosis and in detecting metastatic 
disease, which is present in up to 50% of patients [35, 36]. SRS enables localization of 
(a) (b) (c)
figure 4.4.1.6 A 65‐year‐old woman with benign insulinoma: scintigraphy with 99mTc‐
labeled glucagon‐like peptide 1 (GLP‐1) analogue. A study showing a small lesion of insuli-
noma in tail of the pancreas. Arrows indicate lesion in the tail of the pancreas (a - transverse 
plane, b - sagittal plane, c - coronal plane).
(a) (b)
figure 4.4.1.7 A 60‐year‐old man with recurrence of pancreatic glucagonoma. Somatostatin 
receptor scintigraphy with 99mTc‐EDDA/HyNIC‐TOC showing a recurrence of the disease in 
the head of the pancreas. Arrows indicate the lesion in the head of the pancreas (a - SPECT/
CT image; b - CT image). (See insert for color representation of the figure.)
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95–100% of primary and metastatic sites (Fig. 4.4.1.7) [35, 36]. Similarly, vip‐omas 
are localized in CT scanning in most cases; SRS is useful to confirm the diagnosis and 
to identify metastatic disease [29]. Nikou et al. showed that SRS was superior to con-
ventional anatomic imaging modalities and detected 91% of primary tumors and 75% 
of cases with metastases [37]. somatostatinomas are usually solitary tumors localized 
in the head of the pancreas. Standard imaging such as CT, MRI, and EUS are useful for 
localization and staging. SRS is used to confirm the diagnosis and also for staging [29].
bronchiAl nens
Bronchial NENs consist of enterochromaffin or Kulchitsky cells and are located in the 
bronchial mucosa. Bronchial NENs account for 2–5% of all bronchial tumors. Bronchial 
NENs are usually well or intermediate differentiated, rarely metastatic [38, 39]. This is 
the description of typical and atypical bronchial carcinoids, which are NET G1 and NET 
G2 tumors, respectively [38, 39]. But in some percentage there are poorly differentiated 
large cell neuroendocrine cancer (LCNEC) and small cell lung cancers (SCLC) [38, 39]. 
The most common symptoms are recurrent pneumonia, cough, hemoptysis, and chest 
pain. Peripheral tumors are usually asymptomatic. In some cases, hormonal secretion 
leads to paraneoplastic syndromes or atypical carcinoid syndrome. Most bronchial 
NENs express sstr, and therefore, SRS can be used as diagnostic tool. CT detects 94% 
of primary and 89% of recurrent/metastatic sites [40]. SRS is a useful method to detect 
primary tumor, metastases, and recurrent disease. The results of this examination are 
helpful in planning the treatment and for follow‐up. In doubtful cases, SRS may identify 
neuroendocrine origin of the tumor. In some cases, SRS might be more sensitive than 
conventional anatomic imaging, allowing proper treatment planning or enabling the 
assessment of local recurrence [40, 41]. The sensitivity of SRS does not depend exclu-
sively on tumor size, but rather on a high target‐to‐background ratio associated with the 
density of the sstr on the cells’ surface compared with adjacent tissue. yellin et al. pre-
sented for SRS the sensitivity of 90% and specificity of 83% in diagnosis of primary and 
metastatic disease, respectively [41]. The sstr exist on white body cells, which should be 
taken into consideration in the assessment of the postoperative SRS. In some cases, the 
sites of inflammation or infection may lead to false‐positive results of SRS. Similarly 
as for NENs in other localization imaging, another modality of SRI, with still limited 
use but promising results, is PET/CT with 68Ga‐labeled SSA [40]. FDG PET might 
be a useful diagnostic tool in case of aggressive, atypical LCNEC or SCLC [40], 
while a majority of typical benign and well‐differentiated bronchial NENs are FDG 
PET negative, which was reported for the first time by Erasmus et al. [40].
JeJunoileAl nens
Jejunoileal NENs are usually slowly growing, but even the tumor smaller than 1 cm 
in diameter may be metastatic at presentation. The size of the primary lesion corre-
lates with the presence of lymph nodes and distant metastases, and an early diagnosis 
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is clearly imperative [42]. Jejunoileal NENs are often detected while searching for a 
primary tumor in asymptomatic but metastatic patients [43]. The most frequent initial 
symptom is nonspecific abdominal pain [43–49]. Other nonspecific symptoms 
include weight loss, fatigue, fever of unknown origin, and tumor mass‐related symp-
toms such as nausea, vomiting, jaundice, or gastrointestinal bleeding [43–48]. The 
rate of functionality and the presence of the carcinoid syndrome in patients with 
jejunoileal NENs are about 20–30% [43, 45, 46, 48]. The carcinoid syndrome is 
associated with presence of liver metastases (in at least 95% of patients) [43, 47, 48]. 
The minimally required biochemical tests in case of suspicion of jejunoileal NEN are 
plasma CgA and urinary 5‐hydroxyindoleacetic acid (5‐HIAA) [43, 50, 51]. CgA has 
been shown to be a prognostic factor with higher levels of this marker indicating 
worse prognosis [43, 50, 51].
In diagnosis of jejunoileal NENs, SRI plays very important role. Similarly as for 
NENs in other localization, imaging examinations used to search for the primary 
tumor are abdominal USG, CT, and/or MRI, but these imaging modalities should be 
followed by SRS, especially in combination with SPECT/CT [43]. Jejunoileal NENs 
are usually small tumors; therefore, abdominal USG is usually not sufficient method 
to reveal the primary lesion [43, 52]. However, it may be used for screening of hepatic 
metastases [43, 52]. CT (3‐phase, contrast‐enhanced, multislice‐detector CT) and/or 
MRI (also with contrast media) enable not only imaging of the primary tumor but 
also detection of the lymph node and/or distant metastases [22, 43, 52–54]. CT or 
MR enteroclysis is more sensitive and specific method for detection of the primary 
tumor in the small intestine, but it is not widely available [43, 55, 56]. Colonoscopy 
and gastroscopy are not useful diagnostic tools in case of tumors of the small intestine 
[43]. However, lesions localized close to the ileocecal valve may be revealed with the 
use of colonoscopy [43]. Video capsule endoscopy and double‐balloon enteroscopy 
are more effective techniques to search for primary tumors of the ileum and jejunum, 
but the limitation is also their availability [43, 57, 58].
As it was mentioned earlier, SRI is very useful and important diagnostic procedure 
in case of jejunoileal NENs for detection of primary tumors, for staging, for detection 
of bone metastases, for qualification to PRRT, and for follow‐up [43]. The sensitivity 
of SRS ranges between 80 and 95% and specificity between 80 and 100% [59]. 
OctreoScan has the affinity for receptor types 2 and 5 expressed on the cell mem-
branes of NET [60]. Namwongprom et al. have been searching for the correlation 
between CgA level and SRS findings in the evaluation of metastases in NET [61]. 
SRS proved to be more specific, more sensitive, and more accurate than CgA to 
assess metastatic disease in NET [61]. Positive SRS correlated with elevation of 
serum CgA levels, but serum CgA might be elevated also in patients with negative 
SRS studies. Nevertheless, both SRS and CgA should be taken into consideration in 
the evaluation of metastases in patients with NENs [61]. Except the SRS, another 
SRI is PET with 68Ga with simultaneous CT, which has a high sensitivity ranging 
from 82 to 100% [43, 62]. Results of this examination may change management in 
20–30% of patients [43]. Studies with the use of newer tracers used for PET imaging 
such as 11‐carbon‐5‐HTP or 18‐fluoro‐dihydroxyphenylalanine (18F‐DOPA) are also 
promising, but availability of these methods is even lower than for PET/CT with 
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68Ga‐labeled SSA [43, 62, 63]. However, there are also studies showing that 18F‐
DOPA detected 57–64% of NENs and had lower per‐lesion sensitivity and less intense 
uptake than 68Ga. 18F‐DOPA is reserved for somatostatin‐negative and serotonin‐positive 
tumors [64]. In two separate reports of patients with jejunoileal NENs, the sensitivity of 
18F‐DOPA ranged from 93 to 97% with an impact on management in 50% of patients; in 
patients with noncarcinoid NENs, the sensitivity was 25%. In contrast, SRS sensitivity 
was similar in both groups, with values 81 and 75%, respectively. PET/CT with the use 
of FDG had low sensitivity for slow‐growing tumors; therefore, it does not have an 
important role for the usually well‐ or moderately differentiated jejunoileal NENs [43]. 
FDG uptake increases with increasing proliferation rate and may be a useful marker of 
prognosis in patients with poorly differentiated tumors. It may be a prognostic factor 
for early progression of the disease. Early progression was seen in 93% of FDG‐
positive patients and 82% of SRS‐negative patients [64]. In contrast, only 9% of 
FDG‐negative patients and 26% of SRS‐positive patients had early progression 
[64]. Belhocine et al. compared SRS and FDG in patients with NET. Those authors 
found out that 86% of primary tumors were localized with SRS, but only 57% with 
FDG. Patients with metastatic disease were positive with SRS in 69% of cases, with 
FDG in 47%, and with anatomic imaging in 56% [65].
Figure  4.4.1.8 presents the use of different imaging techniques, including SRI 
(both SRS and 68Ga‐PET/CT), in the follow‐up of jejunoileal NENs.
AppendiceAl nens
Appendiceal NENs are usually diagnosed incidentally on histopathological examina-
tion after appendicectomy; therefore, there are no specific symptoms connected with 
these tumors [43]. The carcinoid syndrome is very rarely described in metastatic NENs, 
so cases with typical carcinoid syndrome should raise a suspicion of jejunoileal 
NEN [43, 66]. Usually, appendiceal NENs are well‐differentiated tumors with 
Minimal examination — CgA, 5-HIAA, triphasic CT and SRI (SRS or PET-CT with labeled
somatostatin analogues)
NET G1 NET G2 NEC G3 NET G1 NET G2 NEC G3
Patients after therapy with curative intent
Every 6–12 months Every 3 monthsEvery 3 months Every 6 months
Patients not curativaly treated
figure  4.4.1.8 Jejunoileal Neuroendocrine Neoplasms (NENs) ‐ Lifelong follow‐up 
(according to [43]). NET, neuroendocrine tumor; NEC, neuroendocrine cancer; CgA, 
 chromogranin A; 5‐HIAA, 5‐hydroxyindoloeacetic acid; CT, computed tomography; SRI, 
somatostatin receptor imaging; SRS, somatostatin receptor scintigraphy; PET, positron 
emission tomography.
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good prognosis, but there are some features connected with the higher risk of 
recurrence or dissemination, such as location at the base of the appendix, size >2 cm, 
deep mesoappendiceal invasion, or margin invasion [43, 66–68]. In case of appendiceal 
NENs, diagnostic procedures are used usually for postoperative staging and follow‐up 
[43, 69]. CgA can be used as a tumor marker, particularly to differentiate NEN from 
goblet cell carcinoids/carcinoma (GCC) [43]. Colonoscopy or CT colonography might 
be considered to diagnose possible synchronous tumors [43, 69]. Follow‐up has to be 
lifelong, as recurrence has been seen even 20 years after diagnosis [69].
SRI has also its place in the follow‐up of patients with appendiceal NENs (Fig. 4.4.1.9).
gcc
GCC is a rare subtype of mixed adenoneuroendocrine carcinomas (MANEC) with 
malignant behavior, similar to the clinical course of adenocarcinoma [43, 67–69]. 
These tumors are also usually incidentally found after appendectomy; therefore, 
diagnostic procedures are rather used for postoperative staging and follow‐up 
[43, 67–69]. Imaging examinations will involve similar procedures as for high‐risk 
(>2 cm) appendiceal NENs [43, 70]. CT or MRI of the abdomen, pelvis, and also 
thorax should be performed [43, 70]. SRI with the use of SRS or PET scanning (with 
CT) should be considered; however, their sensitivity decreases in case of poorly dif-
ferentiated tumors [43, 70]. In those cases, FDG PET might be useful [43]. 
Colonoscopy should be performed for screening of synchronous or metachronous 
tumors, due to the potentially increased risk of secondary neoplasms [43, 69, 70]. In 
case of GCC serum CgA has no value for detection and monitoring of these tumors 
[43, 70]. More useful are markers such as carcinoembryonic antigen (CEA), CA‐19‐9 
and CA‐125 [43, 70]. Follow‐up should be lifelong and should mimic the guidelines 
for colorectal adenocarcinoma [43, 70].
Well-differentiated tumor
+ < 1 cm + R0 resection 
Well differentiated tumor
+ 1–2 cm + R0 resection 
Tumor > 2 cm and/or
localization at the base of the
appendix, mesoappendiceal
invasion < 3 mm or
angioinvasion
Long time follow up:
contract-enhanced multiphase
CT or MRI + SRI (SRS with
SPECT-CT or somatostatin receptor
PET with CT) 6 and 12 months
postoperatively, and then once a year
Postoperative CT or MRI
(searching for lymph node
or distant metastases)
No further diagnostic
figure  4.4.1.9 Appendiceal NENs – Follow‐up (according to [43]). CT, computed 
tomography; MRI, magnetic resonance imaging; SRI, somatostatin receptor imaging; SRS, 
somatostatin receptor scintigraphy; PET, positron emission tomography.
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rAdio‐guided surgery
Radio‐guided surgery (RGS) is an intraoperative localizing technique using 
target‐specific radiotracer that is accumulated in tissues. SRS followed by RGS enables 
detection of the occult tumors and improves the effectiveness of surgical treatment of 
patients suffering from gastrointestinal NENs expressing sstr. The sensitivity of SRS in 
localization of NENs ranges (according to different studies results) between 51 and 
96% and depends on the type of analogue, which is used. The sensitivity of PET exam-
ination is about 95%, which is especially high with the use of 68Ga‐labeled SSA [71]. 
In a few studies based on examination of small group of patients, the sensitivity of 
scintigraphy followed by RGS to detect gastrointestinal NENs was assessed for 90% 
(Fig. 4.4.1.10) [71, 72]. Some authors concluded that intraoperative detection of NEN 
after 111In‐labeled SSA administration is more sensitive than SRS and intraoperative 
palpation [69]. Finding of primary tumors gives the possibility of the radical removal 
of the tumors’ mass.
Some NENs, especially tumors localized in the small intestine, with a relative 
high malignancy rate and small tumors of the pancreas such as insulinoma cause the 
most difficulties in preoperative localization. In these cases, the use of a handheld 
(a) (b)
(c)
figure 4.4.1.10 A 72‐year‐old man with primary unknown origin. 99mTc‐EDDA/HyNIC‐
TOC revealed a primary neuroendocrine tumor of the small intestine confirmed later by radio‐
guided surgery and histopathological examination. Arrows indicate the primary tumor (a, b, c).
COLORECTAL NENS 105
gamma probe enables the localization of tumors, especially in cases with positive 
SRS and negative results of other imaging examinations. SRS followed by RGS can 
localize primary tumors and their metastases, and the density and distribution of cell 
membrane‐bound receptors in a lesion are more determinant than the tumor size [69, 
73]. Adams et al. presented that RGS seems to be the most sensitive diagnostic tool 
for detecting microscopic and occult endocrine tumors [74]. The authors detected 
lesions of 6 mm in diameter [74]. The limitation of this method is false‐positive 
results due to tracer accumulation in the activated lymphocytes within inflammatory 
infiltrates, which expresses sstr [73]. The major limitation of intraoperative gamma 
probe detection is high background activity from the liver, kidneys, and spleen. It is 
extremely important to avoid directing the probe toward such physiological tracer 
accumulation. During exploration of the pancreas, the probe should be placed toward 
the posterior surfaces of the pancreas, directing it up toward the abdominal wall. 
In the case of bowel tumors, the examination is easier. Moving the bowel loop beyond 
the peritoneal cavity, the examination can be performed while avoiding abdominal 
background activity. Intraoperative gamma probe scanning requires careful, slow 
searching of suspected areas, which is time consuming owing to subtle activity dif-
ferences occurring due to background type [69]. In the literature, successful RGS 
tumor detection requires tumor‐to‐nontumor tissue count ratios of at least 1.5–2.0; 
however, a ratio above 2.4 makes detection more reliable [73–75]. In our experience 
in group of patients with midgut tumors, the target/nontarget ratio reached 50 for 
primary lesions and average 2.7 for lymph node metastases. The target/nontarget 
ratio was substantially lower for islet cell pancreatic tumors.
colorectAl nens
Colonic NENs in about 30–40% present with metastases to the lymph nodes, liver, 
mesentery, and peritoneum at the time of diagnosis [76–78]. Patients with metastases 
have a 5‐year survival of about 50% [76, 77]. The clinical symptoms in colonic 
tumors are not specific and include diarrhea, abdominal pain, gastrointestinal 
bleeding, or weight loss [75, 77].
Rectal tumors are usually small, polypoid lesions located between 4 and 20 cm 
above the dentate line on the anterior or lateral rectal wall, most often diagnosed inci-
dentally during the routine sigmoidoscopy [74, 77]. At present, increasing incidence 
of rectal NENs is observed. Small tumors rarely metastasize, but larger tumors, 
above 2 cm in diameter, may present with metastases to the bones, lymph nodes, and 
liver [76, 77]. Overall distant metastases of rectal NENs occur in only 2.3% of cases 
[76, 77]. Rectal NENs may present as an incidental finding on sigmoidoscopy or 
colonoscopy [72, 73].
The base diagnostic tool for colorectal NENs is endoscopy [76, 77]. Full colo-
noscopic assessment is required to exclude concomitant colonic disease, as part of 
staging, and to exclude metastases [76, 77]. Another first‐step examination may 
be CT colonography or barium enema (which has lower sensitivity for colorectal 
neoplasms) [76, 77]. However, tumors detected with the use of these methods 
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require histopathological confirmation; therefore, endoscopic excision has to be 
performed [76, 77].
Standard diagnostic tool such as abdominal ultrasound has low sensitivity for the 
detection of primary lesion and assessment of the local advancement of the disease 
but is useful in searching for metastases and to perform the biopsy of suspected liver 
lesions [76, 77]. Multislice triple‐phase CT is most useful for revealing metastases 
in the thorax, abdomen, and pelvis, but MRI is superior to detect liver metastases 
[76, 77, 79].
In diagnostic management of rectal NENs, endoanal/rectal ultrasound (EUS) is 
very useful in preoperative assessment, and results of the examination influence 
the choice of treatment option [76, 78]. It provides information about the tumor 
size, the depth of invasion, and the presence of pararectal lymph node metastases 
[76, 78].
SRI, with either SRS or 68Ga‐labaled SSA PET/CT, is usually used for 
staging if residual or metastatic disease is suspected [76, 78]. Detection of pri-
mary tumor localized in the rectum with background activity can be difficult 
with SRI [76, 78]. Poorly differentiated colorectal NENs, similarly as in other 
localization, are often negative in SRI. In those cases, PET with FDG might be 
used [76, 77].
The minimum biochemical marker is serum CgA [76, 77].
The use of SRS and PET/CT with labeled SSA in the follow‐up of patients with 
colorectal NENs is presented in the following text (Fig. 4.4.1.11).
Methods of follow-up:
Rectal NENs — EUS, colonoscopy, MRI
Colonic NENs — CT, colonoscopy
Disseminated colorectal NENs — CT, MRI, SRI,
(SRS or Ga-68-labeled somatostatin analogues PET/CT), FDG-PET
NET G1, G2 NET G1, G2 NET G1, G2
Annual follow-up














NEC G3 NEC G3
+ <1 cm + 1–2 cm + < 1 cm + > 2 cm + > 2 cm
+ No lymph nodes metastases
+ No invasion of muscularis
No data to recommend
regular follow-up
figure 4.4.1.11 Colorectal NENs—Follow‐up (according to [76]). NEN, neuroendocrine 
neoplasm; EUS, endoscopic ultrasonography; CT, computed tomography; MRI, magnetic 
 resonance imaging; SRI, somatostatin receptor imaging; SRS, somatostatin receptor scintig-
raphy; PET, positron emission tomography; CgA, chromogranin A.
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nens of unknown origin
NENs, especially neoplasms of the pancreas and intestine (small intestine and right 
hemicolon), are frequently metastatic at the time of initial diagnosis [79, 80]. It is 
also not uncommon that the patient presents with metastases, usually liver lesions, of 
unknown origin [79, 80]. All available diagnostic methods such as endoscopy, CT, 
MRI, SRI (SRS and/or PET/CT with labeled SSA), or FDG PET might be used to 
search for the primary lesion in case of NEN of unknown origin [79, 80]. However, 
in about 5–10% of all such cases, it is not possible to detect the primary lesion [79, 80]. 
In patients with liver metastases of unknown origin, the initial diagnostic approach 
includes histological and immunohistochemical examination of the hepatic lesions with 
assessment of Ki‐67 and/or count of mitoses per 10 high‐power fields as the basis for 
grading of the tumors [79–82]. Analysis of hormones, monoamines, and transcription 
factors may also provide important information in searching for the primary site 
[79, 80]. To search for the primary tumor, the most common primary sites of metastatic 
NENs should be taken into consideration, and adequate diagnostic procedures should 
be performed, that is, colonoscopy for the investigation of the large bowel, double‐
balloon enteroscopy or video capsule endoscopy for the small intestine, and EUS for 
pancreatic tumors [79, 80]. For staging, imaging examinations such as CT and/or 
MRI should be performed [79, 80]. In case of well‐differentiated NENs (NET G1 
and G2), SRI—either SPECT/CT SRS or PET/CT using 68Ga‐labeled SSA such as 
DOTATOC, DOTATATE, or DOTANOC—is required [79, 80, 83–88]. These exam-
inations might be helpful in searching for the primary tumor and are important in the 
assessment of the stage of the disease and very useful in planning the treatment 
[79, 80]. Other promising and useful diagnostic tools are 18F‐DOPA PET/CT or 5‐HTP‐
PET/CT, and these examinations might be considered in case of negative results of SRS; 
however, their availability is limited [35, 79]. Cells of the low‐differentiated NENs (NEC 
G3) do not usually express sstr; therefore, in those cases, FDG PET might be more useful 
[79, 80]. Use of FDG PET in case of NET G2 is not recommended as a routine imaging 
method; however, there are studies indicating its prognostic value [79, 89].
summAry
SRS is a useful imaging modality in case of patients with NENs. SRS provides 
information about both the receptor status of the primary tumor and the extent of the 
disease. On the basis of SRS results (high tumor uptake and favorable target/ nontarget 
ratios), patients with sstr‐expressing tumors are qualified to PRRT or to the treatment 
with long‐acting SSA [90]. The level of the uptake in SRS is also a prognostic factor. 
Usually, a high uptake in SRS indicates a well‐differentiated histotype more likely to 
respond well to therapy, whereas a low uptake, or no uptake at all, is generally corre-
lated with a poorly differentiated histotype and worse prognosis for the patients [90]. 
It is also known that the degree of differentiation may vary between primary tumor 
and metastases. Moreover, it can change also during the treatment [90]. This fact 
should be taken into consideration in the assessment of SRS after therapy.
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SRS can visualize primary tumors and possible metastatic lesions by virtue of 
studying a variety of molecular processes with high sensitivity in the body. Mapping 
of the results with those of anatomic imaging may give individualized information 
about heterogeneity between metastases as well [91]. Due to the aforementioned 
characteristic features, interpretation of SRS images can be difficult due to 
physiological uptake in different organs.
SRS has an established role in diagnostic algorithm in different types of NENs. In 
25–30%, SRS plays an important role in making a therapeutic decision especially 
such as qualification to PRRT. In some cases, SRS is the best method in postopera-
tive follow‐up, in assessment of the extent of the disease (staging), and in follow‐up 
to evaluate potential recurrence. PET scanning with the use of 68Ga‐labeled SSA is 
more sensitive for detection and follow‐up of patients with NENs; therefore, the time 
needed for investigation in comparison to SPECT is reduced. The PET examination 
is performed in a short‐time window, in which it is only possible to assess the 
presence of the receptors. SRS can be performed after the longer interval time, 
according to the type of isotopes that is used for the study. It means that, in addition 
to ascertaining the expression of the receptor on membrane surface, internalization, 
which occurs after binding, can be assessed. And internalization of the radiocom-
pound is a predictor of an efficacy of the radiometabolic therapy. The proof of inter-
nalization is a better guarantee of response to the therapy than early PET imaging, 
and therefore, a further discussion and clinical studies are necessary [91]. It is empha-
sized in the literature that PET imaging had significantly higher sensitivity than SRS 
in patients with NENs [90]. FDG PET might be considered in patients with negative 
SRS [90].
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mIBG metaiodobenzylguanidine
MRI magnetic resonance imaging
NF1 neurofibromatosis type 1
PET positron emission tomography
PGL paraganglioma
PPGLs pheochromocytomas and paragangliomas
SDH succinate dehydrogenase
SDHB SDH subunit B
SDHD SDH subunit D
SPECT single‐photon emission computed tomography
SRS somatostatin receptor scintigraphy
SSTR somatostatin receptor
T/N tumor/nontumor
VHL von Hippel–Lindau syndrome
VMAT‐1 vesicular monoamine transporter type 1
PheochromocytomAs And PArAgAngliomAs
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that 
derive from sympathetic chromaffin tissue in adrenal and extra‐adrenal abdominal or 
thoracic locations [1]. PPGLs arising from the adrenal medulla are commonly referred to 
as pheochromocytomas. Typical locations for extra‐adrenal PPGLs are (1)  the 
Zuckerkandl body, a sympathetic ganglion located at the root of the inferior mesenteric 
artery; (2) the sympathetic plexus of the urinary bladder, the kidneys, and the heart; and 
(3) the sympathetic ganglia in the mediastinum. Head and neck  paragangliomas 
(HNPGLs), also called glomus tumors, arise from parasympathetic paraganglia, mainly 
from the glomus caroticum, glomus (jugulo)tympanicum, and glomus vagale.
The majority of PPGLs produce, metabolize, and secrete catecholamines, whereas 
HNPGLs usually do not. The main symptoms and signs of catecholamine excess due 
to PPGLs include headache, palpitations, diaphoresis, and paroxysmal or chronic 
hypertension. Symptoms and signs of HNPGLs rather relate to the tumor’s local 
space‐occupying effects, including cranial nerve damage.
PPGLs occur sporadically or in association with four known familial syndromes: 
multiple endocrine neoplasia type 2 (MEN‐2), von Hippel–Lindau (VHL) syndrome, 
neurofibromatosis type 1 (NF1), and paraganglioma syndromes associated with 
mutations of genes encoding subunits of the succinate dehydrogenase (SDH) com-
plex, in particular subunits B (SDHB) and D (SDHD). Reported frequencies of germ 
line mutations of the aforementioned genes among patients with PPGLs range from 
27 to 32% [2] and are likely to increase as further tumor susceptibility genes are iden-
tified. Most recently, mutations of genes encoding the SDH complex assembly factor 
2, transmembrane protein 127, SDH subunit A, and MYC‐associated factor X (MAX) 
have been identified as further hereditary causes of PPGLs [3–6].
To establish a biochemical diagnosis of PPGL, plasma and/or 24 h urine 
 con centrations of the catecholamines epinephrine and norepinephrine and their 
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O‐methylated metabolites metanephrine and normetanephrine (“metanephrines”) are 
measured. Especially, plasma‐free metanephrines and urinary fractionated meta-
nephrines both have an excellent sensitivity (>97%) for detecting PPGL [7].
functionAl imAging tArgets
In patients with a biochemically established diagnosis of PPGL, anatomical and 
functional imaging are critical for primary tumor localization and detection of multiple 
primary tumors and metastases, guiding the optimal choice between curative surgery 
and palliative treatment options. CT and MRI provide a high sensitivity and allow pre-
cise tumor delineation. Lesions detected by anatomical imaging can be specifically 
identified as PPGL by functional imaging agents that target the catecholamine synthesis, 
storage, and secretion pathways of chromaffin tumor cells [8]. These techniques include 
[123/131I]‐metaiodobenzylguanidine (123/131I‐mIBG) single‐photon emission computed 
tomography (SPECT) and 6‐[18F]‐fluorodopamine (18F‐FDA) positron emission tomog-
raphy (PET). 123/131I‐mIBG and 18F‐FDA target the norepinephrine transporter of the 
PPGL cell membrane and the vesicular monoamine transporters in the membrane of 
intracellular vesicles. These transporters facilitate the reuptake and storage of catechol-
amines, respectively. The PET tracers 11C‐epinephrine and 11C‐hydroxyephedrine are 
alternatives that accumulate in tumor cells through the same mechanisms but are of 
limited use for clinical imaging because of their (very) short half‐life.
6‐[18F]‐Fluoro‐l‐3,4‐dihydroxyphenylalanine (18F‐DOPA) PET can be used for 
the imaging of the striatal system and neuroendocrine tumors such as carcinoids but 
also for PPGL and HNPGL. The target of 18F‐DOPA is the large amino acid trans-
porter involved in the uptake of amine precursors.
Other less‐specific targets for PPGL imaging are the somatostatin receptors 
(SSTRs) and glucose transporters. For SSTR‐based imaging, 111In‐pentetreotide and 
99mTc‐HYNIC‐TOC/HYNIC‐TATE are available for SPECT and 68Ga‐DOTATATE/
DOTANOC/DOTATOC for PET. 2‐[18F]‐Fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) PET 
provides an index of intracellular glucose metabolism and is taken up by the tumor 
cell through the glucose transporters [8–10]. Functional imaging (SPECT and PET) 
are usually combined with CT for attenuation correction and colocalization. A sche-
matic overview of the targets on PPGL tumor cells for the currently available radio-
pharmaceuticals is given in Figure 4.4.2.1 [11].
sstr exPression in PPgls
The key phenomenon for applying somatostatin receptor scintigraphy (SRS) in 
PPGL imaging is the expression of SSTRs on tumor cells, described for the first 
time in 1992 by Reubi et al. [12]. SSTRs were revealed by autoradiography in 73% 
of studied pheochromocytomas and 93% PGLs. High receptor density was observed 
in 36 and 43% of cases, respectively [12]. This discovery was confirmed by 
Epelbaum et al. [13]. The SSTR status of the examined tumors did not correlate 
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with features such as age, tumor size, tumor location (adrenal vs. extra‐adrenal), 
malignancy, or urinary metanephrine excretion. However, the density of SSTRs was 
significantly higher in tumors with no uptake of labeled mIBG. It is interesting that 
mRNAs of all five subtypes of SSTRs (SSTR1–5) were measurable in PPGLs.
In further studies, Mundschenk et al. confirmed the expression of different SSTRs 
subtypes by immunohistochemistry in up to 94% of examined pheochromocytomas, 
48% of which showed the presence of at least two subtypes [14]. In contrast to gas-
troenteropancreatic neuroendocrine tumors (GEP‐NETs), SSTR subtype 3 was the 
most frequent (90.4% of studied samples), followed by subtype 2A (25%), subtype 5 
(15.4%), subtype 4 (10.4%), and subtype 1 (7.7%). The dominant expression of 
SSTR subtype 3 in benign pheochromocytoma was also confirmed by other authors 
[15]. However, in a recent study on SSTR mRNA expression in PPGLs, the most 
frequent receptor subtypes were SSTR subtype 2 and SSTR subtype 1 (100 and 94% 
of 52 cases included, respectively), with no difference between pheochromocytomas 
and extra‐adrenal PGLs. The level of SSTR subtype 3 and SSTR subtype 5 mRNA 
was low and detectable only in 53 and 47% of cases, respectively; however, both 
















































figure 4.4.2.1 Functional imaging targets in PPGL. Adapted from [11], with permission. 
Nonspecific and specific imaging for pheochromocytoma/paraganglioma. DBH, dopamine‐
beta‐hydroxylase; EPI, epinephrine; 18F‐FDA, 18F‐fluorodopamine; 18F‐FDG, 18F‐fluoro‐2‐
deoxy‐d‐glucose; 18F‐FDOPA, 18F‐dihydroxyphenylalanine; 18F‐FNE, 18F‐free norepinephrine; 
NE, norepinephrine; DOTANOC, DOTA‐Nal3‐octreotide; DOTATOC, DOTA‐Tyr3‐octreotide; 
123/131I‐mIBG, 123/131I‐metaiodobenzylguanidine; l‐AADC, l‐aromatic‐amino acid decarbox-
ylase; NET, norepinephrine transporter; PNMT, phenylethanolamine‐N‐methyltransferase; 
SDHB/C/D, succinate dehydrogenase subunit B/C/D; ST receptor, somatostatin receptor; ?*, 
potential radiopharmaceutical directed at mutations in the mitochondria.
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immunohistochemically stained PPGL samples, SSTR2 mRNA was associated with 
protein expression [16]. No relationship between the SSTR subtype expression 
pattern and malignant behavior of the tumors has been found; however, SSTR2A 
presence is more often being observed in extra‐adrenal lesions.
From the clinical point of view, it is important that metastatic lesions are also 
SSTR positive. It should be emphasized that SSTR expression in primary lesions and 
their metastases, as well as in recurrent lesions, may differ. This phenomenon is well 
known in neuroendocrine tumors.
exPression of sstrs And imAging diAgnostics of PPgls
The first attempt to apply a labeled somatostatin analogue in localization of tumors 
derived from chromaffin cells was undertaken over 30 years ago. In the first study on 
123I‐Tyr‐3‐octreotide performed by Krenning et al., the only pheochromocytoma patient 
included was negative on SRS imaging [17]. The next study with the same agent pub-
lished in 1990 comprised 20 patients with paragangliomas. This time, only two patients 
were negative on imaging, the tumor size (3–5 mm) being the most probable cause of 
false‐negative results [18]. Reubi et al. correlated the SRS results with autoradiographic 
tissue studies. They concluded that low density of SSTRs in PPGLs may result in a lack 
of visualization of the tumor [12]. The group of Krenning was also the first to report the 
high clinical impact of 111In‐octreotide (111In‐pentetreotide) imaging on PPGL patient 
management [19, 20]. The first reports on 99mTc‐labeled somatostatin analogues used in 
the diagnosis of PPGLs came from the early 2000s [21].
As most of the labeled somatostatin analogues currently used in nuclear diagnos-
tics are highly SSTR2 specific, the membrane expression of this subtype of SSTR is 
of crucial relevance for imaging results. In a study of Mundschenk et al., SSTR 
expression was compared with results of preoperatively performed OctreoScan 
(111In‐pentetreotide) scintigraphy. Approximately 50% of patients with positive SRS 
showed membrane expression of SSTR subtype 2A. If SSTR subtype 2A expression 
was absent, SSTR subtype 3 was detected. Negative results of SRS were connected 
with no SSTR subtype 2A or subtype 3 membrane expression or with cytoplasmic 
presence of SSTR3 only [14].
sensitivity And sPecificity of srs
Due to the relatively high malignant potential of especially extra‐adrenal PGLs, and 
no specific histological or immunohistochemical features of the primary tumor to 
confirm its malignancy, the detection of distant metastases is of key importance and 
may influence the choice of the treatment.
It is generally known that SRS is of limited value in nonmetastatic PPGLs. 
Metastases from malignant PPGLs are more frequently being detected with SRS 
(Fig.  4.4.2.2). The study comparing 123I‐mIBG scintigraphy, 18F‐FDA, and 111In‐
OctreoScan in patients with nonmetastatic and metastatic pheochromocytomas 
showed equal sensitivity of 18F‐FDA and 123I‐mIBG (87.5%) and lower of SRS 
SENSITIVITY AND SPECIFICITY OF SRS 117
(28.5%) in patients with nonmetastatic pheochromocytomas [22]. In patients with 
metastatic tumors, the region‐by‐region sensitivity was 78.4% for 18F‐FDA, 58.9% 
for 123I‐mIBG, and 68.5% for 111In‐OctreoScan SRS [22].
The sensitivity of SRS is lower than mIBG scintigraphy in PGLs with exception 
of HNPGLs, in which it ranges from 86 to 100% for malignant tumors [23, 24]. 
Kwekkeboom et al. showed the usefulness of SRS with the 111In‐labeled somatostatin 
analogue in the visualization of PGLs already in 1993—the authors were able to 
detect 94% of previously known lesions and additional foci in 36% investigated 
patients [20]. Bustillo et al. applied the same tracer and proved high accuracy (90%), 
sensitivity (94%), and specificity (75%) of the method in PGLs [25].
In their paper, Koopmans et al. showed the superiority of SRS over scintigraphy with 
labeled mIBG in a group of 29 patients with HNPGLs, in whom SRS revealed additional 
lesions not detected by other methods. The authors suggested that SRS is likely to con-
tribute to optimal lesion characterization in this patient category (a sensitivity of 111In‐
octreotide was 95% vs. 44.5% for 123I‐mIBG). In view of the low yield of mIBG imaging, 
this method should not be routinely used in the evaluation of HNPGL [26]. Similar results 
were obtained for 99mTc‐HYNIC‐TOC: the sensitivity of the tracer in the detection of 
extra‐adrenal PGLs was 92.9% for benign and 100% for malignant tumors (the sensi-
tivity of 123I‐mIBG scintigraphy was 71.4 and 72.7%, respectively) (Fig. 4.4.2.3) [27].
figure  4.4.2.2 131I‐mIBG scintigraphy and 99mTc‐HYNIC‐TATE SRS in a 22‐year‐old 
woman with metastatic pheochromocytoma.
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figure 4.4.2.3 (a) 99mTc‐EDDA/HYNIC‐TOC SRS in a 37‐year‐old woman with multiple 
paragangliomas with prevalent expression of SSTR4 (80% of cells). (A) Axial, (B) sagittal, 
(C) coronal views, (D) whole body scan. (b) Immunohistochemical staining for SSTR subtype 
4 (magn. ×400). Courtesy of Prof. R. Tomaszewska, Dept. of Pathology, Jagiellonian 
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In a study assessing various imaging modalities in the detection of SDHx‐related 
HNPGLs, 18F‐FDOPA PET proved to be the most efficient in detecting such lesions, 
followed by CT/MRI (81% lesions detected), 18F‐FDG PET/CT (77% of lesions), 
and 111In‐pentetreotide (64% of lesions). 18F‐FDA and 123I‐mIBG detected less than 
half of the foci. The authors concluded that SRS or 18F‐FDG PET/CT is the second 
line of imaging in such cases [28].
Implementation of 68Ga‐labeled somatostatin analogues in PET has greatly 
improved the diagnostics of neuroendocrine tumors. Case reports and studies on 
small groups published so far seem to confirm this phenomenon also for PPGLs [29]. 
Larger studies are, however, still missing.
There are three available 68Ga‐labeled SST analogues: DOTATATE with high 
affinity to SSTR subtype 2, DOTATOC binding to SSTR2 and 5, and DOTANOC 
with affinity to SSTR subtypes 2, 3, and 5 [30]. The first report by Fanti et al. showed 
the suitability of 68Ga‐DOTANOC PET in the detection of unknown PGL lesions; 
however, only 3 patients were presented [31]. Similarly, the available clinical data on 
malignant pheochromocytomas suggest that the use of 68Ga‐DOTATOC PET may be 
very helpful in the management of patients. In a work published by Kroiss et al., both 
68Ga‐DOTATOC PET and 123I‐mIBG scintigraphy showed 100% sensitivity, when 
compared with anatomical imaging (CT and MRI). However, in pheochromocytoma 
patients, on a per‐lesion basis, the sensitivity of 68Ga‐DOTATOC PET was essentially 
higher than that of 123I‐mIBG (91.7% vs. 63.3%) [32]. The same group highlighted a 
possible higher sensitivity of 68Ga‐DOTATOC PET than 123I‐mIBG in the detection of 
neuroblastoma metastases. There are also limited literature data on 68Ga‐DOTATATE 
PET, with which significantly more lesions with higher tumor/nontumor (T/N) ratio 
in comparison to 123I‐mIBG have been reported [33, 34].
Better visualization of bone metastases from PPGLs with the 68Ga‐labeled 
somatostatin analogue was also noted [35]. Maurice et al. analyzed the results of 
68Ga‐DOTATATE PET and 123I‐mIBG scintigraphy in a retrospective study of 15 
patients with PPGLs. The authors concluded that 68Ga‐DOTATATE should be con-
sidered as a first‐line investigation tracer in patients at a high risk of PGLs and meta-
static disease, such as in the screening of mutations carriers in familial cases. 
68Ga‐DOTATATE should also be considered as the preferred tracer in patients with 
suspected bone metastases [34]. Data comparing the results of 68Ga‐labeled somato-
statin analogue‐based PET with 18F‐DOPA, 18F‐DA, and 18F‐FDG in PPGL patients 
are not available yet.
Another promising application of labeled somatostatin analogues is radio‐guided 
surgery to improve intraoperative detection of multiple PGLs and to provide radical 
tumor resection [36, 37].
The choice of the most feasible method of pheochromocytoma and paragangli-
oma imaging, as well as suitability for radioisotope treatment, may be influenced not 
only by clinical features (sporadic vs. familial tumors, benign vs. malignant, intra‐ 
vs. extra‐adrenal) but also by the results of qualitative or quantitative assessment of 
SSTRs and monoamine transporters. VMAT‐1‐negative PPGLs do not take up mIBG. 
Preliminary data have shown that the number of SSTR2A mRNA copies corresponds 
with positive SRS results [38].
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sensitivity of other functionAl imAging modAlities
The use of 123I‐mIBG is preferred over 131I‐mIBG because of its higher sensitivity, 
lower radiation exposure, and improved imaging quality with SPECT [10]. Reported 
sensitivities of 123I‐mIBG scintigraphy for localizing nonmetastatic PPGL vary bet-
ween 77 and 98% [39, 40], but only 50–79% for metastases [39, 41]. The specificity 
of 123I‐mIBG SPECT approaches 100% [42]. Despite the low sensitivity for detecting 
PPGL metastases, an advantage of using 123I‐mIBG scintigraphy in the setting of 
metastatic disease is the fact that it might identify patients who possibly benefit from 
palliative treatment with therapeutic doses of 131I‐mIBG [43].
18F‐DOPA PET has a high sensitivity for the localization of PPGL [39, 44, 45] and 
HNPGL [46]. Reported sensitivities vary between 81 and 100%. No specificity data 
are available. The performance of 18F‐DOPA PET is disappointing in case of meta-
static PPGL, especially SDHB‐related cases [9].
For 18F‐FDG PET, sensitivities up to 88% for primary nonmetastatic PPGL were 
reported. Specificity is ~90% (unpublished results). 18F‐FDG PET is highly sensitive 
for the detection of PPGL metastases, especially SDHB‐related cases (region‐based 
sensitivity 97% in reference to CT/MRI) [41] (Fig. 4.4.2.4).
18F‐FDA was initially developed at the National Institutes of Health for functional 
imaging of the sympathetic nervous system and later evaluated as a new imaging 
tool for PPGL. 18F‐FDA PET was shown to have a high sensitivity for both primary 
figure 4.4.2.4 Functional imaging results in a 35‐year‐old male with metastatic SDHB 
PPGL. Anteriorly reprojected images (respectively, 18F‐FDA PET, 18F‐DOPA PET, 18F‐FDG 
PET, 123I‐mIBG SPECT). Adapted from [39], with permission.
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tumors (77–100%) and metastases (77–90%) [39, 42, 47]. The sensitivity of 18F‐
FDA PET exceeds 90% [42]. So far, 18F‐FDA is only available as an experimental 
imaging agent.
The results of a head‐to‐head comparison between different functional imaging 
modalities are presented in Table 4.4.2.1 [39].
imAging Across hereditAry syndromes
Imaging results appear to be largely determined by the underlying genotypes and 
related tumor cell characteristics. There is evidence for differential expression of cel-
lular targets for radiopharmaceuticals. For example, it was shown that there is a lower 
expression of the cell membrane norepinephrine transporter system in VHL‐related 
PPGL cells than in MEN‐2‐related tumor cells [48]. Considering the higher affinity 
of 18F‐FDA than 123I‐mIBG for these transporters, it is no surprise that 18F‐FDA PET 
is superior to 123I‐mIBG SPECT in the context of VHL syndrome [49].
There also appears to be a link between tumor biology and imaging [50]. SDHB 
mutations are associated with PPGLs of a particularly high malignant potential. 18F‐
FDG PET has an excellent sensitivity for SDHB‐associated metastatic PPGL [41, 
51]. 18F‐FDG accumulation is an index of increased tissue glucose metabolism, and 
as a marker of tumor viability, the degree of 18F‐FDG uptake usually reflects tumor 
aggressiveness. 18F‐FDG uptake by PPGL does not appear to be merely an indicator 
of a high metabolic rate due to malignancy per se, but may rather be directly linked 
to SDHB‐specific tumor biology [39]. The SDHB gene encodes for subunit B of the 
mitochondrial SDH complex II, a key enzyme in oxidative phosphorylation. SDHB 
mutations can lead to complete loss of SDH enzymatic activity in malignant PPGL, 
with upregulation of hypoxic–angiogenic‐responsive genes [52]. Impairment of 
tAble 4.4.2.1 sensitivity of functional imaginga
(A) Nonmetastatic PPGL (20 patients)b
CT and/or 
MRI
18F‐DOPA 18F‐FDA 123I‐mIBG 18F‐FDG












(B) Metastatic PPGL (28 patients)c
CT and/or 
MRI
18F‐DOPAA 18F‐FDAB 123I‐mIBGC 18F‐FDGD











bSensitivities are not significantly different between functional imaging modalities.
cA versus B, A versus C, A versus D, B versus C, C versus D: p < 0.01. B versus D: p = 0.760.
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mitochondrial function due to loss of SDHB function may cause tumor cells to shift 
from oxidative phosphorylation to aerobic glycolysis, a phenomenon known as the 
“Warburg effect” [53]. Higher glucose requirement because of a switch to less effi-
cient pathways for cellular energy production may explain the increased 18F‐FDG 
uptake by malignant SDHB‐related PPGL.
The only study on impact of SRS with 111In‐pentetreotide in hereditary SDHx gene 
mutation‐related PPGLs has just been published in 2013. The sensitivity of SRS in 
all PGLs was 69.5% versus 85.4% for MRI and CT and 42.7% for mIBG. SRS per-
formed better than other assessed imaging modalities in thoracic PGL (61.5% vs. 
46.2% and 30.8%, respectively) and was more efficient in detecting HNPGL than 
mIBG, however inferior to CT/MRI (75, 30.6, and 90.4%, respectively). In abdom-
inal PPGLs, SRS was least sensitive [54].
conclusions
Imaging in PPGL patients, if chosen appropriately, adds greatly to the patients’ 
management: treatment options, prognosis, follow‐up, and early detection of recur-
rence. Considering the heterogeneous nature of the disease, imaging modality 
preference should be guided by clinical and genetic background (Fig. 4.4.2.5) [55]. 
Increasing importance of PET tracers should be stressed.
Extraadrenal abdominal




























figure 4.4.2.5 Clinical algorithm for imaging investigations in PCC/PGL. Based on the 
earlier considerations, the following algorithm can be proposed based on the clinical situation. 
This algorithm should be adapted to the practical situation in each institution and should 
evolve with time. In bold, first‐line imaging procedures according to accessibility of tracers 
and clinical approvals in European countries. 18F‐FDA and 68Ga‐DOTA‐SSTa (asterisks) are 
experimental tracers that should be used in the setting of clinical trials. 18F‐FDA PET is cur-
rently used at the NIH only. 68Ga‐DOTA‐SSTa is now accessible in many clinical and research 
centers in Europe [55], with permission.
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In apparently sporadic benign adrenal PGLs (pheochromocytomas), 123I‐mIBG 
should be considered the first line of functional imaging (if such is necessary). Only 
in 123I‐mIBG‐negative cases or in patients on medications interfering with 123I‐mIBG 
uptake other modalities, particularly 18F‐FDOPA PET, should be asked for.
18F‐FDOPA PET is currently considered the best method for detecting HNPGL. If 
not available, SRS either with SPECT or PET traces should be used. 18F‐FDOPA 
PET is also the best functional imaging method for detecting and differential diag-
nosis of retroperitoneal, extra‐adrenal PGLs with unknown genetic background.
Depending on the presence/absence of SDHB subunit mutation, 18F‐FDG and 18F‐
FDOPA PET are the best modalities in approaching the patients with metastatic 
PPGLs. 123I‐mIBG and/or SRS are to be performed if further targeted radionuclide 
therapy is considered.
Currently, the choice of imaging method in PPGL patients should be also guided 
by the type of mutation causing the disease. 18F‐FDOPA is the first line of functional 
approach in all syndromic patient but VHL‐related, SDHB‐related, and SDHx‐related 
metastatic cases, in whom 18F‐FDG seems the most appropriate tracer.
summAry
Summing up, the confirmation of SSTRs expression in neuroendocrine tumors has 
changed modern diagnostic imaging and therapy and starts to influence the approach 
to PPGLs. In vitro studies have revealed SSTR expression, particularly subtypes 2A 
and 3, in PPGLs, the confinement of which to cell membranes is essential for suc-
cessful diagnostic use of somatostatin analogues. Scintigraphy with radiolabeled 
somatostatin analogues is nowadays an approved complementary method for the 
localization of PPGLs, particularly malignant head and neck PGLs, and, if necessary, 
for qualification for PRRT and follow‐up of the patients.
It seems that labeled analogues with a broader affinity to SSTRs may be a good diag-
nostic alternative for PPGL patients. Current place of SRS in PPGLs diagnostics may 
change if tracers labeled with 68Ga and other positron emitters are more profoundly tested.
High tracer accumulation is essential for PRRT in inoperable or disseminated 
SSTR‐positive tumors. Some PPGLs are SRS positive and mIBG negative, suggest-
ing a possible therapeutic role for labeled somatostatin analogues. Promising results 
of radiotherapy with labeled analogues have been recently announced; however, data 
concerning this approach are still scarce (Chapter 6.6).
Overall, the prognosis for patients with PPGLs is good. Most pheochromocytoma 
cases present with the disease limited to the adrenal gland, for whom available 
imaging methods are sufficient. In some patients, finding markers for the 
differentiation between pheochromocytoma and other adrenal masses is challenging. 
The development of nuclear medicine imaging methods is focused on the search for 
new diagnostic targets to improve the detection of multifocal and malignant primary 
and metastatic lesions in PPGL cases, as well as to find alternative therapeutic strat-
egies to control tumor growth. The choice of optimal methods of functional imaging 
including factors like genetic predisposition is also a matter of research.
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Somatostatin analogues with affinity to all known SSTR subtypes (e.g., SOM‐230) 
are one of the line of research, as more than 60% of PPGL cells express SSTR subtype 
3, some 2 and 5, but solely subtype 4 can also be found. Gastrin, GLP‐1, GHRH, LHRH, 
neuropeptide‐Y, and other neuropeptide analogues are also being studied [41, 46].
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RET rearranged during transfection
SRS somatostatin receptor scintigraphy
SSTR somatostatin receptor
introduction
Medullary thyroid cancer (MTC), first described in 1959 [1], is a neuroendocrine 
tumor originating from the calcitonin‐secreting C cells of the thyroid and accounts 
for 3–10% of the thyroid malignancies [2]. It occurs in a sporadic (75%) and a here­
ditary form referred to as multiple endocrine neoplasia (MEN) type 2A (MEN‐2A), 
MEN type 2B, or familial MTC (FMTC). The hereditary forms occur due to germ 
line mutations in the rearranged during transfection (RET) gene [3–6]. Besides a 
100% expression of MTC, patients also develop pheochromocytomas (MEN‐2A and 
MEN‐2B), hyperparathyroidism (MEN‐2A), intestinal ganglioneuromatosis 
(MEN‐2B), and mucosal neuromas (MEN‐2B).
MTC metastasizes early during the course of the disease to regional cervical lymph 
nodes. up to 20–30% of patients with a primary tumor of <1 cm (T1), up to 50% of 
patients with a T2 tumor, and almost all patients with a T3 or T4 tumor present with 
cervical lymph node metastases [7, 8]. Distant metastases are typically found in the 
mediastinum, lungs, liver, and bone.
Surgery, consisting of a total thyroidectomy and an extensive lymph node dissec­
tion, is the only effective curative treatment in primary MTC. Locoregional tumor 
control may be improved by initial extensive surgery consisting of central, bilateral, 
and upper mediastinal neck dissection [9].
However, clinically curative surgery resulted in a cure rate between 33 and 61% in 
groups that routinely employed central and bilateral lymph node dissection [7, 8, 10]. 
Serum calcitonin is the main biochemical and accurate marker used for the detection of 
tumor persistence and recurrence and is of importance in the postoperative management 
of patients with MTC. For patients with recurrent disease and/or lymph node metas­
tases, surgery is the first line of treatment. Patients with distant metastases cannot be 
cured and have a reduced survival [11]. Systemic treatment modalities such as radio­
therapy and chemotherapy have limited success. New molecular targeted therapy 
such as tyrosine kinase inhibitors shows promising results in vitro as well as in vivo; a 
phase III trial has been published recently [12, 13]. The management of patients with 
MTC is also impaired due to the difficulty of imaging persistent/residual and/or met­
astatic tumor lesions. Morphological imaging techniques (ultrasonography of the neck, 
computed tomography (CT), and magnetic resonance imaging (MRI)), scintigraphic 
imaging techniques (99mTc‐V‐dimercapto‐sulfuric acid (99mTc‐V‐DMSA), 111In‐labeled 
somatostatin receptor scintigraphy (SRS)), and positron emission tomography (PET) 
labeled with 18F‐2‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) have complementary values, 
since they are dependent of different tumor characteristics. Also, they depend on tumor 
load. Sensitivity for individual imaging techniques can however be disappointing. 
Newer alternative tracers for PET imaging such as 18F‐dihydroxyphenylalanine 
(18F‐DOPA) and 68Ga‐labeled analogues of somatostatin (DOTA) are more promising.
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Besides the diagnostic application of somatostatin analogues, these have also been 
used in the treatment of MTC. The focus of this chapter is the diagnostic and therapeutic 
use of somatostatin in MTC.
somAtostAtin As An imAging tool in pAtients with mtc
As previously stated, the imaging of residual and/or recurrent (metastatic) MTC can 
be very difficult when conventional imaging techniques such as ultrasonography, CT, 
and/or MRI are used. Patients with postoperative calcitonin levels of <150 pg/ml 
should undergo ultrasonography of the neck according to the ATA guidelines [14]. 
However, when calcitonin levels rise above 150 pg/ml, additional imaging techniques 
are recommended for the detection of distant metastases. For this purpose, 123I(131I)‐
metaiodobenzylguanidine (MIBG) and 99mTc‐V‐DMSA routinely have been used 
and were reported to be able to detect residual or recurrent disease after primary 
surgery, in about 33–70% of patients. After the demonstration of the presence of 
somatostatin in parafollicular C cells and cells of MTC by immunohistochemistry 
in the mid‐1970s [15–17], several somatostatin receptors (SSTR) (including SSTR2 
and SSTR5) have been shown to be present in vitro in MTC cells, thus providing the 
rational for the use of SRS in these patients (Fig. 4.4.3.1) [18–20].
The first report on SRS in three patients with MTC using 123I‐labeled tyr‐3‐octreotide 
(tyr‐3‐SMS 201‐995, a synthetic derivative of somatostatin) showed no uptake [21]. 
Since then, several studies have been published regarding the value of SRS in patients 
with recurrent or residual MTC, but the data do not reveal sensational results. As is 
shown in Table 4.4.3.1, the number of patients that have been studied is limited, and 
the sensitivity range varies between 0 and 75%, illustrating the lack of well‐designed 
studies in selected patients [22]. Sensitivities also differ regarding different metastases 
sites and size of the metastases.
(a) (b)
Figure 4.4.3.1 111In‐labeled somatostatin receptor scintigraphy, with visible metastases in 
the supraclavicular lymph nodes and mediastinal and bilateral hili of the lung. (a) Head/neck 
region anterior view. (b) Chest/abdominal region anterior view.
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So in current patient practice, sensitivities of SRS but also of 123I‐MIBG and 
99mTc‐V‐DMSA are disappointing, and in clinical practice, the application of these 
techniques is waning. Other scintigraphic imaging techniques such as 18F‐FDG PET, 
18F‐DOPA PET, and PET imaging with 68Ga‐labeled DOTA peptides are upcoming in 
the diagnostic workup of patients with residual and/or metastatic disease in addition 
to the conventional imaging. However, the clinical value use of these new tracers has 
not been established yet. Also PET combined with CT imaging and in the future 
combined with MRI may be of additional value in these patients.
It has been reported that 18F‐FDG PET may be superior in patients with short calci­
tonin doubling time and in patients with tumor with a Ki67 score of >2.0% [40–43].





Krenning 1989 [21]  3  0% 123I‐labeled tyr‐3‐octreotide
Frank‐Raue 1995 [23] 26 57%
Krenning 1993 [24] 12 8 out of 12
Kwekkeboom 1995 [25] 17 65% No visualization of liver 
metastases
Krausz 1994 [26] 10 9 out of 10 No visualization of liver 
metastases
Bernà L 1995 [27] 11 55%
Bernà 1998 [28] 20 50%
Celentano L 1995 [29] 14 64%
Rufini L 1995 [30]  7 72%
Baudin E 1996 [31] 24 38% No visualization of small 
tumor sites
Tisell 1997 [32] 22 50% Higher CEA and calcitonin 
in patients with a 
positive scan
Adams S 1998 [33] 18 29% No visualization of small 
tumor sites
Hoegerle 2001 [34] 11 52% 18F‐DOPA PET: 63%
Arslan N 2001 [35] 14 79% Sensitivity combined 99mT 
Tc‐V‐DMSA and SRS: 
86%
De Groot JW 2004 [36] 26 41% Lesion‐based sensitivity
Diehl 2001 [37] 24 25% 24 histological confirmed 
lesions
Kurtaran 1998 [38] 14 71% For the primary tumor
 0% For lymph node metastases
Lodish 2012 [39] 11 45% Pediatric population
Small size: <1 cm. CEA denotes carcinogenic embryonic antigen, 18F‐DOPA PET denotes 
18F‐ dihydroxyphenylalanine position emission tomography, SRS denotes somatostatin receptor scintigraphy, 
and 99mT Tc‐V‐DMSA denotes 99mTc‐V‐dimercapto‐sulfuric acid.
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This may be in contrast to the 18F‐DOPA PET with a reported sensitivity of about 
62%, possibly reflecting the more indolent type of MTC. However, these data have 
to be confirmed in other series [34, 41]. When combining CT imaging with 18F‐
DOPA PET, the reported sensitivities may increase to 94 and 100% [44, 45]. Although 
18F‐DOPA PET has less prognostic value, it can assess the extent of the disease in 
residual MTC [46, 47].
Currently several other tracers for PET imaging binding to somatostatin receptors 
have become available that could be of value in the detection of MTC: 68Ga‐DOTA 
peptides, DOTA‐TOC, DOTA‐TATE, and DOTA‐NOC, bind with high affinity to 
SST‐2. 68Ga‐DOTA‐NOC also binds to SST‐3 and SST‐5 [48]. These new PET traces 
are very promising, although the clinical experience is limited. Conry et al. investi­
gated 18 patients with recurrent MTC with an overall sensitivity of 18F‐FDG PET and 
68Ga‐DOTA‐TATE PET of 77.8 and 72.2%, respectively. On a region‐based analysis, 
18F‐FDG PET was more sensitive [49]. Clearly, more studies with more homogeneous 
patient groups are needed to evaluate the value of these tracers in patients with MTC.
therApeutic use oF somAtostAtin AnAlogues
Since the most effective treatment of MTC, surgery, does not result in a 100% cure 
rate, additional therapies are needed in recurrent/persistent and/or metastatic MTC. 
Radiotherapy is especially used for local tumor control. Chemotherapy has a very 
limited value.
The first therapeutic intervention with somatostatin analogues in patients with MTC 
dates from 1987. A somatostatin analogue was prescribed for a 63‐year‐old man with 
disseminated MTC and pancreatic nesidioblastosis. The analogue had no effect neither 
on the calcitonin hypersecretion nor on the growth of the medullary carcinoma [50].
Since then, there have been several trials studying the effect of somatostatin 
analogues on MTC. Treatment with the current available somatostatin analogues, 
octreotide and lanreotide (both with a high affinity for SSTR2 and SSTR5), does 
not seem to have an effect on survival but may control symptoms of flushing and 
diarrhea in some patients [51–56].
In current guidelines, the use of somatostatin analogues can be considered for 
symptomatic treatment of diarrhea if other antimotility drugs, such as loperamide, 
are ineffective [14].
Experience with peptide receptor radionuclide therapy (PRRT) is limited in this 
patient group and disappointing.
New therapies in the treatment of metastatic MTC use target tyrosine kinase receptors 
inhibitors that belong to the same family group of proteins as RET. Several TK inhibitors 
have already been tested in vitro and evaluated in mostly phase II clinical trials, and 
several phase III trials are currently underway and have been published [12, 13].
In summary, the clinical applications of somatostatin analogues in the diagnosis 
and therapy for patients with MTC are very limited. Possibly, the 68Ga‐DOTA‐labeled 
peptides may be diagnostically applicable, but with the scarce data, the specific 
clinical value in MTC patients must be awaited.
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SCLC small cell lung cancer
SPECT single photon emission computed tomography




The inhibitory action of the somatostatin occurs through its interaction with the 
family of specific membrane receptors, expressed in many organs and tissues. High 
density of somatostatin receptors (SSTRs) has been reported in endocrine and neuro-
endocrine cells, particularly in neoplasms originating from those cells. However, the 
presence, quite often abundant, of functional SSTRs, including type 2, has been also 
confirmed in neuroendocrine malignancies in broader sense (small cell lung cancer 
(SCLC), medullary thyroid cancer, pheochromocytomas and paragangliomas, 
Merkel cell carcinomas (MCC), etc.) and non‐neuroendocrine tumors. SSTRs have 
been found in non‐small cell lung, breast, prostate, colon, and many other cancers, 
not only in neoplastic cells with neuroendocrine features or tumor infiltrating 
immune‐competent cells [1]. This phenomenon implicates the possible auxiliary role 
of somatostatin receptor scintigraphy (SRS) in clinical management of those neo-
plasms. It is also one of the sources of false positive findings, when the “classical” 
neuroendocrine tumors are searched for.
centrAl nervous system
The first experience with SRS in pituitary tumors was reported in 1992. The increased 
uptake of 123I‐labeled Tyr3‐octreotide in sellar region was noted in 12 of 15 acrome-
galic patients studied; the authors also noted that negative scintigraphy results were 
related to the absence of acute growth hormone response to octreotide administration 
[2]. However, further studies with 111In‐pentetreotide failed to confirm the utility of the 
SRS in predicting tumor shrinkage or hormonal response to somatostatin analogue 
therapy in growth hormone producing and non‐functioning pituitary adenomas, as well 
as in detecting the tumor residual mass in non‐radically resected cases [3, 4]. So, 
regardless of the frequently positive SRS in pituitary adenomas, due to its limited 
added value, the method has not been included in routine pituitary patients’ management.
SSTRs are present in leptomeninx. The SSTR type 2 expressing meningiomas have 
been considered the target for SRS. The increased uptake of the 111In‐pentetreotide in 
those tumors has been consistently confirmed from the very beginning [5–7]. For 
meningiomas visualization, two things are essential: (1) the expression of the SSTRs 
and (2) as the SSTR analogues are water‐soluble, only the tumors located outside the 
blood–brain barrier or with disrupted blood–brain barrier are detected [8, 9]. The use of 
99mTc‐labeled depreotide provided better spatial resolution and enabled the detection 
of the smaller lesions than with the use of 111In‐pentetreotide [10]. The sensitivity 
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of 99mTc‐HyNIC‐octreotate in meningioma detection is better than the sensitivity 
of the CT scans (100 vs. 83%, respectively), and the higher tumor/non-tumor ratio 
correlates with higher meningioma grade [11]. Due to high tumor‐to‐background 
ratio, Galium‐68‐labeled somatostatin analogues for PET/CT have also proved to be 
useful in meningiomas localization [12, 13]. The sensitivity of the method has been 
shown to be even better than contrast‐enhanced MRI, which detected 92% of 190 
meningiomas found by 68Ga‐DoTAToC PET/CT[14]. The current role of SRS in 
meningioma management includes mainly differential noninvasive diagnosis of the 
intracranial tumors [15], but the new applications, such as therapy, both surgery and 
radiation, planning and performance improvement, or treatment outcome prognosis, 
are considered [16–18].
Disturbed blood–brain barrier is also the prerequisite of the positive SRS scans in 
patients with gliomas [5]. The uptake of the tracer has been shown mostly in high‐
grade tumors [7, 19], however less intense in comparison to the meningiomas. Although 
the SRS has not been involved in glioma patient management, the regional injections 
of 90‐yttrium‐labeled somatostatin analogues have been applied in palliative treatment 
of the grade II and III malignancies—see also Chapter 6.6 [20, 21].
The SRS has also been successfully applied in childhood medulloblastomas [22], 
primitive neuroectodermal tumors [23], or hemangioblastomas [24].
heAd And neck tumors
The SRS has been mostly applied in imaging of the head and neck tumors with neu-
roendocrine differentiation: carcinoids, small cell cancers, paragangliomas, esthesio-
neuroblastomas, etc. [25, 26]. In the series of 53 patients with neuroendocrine head 
and neck tumors, the sensitivity and specificity of the 111In‐pentetreotide scintigraphy 
were 93 and 92%, respectively, with the tumor‐to‐background ratio depending on the 
tumor type, the highest in case of paragangliomas and carcinoids [27].
The SSTR type 2 expression in tumor tissues has been confirmed in case reports 
on positive SRS imaging in esthesioneuroblastoma [28] and juvenile nasopharyngeal 
angiofibromas [29]. The SRS application in paragangliomas and medullary thyroid 
carcinoma management has been discussed in detail in Chapters 4.4.2 and 4.4.3.
lung
The pulmonary tumors were found to be SSTR positive already in the late 1980s 
[30]. The expression of SSTR type 1, 2A, 2B, 3, 4, and 5 was observed in 79.7, 96.6, 
66.1, 49.1, 5.2, and 0% of typical lung carcinoids, 77.8, 77.8, 77.8, 33.3, 0, and 0% 
of atypical carcinoids, and 27.6, 69, 24.1, 15.5, 0, and 3.4% of SCLCs, respectively 
[31]. Frequent expression of SSTR type 2A in those tumors made them the good 
target for SRS.
The first studies failed to reveal the SSTR expression in non‐small cell lung cancer 
(NSCLC) [32], and the positive results of scintigraphy were explained by the presence 
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of the SSTRs in tumor vessel or in immune‐competent cells infiltrating the tumor. 
However, other authors found SSTR type 2 in NSCLC cells by immunohistochem-
istry; the higher expression, the better differentiated the tumor. However, no correla-
tion between the SSTR type 2 expression and 99mTc‐depreotide uptake was 
confirmed [33].
bronchial carcinoids
Series of case reports stressed the increasing role of SRS in bronchial carcinoids 
quite early. The 111In‐DTPA‐octreotide has been shown to be effective in localizing 
primary tumors, monitoring their growth, and detecting metastatic and/or recurring 
disease [34]. The radiopharmaceutical was proved to be useful in localizing occult 
ACTH‐secreting bronchial carcinoids [35]. The study including 28 bronchial carci-
noid patients showed positive radiolabeled octreotide scans in 71% of the primary 
tumors; however, CT proved to be more effective in detecting primary tumors as well 
as intrathoracic recurrence and liver metastases [36]. Kuyumu et al. compared 111In‐
octreotide with 18F‐FDG PET/CT findings in patients with pulmonary carcinoids 
(both typical and atypical). Sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) of SRS in the detection of primary tumor, lymph 
nodes, and distant metastasis were 76, 97, 95, and 86%, respectively. PET/CT was 
performed in 13 of total 21 evaluated patients, with sensitivity and specificity of 85 
and 89.4 %, respectively [37].
other somatostatin‐based radiotracers have been proved to be able to detect 
bronchial carcinoids, including 99mTc‐EDDA/HyNIC‐ToC (Fig. 4.4.4.1) [38]. one 
of the PET‐dedicated tracers 68Ga‐DoTATATE was compared with 18F‐FDG in 
pulmonary neuroendocrine tumors. All typical carcinoids included in the study were 
68Ga‐DoTATATE positive, whereas 4 of 11 tumors were negative on 18F‐FDG PET/
CT scans. More than a half of higher grade pulmonary neuroendocrine tumors were 
68Ga‐DoTATATE negative, while visualized by 18F‐FDG.68Ga‐DoTATATE was 
more effective in distinguishing inflammation or collapsed lung from tumor [39]. 
Similarly the flip‐flop phenomenon with decreasing uptake of the labeled somato-
statin analogue and increasing uptake of the 18F‐FDG in atypical pulmonary carci-
noids was shown for 68Ga DoTAToC by Jindal et al. [40].
small cell lung cancer
Considering its neuroendocrine differentiation, SCLC was an obvious target for 
imaging with labeled somatostatin analogues. The first analogue available for imaging, 
123I‐Tyr‐3‐octreotide, was tested as the SCLC staging agent already in the early 
1990s [41, 42]. In the first larger series of 20 patients with histologically confirmed 
SCLC, iodine‐123‐Tyr‐3‐octreotide correctly identified 84% of primary tumors, and 
78% of all patients with extensive disease, however with limited ability to detect liver 
and bone metastases [42].
The first study on 111In‐DTPA‐octreotide in SCLC showed primary tumor in 13 of 
15 evaluated cases, 12 of which with more diffuse disease than it was suspected 
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Figure  4.4.4.1 99mTc‐tectrotide scintigraphy in bronchial carcinoid (SPECT/CT) 
(Nuclear Medicine unit, Department of Endocrinology, university Hospital in Krakow, 
Poland). (See insert for color representation of the figure.)
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based on other imaging modalities [43]. However, the radiopharmaceutical showed 
limited ability to detect abdominal, particularly liver, metastases, probably due to high 
physiological hepatic uptake of the tracer [44]. In series of 21 patients 111In‐octreotide 
detected 86% (48/56) of the lesions already known at the time of scintigraphy, including 
94% of mediastinal metastases, 75% of bone metastases, and 71% of abdominal lymph 
nodes metastases; the technique detected five previously unrecognized SCLC lesions 
[45]. The next published data were less enthusiastic: both Bohuslavizki et al. and 
Hochstenbag et al. revealed only limited ability of 111In‐DTPA‐octreotide to correctly 
identify distant metastases and stage SCLC [46, 47].
This prompted a larger multicenter study that included 100 SCLC, which con-
firmed high sensitivity (96%) of the method in visualizing the primary tumor and 
much poorer performance in detecting the regional and distant metastases (60 and 
45%, respectively). The authors concluded that although 111In‐DTPA‐octreotide is 
not suitable for staging of the SCLC, the decrease in tumor/background ratio during 
the chemotherapy noted in patient with remission may be utilized in monitoring the 
treatment [48].
non‐small cell lung cancer
octreotide scintigraphy was shown quite early to be able to detect NSCLC [44]. 
one of the studies compared 99mTc‐octreotide with 18F‐FDG coincidence imaging 
(using the same gantry). The studied group of 44 patients included 25 patients 
with NSCLC. The sensitivity, specificity, PPV, and NPV of 99mTc‐octreotide for 
detecting the primary lesion were 100, 75.7, 90.1, and 100%, respectively, and 
of 18F‐FDG they were 100, 46.1, 83.8, and 100%, respectively. The sensitivity of 
99mTc‐octreotide for the detection of lung cancer at the primary lesion was comparable 
with that of 18F‐FDG coincidence imaging. SPECT 99mTc‐octreotide scintigraphy 
was less effective in detecting hilar and mediastinal lymph node  metastases; 
however, it proved to be successful in detecting distant metastases [49]. The other 
radiopharmaceuticals tested in NSCLC included 111In‐DoTA‐lanreotide [50] and 
68Ga‐DoTAToC [51].
However, it was 99mTc‐P829, later named 99mTc‐depreotide, to be the radiotracer 
most frequently applied in NSCLC [52]. Although it has been mostly applied for the 
noninvasive assessment of lung nodules, 99mTc‐depreotide was also used for NSCLC 
staging and was compared with other modalities used for that purpose. The largest study 
published so far comprised data from 166 NSCLC patients. Whole body and SPECT 
99mTc‐depreotide scintigraphy results were compared with attenuation‐corrected 18F‐
FDG PET. 99mTc‐depreotide scintigraphy was equally sensitive as 18F‐FDG PET 
(94% (CI: 88–98%) vs. 96% (CI: 90–98%), respectively), but less specific (51% (CI: 
34–68%) and 71% (CI: 54–85%), respectively). The staging accuracy of both methods 
proved to be similar (45 and 55%, respectively); however, the authors concluded it to 
be insufficient to correctly assess the extent of the disease [53]. Another study on the 
assessment of locoregional lymph nodes involvement with 99mTc‐depreotide con-
ducted on 86 patients with 204 lymph node stations in total, although revealing high 
sensitivity of 99% and NPV of 98% of the method, failed to confirm any added value 
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of scintigraphy with equal to CT diagnostic accuracy of 76.4%. The method accurateness 
did not benefit from quantitative assessment of the tracer uptake [54].
solitary pulmonary nodule
The first experience with 99mTc‐depreotide in evaluation of the solitary pulmonary 
nodules was published in 1999 by Blum et al. [55]. It was followed shortly by the 
announcement of the results of a multicenter trial, which included 144 patients (88 
malignant lung lesions). The sensitivity of the method with chest CT as the reference 
was 96.6% and specificity was 73.1%, comparable with the performance of 18F‐
FDG PET assessment carried out at the end of the twentieth century [56].
The sensitivity and specificity of the 99mTc‐depreotide scintigraphy in detecting 
the malignancy in solitary pulmonary nodule varies from 88 to 100% and from 43 to 
88%, respectively (Table 4.4.4.1) [55–67]. The results of the meta‐analysis by Cronin 
et al. comparing different methods of cross‐sectional imaging in solitary pulmonary 
nodule differential diagnosis are summed up in Table 4.4.4.2 [68].
The 99mTc‐depreotide in solitary pulmonary lesions was compared head‐to‐head 
with other functional imaging modalities. 99mTc‐depreotide was proved to be equally 
sensitive and specific as 201Tl chloride in characterization of the pulmonary lesion, 
with false positive results being the main disadvantage [63]. Studies assessing 99mTc‐
depreotide and 18F‐FDG usually show greater sensitivity and/or specificity of the 
latter; however, it has been concluded that 99mTc-depreotide SRS is valuable 
alternative for 18F‐FDG and should be considered if PET is not available [53, 61, 62].
other labeled somatostatin analogues used in solitary pulmonary nodule assessment 
were 99mTc‐octreotide acetate and 99mTc‐EDDA/HyNIC‐ToC [49, 69]. The sensi-
tivity of the second tracer was 90% in the largest studies published so far, and true 
negative results were obtained in 79% of the benign lung nodules [69]. The performance 
tAble 4.4.4.1 sensitivity and specificity of 99mtc‐depreotide in solitary pulmonary 
nodule assessment
References Number of subjects Sensitivity Specificity
Blum (1999) [55] 14 0.93 0.88
Blum (2000) [56] 114 0.97 0.73
Grewal (2002) [57] 39 1.0 0.43
Baath (2004) [58] 28 0.94 0.64
Chcialowski (2004) [59] 31 0.94 0.44
Kahn (2004) [53] 157 0.94 0.51
Martins (2004) [60] 40 0.97 0.63
Halley (2005) [61] 28 0.89 0.80
Ferran (2006) [62] 29 0.84 0.88
Boundas (2007) [63] 33 1.0 0.65
Szalus (2008) [64] 50 0.89 0.60
Axelsson (2008) [65] 99 0.94 0.52
Harders (2012) [66] 140 0.94 0.58



















































































































































































































































































































































































of the method was facilitated by semi‐quantitative analysis of the tracer uptake [70]. 
Head‐to‐head comparison of 99mTc‐depreotide and 99mTc‐EDDA/HyNIC‐ToC 
showed similar efficacy of two somatostatin analogue–based tracers in distinguishing 
malignant pulmonary nodules; however, the higher number of false positive results 
with 99mTc‐depreotide was stressed [71]. Similar results were obtained for a two 
subset of patients, each evaluated with one of two somatostatin‐based tracers [67].
breAst
SSTRs presence, particularly type 2, has been confirmed in breast cancer tissue [30, 
72]. Positive correlation between SSTR type 2 mRNA and estrogen and progesterone 
receptors expression has also been found [73, 74], and the SSTR expression is regulated 
by the estrogens in cell line studies [75]. These findings led to the clinical application 
of the SRS as early as in 1994. Positive scintigraphy with 111In‐DTPA‐D‐Phe1‐
octreotide in 39 of 52 primary breast cancers (75%) was reported, particularly in 
invasive ductal carcinomas, and nonpalpable cancer‐containing lymph nodes were 
detected in 4 of 13 patients with subsequently histologically proven metastases [76]. 
Subsequent studies confirmed similar sensitivity of the 111In‐pentetreotide scintigraphy 
in presurgical assessment of breast cancer patients [77, 78]. The 111In‐pentetreotide 
scintigraphy seemed to be less effective in the assessment of axillary lymph nodes 
involvement [79], which may be due to the weaker expression of the SSTR2 mRNA 
expression in metastatic breast cancer [74].
The positivity of the 111In‐pentetreotide scintigraphy was reported to be related to 
the SSTR type 2 (P = 0.025), as well as SSTR type 5 (P < 0.001) expression in cancer 
tissue [80]. The 99m‐Technetium labeled compounds have been also tested in breast 
cancers. The 99mTc‐depreotide value in prediction of the response to hormonal 
therapy was tested in breast cancer bone metastases—99mTc‐depreotide was more 
specific but less sensitive and accurate than 99mTc‐MDP in metastases detection. 
Depreotide‐positive patients remained stable during the follow‐up, whereas five of six 
depreotide‐negative patients progressed [81]. In the larger group of patients with 
advanced breast cancer, the 99mTc‐depreotide scintigraphy was performed twice: 
before and 3 weeks after initiation of the hormonal treatment. The PPV and NPV  of 
baseline 99mTc‐depreotide scintigraphy for therapy responsiveness were 73% (8/11) 
and 100% (7/7), respectively. Sequential scans were always both positive or both neg-
ative. The 99mTc‐depreotide uptake in subsequent scans decreased in responders and 
increased in the nonresponders (P = 0.017). Baseline and follow‐up scans combined 
predicted the responsiveness to the hormonal therapy with 100% accuracy [82]. The 
sensitivity, specificity, PPV, and NPV of 99mTc‐octreotide in the detection of primary 
breast cancer lesion were 91.8, 22.2, 71.8, and 57.1%, respectively; however, the 
lymph node metastases may be obscured by the nonspecific breast tissue uptake [83]. 
68Ga‐DoTAToC PET/CT has been reported to be able to detect both breast metas-
tases from neuroendocrine tumors and primary breast cancer lesions [84].
The radio‐guided surgery with 125I‐lanreotide was first reported in 1999. The 
overall accuracy of nodal evaluation with 125I‐lanreotide/intraoperative gamma 
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detection was 77% and the NPP of this technique was 97%. False positive results 
were obtained in 20% of histologically negative axillary lymph nodes. A significant 
statistical correlation between histology and gamma probe counts (P < 0.0001) was 
found [85]. Intraoperative gamma‐probe detection with 111In‐octreotide of the axil-
lary lymph node involvement in SRS positive primary breast tumors was shown to be 
ineffective in microscopic (in situ) nodal metastases [86].
other chest tumors
The use of SRS in thymic malignancies evaluation has been mostly described in 
case reports. Two patients’ series have been published so far. 111In‐DTPA‐D‐Phe1‐
octreotide scintigraphy performed in a group of 18 patients was effective in the 
detection of thymic masses larger than 1.5 cm and in differential diagnosis of malignant 
lesions—thymic hyperplasia was negative on SRS scans [87]. In the second series 
of 14 cases, the 111In‐pentetreotide scintigraphy was positive in 13 cases, whereas in 
11 cases, expression of at least one SSTR subtype was confirmed by immunohisto-
chemistry [88].
digestive system
The experience in SRS in digestive system malignancies other than gastroen-
teropancreatic neuroendocrine neoplasms is limited to case reports and single 
small series.
oesophageal cancers
99mTc‐depreotide has been the only somatostatin analogue tested in oesophageal 
cancer patients. Although statistically significant difference in tracer uptake between 
malignant and nonmalignant oesophageal lesions was confirmed, limited sensitivity 
of the method (76%) makes it unsuitable for the screening and/or primary diagnosis 
[89]. Although SSTR expression was confirmed by immunohistochemistry mostly in 
oesophageal adenocarcinoma, the 99mTc‐depreotide uptake did not correlate with 
tumor type and SSTR expression [90].
gastrointestinal stromal tumors
The only published report including SRS in gastrointestinal stromal tumor 
(GIST) patients showed positive scans in 50% of six patients evaluated with 
111In‐octreotide [91]. However, tumor cells in primary culture (gastric and small 
intestinal GIST) specifically bound and internalized 177Lu when incubated 
with the therapeutic compound 177Lu‐octreotate for 4–48 h, which makes the 




99mTc‐HyNIC‐Tyr(3)‐octreotide scintigraphy has been proved to detect human 
hepatocellular cancer (HCC) xenografts in nude mice [92]. The human studies 
showed positive 111In‐octreotide scans in less than 50% of HCC cirrhotic patients—
the imaging may be used as the examination qualifying the patient to the subsequent 
treatment with long‐acting somatostatin analogues [93, 94].
Although hepatic cholangiocarcinomas and adenocarcinomas of the gallbladder 
were proved to take up 111In‐DoTA‐LAN, the positive scans did not predict the 
response to the lanreotide treatment [95].
urogenitAl neoplAsms
kidney
The SRS has been mostly used in renal cell carcinomas (RCC). The largest series 
published so far included 16 patients with advanced RCC. Although nine of them 
were positive on 111In‐pentetreotide scintigraphy, lesion‐based analysis showed only 
12.1% sensitivity, proving negligible value of the method in this setting [96].
prostate
The first published study on hormone‐refractory metastatic prostate adenocarcinoma 
compared 111In‐DTPA‐D‐Phe1‐octreotide (octreoScan) with 99mTc‐HDP. Nearly 
95% of 31 patients had at least one metastasis positive on octreoScan, and 37% of all 
bone metastases were detected with SRS [97]. Small pilot study results suggested that 
111In‐DTPA‐D‐Phe1‐octreotide scintigraphy might be useful in selecting prostatic 
cancer patient who benefit from somatostatin analogue therapy [98].
Similar Ga‐68‐DoTAToC PET/CT sensitivity of 30% in per‐lesion analysis was 
showed in prostatic cancer focal bone metastases. one‐third of the patients with super-
scan was negative with this imaging method. The maximum Delta SuV(max) between 
metastases and normal bone was 4.9 (mean =1.6 ± 0.9) and between the prostate and 
adjacent tissue was 5.9 (mean = 2.8 ± 1.6), suggesting only weak expression of the 
SSTR type 2 and 5 in tumor tissue [99].
neuroblAstomA
Neuroblastoma is the most common extracranial solid tumor of the childhood. The 
nuclear medicine, particularly mIBG‐scintigraphy, has been established as the 
valuable tool for detecting, staging, and qualification for the radionuclide therapy 
[100]. As the SSTR type 2 expression has been shown in some of the neuroblas-
tomas, somatostatin analogue–based imaging and/or treatment offers an alternative 
management, particularly for the mIBG negative patients [100, 101]. The study com-
paring 123I‐mIBG and 111In‐pentetreotide scintigraphy results showed concordant 
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results in 85% of studied patients. The positive SRS scans were connected with more 
favorable prognosis [102].
The larger study including 88 neuroblastoma patients confirmed better 123I‐mIBG 
sensitivity (94 vs. 64% for 111In‐pentetreotide) in tumor detection. However, SRS 
provided important prognostic information: 4‐year survival and 4‐year event free–
survival were significantly better for 111In‐pentetreotide positive than negative children 
(survival: 90 vs. 48%, log rank P < 0.003; event‐free survival: 83 vs. 39%, log rank 
P < 0.0002) [103].
Peptide receptor radionuclide therapy (PRRT) in neuroblastoma patients is discussed 
in Chapter 6.6.
merkel cell cArcinomA
MCC, rare and highly malignant cutaneous tumor, is also considered a neuroendo-
crine neoplasia and as such is a potential target for SRS [104]. The first reports of the 
successful visualization of the MCC larger than 0.5 cm with SRS came from 1992 
[105]. In the prospective study in a group of 20 patients, 111In‐octreotide sensitivity 
and specificity for grade I and II tumors were 78 and 96%, respectively. SRS was 
able to detect the occult tumor lesions; however, the metastases to the organs with 
physiologic high uptake of the tracer may be omitted [106]. The German group 
showed in contrast false negative results of 111In‐octreotide scintigraphy in 5 of 11 
examined patients [107].
A study comparing 111In‐pentetreotide with18F‐FDG PET/CT showed a better 
detection rate with the latter agent resulting in frequent upstaging of the patients. 
None of the octreotide positive patients was negative on 18F‐FDG PET/CT, suggest-
ing that currently this method is the preferred in the functional evaluation of MCC 
patient [108]. However, one case report suggested that 68Ga‐DoTATATE PET/CT 
might be more accurate in the evaluation of the tumor burden [109]. Positive SRS in 
MCC resulted in the first attempts of PRRT in progressive patients [110].
lymphomA
Both somatostatin and SSTRs are detected in the immune system. In human studies, 
somatostatin mRNA has been found in the thymic epithelial cells and spleen [111], 
and SSTRs expression in various lymphoid organs [112]. The SSTR type 3 mRNA 
was shown to be consistently expressed in normal human lymphocytes, their activation 
resulted in upregulation of SSTR type 5 mRNA. SSTR type 2 expression in peripheral 
blood mononuclear cells (PBMC) has been regarded to be low in comparison to the 
cell lines and PBMC from leukemic patients, and to increase after activation with 
phytohemagglutinin [113, 114]. However, in the quantitative assessment by RT‐PCR, 
the SSTR2 mRNA expression was found to be low, corresponding to the low binding 
of [(125)I‐Tyr(3)]octreotide and absent immunoreactivity for SSTR type 2 in immu-
nohistochemistry [115]. It was concluded that lymphomas are not the good candidates 
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for PRRT with labeled somatostatin analogues, which have been however tried in 
imaging to stage the tumors and to assess therapy response.
The successful attempts to detect the lymphoma tissue by SRS were reported in 
early 1990s [116, 117]. The sensitivity of 111In‐DTPA‐D‐Phe‐1‐octreotide in Hodgkin’s 
disease (HD) varied from 70 to 98% (with lowest detection rate for the disease local-
ized in abdomen) [118–121]. For stage I–II HD SRS resulted in upstaging in18% of 
the patients [122].
In non‐Hodgkin’s lymphoma (NHL) patients, the sensitivity of the method has 
been considered to be lower and varied between 35 and 85% (29–35% for low‐grade 
and 43–44% for high‐grade disease) [118, 120, 121]. 99mTc‐depreotide has also 
been tested in NHL as the potential targeting agent, although high bone marrow 
uptake made it unsuitable for that purpose [123]. 111In‐octreotide scintigraphy was 
found to be able to distinguish between gastric and non‐gastric primary mucosa‐
associated lymphoid tissue (MALT) lymphoma [124]. SRS effectiveness in staging 
of cutaneous lymphomas is very limited—43% of B‐cell and none of the T‐cell 
cutaneous lymphomas were detected [125].
In SRS effectiveness studies, anatomical imaging (CT, ultrasound) was used as 
a standard. only a few studies comparing SRS with other functional method have 
been published so far. The head to head comparison of 111In labeled octreotide 
with 18F‐FDG was published in 1993. In a group of 22 malignant lymphoma 
patients, metabolic imaging yielded a higher rate of detection of lymphoma 
 manifestations (92% vs. 64%) and better tumor contrast [126]. The study 
 comparing 67Ga citrate, 111In‐DoTA‐dPhe(1)‐Tyr(3)‐octreotide (111In‐DoTA‐
ToCT), and 111In‐DoTA‐ lanreotide (111In‐DoTA‐LAN) scintigraphy in patients 
with proven MALT‐type lymphoma showed similar detection rate (63, 60, and 
64%, respectively) and false positive cases. Whereas SRS was better in detecting 
infradiaphragmatic lesions, 67Ga‐citrate was more sensitive in detecting supra-
diaphragmatic disease [127].
tumor‐induced osteomAlAciA (tio)
After a series of case reports on SRS in detection of the hypophosphatemia causing 
neoplasia, a few larger studies has been published. 68Ga‐DoTATATE PET/CT was 
able to find FGF‐23‐secreting tumors in all six patients included in the multicenter 
Australian study [128]. The largest study published so far included 183 patients 
with hypophosphatemia, 80 of whom were considered to have TIo. The sensitivity 
of 99mTc‐HyNIC‐ToC was 86.3%, specificity 99.1%, and the overall accuracy 
93.4% [129].
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introduction
Inflammatory diseases are a heterogeneous class of diseases characterized by 
chronic inflammation of the target organ, often relapsing, invalidating, and 
requiring lifelong treatment. The so‐called aseptic chronic inflammatory dis­
eases include autoimmune diseases, graft rejection, sarcoidosis, vasculitis, ath­
erosclerosis, and some degenerative diseases. In these patients, it is very 
important to achieve specific immune suppression to extinguish the immune 
process with the aim of stopping the disease, preventing or delaying complica­
tions, and avoiding disease relapse. It is important that while attempting to 
improve the quality of life of these patients by means of anti‐inflammatory 
drugs, side effects are reduced to a minimum via the use of specific immune 
therapies that block as selectively as possible the pathologic mechanisms 
responsible for the disease.
New therapeutic options are being developed for specific targeted therapies. 
Several trials are being performed to assess the efficacy and safety of new 
approaches. All of them, however, rely mostly on the clinical assessment of the 
patients to evaluate the effect of treatment. It would be important to use an objective 
and reliable method to highlight directly the immune process underlying the 
individual disease; specific diagnostic tests, furthermore, may allow the selection 
of patients to be treated.
Nowadays, nuclear medicine techniques are not often used for the diagnosis of 
chronic inflammatory diseases but greatly contribute to the management and prog­
nosis of the disease. Most importantly, somatostatin receptor scintigraphy (SRS) has 
been proposed for the evaluation of the state of activity of some inflammatory dis­
eases and to early evaluate therapy efficacy. This is particularly important because 
new molecular therapeutic biological agents that specifically target and block 
inflammatory reactions are continuously being developed. The referring physician 
not only obtains information on the activity of the disease but also on the nature of 
the process and can, therefore, decide which treatment to start, when to start it, and 
when to stop it or modify it.
somAtostAtin receptor expression in inflAmmAtory 
diseAses
Many hormones and some neuropeptides and neurotransmitters play a key role in 
regulating lymphoid cells; somatostatin, in particular, is involved in numerous regu­
lating mechanisms of cell activities in the immune system. The expression of somato­
statin receptors in the thymus in man has prompted the hypothesis that this hormone 
participates in the maturation process of T lymphocytes.
Somatostatin receptors are expressed on both activated lymphocytes and inflamed 
vascular endothelium. SRS holds important information not only by demonstrating 
the presence of inflammation but also by providing a rationale, in positive patients, 
for the use in selected cases, of unlabelled somatostatin for the treatment of the 
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disease. The expression of receptors for somatostatin has been investigated in patients 
with autoimmune diseases and cancer [1].
Hyperexpression of the somatostatin receptor (SSTR) has been found in intestinal 
samples from patients with active ulcerative colitis and Crohn’s disease. SSRs were 
localized in intramural veins and were not detected in noninflamed control intestine 
[2]. SSRs were reported in vitro in patients with active rheumatoid arthritis [3].
SRS is applicable in imaging of chronic inflammation but is unsuitable for visual­
ization of acute infectious diseases [4]. Ten Bokum et al. showed in 2002 accumulation 
of In‐111 DTPA‐octreotide in the thymus and the pituitary of normal Balb/c mice 
and of nonobese diabetic mice, a strain prone to autoimmune type 1 diabetes. They were 
unable, however, to show any uptake in the inflamed pancreas of prediabetic animals [5].
Radiolabeled somatostatin analogues have been extensively used for the study 
of neuroendocrine tumors [6], particularly in gastroenteropancreatic tumors, where 
the presence of receptors for somatostatin has been demonstrated [7]. The most 
commonly used analogue is 111In‐[d‐Phe1]‐pentetreotide (OctreoScan), a small 
octapeptide that binds with high affinity to the somatostatin type 2 receptor 
expressed on the cell membrane of the target tissues. It has no side effects. Several 
analogues have been synthetized and are currently used in routine clinical practice. 
A recent analogue that has been used in autoimmune diseases is 99mTc‐HYNIC‐
[d‐Phe1,Tyr3]‐octreotide (99mTc‐HYNIC‐TOC), which has extensively been used 
in neuroendocrine tumors and in inflammatory diseases [8]. 99mTc‐Depreotide is 
another analogue that has been used to localize sites of inflammation in patients 
with viral myocarditis [9] and in patients with bone infection [10, 11].
study of sJÖgren syndrome by srs
Sjögren syndrome (SS) is characterized by dry mouth and dry eyes (sicca syndrome) 
as a result of autoimmune destruction of salivary and lacrimal glands. Specific auto­
antibodies (anti‐SSA and anti‐SSB) are detectable in the peripheral blood, but the 
diagnosis of the disease is based on biopsy and/or salivary gland hypofunction as 
detected by Schirmer test (AeCG criteria). The role of salivary gland scintigraphy 
(scialoscintigraphy) is still a matter of debate and new imaging modalities are indeed 
required to demonstrate the presence of lymphocytic infiltration in the salivary glands. 
New immunological treatments are being tested for SS (infliximab, rituximab), and it 
would be useful to have a diagnostic test capable of detecting infiltrated glands that 
could be used for therapy selection and monitoring (Fig. 4.4.5.1).
A recent study has described the use of the new somatostatin analogue 99mTc‐
HYNIC‐Tyr(3)‐octreotide for the diagnosis of the state of activity in patients with 
rheumatoid arthritis and secondary SS before and after treatment with infliximab. 
Results showed that inflamed parotid glands could be diagnosed by this radiophar­
maceutical. Inflamed joints were also detected in patients with active rheumatoid 
arthritis [8]. Interestingly, after treatment with infliximab, normalization of the 
uptake in most inflamed joints was noted but not in salivary glands, probably 
reflecting the different nature of the two diseases.
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study of thyroid diseAses by srs
Autoimmune thyroid diseases, including Graves’ disease, primary myxedema, and 
Hashimoto’s thyroiditis, appear related in certain aspects of their pathogenesis and 
clinical course. evidence of humoral immunity is provided in all of these disorders 
by the presence of antibodies against thyroid peroxidase (formerly known as micro­
somal antigen) and often against thyroglobulin. Antibody titles tend to be highest in 
Hashimoto’s disease and lowest in primary hypothyroidism at the time it is diag­
nosed. More specific to Graves’ disease are circulating autoantibodies that are 
capable of binding to the thyroid‐stimulating hormone receptor (TSHr) on the sur­
face of thyroid cells and stimulate cell growth and hormone production. Graves’ 
disease, primary myxedema, and Hashimoto’s thyroiditis all share evidence of cell‐
mediated immunity against thyroid antigens and are characterized by a varying 
degree of infiltration by lymphocytes and plasma cells. The infiltrating cells collect 
in aggregates, forming lymphoid follicles with germinal centers [12, 13].
exophthalmos is a frequent manifestation of Graves’ disease that may lead to severe 
complications. It is caused by muscle hypertrophy and lymphocytic infiltration of the 
retro‐orbital space, which may eventually turn into fibrosis. exophthalmos is usually 
treated with corticosteroids and/or cyclosporin or by local X‐ray therapy. It would be 
extremely important to be able to diagnose the state of activity of the disease and to differ­
entiate between active infiltration and fibrosis because of the difference in their treatment.
Current diagnosis of thyroid autoimmunity is based on the detection of auto­
antibodies (anti‐TSHr, anti‐TPO, and anti‐TG) and clinical signs and symptoms. 
figure 4.4.5.1 SRS in a patient with Sjögren syndrome showing pathological uptake of 
labeled octreotide in major salivary glands. A minor uptake is also detectable in the thyroid 
gland. SRS—somatostatin receptor scintigraphy.
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However, the relationship between autoantibodies and disease activity is still unclear, 
and it is generally believed that the activity of the autoimmune process is determined 
by the intensity of intrathyroidal lymphocytic infiltration. In vivo measurement of 
thyroid cellular infiltration, particularly in patients with undetectable serum thyroid 
autoantibodies, would be ideal for evaluating the disease activity, determining the 
need for therapy, and monitoring the efficacy of treatment (Fig. 4.4.5.2).
Forster and colleagues described the use of SRS in patients with Graves’ ophthal­
mopathy and stressed the importance of SPeCT acquisition although with high inter­
operator variability [14]. Very elegantly, Savastano and colleagues demonstrated the 
TSHr dependence of Graves’ ophthalmopathy in a patient with negative orbital SRS 
that became positive after the administration of recombinant TSH [15]. Krassas et al. 
postulated in their review that the accumulation of the radionuclide is most probably 
due to the presence in the orbital tissue of activated lymphocytes bearing somato­
statin receptors; alternative explanations are binding to receptors on other cell types 
(myoblasts, fibroblasts, or endothelial cells) and local blood pooling due to venous 
stasis by the autoimmune orbital inflammation [16].
Krassas et al. in 1997 used 111In‐octreotide scan to select patients with thyroid eye 
disease to be treated with lanreotide and to follow them up to evaluate the response 
to the treatment [17]. Diaz and colleagues in 1994 demonstrated, in 40 patients, the 
diagnostic value of somatostatin receptor scan not only for detecting and quantifying 
the inflammation severity in the retrocular space but in the follow‐up of the disease 
[18]. This same observation was made by Moncayo et al. who observed the inflam­
mation in the retrobulbar tissue with 111In‐octreotide and used it for evaluating the 
response to the therapy [19]. Likewise, in another study, Colao et al. used 
figure 4.4.5.2 SRS in a patient with autoimmune thyroid disease (Graves’ disease with 
mild orbitopathy) showing pathological uptake of labeled octreotide in the thyroid gland. No 
activity is detectable in salivary glands. SRS—somatostatin receptor scintigraphy.
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111In‐octreotide to predict the clinical response to corticosteroid treatment in Graves’ 
ophthalmopathy and suggested using it as a useful approach to select patients for the 
proper treatment [20].
111In‐pentetreotide has been used in imaging of Graves’ disease, obtaining differ­
ent contrasting results: a few studies have reported that this radiopharmaceutical 
accumulates in thyroid and in the retro‐orbital space in patients with exophthalmos 
and there is a positive correlation with the activity of disease [21, 22], in disagree­
ment with other authors [23, 24]. Differences between authors might be explained by 
the possible mechanisms of accumulation of octreotide: uptake occurs in the early 
phases of Graves’ ophthalmopathy when active infiltration is present; in the later 
stage of the disease, there is fibroblastic activity with subsequent fibrosis in the retro‐
orbital region without expression of somatostatin receptors [25, 26].
A study was performed with 111In‐pentetreotide orbital scintigraphy on patients 
with severe ophthalmopathy caused by Graves’ disease, Hashimoto’s thyroiditis, and 
Means’ syndrome. Activated lymphocytes express somatostatin receptor during the 
active phase of the disease, permitting 111In‐pentetreotide scintigraphy. Authors con­
cluded that 111In‐pentetreotide scintigraphy allows to select patients for octreotide 
therapy, which seems to be adequate in active, moderately severe thyroid eye disease, 
especially when it involves soft tissues [27–30].
Finally, Galuska et al. studied patients with Graves’ orbitopathy with 99mTc‐depre­
otide with comparable results as for the other somatostatin analogues but showing 
excellent SPeCT images [31, 32].
study of sArcoidosis by srs
Octreotide is not suitable for the imaging of experimental abscesses [4], but SSRs were 
observed in vitro in multiple confluent granulomas in patients with active sarcoidosis. In 
this case, SSRs are not expressed on the surface of lymphocytes but are located in the 
areas containing epithelial cells (Fig. 4.4.5.3). In patients successfully treated with ste­
roids with complete sclerosis of the granulomatous lesion, SSRs were not found. These 
studies are in agreement with studies in patients with tuberculosis [33]. A recent study 
by Lebtahi et al. compared the use of 111In‐pentetreotide to that of 67Ga‐citrate in patients 
with sarcoidosis, showing similar diagnostic accuracy [34]. A study by Migliore et al. 
assessed the role of SRS using 99mTc‐HYNIC‐Tyr(3)‐octreotide in a patient with 
systemic sarcoidosis. The study showed that the technique was able to detect pulmonary 
and extrapulmonary localization of sarcoidosis. It was also possible to select the best 
therapeutic options. After treatment with infliximab, the patient showed normalization 
of the scan that correlated with improvement of clinical status [35]. Kwekkeboom et al., 
in a study of 46 patients with sarcoidosis, demonstrated uptake of 111In‐pentetreotide in 
36 of 37 patients with known mediastinal, hilar, and interstitial disease. They postulated 
that somatostatin receptor imaging can demonstrate active granulomatous disease in 
patients with sarcoidosis [36]. The possible role of SRS in diagnosis, staging, and 
follow‐up of patients suffering from sarcoidosis was reviewed by Dalm et al. [37].
Shorr et al. used 99mTc‐depreotide in patients with sarcoidosis [38].
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study of ibd by srs
Crohn’s disease is characterized by a chronic mononuclear cell infiltration of the 
intestinal wall and hypertrophy of local lymphoid tissues [39]. Immune erosion of 
the intestinal wall may lead to severe complications of the affected bowel such as 
stenosis and ulceration, which may require surgical resection. In over 70% of patients, 
relapse of the disease is noted within 1 year after the intervention. In the early relapse 
phase, the symptoms are infrequent and nonspecific, and conventional X‐ray exami­
nations are negative. Since effective therapies are available, early diagnosis of the 
relapse might allow prompt initiation of therapy to prevent the onset of complications 
and the need for further surgical resection [40].
Hyperexpression of the somatostatin receptor has been found in intestinal samples 
from patients with active ulcerative colitis and Crohn’s disease. SSR were localized 
in intramural veins and were not detected in noninflamed control intestine [2]. The 
use of SRS in inflammatory bowel diseases (IBD) has been explored so far.
study of rheumAtoid Arthritis by srs
Rheumatoid arthritis is a chronic autoimmune disease characterized by severe short‐ 
and long‐term complications of the joints. Chronic mononuclear cell infiltration of 
the synovial membrane and subsequent erosion of cartilage and bone lead to joint 
ankylosis. The typical hemodynamic changes of acute inflammation and the persis­
tence of the chronic infiltrate are both present.
figure 4.4.5.3 SRS in a patient with pulmonary sarcoidosis showing diffuse uptake in 
both lungs. Little activity is detectable also in the thyroid. SRS—somatostatin receptor 
scintigraphy.
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figure 4.4.5.4 SRS in two patients with rheumatoid arthritis showing pathological uptake 
in knees (upper panel) and wrist and interphalangeal joints (lower panel). It is interesting to 
note that the left knee shows more uptake of labeled 99mTc‐HYNIC‐TOC compared to the right 
knee, indicating a different activity of the disease in the two joints. SRS—somatostatin 
receptor scintigraphy.
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Specific and nonspecific signs of inflammation are normally used for the clinical 
diagnosis and follow‐up of the disease. Systemic treatment with anti‐inflammatory 
drugs (steroidal and nonsteroidal) is commonly employed for relief of symptoms and 
to delay disease progression. Treatment is usually lifelong and is accompanied by 
several side effects; local therapy is also used and has the advantage of higher local 
concentrations and fewer side effects. It would be very useful for the prevention of 
disease progression to diagnose affected joints before they become clinically evident, 
and local therapies could be applied before complications develop (Fig.  4.4.5.4). 
Rheumatoid arthritis has been extensively studied by nuclear medicine techniques, 
and all radiopharmaceuticals tested showed accumulation in the inflamed joints [41].
SSRs were reported in vitro in patients with active rheumatoid arthritis [42]. Van 
Hagen et al. in 1994 in a sample of 14 patients with active AR and 4 with severe oste­
oarthritis showed uptake in 76% of the painful and swollen joints of AR group 
positive findings [33].
conclusions
SRS has extensively been studied in several chronic inflammatory diseases and offers 
a valuable diagnostic tool that cannot be obtained by conventional diagnostic 
imaging. The radiopharmaceutical is commercially available, and the scintigraphy is 
easy to perform and may be used in all departments.
The main indications of SRS in inflammation are the selection of patients with 
active disease to be treated with immunomodulating therapies and monitoring of 
their efficacy, in particular where conventional diagnostic imaging lack to offer 
valuable information, such as Graves’ ophthalmopathy. It may also offer advantages 
for the study of systemic diseases, such as sarcoidosis or rheumatoid arthritis; for the 
staging of the disease; and for the study of associated pathologies.
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Somatostatin is a cyclic peptide, which is present in the mammalian circulation in 
two bioactive forms: somatostatin-14 and somatostatin-28 [1, 2]. Somatostatin-14 was 
detected accidentally during studies of the distribution of growth hormone-releasing 
factor in the hypothalamus of rats [3, 4]. Subsequent studies showed that somato-
statin is present and plays an inhibitory role in the regulation of several organ  systems 
and tissues in man and other mammals, like the intestinal tract, the exocrine and 
endocrine pancreas, the central nervous system, the hypothalamus and the pituitary 
gland, the immune system, the retina, and the blood vessels. Somatostatin inhibits a 
variety of physiological functions in the gastrointestinal tract, like gastrointestinal 
motility, gastric acid production, pancreatic enzyme secretion, and bile and colonic 
fluid secretion. It inhibits the secretion of pancreatic and intestinal hormones like 
insulin, glucagon, secretin, and vasoactive intestinal polypeptide. In view of the 
ability of somatostatin to inhibit such a variety of physiological processes, it was 
predicted that this peptide might be of therapeutic value in clinical conditions 
involving hyperfunction or hypersecretion of the organ systems mentioned earlier. 
However, the multiple simultaneous effects of pharmacological concentrations of 
somatostatin in different organs, the need for intravenous administration, the short 
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 postinfusion rebound hypersecretion of hormones considerably hampered the initial 
enthusiasm, as well as its clinical use [5].
Octreotide acetate (Sandostatin®, SMS 201-995) was the first octapeptide somato-
statin analogue that was synthesized. Its elimination half-life after subcutaneous 
administration is two hours, and rebound hypersecretion of hormones does not occur 
[6]. Somatostatin and its commercially available analogues octreotide and lanreotide 
(Somatuline®, BIM 23014) exert their effects through interaction with somatostatin 
receptor, which are expressed on the cells. Somatostatin binds with high affinity to all 
somatostatin subtypes 1 through 5 (sst
1–5
), whereas octreotide and lanreotide bind only 




 [5, 7]. expression of somatostatin receptors by 
endocrine tumors is essential for the control of hormonal hypersecretion by the 




-positive patients, clinical symp-
tomatology related to hormonal hypersecretion can be controlled by the chronic 
administration of one of the currently available octapeptide somatostatin analogues 
[5, 8–11]. These drugs may also exert antiproliferative actions in these patients [9, 12–15].
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In the early 1980s, several somatostatin analogues were developed including SMS 
201‐995 (octreotide acetate, Sandostatin®; Novartis, Basel, Switzerland), RC‐160 
(Vapreotide, Sanvar®, Octastatin), BIM‐23014 (lanreotide, Somatuline®; Ipsen, Paris, 
France), and MK 678 (Seglitide). These new drugs are more resistant to biological 
degradation in the body than native somatostatin [1, 2]. As a result, their half‐lives 
and biological activities are considerably longer than that of native somatostatin 
(1.5–2 h vs. 1–2 min). At present, only octreotide and lanreotide are still clinically 
used.
While native somatostatin binds with high affinity to all somatostatin receptor 
subtypes (sst
1–5





 (Table  5.1.1) [3]. Octreotide acetate (Sandostatin®) was the first octapeptide 
somatostatin analogue developed for clinical use [4]. Another advantage of this drug 
over native somatostatin is that rebound hypersecretion of hormones does not occur 
[4]. Octreotide has to be administered two to three times daily as a subcutaneous for-
mulation (in single doses ranging from 100 to 500 µg) or can be administered as a 
continuous intravenous infusion [5]. The development of an intramuscular depot for-
mulation of octreotide, Sandostatin® long‐acting repeatable (LAR®) (Novartis, Basel, 
Switzerland), which can be administered up to 30–90 mg once every 3–4 weeks, 
has  to a large extent abolished the need for daily injections. Thirty milligrams of 
SomatoStatin analogueS in 
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lanreotide (Somatuline® PR; Ipsen, Paris, France) has to be administered intramuscu-
larly every 10–14 days and roughly has an equal efficacy to octreotide [6]. A slow‐
release depot preparation of lanreotide, lanreotide Autogel® (Ipsen, Paris, France), has 
to be administered deep subcutaneously (s.c.) in dosages ranging from 60 to 120 mg 
once every 3–6 weeks [7, 8].
expression of somatostatin receptors by endocrine tumors is essential for the con-





patients, clinical symptomatology can be controlled by the chronic administration of 
one of these currently available octapeptide somatostatin analogues [1, 9]. Octreotide 
(Sandostatin®) and lanreotide (Somatuline®) have been registered in most countries 
for the control of hormonal symptoms in patients with well‐differentiated neuroen-
docrine tumors of the digestive tract (carcinoids) and pancreas and in patients with 
acromegaly [2, 5, 10]. These drugs may also exert antiproliferative effects on tumors in 
these patients [11, 12]. In patients with well‐differentiated neuroendocrine tumors of the 
digestive tract (carcinoids) and pancreas, treatment with very high doses of somato-
statin analogues might induce more antiproliferative effects than relatively low doses 
[10, 13, 14]. In the past, treatment of these patients with ultrahigh‐dose octreotide 
pamoate (Onco‐LAR®; Novartis, Basel, Switzerland), of which 160 mg had to be admin-
istered intramuscularly every 2–4 weeks, did show promising results [15]. However, the 
development of this drug was discontinued by the manufacturing company.
Pasireotide (SOM 230) is a somatostatin analogue that binds to all somatostatin 
receptor subtypes, except sst
4
 (Table 5.1.1) [16]. The drug is currently produced as a 
short‐acting formulation that has to be administered s.c. and a long‐acting intramus-
cular LAR formulation. These drugs currently undergo phase III study programs in 
Cushing’s disease, acromegaly, and well‐differentiated neuroendocrine tumors of the 
digestive tract (carcinoids) and the pancreas [17–21]. Pasireotide is generally well 
tolerated, although impaired glucose tolerance and hyperglycemia can occur.
New fundamental insights in receptor physiology also opened the concept of mul-
tireceptor family crosstalk, like between somatostatin and dopamine receptors. Focus 
has, therefore, been directed toward the development of new drugs interacting with 
these phenomena [22]. BIM‐23A760 (Ipsen, Paris, France) is a chimeric molecule 




 and dopamine receptor 2 [23]. However, in a phase IIb study 
in patients with acromegaly, this drug showed strong dopaminergic activity but only 
very weak somatostatinergic activity. On the basis of these preliminary data, the 
manufacturing company decided to discontinue the development of this drug.
table 5.1.1 Properties of somatostatin receptor subtypes
Binding affinity: IC
50











SS‐14 0.93–2.3 0.2–0.3 0.6–1.4 1.5–1.8 0.3–1.4
Lanreotide 180–2330 0.5–0.8 14–107 230–2100 5.2–17
Octreotide 280–1140 0.4–0.6 7.1–34.5 >1000 6.3–7.0
Pasireotide 9.3 1.0 1.5 >100 0.2
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GHRH growth hormone-releasing hormone
HDL-C high-density lipoprotein cholesterol
i.m. intramuscular
IGF-1 insulin-like growth factor type 1
LAN lanreotide
LAR long-acting release
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LDL-C low-density lipoprotein cholesterol
LH luteinizing hormone
NFA nonfunctioning adenomas
NFPT nonfunctioning pituitary tumors
oCT octreotide
oR odds ratio
PPARγ peroxisome proliferator-activated receptor gamma
PRL prolactin
s.c. subcutaneously






TSH thyroid-stimulating hormone, thyrotropin
uFC urinary free cortisol
introduction
Pituitary tumors, mainly adenomas, are one of the most frequent brain neoplasias. 
Their prevalence varies depending on the population and method of the assessment. 
on the autopsy and radiological examination, the small pituitary tumors including 
clinically nonsignificant tumors (incidentalomas) are present in one in every six 
 people [1]. The prevalence of clinically significant pituitary lesions in a large cross- 
sectional study performed in Liege, Belgium, was 1 per 1064 individuals [2]. In this 
study, the prolactinomas, null cell adenomas, somatotropinomas, and corticotropinomas 
constituted 60, 14.7, 13.2, and 5.9% of all pituitary tumors, respectively [2]. Mani-
festations of clinically apparent pituitary adenomas are related to the hormone 
 oversecretion and/or mass effect (hypopituitarism included).
Treatment options for patients with pituitary tumors are neurosurgery, radiotherapy, 
and pharmacotherapy, alone or in combination. Neurosurgery, usually via transsphe-
noidal approach performed by an experienced neurosurgeon, is chosen to alleviate the 
compressive mass effect symptoms or to provide control of hormonal hypersecretion 
in tumors not suitable or resistant to the medical treatment, particularly if curative 
resection is possible and patient is willing to. Radiotherapy is indicated for persistent 
hormonal hypersecretion or residual mass after surgery or when surgical resection of 
compressive mass is contraindicated. It should be also considered in aggressively 
growing or recurring tumors [3]. Medical therapy with dopamine agonists (DAs) is 
considered the first-line treatment for prolactin (PRL)-secreting adenomas; however, 
the pharmacotherapy role in managing patients not suitable for surgical treatment, in 
preparing for tumor debulking, or in hypersecretion control is rapidly increasing.
Somatostatin (SST) has been initially identified as a factor inhibiting pituitary 
growth hormone (GH) secretion [4], but it also plays a role in the regulation of 
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secretion of various pituitary hormones. SST effects are mediated by five membrane 
receptors (SSTR1–5) belonging to the G-protein-coupled receptor family [5]. The 
pattern of tissue SSTR expression and interaction between SSTR subtypes determine 
the physiological action of SST. In the normal pituitary gland, SSTR types 1, 2, 3, 
and 5 are expressed, the last being the predominant subtype [6, 7]. The SSTR subtype 
4 is present only in the human fetal anterior pituitary [8]. The expression of SSTR 
subtypes in pituitary adenomas is presented in Table 5.2.1 [7]. Pituitary tumors may 
also express SSTR variants, for example, truncated forms of SSTR5—sst5TND5 and 
sst5TMD4—have been identified in the cytoplasm of NFA, corticotropinomas, 
somatotropinomas, and prolactinoma. Those isoforms are not detected in normal 
anterior pituitary cells and in spite of intracellular localization are functional [9].
SST seems rather to acutely decrease pituitary hormone exocytosis rather than 
the synthesis. GH secretion is inhibited by SST via SSTR2, SSTR5, and, to some 
extent, SSTR1; thyroid-stimulating hormone (TSH) secretion via SSTR2 and SSTR5; 
and PRL secretion via SSTR2. The exact role of SST in regulating corticotrophin 
( adrenocorticotrophic hormone (ACTH)) release has not been elucidated yet, 
although the main role of SSTR5 is postulated. The inhibiting effect of SST on 
luteinizing  hormone (LH) and follicle-stimulating hormone (FSH) secretion is  modest, 
and the responsible mechanism has not been discovered yet [7, 10]. The ability of 
SST and somatostatin analogues (SSAs) to decrease pituitary hormone secretion 
may also be altered by the presence of truncated isoforms of SSTR, particularly 
SSTR5, which (viz., sst5TMD4) is negatively correlated with the ability of SSA to 
inhibit GH release [11].
Inhibition of pituitary/pituitary tumor cell growth usually accompanies the 
 inhibition of the hormone secretion. It seems that this effect is due to induction of 
apoptosis or cell senescence rather than to mitosis rate decrease, and it is still 
 disputed which SSTR is mediating the process: SSTR2 or/and SSTR5 [7].
The short life of natural SST (t½ ≤ 3 min), which makes it unsuitable for clinical 
use, has led to the development of SSAs with longer half-life. The first clinically 
used SMS 201-995—octreotide (oCT)—was prepared as acetate salt solution for 
frequent subcutaneous or intravenous injections [12]. As the continuous subcuta-
neous administration of oCT resulted in better control of GH levels in acromegalic 
patients than subcutaneous injections a few times a day [13], the long-acting 
 formulations of SSA (octreotide long-acting release (oCT LAR), lanreotide slow 
release (LAN SR), or lanreotide Autogel (LAN ATG)) have been manufactured, 
resulting in better clinical outcome and improved quality of life of patients [14]. 
Modifications of the SST  structure increasing the molecules half-life have changed 
their affinity to SSTR  subtypes (Table 5.2.2) [15]. oCT and LAN bind with the 
greatest affinity to SSTR2. The novel multireceptor-targeted SSA—pasireotide 
(SoM230)—has a 39-, 30-, and 5-fold higher binding affinity for SSTR5, SSTR1, 
and SSTR3, respectively, and 2.6 times lower affinity for SSTR2 compared with 
oCT. Pasireotide has a two-fold higher binding affinity for SSR5 than endoge-
nous SST (Table 5.2.2). Pasireotide exhibits also greater metabolic stability than 
oCT because of the presence of cysteine– cysteine bridge that protects the 
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prolongedvpharmacologic effect compared with oCT [5, 16]. More detailed 
information about the currently used SSA is presented in Chapter 5.1.
This chapter is focused on medical therapy of pituitary adenomas with SSAs.
PituitAry tumors Producing gh: AcromegAly
Acromegaly, due to increased levels of GH and insulin-like growth factor type 1 
(IGF-1), is related to cardiovascular, metabolic, and respiratory morbidities and 
 premature death [1, 17–20].
Acromegaly is also related to higher incidence of cancers [21]. The mortality risk 
in patients with acromegaly is 2.4- to 4.8-fold higher than in the general population; 
60, 25, and 15% of acromegalic patients, respectively, will die from cardiovascular 
and respiratory disease and cancers [22–24]. A meta-analysis published in 2008, in 
which 16 studies on mortality in acromegaly were included, has confirmed increased 
all-cause mortality risk in acromegalic patients (a weighted mean of standardized 
mortality ratio (SMR) of 1.82 (95% confidence interval (CI), 1.12–1.56), even treated 
with transsphenoidal surgery (a weighted mean of SMR of 1.32 (95% CI, 1.12–1.56) 
in studies including at least 80% of patients treated surgically) [25].
The goals of the therapy are to control biochemical indices of activity, control 
tumor size and prevent local mass effect, reduce signs and symptoms of the disease, 
and eliminate morbidity and restore mortality rates to normal age- and sex-adjusted 
rates [26, 27]. The normalization of serum GH and IGF-1 restores acromegalic 
patients’ mortality to normal level (SMR of 1.1 (95% CI, 0.9–1.4) vs. 1.9 (95% CI, 
1.5–2.4) in patients with random GH <2.5 and >2.5 µg/l, respectively; SMR of 1.1 
(95% CI, 0.9–1.4) vs. 2.5 (95% CI, 1.6–4.0) in patients with IGF-1 levels within 
 sex- and age-adjusted normal range and without IGF-1 normalization) [28].
As in other pituitary adenomas, the treatment options for acromegaly includes 
neurosurgery, radiation, and medical. The optimal use of each modality is the issue 
of still ongoing discussion [29]. The curative neurosurgery rates in intrasellar micro-
adenomas reach 75–95%, whereas in noninvasive macroadenomas, they drop to 
40–68% [29]. Surgery remission rate in patients harboring adenomas larger than 
20 mm is as low as 20% [30]. Another factor limiting therapy success is high GH 
level [30]. Radiation is usually considered the last line of therapy in acromegaly. 
tAble 5.2.2 binding affinities of somatostatin (sriF-14), pasireotide, octreotide,  
and lanreotide to the five human sstrs [15]a
Compound SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Somatostatin 
(SRIF-14)
1.0–2.3 2.0–1.3 0.3–1.6 0.3–1.8 0.2–0.9
Lanreotide 180 to >1000 0.5–1.8 14–107 66 to >1000 0.6–17
octreotide 280 to >1000 0.4–2.1 4.4–34.5 >1000 5.6–32
Pasireotide 9.3 1.0 1.5 >1000 0.16
a Courtesy of BioMed Central.
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Conventional radiotherapy results in normalization of GH and IGF-1 levels in over 
60% of patients; however, usually the maximum response is seen even 15 years after 
its administration. A faster response is seen when Gamma Knife or linear accelerator 
are applied, maybe because they are used in patients with smaller tumors [29]. The 
other issue is radiation safety: a substantial rate of hypopituitarism, risk of visual 
 deterioration, secondary brain tumors, and radiation vasculopathy [29]. Excess mortality 
in patients undergoing conventional radiotherapy has also been postulated [23].
Three types of medical therapy are currently available in acromegaly treatment: 
SSAs, DAs, and GH receptor agonists, alone or in combination [29]. SSAs are the 
most widely used medical therapy to control the disease [31]. Approximately 90% of 
somatotrophs of GH-secreting adenomas express SSTR2 and SSTR5. SSTR ligands 
cause decrease secretion of GH and finally IGF-1 synthesis. It has been also demon-
strated that SSTR ligands can also influence the peripheral action of GH through 
binding to the SSTRs present on hepatocytes and directly inhibiting liver IGF-1 
secretion [32]. The ability of levodopa to reduce GH levels in acromegalic patients 
was observed already in the 1970s [33]. However, bromocriptine normalizes serum 
IGF-1 levels only in 10% of acromegalic patients and cabergoline in about 39%, 
 particularly with lower pretreatment IGF-1 levels [34, 35]. Pegvisomant, a GH 
receptor antagonist, normalizes IGF-1 levels in a dose-dependent manner in up to 
90% of patients. Currently, it is recommended as the second-line medical treatment 
when SSAs fail to achieve adequate biochemical control of acromegaly [35].
The first ever report on inhibiting GH release in acromegalic patients with SST was 
already published in 1974 [36]. However, only SST infusions gave satisfactory, from 
the clinical point of view, results [37]. In 1984, oCT was announced as the first SSA 
suitable for clinical management of acromegaly [38]. As it has been already mentioned, 
the introduction of SSA of modified release has impacted routine clinical practice.
SSAs in acromegaly are used as adjunctive (secondary) or primary therapy, as 
well as a presurgical pretreatment. up to 75% of patients treated for 12–36 months 
with oCT LAR as adjuvant therapy achieved control of GH or GH/IGF-1 levels [39]: 
47–75% (mean 56%) of patients achieved GH levels <2.5 µg/l, and 41–75% (mean 
66%) IGF-1 normalization. In patients treated with LAN SR as adjuvant therapy, 
14–78% (mean 49%) of patients achieved control of GH levels <2.5 µg/l, and 30–63% 
(mean 47%) IGF-1 normalization [39]. In meta-analysis by Freda et al. including 
patients on secondary and primary treatment with long-acting SSAs, oCT LAR was 
more effective than LAN SR in providing biochemical control in unselected 
population (GH efficacy criteria met in 54 and 48% of patients, respectively; IGF-1 
normalization obtained in 63 and 42% of subjects, respectively). If the patients were 
preselected—assessed for SSA responsiveness before entering the study—the 
difference in efficacy between those two analogues no longer existed [40]. Treatment 
results are usually less satisfactory in unselected populations. In a prospective, 
 multicenter study on oCT LAR as the primary therapy after 48 weeks, GH level 
below 2.5 µg/l was observed in 44% of patients, and IGF-1 normalization in 34% 
[41]. A summary of results from other studies on oCT LAR as the first-line therapy 
is presented in Table 5.2.3 [15]. Retrospective head-to-head comparison of oCT 











































































































































































































































































































































































































































176 PITuITARy TuMoR TREATMENT wITH SoMAToSTATIN ANALoGuES
difference in disease control, in tumor shrinkage, or in improvement of cardiovas-
cular risk markers [51]. A randomized, open-label, multicenter study including 104 
patients indicated that the outcome of the primary treatment with oCT LAR did not 
significantly differ from the surgery [50]. In meta-analysis of the effects of SST 
 analogues on tumor volume, oCT was shown to induce tumor shrinkage in 53% 
(95% CI, 45–61%) of treated patients, and its LAR formulation—in 66% (95% CI, 
57–74%). The mean reduction of tumor size was 37.4% (95% CI, 22.4–52.4%) and 
50.6 (95% CI, 42.7–58.4%), respectively [52].
SSA as the primary therapy is suitable also for a long-term first-line treatment. A 
prospective long-term study (up to 108 month) comprising 67 de novo acromegalic 
patients with macroadenoma treated with individually tailored oCT LAR confirmed 
high efficacy of such approach. In this study, 68.7% of patients achieved safe GH 
level (<2.5 µg/l), 70.1% IGF normalization, and 82% tumor shrinkage by more than 
25% of initial volume [47]. The nadir of GH and IGF-1 levels may be obtained even 
10 years after the SSA treatment has been started [53]. Tailoring of the SSA dose 
according to the GH and/or IGF-1 level may increase the efficacy of treatment, as 
demonstrated in the study by Colao et al. [48].
Lanreotide Autogel (LAR ATG) is a long-acting aqueous preparation in prefilled 
syringe, suitable and approved for self-administration. In a 3-month study in 107 
patients, the GH normalization rate with LAN SR was 48 and 56% with the use of 
LAN ATG. Normal IGF-1 was observed in 45 and 48% of patients treated with SR or 
ATG LAN formulation, respectively [54]. In the one-year extension of this study, 
dose titration of the LAN ATG improved GH and IGF-1 control beyond that achieved 
by fixed dose [55]. In the 3-year extension of the previous study in 14 patients on 
LAN ATG, the frequency of normal GH increased from 36 to 77% and normal IGF-1 
from 36 to 54% [56]. In a meta-analysis by Roelfsema et al. published in 2008, 
treatment with LAN SR and LAN ATG normalized GH and IGF-1concentrations in 
about 50% of acromegalic patients [57]. The efficacy of 120 mg LAN LTG on GH 
and IGF-1 was comparable with that of 20 mg oCT LAR. There were no differences 
in the improvement of cardiac function, decrease in beta cell pancreatic function, and 
side effects between both SSA formulations [57].
The role of preoperative medical therapy with SSAs has been intensively studied. 
The preoperative treatment with SSAs might affect the quality of the tumor and 
therefore improve the effectiveness of the surgery [58]. In the study by Abe and 
Ludecke from 2001, higher rates of GH and IGF-1 normalization were observed in 
patients pretreated with oCT before surgery compared to those who were medically 
naive preoperatively [58]. Also in the multicenter study conducted in Norway, the 
6-month pretreatment with oCT LAR (20 mg monthly) resulted in surgical and 
biochemical remission (defined as normal IGF-1 level) in 50% of patients with 
 macroadenomas in comparison to 16% of those who underwent surgery without 
 pretreatment. However, if biochemical remission was defined as a GH level lower 
than 1 ng/ml after glucose suppression test, the difference between the pretreatment 
and no pretreatment group was no longer statistically significant [59]. Colao et al. in 
67 patients treated preoperatively with oCT LAR for 12 months reported GH control 
in 52%, IGF-1 normalization in 58%, and tumor shrinkage of more than 25% in 85% 
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of patients [49]. In contrary, the difference in surgery outcome (surgical remission 
and complication rate) in retrospective analysis was not significant between patients 
pretreated with oCT or LAN and matched, medically naive controls [60].
The potential role of preoperative treatment with SSAs in the decrease of 
cardiopulmonary comorbidities and decrease of anesthesia-related risk of surgical 
treatment has been discussed. Treatment with SSAs improves cardiac function 
and  reduces the incidence of cardiac dysrhythmias, which can improve the surgery 
 outcomes. It is also related to the reduction of soft tissue swelling, which can result 
in the resolution of sleep apnea and reduction of intubation-related complications. 
These issues however need further examination for higher quality of evidence.
Increasing use of SSA as a primary therapy brings a question of long-term 
 efficacy, particularly mortality reduction. In a retrospective cohort study including 
438 consecutive acromegalic patients, Bogazzi et al. compared the effects of differ-
ent therapies (curative neurosurgery, adenomectomy with SSA therapy, and primary 
therapy) on survival. In whole studied population, the following risk factors were 
associated with excessive mortality: age, physical status, macroadenoma, hypopitu-
itarism, and uncontrolled disease. Patients treated with adenectomy, adenectomy 
plus SSA, and primary SSA therapy had similar risk of death (HR of 1, 0.3 (95% CI, 
0.04–2.36), and 3.24 (95% CI, 0.61–17.33)). Primary SSA therapy harbored increased 
risk of death when compared with neurosurgery (regardless adjunctive treatment 
with SSA; HR of 5.52 (95% CI, 1.06–28.77); however, increased mortality was 
observed only in diabetic patients (HR of 21.94 (95% CI, 1.56–309.04) vs. 1.3 (95% 
CI, 0.04–38.09) for diabetic and nondiabetic patients, respectively) [61]. Good 
biochemical disease control, not the way of achieving it, determines improvement in 
glucose tolerance and insulin sensitivity parameters [62]. Patients with acromegaly 
after curative surgery and on SSA therapy were shown to harbor a similar risk of 
 deterioration of glucose tolerance in long-term follow-up [63]. Even partial biochemical 
control may result in amelioration of cardiovascular risk factors: a significant reduction 
in systolic and diastolic blood pressure, glucose, insulin, HbA1c, total cholesterol 
(T-C) and low-density lipoprotein cholesterol (LDL-C), and triglyceride levels and a 
significant increase in apoA1, high-density lipoprotein  cholesterol (HDL-C), and 
insulin sensitivity compared to pretreatment levels [64].
The multireceptor binding profile of pasireotide suggests its possible use in resistant 
or refractory to oCT and/or LAN acromegalic patients. As it was demonstrated in the 
phase II study, pasireotide effectively controlled GH and IGF-1 as well as significantly 
reduced the tumor size in patients with de novo or resistant/refractory to oCT 
 acromegaly [65]. In an open-label, single-arm, open-ended extension of phase II study, 
biochemical control was achieved in 6, IGF-1normalization in 13, and proper GH 
 control in 12 of 26 patients evaluable at month 6. Significant tumor size reduction was 
observed in 17 (9 in core study, 8 at extension) of 29 patients with MRI data [66].
Results of the phase III study performed in 358 patients with active acromegaly 
who were de novo diagnosed with a visible adenoma on MRI or medically naïve 
(no previous medical therapy, but prior pituitary surgery) showed that pasireotide 
LAR was significantly more effective at inducing full biochemical control (GH 
≤2.5 µg/l and/or IGF-1 upper limit of normal) compared to the current standard 
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medical therapy (oCT LAR i.m. injections). The study met its primary end point, 
with significantly more patients treated with pasireotide LAR (31.3%) experiencing 
full control of their disease than those taking oCT LAR (19.2%). Patients treated 
with pasireotide LAR were 63% more likely to achieve control of their disease than 
those on oCT LAR. Tumor volume reduction and relief in clinical symptoms were 
similar in both treatment groups [67].
The tolerability of SSAs in most patients is good, most of the adverse events 
(AEs) are transient with mild or moderate severity. Discontinuation of the treatment 
due to the side effects is rare. The most common AEs of SSAs are injection site 
discomfort, erythema, and gastrointestinal problems like diarrhea, abdominal pain, 
flatulence,  steatorrhea, nausea, vomiting, and gallstone formation [39]. The most 
common AEs with pasireotide LAR versus oCT LAR were diarrhea (39.3% vs. 
45%), cholelithiasis (25.8% vs. 35.6%), headache (18.5% vs. 26.1%), and hyper-
glycemia (28.7% vs. 8.3%) [67].
Based on clinical research, the Acromegaly Consensus Group updated guidelines 
for acromegaly management published in 2009 has recommended the following use 
of SSA [29]: (a) as the first-line therapy when the probability of surgical cure is low, 
(b) after surgery has failed to achieve biochemical control, (c) before surgery to 
improve severe comorbidities that prevent or could complicate immediate surgery, 
and (d) to provide disease control, at least partial, in the time between radiation 
therapy and the onset of maximum benefit from that treatment.
New formulations of the oCT have been recently tested. The oral formulation of 
oCT—octreolin—uses transient permeability enhancer technology, which enables 
intestinal absorption of the peptide by reversible opening of the intestinal epithelial 
cell tight junctions. octreolin administration in human subjects resulted in dose-
dependent increased plasma octreotide concentrations, with observed rate of plasma 
decay similar to parenteral administration. A single dose of 20 mg of octreolin 
resulted in similar pharmacokinetic parameters to the injection of 0.1 mg of oCT; it 
also suppressed both basal and GHRH-stimulated GH levels by 49 and 80%, 
 respectively [68]. The study on efficacy and safety of octreolin for acromegaly 
(NCT01412424) is expected to be finished in December 2014 [69].
The research on prolonged-release i.m. formulation of oCT (octreotide C2L) 
has  been terminated, in spite of encouraging results, due to commercial reasons 
(NCT00642421) [70].
the combination therapy
The mechanism by which DAs inhibit GH release from somatotrophs is not known; 
however, the addition of the DAs cabergoline to SSAs may improve the response to 
SSA in patients not fully controlled with SSA or in mixed tumors cosecreting GH 
and PRL [71]. The combination of SSA and DA is effective in long-term treatment—
the addition of cabergoline in 19% not properly controlled on oCT LAR alone 
resulted in normalization of IGF-1 levels in 37% of them during a mean 18-month 
follow-up [72]. The additive role of DA is independent of PRL cosecretion and is 
observed even in patients with basal PRL levels within the normal range [71, 73].
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observations from in vitro and clinical studies on enhanced efficacy of SSAs and 
DAs in controlling GH secretion, as well as the discovery of SSTRs and DA heterodi-
merization, have led to the creation of hybrid SST/DA molecules [74, 75]. one of the 
hybrid molecules tested was BIM 23A760.The initial reports from in vitro studies 
suggested higher efficacy and longer duration of GH suppression with this molecule 
[76]; however, additive effects were vanishing with prolonged administration, 
 probably due to interfering metabolite accumulation [77]. Due to lack of expected 
efficacy in suppressing GH and IGF-1 in acromegalic patient, the clinical trial 
NCT00994214 with BIM-23A760 has been terminated [78].
More detailed information on dopastatins is presented in Chapter 9.
Another option of combination treatment is cotherapy with SSA and pegvisomant—
a GH receptor antagonist. Although pegvisomant is very efficient in achieving 
biochemical control, there is some risk of liver failure and/or an increase in pituitary 
adenoma size [35], particularly after SSA discontinuation [79].
Trainer et al. in a randomized controlled trial proved that in patients suboptimally 
controlled on oCT LAR, adding pegvisomant to SSA is equally efficient in  optimizing 
acromegaly control as switching to the GH receptor antagonist alone [80]. A 7-month 
treatment with LAN ATG and pegvisomant resulted in the normalization of IGF-1 in 
57.9% of patients previously biochemically uncontrolled on SSA or pegvisomant, 
particularly in nondiabetic and older ones [81]. A study by Neggers et al. showed that 
long-term combination treatment with SSA and pegvisomant is safe—the most 
common side effect of therapy was transient liver enzymes elevation, to which patients 
with diabetes mellitus were particularly prone (odds ratio (oR), 2.28 (95% CI, 
1.16–9.22)) [82]. In patients well controlled on SSA, the addition of a small dose of 
pegvisomant allows the reduction of analogue dose by 50% [83]. During combine 
treatment, pegvisomant injection may be effectively administered once weekly [84].
PituitAry tumors Producing Acth: cushing’s diseAse
Cushing’s disease is a rare condition [85] associated with chronic hypercortisolemia-
related increased mortality, mainly due to cardiovascular complications like coronary 
heart disease, congestive heart disease, and cerebrovascular disease [86]. The main 
aim of the Cushing’s disease treatment is to reverse clinical symptoms, to normalize 
cortisol level, and to achieve long-term disease control with no recurrence. The 
 first-line therapy in Cushing’s disease is surgery. If curative, it usually normalizes the 
increased mortality (SMR of 0.31 (95% CI, 0.01–1.72) in Danish patients successfully 
treated with surgery vs. SMR of 5.06 (95% CI, 1.86–11.0) in patients with persistent 
hypercortisolism after initial neurosurgery) [85]. The second-line therapies include 
repeated surgery, radiotherapy, medical therapy, and bilateral adrenalectomy [87]. 
unfortunately, the outcomes of neurosurgery and radiotherapy in Cushing’s disease 
are not satisfactory; the 10-year cure rates of both are 77 and 65%, respectively [88]. 
Bilateral adrenalectomy provides immediate control of the hypercortisolism; however, 
patient requires lifelong substitution of gluco- and mineralocorticoids. About one 
quarter of adrenalectomized patients will develop aggressive pituitary tumor secreting 
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large quantities of ACTH—the Nelson’s syndrome [89]. The medical therapies used 
in Cushing’s disease are not curative, but usually adjuvant to neurosurgery or radia-
tion. There are (a) adrenal-directed therapies (i.e., ketoconazole and metyrapone), 
which lower cortisol levels by inhibiting its adrenal production; (b) glucocorticoid 
receptor antagonist (mifepristone), which blocks the peripheral action of cortisol; 
and (c) the new pituitary-directed therapies aimed at the oversecretion of ACTH by 
tumor cells. Several pituitary targeting agents are being investigated, for example, 
peroxisome proliferator-activated receptor gamma (PPARγ) agonists, DAs, and 
SSAs [90].
The rationale for SSA use in Cushing’s disease is the expression of the various 
SSTR subtypes—mainly SSTR5—on corticotrophs [91]. The studies on oCT in 
Cushing’s disease showed however its ineffectiveness probably due to high affinity 
of oCT to SSTR2 and moderate to SSTR5. It can also be explained by downregula-
tion of SSTR2 in tumor cells [92].
The high affinity of pasireotide to SSTR5 predominately expressed in cortico-
trophs has made it more suitable for further testing in Cushing’s disease [5]. In in 
vitro studies, pasireotide has caused significant inhibition of basal and stimulated 
ACTH secretion by cultured human corticotroph tumors, as well as suppression of 
their proliferation [93, 94]. In studies on murine corticotroph tumor cells, similar 
effect was observed [95]. Pasireotide has also shown significant inhibition of cortico-
trophin-releasing hormone (CRH)-induced ACTH release in rats [96].
The results of in vitro studies on pasireotide prompted further clinical research in 
humans. In a multicenter phase II open-label study in 29 patients with de novo or 
persistent Cushing’s disease receiving 600 µg of pasireotide self-administered twice 
a day (b.i.d) subcutaneously (s.c.) for 15 days, urinary free cortisol (uFC) levels 
decreased in 22/29 (76%) patients, of whom five had normalized uFC. Serum cor-
tisol and plasma ACTH levels were also reduced [97]. Results from the extension of 
this study showed reduction of uFC in 56% of patient eligible for efficacy analysis 
and uFC normalization in 22% at month 6. of the four patients who remained on 
pasireotide for 2 years, one had normalized uFC. The most frequent AEs were 
 diarrhea, nausea, hyperglycemia, and abdominal pain [98].
Results of a 12-month phase III study (6 months of double-blind treatment 
 followed by 6 months open-label treatment) of pasireotide in Cushing’s disease has 
been published in 2012. In this study, 162 adults with Cushing’s disease and uFC 
levels of at least 1.5 times the upper limit of the normal range were randomly assigned 
to receive pasireotide at a dose of 600 µg (82 patients) or 900 µg (80 patients) s.c. 
b.i.d. Patients with uFC not exceeding two times the upper limit of the normal range 
and not exceeding the baseline level at month 3 continued to receive their randomly 
assigned dose; all others received an additional 300 µg b.i.d. The primary end point 
was a uFC level at or below the upper limit of the normal range at month 6 without 
an increased drug dose. 12 of the 82 patients in the 600 µg group and 21 of the 80 
patients in the 900 µg group met the primary end point. The median uFC level 
decreased by approximately 50% by month 2 and remained stable in both groups. A 
normal uFC level was achieved more frequently in patients with baseline levels not 
exceeding five times the upper limit of the normal range than in patients with higher 
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baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, 
and clinical signs and symptoms of Cushing’s disease diminished. Pasireotide was 
associated with hyperglycemia-related AEs in 118 of 162 patients; other AEs were 
similar to those associated with other SSAs [99].
Treatment with DA is based on evidence of the dopamine receptor D2 expression 
in more than 75% of corticotrophs [100]. Cabergoline, a dopamine receptor subtype 
2 (D2R) agonist, is also able to normalize uFC level; however, this effect is often not 
maintained during prolonged treatment [101].
The use of mixed medical treatment, “a pharmacological cocktail” with three 
 different drugs targeting SSTR5, D2R, and steroidogenic enzymes in the adrenal 
cortex, was studied in a prospective, open-label, multicenter trial in 17 patients with 
Cushing’s disease. This stepwise approach with pasireotide as the initial form of 
treatment and the sequential addition of cabergoline and low-dose ketoconazole 
resulted in biochemical control in nearly 90% of patients: 29% received pasireotide 
(100–250 µg three times a day), 24% pasireotide and cabergoline, and 35% pasireo-
tide–cabergoline–ketoconazole cocktail [102].
The potential for interaction between SST and dopamine receptors to achieve 
greater suppression of ACTH levels has been explored with the chimeric agent BIM 
23A760 with high affinity to SSTR2 and D2R and moderate affinity to SSTR5 [76]; 
however, its clinical evaluation in Cushing’s disease has not yet been done.
Pasireotide may be also effective in targeting aggressive corticotroph tumor 
growth in the Nelson’s syndrome [103]. Case reports on significant clinical and 
biochemical response to pasireotide administration have already been published 
[104]. Patients are currently recruited for the open-label, longitudinal study of the 
effects of subcutaneous pasireotide therapy on adrenocorticotrophic hormone and 
tumor volume in patients with Nelson’s syndrome (NCT01617733) [105].
PituitAry tumors Producing tsh: thyrotroPinomAs
TSH-producing pituitary tumors (TSH-secreting adenomas) account for 0.5–1.1% of 
all pituitary tumors [106]. The diagnosis is usually delayed as the clinical symptoms 
are very heterogeneous and vary from the symptoms of hyperthyroidism to neurolog-
ical ones such as headache and visual disturbances—the results of the mass effect 
[107]. Surgery is the first-line treatment; however, due to the usually large size of 
the  tumor and local invasion, the prevalence of persistent hyperthyroidism after 
 neurosurgery is reported to be more than 50% of cases [108]. In such cases or in 
inoperable masses, medical therapy is usually needed.
Due to the rarity of the disease, the experience with pharmacotherapy of 
 TSH-secreting pituitary adenomas comes from a small series or case reports. The 
expression of SSTR2 and SSTR5 on tumor cells prompted the use of SSA [107, 109]. 
In approximately 90 and 75% of patients with TSH-secreting adenomas treated with 
oCT, TSH secretion has been reported to be decreased and normalized, respectively. 
Circulating hormone levels were normalized in 96% of cases and goiter volume 
diminished in 20% of them [107, 108, 110–112]. LAN SR and oCT LAR treatment 
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has also been shown to decrease TSH, free thyroxine (fT4), and free triiodothyronine 
(fT3) levels [111, 112]. Colao et al. also reported efficient normalization of TSH and 
fT4 and fT3 after 3–6 months of treatment with low dose of LAN, oCT, and oCT 
LAR without any significant side effects [113].
PituitAry tumors Producing Prl: ProlActinomAs
Prolactinomas are the most common pituitary tumors accounting for approximately 
40–60% of them. The aim of the prolactinoma treatment is to normalize PRL level, 
restore gonadal function and fertility, and diminish the size of the tumor. In the 
majority of patients, medical therapy with the use of DAs is sufficient. However, in 
some cases resistant to DAs, other methods of treatment like neurosurgery and 
radiotherapy might be necessary. The other medical therapy for DA resistant tumors 
is also searched for [114].
Shimon et al. demonstrated the inhibition of the PRL secretion with SSTR5-
selective analogues in vitro in cultured prolactinomas [115]. Similar effect was 
observed in vitro when pasireotide was applied [116]. In selected prolactinoma case 
reports or in experimental settings, SSAs have been used to date. However, SSAs 
have not been used in prolactinomas in the routine clinical practice [114].
The hybrid molecules possessing selective agonist activity to SSTR2 and D2R 
have been experimentally used in prolactinomas. As it was mentioned earlier, SSTR2 
and D2R after heterodimerization in the presence of the appropriate ligands show 
enhanced adenyl cyclase inhibitory activity [74]. In in vitro study in primary cultures 
of prolactinomas responsive and nonresponsive to DA, the chimeric SST/DA 
 molecule BIM-23A760 was compared with cabergoline in suppressing PRL secre-
tion. In this study, BIM 23A760 and cabergoline produced a similar partial inhibition 
of PRL secretion [117].
nonFunctioning PituitAry tumors
Nonfunctioning pituitary tumors (NFPT) are a very heterogeneous group of tumors, 
representing up to 25% of all pituitary tumors. Most of NFPTs are producing small 
amounts of glycoproteins (FSH, LH, and their α and β subunits). Less commonly, 
they are nonfunctioning somatotroph, lactotroph, or corticotroph adenomas. Due 
to the lack of the clinical syndrome of hormonal activity, these tumors are diag-
nosed with a variable delay usually at the time of the presence of the neurological 
symptoms related to mass effects [118]. The main presenting symptoms of NFPTs 
are visual impairment, headache, and hypogonadism. As in hormone-overproducing 
tumors, the first-line treatment in these tumors is neurosurgery. However, due to 
the tumor extension, frequently, it is nonradical with the residual tissue left. 
Reported “gross total removal” rate ranges from 27 to 87%. The radiotherapy 
is used to prevent tumor recurrence, although less and less frequently due to asso-
ciated side effects like hypopituitarism and early cerebrovascular mortality 
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attributed particularly to the conventional technique. No routine medical therapy 
of NFPTs has been established so far [118].
The presence of the different subtypes of the SSTRs and dopamine receptors on 
cell membranes gave the rationale for the medical treatment of NFPTs with SSAs and 
DAs or the combination of both. In NFPT, the dominant receptor subtypes expressed 
are SSTR3 followed by the SSTR2. SSTR1, SSTR4, and SSTR5 are detected less 
commonly [119]. Pawlikowski et al. [120] demonstrated inhibition of chromogranin 
A (CgA) and α subunit secretion by NFPTs cells incubated in vitro with the native 
SST and SSA selective to SSTR3 and SSTR2. The expression of SSTR2 and SSTR5 
was associated with NFPTs cell viability reduction when exposed to the SSA [121]. 
The use of pasireotide (SoM230) completely abolished the promoting effects of 
vascular endothelial growth factor on the NFPTs cell viability [122].
There are only a few clinical trials that have been conducted to examine the 
effects of oCT in NFPTs summarized by Colao et al. [123]. Tumor shrinkage was 
seen in 12% of treated cases. Most of the treated patients had stable remnant tumor. 
only in 5% of the patients treated with oCT that the increase in the tumor size was 
observed. Visual field improvement was reported in 32% (27 of 84) of patients, and 
its compromise in 8% (7 of 84) of oCT-treated patients (the daily dose varied from 
100 to 1500 µg s.c.) [123]. The strength of the data on preventive effect of oCT 
treatment in NFPT recurrence prevention is limited by the short-term follow-up.
In reports of warnet et al. [124, 125], the use of oCT in NFPT patients caused 
rapid improvement in visual impairment and headache with no change in the tumor 
size probably explained by the direct effect on the retina and the optic nerve [126].
The experience with the use of the combination treatment, with SSA and DA in 
NFPT is very limited. Andersen et al. observed more than 10% shrinkage of the 
tumor in 60% of the six NFPTs patients treated for 6 months with oCT (200 µg three 
times daily) and cabergoline (0.5 mg a day) [127]. Colao et al. found a significant 
shrinkage of the tumor associated with improved mean defect at visual perimetry 
with the use of LAN (60 mg every fortnight) and CAB 0.5 mg every alternate day for 
six months [113]. However, due to the lack of placebo-controlled longitudinal studies 
on the SSA treatment and combination treatment with SSAs and DAs, such therapies 
are still not evidence based.
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AbbreviAtions
ACTH adrenocorticotropic hormone
cAMP cyclic adenosine monophosphate
EGF epidermal growth factor EGF
IGF‐1 insulin‐like growth factor
PDGF platelet‐derived growth factor PDGF
pre‐proSST somatostatin amino acid precursor
PTHrp parathyroid hormone‐related peptide
SST somatostatin
SSTR somatostatin receptor
VEGF vascular endothelial growth factor
VIP vasoactive intestinal peptide
The discovery of somatostatin and the synthesis of a variety of analogues constituted 
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biology
natural somatostatin
The somatostatin (SST) neuropeptide family comprises peptides that originate from 
different posttranslational processing of a 116‐amino‐acid precursor (pre‐proSST), 
which is encoded by a single gene located in humans on chromosome 3q28. Pre‐
proSST is processed to proSST (96 amino acids), which is further cleaved to produce 
two bioactive proteins, the predominant but functionally less active SST molecule 
consisting of 14 amino acids (SST‐14) and a larger more potent molecular form 
(SST‐28) [1]. The SSTs have a very short circulation half‐life of 1.5–3 min, rendering 
analysis of their physiological activity difficult. SST is a pan‐inhibitory agent for all 
known gastrointestinal tract hormones.
sst receptors
Twenty years after the discovery of SST in 1972, molecular cloning facilitated the 
identification of its receptor structure. Subsequently, it has become apparent that in 
mammals, SST mediates its inhibitory effects through binding to at least G‐protein‐
coupled membrane receptors. Five different receptor subtypes have been cloned and 
characterized (SSTR1–5). Each receptor consists of a single polypeptide chain with 
seven transmembrane‐spanning domains with the extracellular domains exhibiting 
the ligand‐binding sites and the intracellular sites providing linkage to second 
messenger activation [1].
The diverse inhibitory effects of SST on neurotransmission, motor and cognitive 
functions, smooth muscle contractility, glandular and exocrine secretions, intestinal 
motility, and absorption of nutrients and ions are all mainly mediated by cyclic 
adenosine monophosphate (cAMP) (a second messenger that is important in many 
biological processes and used for intracellular signal transduction) and Ca2+ reduction 
with activation of protein phosphatases [1].
All five SST receptors (SSTR) have been identified throughout the gastrointestinal 
tract and endocrine and exocrine glands, as well as on inflammatory and immune cells. 
Abundant expression of SSTR has been identified in endocrine tumors of the gastroin-
testinal tract and pancreas. SSTR expression varies between patients and between 
tumors, but SSTR2 predominance is found in more than 80% of these tumors. The 
expression of SSTR by human endocrine tumors has important clinical implications, 
such as inhibition of tumoral peptide hormone secretion and inhibition of tumoral 
growth by SST analogues.
sst Analogues
The clinical utility of native SST was clearly limited given its rapid blood clearance. 
The development of stable and potent analogues therefore became necessary for 
therapeutic efficacy. Several structural analogues of SST have been synthesized 
(Fig. 5.3.1). Compared with natural SST, octreotide contains three substituted amino 
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acids that make it resistant to metabolic degradation and increase its in vivo half‐life. 
SST analogues have restricted receptor affinity profiles (high affinity to SSTR2 and 
SSTR5, low affinity to SSTR3, and no affinity to SSTR1 and SSTR4). octreotide 
and lanreotide are synthetic octapeptide with similar binding profiles. Both are 
available either in a rapid action form administrated subcutaneously or intrave-
nously (octreotide, Sandostatin®, novartis, and lanreotide, Somatuline®, Ipsen) or in 
a slow‐release intramuscular/deep subcutaneous depot formulation (octreotide, 
Sandostatin lAR®, novartis, and lanreotide, Somatuline lAR®, Ipsen).
symPtomAtic effects
carcinoid syndrome
Pooled data of octreotide and lanreotide trials from the past 20 years, including more 
than 400 patients, show a mean symptomatic response rate of 73% (range of 
50–100%), with similar results for immediate‐release and long‐acting formulations 
[2]. Disappearance of flushing episodes is observed in approximately 60% of patients, 
while the frequency and/or the severity of the flushing periods can be reduced to less 
than 50% in more than 85% of patients [3, 4]. Disappearance of diarrhea is observed 
in more than 30%, and more than 50% improvement is seen in more than 75% of 
patients. The antisecretory effect results in a reduction of biochemical markers (chro-
mogranin A and urinary 5‐hydroxyindoleacetic acid) in up to 40–60% of patients. 
Tolerance to SST analogues and efficacy should be tested individually by initiating 
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figure 5.3.1 The structure of native somatostatin‐28 and somatostatin‐14 and the 
somatostatin analogues octreotide, lanreotide, and vapreotide.
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Thereafter, depot formulations, usually octreotide lAR (20–30 mg) or lanreotide 
Autogel (90 mg) every 4 weeks, can be started and should be individually titrated [5]. 
The efficacy of lanreotide and octreotide is comparable [6]. To prevent carcinoid 
crisis during interventional procedures, SST analogues should be given intrave-
nously. Moreover, carcinoid heart disease secondary to serotonin production of the 
tumor has been significantly reduced by the introduction of SST analogue therapy.
The duration of the effect of SST varies and can be limited due to tachyphylaxis or 
desensitization, which can be temporarily circumvented by an increase in dose. If the 
treatment is insufficient, it can also be proposed to decrease interval time between two 
injections or to add short‐acting SST analogues. Another cause of diarrhea must also be 
considered, such as bacterial overgrowth, large small bowel resection, diarrhea linked 
to biliary salts, exocrine pancreatic insufficiency, and specific treatment required.
other hypersecretion syndromes
SST analogues are also recommended for patients with other functioning tumors.
In patients with glucagonoma, SST analogues are effective in controlling the 
necrolytic migratory erythema but less effective in the management of weight loss 
and diabetes mellitus.
Vipoma syndrome often requires intensive intravenous supplementation of fluid 
losses and careful correction of electrolyte and acid–base abnormalities. SST ana-
logues reduce tumoral vasoactive intestinal peptide (VIP) secretion and thus inhibit 
intestinal water and electrolyte secretion. By this mechanism, these drugs control the 
secretory diarrhea in more than 70% of patients.
In patients with insulinoma, SST analogues are of limited use because less than 
40% of insulinomas express SSTR subtypes that bind these drugs. Moreover, caution 
must be exercised in SST analogue therapy in these patients, since hypoglycemia may 
worsen due to a more profound suppression of counterregulatory hormones, such as 
glucagon. Diazoxide is the most effective drug for controlling hypoglycemia.
In patients presenting gastrinoma, gastric acid hypersecretion should always first be 
treated medically with high doses of proton pump inhibitors. SST analogues are also effec-
tive in reducing both gastrin and acid secretion in Zollinger–Ellison patients; however, 
they are rarely used because proton pump inhibitor is the drug of choice (high potencies, 
long duration of action, oral medication with once‐a‐day or twice‐a‐day dosing) [7].
Cushing’s syndrome in patients with ectopic adrenocorticotropic hormone 
(ACTH) production can be controlled by SST analogues in combination with keto-
conazole, metyrapone, and etomidate or by biadrenalectomy.
Hypercalcemia in patients with paraneoplastic parathyroid hormone‐related pep-
tide (PTHrp) can be controlled by SST analogues and bisphosphonates.
side effects
Minor side effects include pain at injection site, abdominal discomfort, bloating, and 
sometimes steatorrhea. Gallstones can develop in 20–50% of cases; however, virtu-
ally all remain asymptomatic. Moreover, patients with diabetes mellitus should be 
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SST analogues have been implicated in tumor proliferation in some nonendocrine and 
endocrine tumors. Several mechanisms involving SSTR‐mediated control of cell prolif-
eration have been described: inhibition of the mitogenic signal of serum growth factors 
(epidermal growth factor (EGF), platelet‐derived growth factor (PDGF), insulin‐like 
growth factor (IGF‐1)) and direct inhibition of the proliferation by regulating tyrosine 
kinase, tyrosine phosphatase, nitric oxide synthase, and cyclic guanosine 3′,5′‐cyclic 
monophosphate‐dependent protein kinase. Signaling via SSTR2 or SSTR3 has also 
been shown to result in apoptosis via p53‐dependent pathways [8]. Several in vitro and 
in vivo studies support the observation that SST analogues inhibit angiogenesis. 
Although SST analogues may exert an angiogenic effect directly on SSTR‐positive 
cells, such as endothelial and monocyte cells, they may also have indirect effects via 
inhibition of the production of angiogenic factors, such as vascular endothelial growth 
factor (VEGF) [2].
results
Since the introduction of SST analogues, multiple retrospective series and phase II 
trials have demonstrated that SST analogue treatment is associated with prolonged 
survival and disease stabilization. But these studies are difficult to interpret for several 
reasons: heterogeneity of tumor types (site, histology, tumor load), use of different 
formulations and doses, lack of objective tumor progression prior to treatment with 
SST analogues, and complete lack of randomized study examining the question. 
Although objective radiological response rates have been rare (generally <5%), the 
rate of tumor stabilization observed in most studies has ranged from 40 to 60%, with 
a response duration of 10–25 months [9, 10]. Recently, a review article by Modlin 
et al. [1] reported overall tumor response (stable disease and partial response) in the 
entire patient population treated with octreotide of 57.4% (36.5–100%), octreotide 
lAR 69.8% (47.0–87.5%), lanreotide 46.6% (32.0–75.0%), and long‐acting lanreotide 
64.4% (48.0–87.0%) (Fig. 5.3.2).
To prove or to disprove an antiproliferative effect of octreotide lAR 30 mg, 
the PRoMID study was initiated [11]. This randomized, double‐blind, placebo‐
controlled phase III trial reports the effect of octreotide lAR in the control of 
tumor growth in patients with metastatic endocrine midgut tumors. Eighty‐five 
treatment‐naïve patients were randomly assigned to receive 30 mg monthly 
octreotide lAR or placebo. Median time to tumor progression in the octreotide 
lAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio = 0.34; 
95% CI, 0.20–0.59; P = 0.000072). After 6 months of treatment, stable disease 
194 SoMAToSTATIn AnAloGuES In PHARMACoTHERAPy
was observed in 67% of patients in the octreotide lAR group and 37% of patients 
in the placebo group, a highly significant difference. Functionally active and 
inactive tumors responded similarly. The most favorable effect was observed in 
patients with low (<10%) hepatic tumor load (median time to progression 29.4 
vs. 6.1 months, respectively) and resected primary tumor (median time to progres-
sion 29.4 vs. 5.9 months, respectively). In conclusion, octreotide lAR significantly 
lengthens time to tumor progression compared with placebo in patients with 
functionally active and inactive metastatic midgut endocrine tumors (Fig. 5.3.3). 
Because of the low number of observed deaths, survival analysis was not 
confirmatory.
A randomized phase III trial evaluating the effect of lanreotide versus placebo on 
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figure 5.3.2 A compilation of the efficacy of different somatostatin analogues and different 
formulations. (a) Symptomatic response; (b) biochemical response; (c, d) tumor response. PR, 
partial response; CR, complete response; SD, stable disease. Mean (top) and median in 
brackets. From Modlin et al. [1]. By permission of Elsevier, Trends in Endocrinology & 
Metabolism, 2010.
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Predictive factors of tumor control under sst Analogues
A small intestinal tumor origin has been suggested as likely to predict a better tumor 
stabilizing response [12]. In a clinical trial with high doses of lanreotide, higher 
rates of tumor growth inhibition were observed in midgut tumors in contrast to 
foregut tumors [13]. Recently, a retrospective study reported that Ki‐67 index ≤5%, 
pretreatment stability, and liver tumor invasion ≤25% were significantly associated 
with disease stability under lanreotide. Gender, age, origin of the primary tumor, 
discovery mode, functionality, and presence of extrahepatic metastases were not 
predictive factors of tumor control by lanreotide [14].
results of combination therapies
The question whether SST analogues and interferon exhibit a synergistic effect in the 
management of neuroendocrine tumor is controversial. Some studies reported that 
the biochemical response rate was higher with the association than with single agent, 
but the combination conferred more adverse events and patients had a significantly 
poorer quality of life compared to patients who received SST analogues alone. no 
improved effect on tumor size compared with single agent treatment has been shown 
in two prospective randomized clinical trials [13, 15].
In a phase II study, the combination of octreotide and bevacizumab (monoclonal 
antibody against vascular endothelial growth factor) improved progression‐free 
survival and increased the rate of partial remission, in comparison with the 
combination of octreotide and pegylated interferon [16].
The activity of the oral inhibitor of mammalian target of rapamycin (mToR) (evero-
limus) in combination with octreotide lAR was recently reported in a prospective, 
randomized phase III study including 410 patients with advanced, low‐grade, or 
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figure 5.3.3 Kaplan–Meier curve demonstrating time to tumor progression in patients 
treated with octreotide lAR versus placebo in the PRoMID phase III trial. From Ref. [11]. 
© Wiley.
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intermediate‐grade pancreatic endocrine tumors [17]. The median progression‐free 
survival was 11.0 months with everolimus as compared with 4.6 months with placebo.
WhAt About neW sst AnAlogues?
new classes of SSTR subtype‐selective analogues are being developed and tested. 
These new analogues may prove valuable for the treatment of tumors that express 
SSTR subtypes other than SSTR2 and SSTR5.
The multi‐SST analogue SoM230 (pasireotide) has high affinity for SSTR1, 
SSTR2, SSTR3, and SSTR5. In an in vitro study evaluating the use of octreotide and 
pasireotide on HEK293 cells expressing SSTR2 subtype on the cell membrane, 
treatment with octreotide resulted in an internalization of SSTR2 at 30 min, whereas 
treatment with pasireotide did not lead to SSTR2 internalization. Such findings 
may suggest that a persistent and more durable efficacy could be obtained with 
pasireotide.
Pasireotide is currently under evaluation in phase II and III trials in patients with 
octreotide‐resistant carcinoid tumors. A phase II, open‐label, multicenter trial evalu-
ated the efficacy and safety of SoM230 in 44 patients with metastatic digestive 
endocrine tumors whose symptoms (diarrhea and flushed skin) were resistant to stan-
dard treatment with octreotide lAR. At subcutaneous doses up to 900 µg, SoM230 
controlled these symptoms in up to 27% of patients [18].
Moreover, SoM230 inhibits IGF‐1 action, inhibits VEGF secretion, and induces 
apoptosis in human cell cultures, supporting the hypothesis that pasireotide may have 
potential in the treatment of these tumors.
Chimeric molecules that bind SSTR2 and the dopamine receptor D2 (BIM‐23A760) 
are also being developed and are in clinical trials in carcinoid tumors.
conclusions
SST analogues are the best therapeutics for reducing symptoms in patients with 
digestive neuroendocrine tumors [2]. long‐acting formulations of SST analogues 
have significantly improved the quality of life of these patients. The antiproliferative 
effects of SST analogues require further investigation, as well as future studies to 
confirm the findings of the PRoMID study. It will also be important to determine 
whether high‐dose therapy with SST analogues might increase the antiproliferative 
effects in tumor cells in clinical and in preclinical trials. The effects of combination 
of SST analogues with drugs such as interferon, mToR inhibitors, or vascular endo-
thelial growth factor inhibitors must also be studied in prospective randomized 
clinical trials. Studies of pan‐receptor analogues, such as pasireotide, might provide 
further insight into the antiproliferative effects of SST analogues and provide better 
control of patients’ symptoms. Clinical trials of chimeric molecules that bind SSTR2 
as well as D2 will provide information about the crosstalk between different 
G‐ protein‐coupled receptors in the development of neuroendocrine tumors. Further 
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development of these types of drugs has the potential to improve the efficacy of 
neuroendocrine therapies and clarify the pathogenesis of these tumor types.
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introduction
Somatostatin analogues (SSA) are actually widely used in the treatment of pituitary 
and neuroendocrine tumors to control clinical symptoms and tumor growth. Due to 
somatostatin properties, like decreasing hormone and enzyme secretion, inhibiting 
cell proliferation, reducing splanchnic pressure, and modulating immune response, 
SSA have also been used in other, both endocrine‐related and non‐endocrine‐related, 
diseases, usually off‐label or in experimental setting.
Recent investigations show increase in therapeutic applications of SSA. 
Development of new SSA with high affinity to somatostatin receptor (SSTR) sub-
types other than type 2 (SSTR type 2) might bring new therapeutic targets, as some 
tumors present the high expression of SSTR1 or SSTR5. Other than generally 
approved applications of SSA are discussed in the following.
ssA use in gAstroenterology
The most vast evidence for nonconventional use of somatostatin and its analogues 
exists for gastric tract disease treatment. Somatostatin properties to inhibit secretion 
of many hormones, such as gastrin, cholecystokinin, glucagon, growth hormone, 
insulin, secretin, pancreatic polypeptide, TSH, and vasoactive intestinal peptide, 
have been widely investigated. However, somatostatin also reduces secretion of 
fluids in the intestine and pancreas, reduces gastrointestinal motility, and inhibits 
contraction of the gallbladder. Somatostatin and its analogues can cause vasocon-
striction and reduce pressure in portal circulation.
variceal and other gastric tract bleedings
The first attempts to use somatostatin and its analogues to control variceal bleeding 
date to the early 1980s. Variceal bleeding is an important life‐threatening 
consequence of cirrhotic liver disease related to high mortality rates. Endoscopic 
treatment is the first‐line therapy; however, several drugs have been tested to assist 
the endoscopic interventions, including SSA. One of the mechanisms of action of 
somatostatin is through reducing portal pressure. Somatostatin and all commer-
cially marketed analogues (octreotide, lanreotide, and vapreotide) have been tested 
for that indication. The early results show their efficacy to control acute variceal 
bleeding as well as to reduce the risk of recurrent bleeding and death, especially 
when started prior to endoscopy. Somatostatin and SSA are easy to administer and 
have few minor side effects.
Meta‐analysis published in 2003, in which 15 trials were included, comparing 
emergency sclerotherapy with vasoactive drugs for variceal bleeding, demonstrated 
that sclerotherapy was not superior to terlipressin, somatostatin, or octreotide for 
mortality, blood transfusions, use of balloon tamponade, initial hemostasis, and 
rebleeding. Sclerotherapy was associated with significantly more adverse events than 
somatostatin [1].
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However, later data have not supported the routine use of SSA in that setting. The 
Cochrane Database systematic review from 2008 analyzed somatostatin and its ana-
logues as the agents to reduce the need for blood transfusions and to improve the 
survival rate in patients with bleeding esophageal varices. 21 trials were included 
(2588 patients). The drugs did not reduce mortality significantly (relative risk (RR) 
0.97 and 95% confidence interval (CI) 0.75–1.25 for the trials with a low risk of bias 
and RR 0.80 and 95% CI 0.63–1.01 for the other trials). Units of blood transfused 
were 0.7 (0.2–1.1) less with drugs in the trials with a low risk of bias and 1.5 (0.9–2.0) 
less in the other trials. The number of patients failing initial hemostasis was reduced, 
RR 0.68 (0.54–0.87). The number of patients with rebleeding was not significantly 
reduced for the trials with a low risk of bias, RR 0.84 (0.52–1.37), while it was sub-
stantially reduced in the other trials, RR 0.36 (0.19–0.68). The author concluded that 
slight reduction in the volume of the transfused blood did not support the regular 
SSA therapy in the acute variceal bleeding [2].
Recently published meta‐analysis compared the efficacy of vasoactive medica-
tions (terlipressin, vapreotide, and octreotide) in patients having acute variceal 
bleeding. The search identified 30 trials with a total of 3111 patients. The use of 
vasoactive agents was associated with a significantly lower risk of acute all‐cause 
mortality and transfusion requirements and improved control of bleeding and shorter 
hospital stay. Studies comparing different vasoactive medications failed to demon-
strate a difference in efficacy [3].
Considering the differences in the studies and meta‐analyses outcomes, the current 
evidence to routinely apply SSA in acute bleeding from esophageal varices is too 
limited. However, it seems worthwhile to conduct the large‐scale, randomized trial, 
focused also on long‐term mortality.
Somatostatin and SSA have also been tested in gastric bleeding of nonvariceal eti-
ology. The experience is limited to a few small trials in which somatostatin seemed to 
effectively control gastric bleeding and performed better than, for example, ranitidine [4].
Pancreatic surgery and Pancreatitis
Somatostatin and SSA have been also used to prevent postoperative complications in 
patients undergoing major pancreatic surgery. Continuous pancreatic juice secretion 
and soft structure of the pancreatic parenchyma are major risk factors of serious post-
operative complications like fistula, fluid collection, and leakage from the anasto-
mosis. Several studies suggested that SSA given preoperatively through inhibition of 
perioperative pancreatic secretion reduces serious postoperative complications [5].
Two meta‐analyses assessing the effectiveness of SSA for pancreatic surgery have 
been published recently. In a 2010 paper, seventeen trials involving 2143 patients 
were identified. The overall number of patients with postoperative complications was 
lower in the SSA group (RR, 0.71; 95% CI, 0.62–0.82) with no difference between 
the groups in perioperative mortality (RR, 1.04; 95% CI, 0.68–1.59), reoperation rate 
(RR, 1.15; 95% CI, 0.56–2.36), and hospital stay (mean difference (MD), −1.04 days; 
95% CI, −2.54 to 0.46). The incidence of pancreatic fistula was lower in the SSA 
group (RR, 0.64; 95% CI, 0.53–0.78). Analysis of results of trials that clearly 
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distinguished clinically significant fistulas revealed no difference between the two 
groups (RR, 0.69; 95% CI, 0.34–1.41). Subgroup analysis revealed a shorter hospital 
stay in the SSA group than among controls for patients with malignant etiology (MD, 
–7.57 days; 95% CI, −11.29 to −3.84) [6].
The most recent 2012 meta‐analysis was aimed to determine whether prophy-
lactic SSA should be used routinely in pancreatic surgery. Nineteen trials were iden-
tified (17 trials of high risk of bias) involving 2245 patients. There was no significant 
difference in the perioperative mortality (RR, 0.80; 95% CI, 0.56–1.16) or the number 
of patients with drug‐related adverse effects between the two groups (RR, 2.09; 95% 
CI, 0.83–5.24). The overall number of patients with postoperative complications was 
significantly lower in the SSA group (RR, 0.69; 95% CI, 0.60–0.79), but there was 
no significant difference in the reoperation rate (RR, 1.26; 95% CI, 0.58–2.70) or 
hospital stay (MD, −1.04 days; 95% CI, −2.54 to 0.46). On inclusion of trials that 
clearly distinguished clinically significant fistulas, there was no significant difference 
between the two groups (RR, 0.69; 95% CI, 0.34–1.41; N = 247). The authors con-
cluded that SSA may reduce perioperative complications but do not reduce periop-
erative mortality. The authors stressed the need of further adequately powered trials 
with low risk of bias [7].
The use of octreotide has been also investigated in several clinical studies in 
patients with moderate to severe acute pancreatitis, particularly ERCP associ-
ated. In the meta‐analysis published in 2010, which included 3818 participants, 
efficacy of somatostatin or octreotide for this ERCP complication prevention 
was assessed. Authors concluded that somatostatin and high‐dose octreotide 
may prevent post‐ERCP pancreatitis, particularly if administered to the 
pancreatic duct, or if biliary sphincterotomy is performed, or high‐dose drug is 
administered over 12 h [8].
Similarly favorable outcomes in terms of reducing post‐ERCP pancreatitis and 
hyperamylasemia rates by intravenous bolus injection of somatostatin were reported 
in the meta‐analysis published in 2007 [9].
Abdominal pain, which is the most important clinical symptom of chronic pancre-
atitis, possibly results from an increased intraductal pressure during secretion. The 
inhibiting effect of octreotide treatment on the pain has been also investigated. In the 
study in which octreotide was used for 3 weeks, significantly less pain and analgesic 
use were recorded during octreotide treatment than during placebo. It was also shown 
that combined therapy with diclofenac and somatostatin can reduce the frequency 
and severity of postendoscopic retrograde cholangiopancreatography (ERCP) pan-
creatitis [10].
A scarce evidence exists that SSA may be useful in the prevention of the exacer-
bation of pancreatitis. Recently published results of a small, multicenter, randomized 
controlled trial showed that prolonged intravenous administration of octreotide hours 
in the early stage of acute pancreatitis could prevent the development of severe form 
of the disease in the obese patients [11].
However, it should be remembered that SSA treatment is the risk factor for chole-
lithiasis and choledocholithiasis, and the acute pancreatitis cases complicating the 
long‐term treatment with SSA have been also reported.
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Postsurgical Pain relief
The effect of intravenous infusion of octreotide has also been tested on postoperative 
pain relief in patients after major abdominal surgery. It was demonstrated that peri-
operative octreotide infusion could be an adjuvant to opioid analgesia due to a pirit-
ramide opioid‐sparing effect. Octreotide infusion was suggested as alternative 
treatment to patients who cannot tolerate the adverse effect of opioids [12].
refractory diarrhea
Refractory diarrhea, lasting more than 2 weeks and nonresponding to the standard 
treatment, is one of the conditions, in which SSA have been tested off‐label. They 
have been tried in diarrhea of different etiologies: cancer‐related diarrheas, including 
related to chemotherapy and radiotherapy, and also noncancer related, including 
short bowel syndrome, Crohn’s disease, ileo‐ and jejunostomy dumping syndrome, 
graft‐versus‐host disease, and AIDS‐related diarrhea. Most of the experiences come 
however from case reports and uncontrolled small‐scale trials [13].
In 2001, a systematic review of SSA use in refractory diarrhea of different eti-
ology was published. The response percentage was 73% overall in case series and 
64% in randomized controlled trials (not significant). In the most homogenous group 
of AIDS patients, somatostatin and octreotide were less effective, whereas in highly 
heterogenous postchemotherapy group, both drugs were highly effective [14].
ssA use in oPhthAlmology
retinopathy
In retinopathies, especially proliferative diabetic retinopathy, the rationale for 
somatostatin as a therapeutic agent for retinal neovascularization is under 
discussion. Retinal cells express SSTR2 and SSTR3. They are the most important 
receptor subtypes mediating growth hormone secretion and endothelial cell cycle 
arrest, retinal endothelial cell apoptosis and release of insulin. SSA have shown to 
be an effective treatment for severe proliferative diabetic retinopathy through 
blocking the local and systemic production of growth hormone and insulin‐like 
growth factor type 1 associated with angiogenesis and endothelial cell prolifera-
tion. Long‐acting SSA use in patients who fail panretinal photocoagulation is of 
particular interest. There are studies on the possibility of the use of SSA in other 
retinal vascular proliferative diseases such as retinopathy of prematurity and age‐
related macular degeneration [15, 16].
SSA has been also used in the treatment of cystoid macular edema in diabetic 
patients. It is believed that in this pathology, SSA, through direct antiproliferative 
effect on the retinal endothelium, may help to restore the inner blood–retinal barrier 
and intensify the active transport of fluid out of the retina toward the choroids [17].
In the studies on nonfunctioning pituitary adenomas, long‐term high‐dose 
treatment with octreotide caused rapid improvement in visual impairment with no 
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change of the tumor size that could be explained more likely by the direct effect of 
SSA on the retina and the optic nerve [18].
The novel SSA pasireotide is also of interest as the retina‐protective agents. In 
animal studies, it showed neuroprotective properties at the concentration or dose of 
100 nM regardless of the model of retinal ischemia [19].
graves’ ophthalmopathy
Graves’ ophthalmopathy (GO) is an autoimmune condition affecting orbital tissues. 
Due to immunomodulatory effects of somatostatins, they can be used in some GO 
cases not responding to standard treatment. Somatostatin receptors have been identi-
fied on orbital fibroblasts and activated lymphocytes. In primary cultured retro‐orbital 
fibroblasts of patients with GO expression of SSTR genes, all the SSTR subtypes 
(SSTR2, SSTR3, SSTR5) that are required for the negative cell growth signal and that 
bind SSA were found. It was also demonstrated that octreotide inhibits in vivo growth 
and activity of retro‐orbital fibroblasts from GO patients. Activity of the GO has been 
shown to correlate with the uptake of somatostatin analogues in orbital scintigrams.
Somatostatin inhibits lymphocyte proliferation and production of factors involved 
in the orbital autoimmune process: colony‐stimulating factor, inflammatory cyto-
kines, and immunoglobulins [20]. Results of small pilot studies suggested benefit 
from SSA in GO; however, recently published randomized clinical trials with the use 
of lanreotide or octreotide have shown limited improvements. In a meta‐analysis of 
randomized, controlled trials of treatment modalities for GO with the clinical activity 
score (CAS) as the primary outcome, four studies comparing long‐acting release for-
mulations of SSA (octreotide and lanreotide) with placebo were included. The 
treatment duration ranged from 3 to 8 months, with follow‐up periods of 3–14 months. 
The combined results at the end of follow‐up showed a minor but statistically 
significant lower CAS for patients treated with SSA over placebo (MD, −0.63; 95% 
CI, −0.98 to −0.28). There was no advantage for somatostatin analogues in other out-
comes, including diplopia, proptosis, and lid aperture. Patients in the SSA group had 
significantly more adverse events (OR, 2.57; 95% CI, 1.09–6.05), mostly gastrointes-
tinal (in 60% of patients), that did not result in the discontinuation of the drug. The use 
of novel SSA with the broader binding affinity in GO needs to be tested [21].
ssA use in the treAtment of hyPoglycemiA
The other applications of SSA have included the treatment of hypoglycemia of dif-
ferent etiology. In animal model, selective antagonism of somatostatin receptor type 
2 (SSTR2) normalizes glucagon and corticosterone responses to hypoglycemia and 
largely ameliorates insulin‐induced hypoglycemia. In the same model, catechol-
amine responses were not affected by somatostatin [22].
SSA have been used in toxicology in the treatment of prolonged recurrent hypo-
glycemia after sulfonylurea overdose. The available data suggest that octreotide 
could be considered first‐line therapy in both pediatric and adult sulfonylurea 
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poisoning with clinical and laboratory evidence of hypoglycemia. Maintenance 
doses of octreotide may be required to prevent recurrent hypoglycemia [23].
Congenital hyperinsulinism (CH) is a very rare disease referring to a variety of 
inborn disorders in which hypoglycemia is caused by excessive insulin secretion.
Conservative management option for CH are SSA added to frequent feeding, 
diazoxide, and, in some cases, glucagon. Such treatment can be effective in terms of 
achieving normoglycemia, normal growth, and neurodevelopment. Typical side 
effects of SSA in the treatment of CH were in most cases transient. Octreotide was 
administered subcutaneously either by multiple injections (every 6–8 h) or by contin-
uous infusion via a pump. The results of studies on the effective use of long‐acting 
somatostatin analogues in these disorders showed improved life quality with long‐
acting somatostatin analogue formulation treatment when compared to continuous 
infusion of the drug via a pump [24].
oncology
The frequent expression of SSTRs in various malignancies has given the promise of 
the new effective treatment modalities. However, with some exceptions, SSA in 
oncology outside of the neuroendocrine tumors have been tested in in vitro or animal 
models or very small human series. The published results are somewhat conflicting 
and no clinical recommendations have been issued in this field.
One of the most examined neoplasms in which those agents have been tried is 
hepatocellular carcinoma (HCC). Meta‐analysis of nine randomized controlled in 
HCC showed that the 6‐month and 12‐month survival rates in the octreotide group 
were significantly higher than those of the control group (6 months, RR, 1.41; 95% 
CI, 1.12–1.77; P = 0.003; 12 months, RR, 2.66; 95% CI, 1.30–5.44; P = 0.008). When 
including the studies using no treatment as control or being performed in China, 
including more than 50 patients and with follow‐up longer than 2 years, the sensi-
tivity analyses tended to confirm the primary meta‐analysis. Whereas, when including 
the studies using placebo as control or being performed in Western countries, the 
difference was not significant [25].
There were also studies on the use of SSA in breast cancer; however, octreotide 
depot failed to show any clinical benefit, when added to the tamoxifen in breast can-
cer patients [26].
The treatment of the postsurgical lymphorrhea complications after axillary node 
dissection in breast cancer with lanreotide was also ineffective [27]. However, the 
new cytotoxic SSA with SSTR2 affinity (among others, AN‐162) are being tested in 
in vitro models with promising result [28].
A meta‐analysis of uncontrolled studies on SSA plus dexamethasone as the 
treatment for castration‐resistant prostate cancers revealed that such drug combination 
resulted in partial response in about 60% of patients, with median progression‐free 
survival of 7 months and median overall survival of 16 months.. Other available data 
address rather biochemical markers of prostate cancer, with no sustained decline in 
PSA levels after octreotide administration [29, 30].
REFERENCES 205
New cytotoxic SSA AN‐162 has been tried in studies on non‐small cell lung can-
cer cell (NSCLC) lines. AN‐162 induced apoptosis‐related genes expression in 
NSCLC cells, and it should be considered for further therapy [31, 32].
Substantial expression of SSTR in meningiomas has induced the concept of the 
therapeutic use of SSA in inoperable/recurrent/progressive tumors. Observational 
studies have indicated that although SSA are not able to induce the tumor regression, 
they may halt the meningioma growth and arrest tumor progression [33].
In 2011, results of phase II study of subcutaneous octreotide in patients with pro-
gressive or recurrent meningioma and meningeal hemangiopericytoma have been 
published. Twelve patients were treated with subcutaneous short‐acting octreotide; 
the primary measure was radiographic response rate. Eleven of the twelve patients 
experienced progression, with a median time to progression of 17 weeks. Two 
patients experienced long progression‐free intervals (30 months and ≥18 years). 
Octreotide failed to produce objective tumor response [34].
inflAmmAtory diseAses
Somatostatin is known for having immunomodulating properties. Experimental 
models of arthritis revealed that antinociceptive and anti‐inflammatory actions of 
octreotide and pasireotide are largely mediated via the SSTR2 receptor [35].
However, the studies on SSA in inflammatory or autoimmune diseases are scarce. 
Long‐acting octreotide in refractory rheumatoid arthritis was tested in a small, open‐
labeled pilot study. Although the results were encouraging and treatment led to 
clinical improvement in a subset of patients with active refractory arthritis, the 
placebo‐controlled trials were not conducted or their results not published. In con-
trast, a few cases of arthritis related to the SSA treatment have been reported [36].
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Radionuclide therapy, sometimes called molecular radiotherapy, remains something 
of a minority interest in nuclear medicine. Many nuclear medicine departments do 
not offer radionuclide therapy or limit its use to I‐131. However, the use of radiola-
beled somatostatin analogues provides the possibility of a truly holistic service from 
imaging to treatment and reassessment. The basic principle is that if you can see it, 
you can treat it. Though there has been a desire to pursue such a policy with a wide 
range of solid tumors, good clinical results have remained elusive. There appear to be 
two main reasons for this. To be effective, there needs to be a high tumor‐to‐
background ratio, which may be difficult to achieve with antibody‐based products 
but seems to be possible with radiolabeled somatostatin analogues. The second factor 
is the tumor itself. The most common forms of tumor treated are represented by the 
neuroendocrine family of cancers. The most common of these is the carcinoid tumor, 
but there are many others, some producing excretory peptides and others appearing 
to be “silent.” Most of these tumors arise from the midgut. They tend to share some 
characteristics. They all overexpress somatostatin receptor subtype 2, which can be 
visualized with a range of products including In‐111 pentetreotide, and they are often 
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slow growing. This second factor is important as it means that most chemotherapy 
drugs that target cell division have little impact on neuroendocrine tumors (neTs) 
and there is time to give multiple cycles of treatment and assess results.
the soil
neuroendocrine tumors (neTs) represent a family of tumors, which can be characterized 
either in terms of morphology, special immunostaining, or functionally by their expres-
sion of somatostatin receptors. neTs are associated with the gut and often have parallel 
names, which reflect this origin including gastroenteropancreatic (geP) tumors. However 
this approach excludes some other tumor types that could also be included as neTs such 
as lung, thymic, renal, and ovarian neTs those these are much rarer as well as medullary 
cell thyroid cancer (MTc), paraganglioma, and pheochromocytoma. a further division 
can be related to the part of the embryonic gut from which the cells in the tumor originate. 
Foregut tumors, which include those of the lung and pancreas, tend to be more aggressive 
and have a better response to chemotherapy agents [1, 2]. The pancreatic tumors may also 
produce other hormones such as insulin, gastrin, and even somatostatin. a higher 
proportion of these pancreatic tumors do not appear to express somatostatin receptor type 
2 in high concentration, and radionuclide therapy may be less useful. In addition, these 
pancreatic tumors can be associated with multiple endocrine neoplasia type 1 of which 
50% are familial and due to a defect in a protein called menin [3]. The majority of foregut 
tumors probably do not excrete an endocrine substance that we can detect.
Midgut carcinoids tend to be much slower growing, resistant to chemotherapy, 
and often present with liver metastases. The majority are secretory and produce sero-
tonin. once tumor is in the liver, the patients can present with classical carcinoid 
syndrome. These midgut‐originated tumors tend to have high expression of various 
somatostatin subtypes, but subtype 2 predominates. The primary method of control 
is biological through somatostatin analogues [4, 5]. Hindgut neTs are rare normally 
nonsecretory with little or no expression of somatostatin receptors.
Many other tumors especially with a gut origin can express some neuroendocrine 
features; however, this does not mean they are true neTs and would not normally be 
treated as such.
other types of neTs such as MTc, paragangliomas, and pheochromocytomas fall 
outside of this classification. Recently, these tumors also have been considered for 
radiolabeled somatostatin analogue treatment, especially as it has been found that 
ga‐68‐labeled products with PeT are finding tumors considered negative on In‐111 
pentetreotide imaging [6, 7].
the PePtides
The initial proposal from Krenning’s group was to use the auger electron present in 
In‐111 pentetreotide for therapy. This would require giving very high activities (up to 
11 gBq In‐111 pentetreotide 3–6 weekly). This is an expensive form of treatment, 
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but in three published trials [8–10], there is evidence for some efficacy and minimal 
toxicity. The real problem is that it was difficult to give a sufficient radioactive dose 
to the tumor. This problem is explored in the chapter by Bodei in her explanation of 
the development of radiolabeled somatostatin therapy. The range of an auger elec-
tron is 1–2 cells so to just irradiate the tumor at least one out of every two its cells has 
to have uptake of the In‐111‐pentetreotide. The quantity of this product, which 
needed to be administered to obtain the therapeutic results, has made it not feasible 
for treatment purposes.
Much better tumor kill was needed, so the Basle group came up with a doTa 
linker that enabled y‐90 to be attached to the somatostatin. early results were encour-
aging, but the effect was limited by renal toxicity. This was found to be due to direct 
cross‐reaction with receptors in proximal tubules of the nephrons. It was rapidly pro-
posed and then conformed by good science that the administration of negatively 
charged amino acids such as lysine and arginine in sufficient quantities was 
renoprotective.
By the late 1990s, there was some initial interest in a clinical trial from novartis, which 
was the legacy holder of the patent for octreotide. an international multicenter phase II 
trial was performed but not published until 10 years after the trial completion [11].
as part of the trial, some superb dosimetric work was performed by Jamar’s group 
using y‐86 doTaToc PeT imaging [12]. This modeled the radiation dose to the kid-
neys and showed the reduction that could be obtained using amino acid coinfusion.
obtaining sufficient peptide for labeling proved problematic for many centers, but 
Virgolini’s group from Vienna and then Innsbruck developed a y‐90 doTa lanreo-
tide. lanreotide had a much less precise receptor profile and could be considered a 
pan‐receptor agent. In a multicenter trial of 154 patients, just over half the patients 
had stable disease or partial response [13]. Renal toxicity was not seen, but there was 
sufficient bone marrow suppression to limit the activity that could be administered to 
about 1.3 gBq in three cycles. This appeared to be insufficient for a good therapeutic 
response. one novel solution was to administer the product intra‐arterially; this dou-
bled the partial response rate [14], and the same technique was also applied to treat 
primary brain tumors [15]. This method is explored in the chapter by Virgolini.
soon though, additional sources of y‐90 octreotide or doTaTaTe became avail-
able and have been used by a variety of centers worldwide. The biggest group of just 
over 1000 patients came from the Basel group that has the longest experience using 
this agent [16].
concerns about toxicity especially in the kidneys where between 1 and 4% of 
patients may end up with significant renal damage lead to the search for an alternative 
isotope to y‐90 with its energetic beta‐emission.
lu‐177‐labeled somatostatin analogues appeared to be the answer; its lower pen-
etrating beta and also a gamma for imaging allowed activities to be given up to 7 gBq 
and posttherapy imaging for dosimetry. This search for the ideal agent is documented 
in the chapter by van Vliet. Most of the published work originates from Rotterdam 
with over 500 patients treated so far. It does appear to be well tolerated with renal 
damage occurring in less than 1% of treated patients. survival looks to be better than 
with y‐90, but twice as many patients fail treatment than fail with y‐90 [16, 17]. It is 
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still unclear when y‐90‐labeled somatostatin analogues should be given in preference 
to lu‐177‐labeled somatostatin analogues. However, following animal work from de 
Jong at Rotterdam, sequential y‐90 and lu‐177 doTaTaTe have been given, and 
early results suggest a synergistic effect [18]. some early work had looked at the 
coadministration of y‐90‐ and lu‐177‐labeled somatostatin analogues [19], and this 
is explored in the chapter by Baum.
success and FailuRe
With the reports of over 2000 patients treated with radiolabeled somatostatin analogues 
and now good results being obtained from the most up‐to‐date combinations of pep-
tides and radionuclides, this should be a story of unqualified success [20]. This has not 
been the case. Though there has been commercial interest in both lu‐177 doTaTaTe 
and y‐90 octreotide, there has been little progress toward registration. This has pri-
marily been due to the fact that the research has been led by academia where the ques-
tions asked from any study are different from those needed for drug registration.
There have as of the date of publication been any randomized phase III trials com-
paring treatment with any form of radiolabeled somatostatin analogue with a placebo, 
alternate therapy, or best supportive care. For most drugs, this is considered necessary 
for registration purposes. While there has been some phase II trial data published, often, 
the results are not comparable. some centers will only treat patients with evidence of 
tumor progression either radiologically or biochemically. In these cases, even stable dis-
ease can be considered a favorable outcome [21]. other trial centers have also treated 
patients with stable disease. In this case, it is difficult to determine if the treatment had 
any efficacy as they may have remained with stable disease even without therapy.
What is needed is a standardized approach as to when treatment should be started, 
and it would not be too controversial to use the normal oncological standard of com-
mencing treatment only when there is evidence for progression. The special nature of 
neTs would allow that to be biochemical as well as radiological. an example would 
be that treatment would be started if the patient’s carcinoid syndrome was no longer 
being controlled by somatostatin analogues.
does it WoRk?
The second major issue is how to measure success. Here, there are wide variations in 
the reporting of different series. some concentrate on radiological response, and 
others measure symptom relief. only a few trials look at measures such as progres-
sion‐free survival or overall survival, and even fewer use methods such as Kaplan–
Meier statistics. This failure to record basic information concerning tumor response 
and survival makes it very difficult to produce a reasoned meta‐analysis and Forest 
plots, which could be used as a substitute for a randomized controlled trial.
The main standard used in oncological trials to determine response is to use radio-
logical criteria that define a successful treatment as either complete radiological 
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disappearance of the tumor or a reduction of 50% in the tumor mass volume. all the 
criteria for the WHo to RecIsT1.1 are based on this principle. However, again, 
many authors do not use these formal criteria when measuring response to radiopep-
tide therapy. some authors have applied their own criteria such as “minimal response” 
[17], but without some consensus as to what this means, which is widely accepted, it 
is of little value. Timing has also been shown to be vital with reports that a year may 
need to pass between the past treatment and any meaningful tumor size reduction 
[21]. Therefore, other markers of response are needed. It would appear that the stron-
gest of these is biochemical and symptomatic response, which has been shown to 
influence survival [21]. again, measuring symptoms should use a validated system 
such as the eoRTc QlQc30 for neTs [22]. Therefore, for many studies, the only 
meaningful results that can be compared to alternate treatments such as biological 
and chemotherapy regimens are median progression‐free and overall survival. The 
provision of this data from different trials has been better but is often incomplete. For 
example, in one reported series of 500 patients, follow‐up data and therefore good 
quality survival data were only available in 60% of patients [17]. did the remaining 
40% feel so well that they did not come back for follow‐up or were they dead? If 
either was the case, it would have a profound effect on the results as published. What 
most studies do agree on is that if the neT patient feels worse after treatment or has 
radiological progression of tumor, then the outcome for them is bleak measured in 
only a few months of life [17, 21].
dosimetRy
Much of the published work on radiolabeled somatostatin analogues focuses on the 
clinical response. activities given have been related to pragmatic issues such as cost 
and availability. It was quickly found that the primary critical organ was the kidney 
[23]. understanding of the biodistribution and pharmacokinetics of these radiopep-
tides meant that it would be possible to reduce the possibility of toxicity with y‐90‐
labeled products if a renal radiation dose of less than 30 gy could be achieved by use 
of amino acid coinfusion and keeping the accumulated activity to less than 15 gBq 
[24]. Much of this work was performed using y‐86 as a PeT tracer [12]. However, 
the move to treatment with lu‐177 doTaTaTe allows for posttherapeutic imaging. 
This has resulted in regimes that use the dosimetry for one treatment to modify 
subsequent therapies and attempt to produce a personalized medicine solution to 
tumor treatment [25].
Ways FoRWaRd?
Much work has been done and thousands of patients treated, but radiolabeled somato-
statin analogues remain outside of the mainstream oncological treatments. some of 
this is structural as oncologists may not wish to refer patients for treatments outside 
of their control but also some of this is because of the way we have reported our 
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work. While understanding that the reason trials have been reported the way they 
have may have been for good pragmatic reasons, it is important to understand that if 
radiolabeled somatostatin analaogues are to have a sustained future in the treatment 
of patients with disseminated neTs, we must present results in a way that is under-
standable to oncologists. This means: (a) the necessity of the development of 
randomized controlled, preferably multicentre, trials, (b) the need to deliver results 
using the standard terms such as partial and complete response for radiological 
assessment of tumors, (c) the use of Kaplan–Meier statistics to calculate survivals 
and also to include data on quality of life measured in a way that has been accepted.
There are other tumors that express somatostatin including medullary cell cancers 
of the thyroid, paragangliomas, malignant pheochromocytomas, and neuroblastomas 
[26, 27]. However, they tend to be rarer tumors. The real challenge will be the possi-
bility of application of  radiopeptides against the somatostatin receptor in non‐small 
cell lung cancer and primary brain tumors which are much more common.
conclusions
nuclear medicine has come a long way in the development of radiolabeled somato-
statin analogues showing that best results come from both optimal combinations of 
therapeutic isotope such as lu‐177 and y‐90 and optimized peptides such as 
doTaTaTe. Wide acceptance of this work means that investigators must be 
disciplined in their approach both to methodology and reporting results so that the 
studies allow easier comparison to other forms of radionuclide therapy.
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introduction
Gastroenteropancreatic neuroendocrine tumors (GEPNETs), which comprise func­
tioning and nonfunctioning endocrine pancreatic tumors and carcinoids, are usually 
slow growing and are often metastasized at diagnosis. Treatment with somatostatin 
analogues such as octreotide and lanreotide can reduce hormonal overproduction and 
results in symptomatic relief in most patients with metastasized disease. Objective 
responses however in terms of tumor size reduction are seldom achieved [1–3]. 
However, it was recently shown that the long‐acting somatostatin analogue octreo­
tide LAR (Sandostatin LAR®; Novartis, Basel, Switzerland) significantly lengthens 
time to tumor progression when compared with placebo in patients with functionally 
active and inactive metastatic midgut neuroendocrine tumors (NETs) [4].
The majority of GEPNETs abundantly express somatostatin receptors (ssts), 
and these tumors can be visualized in patients using the radiolabeled somatostatin 
analogue [111Indium‐DTPA0]octreotide (OctreoScan®; Covidien, Petten, the 
Netherlands). A logical next step to this tumor visualization in vivo was to also try to 
treat these patients with radiolabeled somatostatin analogues.
somAtostAtin AnAlogues And chelAtors
Radiolabeled somatostatin analogues that are used for therapy consist of three parts: 
a cyclic octapeptide, a chelator, and a radionuclide. Combinations of different pep­
tides, chelators, and radionuclides have been tested in vitro and/or in vivo for their 
use in peptide receptor radionuclide therapy (PRRT).
Peptides that have been used are octreotide, [Tyr3]octreotide, octreotate, [Tyr3]
octreotate, lanreotide, and vapreotide. In [Tyr3]octreotide, phenylalanine (Phe) in 
position 3 in the amino acid sequence is being replaced by tyrosine (Tyr), resulting in 
a more hydrophilic peptide. In octreotate, threoninol (Thr(ol)) at the C‐terminus (as 
used in octreotide) is replaced by the natural amino acid threonine (Thr).
As chelators, diethylene triamine pentaacetic acid (DTPA), 1,4,7,10‐tetraazacy­
clododecane‐1,4,7,10‐tetraacetic acid (DOTA), and 1,4,8,11‐tetraazacyclotetradecan
e‐N,N′,N″,N′″‐tetraacetic acid (TETA) can, among others, be used. Figure  6.1.1 
shows the chemical structures of these chelators.
Figure 6.1.1 Chemical structures of DTPA, DOTA, and TETA (Note: …  is the site for 
binding a peptide).
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The most used combinations of peptide–chelator complexes are [DOTA0,Tyr3]
octreotide (DOTATOC) and [DOTA0,Tyr3]octreotate (DOTATATE). DTPA‐octreo­
tide (as used in OctreoScan® when it is coupled to 111Indium (111In) ([111In‐DTPA0]
octreotide)) was used when PRRT started in the 1990s. Another peptide–chelator 
complex used is [DOTA0‐1‐Nal3]octreotide (DOTANOC), in which the third amino 
acid of octreotide (Phe) is replaced by (1‐naphthyl)‐alanine. DOTANOC has a good 
affinity for sst
2





 as opposed to DOTATOC and DOTATATE [5]. This may be important for 
imaging and treatment of tumors with less pronounced expression of sst
2





. A preliminary report [6] stated that scintigraphy with 111In‐DOTANOC 
showed higher tumor uptake compared to [111In‐DTPA0]octreotide (111In‐octreotide) 
in most of the patients. Unfortunately, uptake in the background was also higher, 
which resulted in lower tumor‐to‐background ratios: in only 2 of 31 patients (1 with 
follicular thyroid carcinoma and 1 with hepatocellular carcinoma), tumor‐to‐
background ratio was higher with 111In‐DOTANOC. Figure 6.1.2 shows the chemical 
structures of DTPA‐octreotide, DOTATOC, DOTATATE, and DOTANOC.
Changing the peptide, chelator, or radionuclide can considerably affect the binding 
affinities for the somatostatin receptor, as has been shown by Reubi et al. [7]. These 
authors tested various combinations of peptides, chelators, and radiometals for their 
binding affinities for the five different somatostatin receptor subtypes. Table 6.1.1 
gives an overview of the affinity profiles of various somatostatin analogues. Most 
importantly, Reubi et al. demonstrated what effect even apparent small changes in, 
for example, peptide structure have on binding affinities for the various ssts.
The replacement of Phe by the more hydrophilic Tyr at position 3 in [yttrium‐
DOTA,Tyr3]octreotide or in [Gallium‐DOTA,Tyr3]octreotide resulted in an improved 
binding affinity to the sst
2
 receptor. The more lipophilic Phe showed improved 
binding affinity to sst
3
 when compared to Tyr3. Addition of a radiometal (y or Ga) to 
[DOTA,Tyr3]octreotide resulted in a better sst
2
 binding affinity. A possible explana­
tion for this could be the difference in charge of the molecule when adding a radio­
metal. Furthermore, addition of Ga to [DOTA,Tyr3]octreotate resulted in an eightfold 
improvement in sst
2
 binding affinity when compared with [y‐DOTA,Tyr3]octreotate. 
The same held true when these radiometals were labeled to octreotide, with a fivefold 
improvement in sst
2
 binding affinity with labeled [DOTA,Tyr3]octreotide when y 
was replaced by Ga. Substitution of a chelator, DTPA, by DOTA, coupled to the 
octreotide molecule, improved the sst
3
 binding affinity 14‐fold. Furthermore, 
substitution of DTPA by DOTA when coupled to [Tyr3]octreotate improved binding 
to the sst
2
. [y‐DOTA]lanreotide and [y‐DOTA]vapreotide showed higher binding 
affinity to the sst
5
 compared to [y‐DOTA,Tyr3]octreotide. Since the hydrophilicity of 
DOTA‐vapreotide and DOTA‐lanreotide is less than that of [DOTA,Tyr3]octreotide, 
it seemed that lower hydrophilicity improves the affinity for sst
5
. [In‐DTPA,Tyr3]
octreotate and [y‐DOTA,Tyr3]octreotate showed better binding affinity for sst
2
 than 
[In‐DTPA]octreotide and [y‐DOTA,Tyr3]octreotide, respectively.
In conclusion, Reubi et al. demonstrated that the affinity for the five different 
somatostatin receptors is influenced mostly by changes in the peptide and, to a lesser 
degree, by metal replacement or chelator substitution. These differences in affinity 
Figure 6.1.2 Structures of DTPA‐octreotide, DOTATOC, DOTATATE, and DOTANOC.
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for the somatostatin receptor are reflected by the differences in tumor uptake when 
using either octreotide‐ or octreotate‐based radiolabeled somatostatin analogues for 
the treatment of somatostatin receptor‐positive tumors. Various preclinical and 
clinical studies demonstrated an advantage of the use of [Tyr3]octreotate in 
comparison with [Tyr3]octreotide when labeled with various radiometals in the 
amount of tumor uptake and antitumor activity in animals and also in man [8–10].
pansomatostatins
Newly developed peptides are the so‐called pansomatostatin agonists. These are 
somatostatin agonists characterized by the ability to bind to all five somatostatin 
receptors. Reubi et al. [11] described the binding affinity of KE108, a somatostatin 
agonist that showed high affinity for all five somatostatin receptors. They demon­
strated that KE108, as well as SS‐28 (the 28‐amino‐acid form of somatostatin, one 
of the two natural forms of somatostatin), inhibits forskolin‐stimulated cAMP 
accumulation, hence showing its agonistic properties, in all five receptor subtypes. 
Another multireceptor ligand somatostatin analogue is pasireotide (SOM230) [12], 








. The use of such ana­
logues in combination with radiometals via a suitable chelator is of interest for both 
diagnostic and therapeutic purposes. However, these combinations have to be tested 
to establish their in vivo stability, biodistribution, and affinity profiles, as well as 
their pharmacokinetic and toxicological properties, before clinical trials with these 
compounds can be initiated. Another study [13] investigated the use of a chelated 
pansomatostatin analogue, KE88, coupled to, among others, 111In. It showed a high 












Somatostatin‐28 5.2 (0.3) 2.7 (0.3) 7.7 (0.9) 5.6 (0.4) 4.0 (0.3)
Octreotide >10,000 2.0 (0.7) 187 (55) >1,000 22 (6)
DTPA‐octreotide >10,000 12 (2) 376 (84) >1,000 299 (50)
In‐DTPA‐octreotide >10,000 22 (3.6) 182 (13) >1,000 237 (52)
In‐DTPA‐[Tyr3]octreotate >10,000 1.3 (0.2) >10,000 433 (16) >1000
DOTA‐[Tyr3]octreotide >10,000 14 (2.6) 880 (324) >1,000 393 (84)
DOTA‐[Tyr3]octreotate >10,000 1.5 (0.4) >1000 453 (176) 547 (160)
DOTA‐lanreotide >10,000 26 (3.4) 771 (229) >10,000 73 (12)
y‐DOTA‐[Tyr3]octreotide >10,000 11 (1.7) 389 (135) >10,000 114 (29)
y‐DOTA‐[Tyr3]octreotate >10,000 1.6 (0.4) >1000 523 (239) 187 (50)
y‐DOTA‐lanreotide >10,000 23 (5) 290 (105) >10,000 16 (3.4)
y‐DOTA‐vapreotide >10,000 12 (2) 102 (25) 778 (225) 20 (2.3)
Ga‐DOTA‐[Tyr3]octreotide >10,000 2.5 (0.5) 613 (140) >1,000 73 (21)
Ga‐DOTA‐[Tyr3]octreotate >10,000 0.2 (0.04) >1000 300 (140) 377 (18)
aAdapted from Reubi et al. [7].
All values are half maximal inhibitory concentration (IC50) (SEM) in nM. No data are available for 
Lu‐loaded somatostatin analogues.
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internalization rate of [111In‐DOTA]KE88 in sst
3





‐expressing cells was low to absent. The same was demon­
strated in an animal model in which [111In‐DOTA]KE88 had a high and persistent 
uptake in sst
3
‐expressing tumors but a low uptake in sst
2
‐expressing tumors. Since 
most NETs overexpress the sst
2
, the role of KE88 in tumor targeting and treatment 
of NETs is therefore not promising.
However, it was demonstrated that NETs may express different somatostatin 
receptors concomitantly [14, 15]; therefore, the use of pansomatostatins may be of 
importance for those tumors for optimal tumor targeting.
Recently, Cescato et al. [16] demonstrated that binding of KE108 and SOM230 to 
the sst
2a
 receptor had different effects than native somatostatin (SS‐14 (the 14‐amino‐
acid form of somatostatin)) on its postreceptor signaling. Together with SS‐14, both 
analogues were agonists for the inhibition of adenylyl cyclase but antagonized SS‐14 
actions on intracellular calcium and extracellular signal‐regulated kinase (ERK) 
phosphorylation. Hence, the pansomatostatin agonists KE108 and SOM230 cannot 
be considered as simple mimics of somatostatin. Since NETs mainly express sst
2
 
[15], these observations are of utmost importance for the possible use of these pan­
somatostatins in the treatment of NETs. Furthermore, the pansomatostatin agonist 
SOM230 was not able to trigger sst
2
 internalization in vitro or in vivo [17]. 
Internalization of the receptor–ligand complex is one of the crucial steps for success 
of tumor cell targeting by radionuclides, as is discussed in the following.
somatostatin Antagonists
All studies on PRRT in patients so far have been performed with somatostatin 
receptor agonists, because agonists are internalized in the (tumor) cells and are there­
fore relatively long retained within the tumor. Somatostatin receptor antagonists 
however are not internalized in the (tumor) cells and were therefore thought to be 
inappropriate for PRRT. Recently, however, Ginj et al. [18] demonstrated almost 





ANT during the first 24 h compared to the agonist [111In‐DTPA]octreotate and this 
despite a lower affinity for the sst
2
 of the antagonist. This is thought to be caused by 
binding of the antagonist to a larger variety of receptor conformations. These results 
were unexpected and are very promising in the attempt to increase the radiation dose 
to tumors. Unfortunately, no data have been published for the amount of activity 
beyond 24 h after injection, which is a very important factor as well for estimating 
the total amount of radiation to the tumor. Also, no data have been published yet on 
toxicity and biodistribution of (radiolabeled) somatostatin antagonists in man. 
Another study [19] demonstrated that various sst
2
‐selective somatostatin antagonists 
showed higher binding affinity for the sst
2
 receptor when compared to sst
2
‐selective 
somatostatin agonists. All of these somatostatin antagonists were coupled to DOTA 
as a chelator, which enables their radiolabeling with 111In, 90yttrium (90y), or 
177Lutetium (177Lu), hence making them potential candidates for tumor targeting.
The use of the [64Cu‐CB‐TE2A]sst
2
 antagonist as a somatostatin antagonist for 
positron emission tomography (PET) imaging was tested by Wadas et al. [20]. This 
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study demonstrated that although the affinity of this antagonist was less than that of 
the agonist [64Cu‐CB‐TE2A‐Tyr3]octreotate for the sst
2
 receptor, the antagonist had 
superior tumor‐to‐background ratio, making it an interesting radionuclide for 
imaging. However, for therapy, the absolute amount of uptake in the tumor is of 
great importance, and this is not necessarily reflected by a better tumor‐to‐
background ratio.
rAdionuclides used in prrt
Various radionuclides can be used for PRRT. Of course, these radionuclides must be 
coupled to the peptide in a stable manner, necessitating the use of chelators, because 
many radionuclides are so‐called bone seekers, implying potential grave bone 
marrow toxicity if the radionuclide is present in an unbound state in vivo.
111In, 90y, and 177Lu are radionuclides that have been used in PRRT.
111In emits Auger electrons with a maximum tissue penetration range of 10 µm. In 
addition, it has γ‐emission at 171 and 245 keV. Its half‐life is 2.8 days. Due to its very 
short tissue penetration range, the presence of Auger electrons close to the DNA is 
necessary to cause DNA breakage and cellular death, emphasizing the need of 
sufficient internalization for successful treatment when using 111In.
90y is a pure, high‐energy β‐emitter, with a maximum energy of 2.27 MeV. Its 
maximal tissue penetration is 12 mm and its half‐life is 2.7 days. These characteris­
tics make 90y more suitable for a tumoricidal effect as such. Also, because of the 
larger tissue penetration range, it may be more suited for larger tumors and for known 
heterogeneous receptor distribution within the tumor. The latter proposed effect is 
only possible due to the “cross‐fire” effect, that is, the tumoricidal effect of indirect 
irradiation of tumor cells without any sst expression via radiation originating from 
receptor‐positive cells on neighboring tumor cells. It is very likely that the “cross‐
fire” effect is becoming more important with increasing tissue penetration range of 
the used radionuclide. A disadvantage of 90y, since it is a pure β‐emitter, is that no 
posttreatment imaging and thus no direct dosimetric calculations can be done. For 
dosimetry, analogues labeled with the positron emitter 86y are needed. However, this 
may still be questioned because of the shorter half‐life (14.8 h) of 86y in comparison 
to 90y (64 h). Alternatively, the use of [111In‐DOTA0,Tyr3]octreotide has been advo­
cated as a surrogate for [90y‐DOTA0,Tyr3]octreotide for dosimetry. However, as 
described earlier, Reubi et al. [7] have demonstrated that replacement of the metal 
element (e.g., In for y or Ga) influences the receptor affinity of these compounds, 
even when the peptide–chelator complex is unchanged. Therefore, the assumption 
that the biodistribution of the In‐ and y‐labeled peptide analogues is similar or 
comparable has to be proven in vivo, before the use of In‐labeled substitutes can be 
accepted for clinical dosimetry studies.
177Lu is a medium energy β‐emitter, with a maximum energy of 0.5 MeV and with a 
maximal tissue penetration of 2 mm. Its half‐life is 6.7 days. 177Lu also emits low‐energy 
γ‐rays at 208 and 113 keV with 10 and 6% abundance, respectively, allowing scintig­
raphy and subsequent dosimetry using the same therapeutic compound. The smaller 
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particle range of 177Lu can in theory be advantageous for the use in small tumors, 
because less of the radiation is lost to surrounding tissue, if compared with 90y.
The combination of 177Lu and 90y for therapy has been tested by de Jong et al. 
[21]. Rats bearing both small and large tumors were treated with somatostatin ana­
logues labeled with 90y, 177Lu, or the combination of these two compounds. It was 
demonstrated that animals treated with the combination of 90y and 177Lu had a sig­
nificantly longer median survival compared to rats treated either with 90y or with 
177Lu alone. The authors postulated that 177Lu is more suitable for PRRT in small 
tumors, whereas PRRT with 90y is more suitable for larger tumors and for tumors 
with heterogeneous receptor distribution. However, the best antitumor results were 
achieved with a combination of 90y and 177Lu radiolabeled somatostatin analogues. 
The tumor in this rat model is rapidly growing, which may cause a more heteroge­
neous receptor distribution because of tumor necrosis associated with rapid tumor 
growth. In contrast, NETs in man in general have a homogeneous receptor distribu­
tion and grow slowly, hence making it difficult to extrapolate these findings directly 
to NETs in man.
A preliminary report [22] stated that patients treated with the combination of [90y‐
DOTA0,Tyr3]octreotate and [177Lu‐DOTA0,Tyr3]octreotate had a longer median time 
of survival than patients treated with [90y‐DOTA0,Tyr3]octreotate only. However, 
group sizes were small (only 16 patients in each group), so the results are very likely 
influenced by an inclusion bias and confirmatory results are lacking. Ideally, a trial 
with patients randomized to one of these compounds or the combination should be 
performed to establish the best treatment option for GEPNET patients.
That different radionuclides may be more suitable for tumors of different sizes is 
also supported by a mathematical model evaluating tumor curability in relation to 
tumor size, using 22 different β‐emitting radionuclides [23], where it was shown that 
the optimal tumor diameter for tumor curability calculated for 90y was 34 mm, 
whereas it was 2 mm for 177Lu.
That tumor response is indeed dependent of tumor size has been shown in a rat 
somatostatin receptor‐positive pancreatic model [24]. Animals were treated with 
370 MBq [90y‐DOTA0,Tyr3]octreotide. In animals bearing medium‐sized tumors 
(3–9 cm2 (mean, 7.8 cm2)), 100% complete response was found, whereas in animals 
bearing small tumors (≤1 cm2) or large tumors (≥14 cm2), the amount of complete 
response was 50 and 0%, respectively. The authors postulated that in tumors ≤1 cm2, 
the 90y radiation energy will not be completely absorbed in the tumor, whereas in 
tumors ≥14 cm2, the failure to reach a cure may be explained by the increased number 
of clonogenic and probably hypoxic tumor cells.
Another radionuclide that is under investigation for its use in PRRT is 64Copper 
(64Cu). 64Cu has a half‐life of 12.8 h. It emits a 0.58 MeV β‐ particle (40%), a 0.66 MeV 
β+ particle (19%), and a γ photon of 1.34 MeV (0.5%), yielding a mean range of pen­
etrating radiation of 1.4 mm in tissue. A preclinical study with [64Cu‐TETA‐Tyr3]
octreotate showed a favorable high capacity for binding to somatostatin receptors 
both in vivo and in vitro [25]. Furthermore, in two animal tumor models used in this 
study, [64Cu‐TETA‐Tyr3]octreotate showed a twofold increase in tumor uptake com­
pared to [64Cu‐TETA]octreotide. However, [64Cu‐TETA‐Tyr3]octreotate showed a 
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particularly high uptake in the bone. This is less attractive, because the bone marrow 
is considered to be a dose‐limiting organ for PRRT.
Lewis et al. [26] demonstrated that therapy of rats bearing somatostatin receptor‐
positive CA20948 rat pancreatic tumors with three doses of 20 mCi (740 MBq) of 
[64Cu‐TETA‐Tyr3]octreotate resulted in complete regression of the tumors, with no 
palpable tumors for 10 days. Furthermore, the mean survival time of these rats was 
nearly twice that of controls. Toxicity only comprised transient changes in blood 
and liver chemistry. Absorbed dose estimates showed the kidneys to be the dose‐
limiting organ.
Also, high linear energy transfer (LET) α‐particle emitters have been evaluated 
for their use in PRRT [27, 28], but the use of these compounds is seriously hampered 
by major toxicity, especially to the kidneys.
prerequisites For the design oF rAdiolAbeled peptides
When designing new radiolabeled peptides for therapy, biological in vivo stability, 
strong target (receptor) affinity, target (receptor) specificity, as well as pharmacoki­
netic characteristics play an important role. For example, the biological stability of 
native somatostatin (SS‐14) is poor due to rapid enzymatic degradation within the 
range of minutes after intravenous administration. The somatostatin analogue octreo­
tide that contains eight amino acids is more resistant to this enzymatic degradation 
due to various modifications including the introduction of D‐amino acids and short­
ening of the molecule to the bioactive core sequence.
internalization
It is important to emphasize that not only binding of the radiolabeled somatostatin 
analogue to the receptor is of importance for successful targeting of tumor cells by 
somatostatin receptor‐mediated radionuclide therapy but also internalization of the 
receptor–ligand complex into the cell interior. Furthermore, for successful targeting 
of tumor cells by somatostatin receptor‐mediated radionuclide therapy, the amount 
of radioactivity concentrated within tumor cells should be sufficient, which, besides 
high receptor density on the tumor cell membrane, is determined by the rate of inter­
nalization of the radioligand and by intracellular retention of the radionuclide. 
Internalization is especially necessary for radionuclides with a short tissue penetra­
tion range like 111In. For radionuclides with a longer tissue penetration range, like 90y 
and 177Lu, internalization as such is probably less important for therapy considering 
the “cross‐fire” effect. Furthermore, when tumor uptake is high, effective tumor 
therapy would be still possible despite lack of internalization, provided that the 
residence time at the receptor is sufficient, as has been suggested by Ginj et al. in 
their study using radiolabeled somatostatin receptor antagonists [18].
Other factors with influence on the internalization efficacy were studied by de 
Jong et al. [29]. In this study, it was demonstrated that the internalization in vitro 
of [111In‐DTPA0]octreotide and of [90y‐DOTA0,Tyr3]octreotide in sst
2
‐positive rat 
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pancreatic tumor cells is a highly specific and temperature‐dependent process. 
Internalization was strongly reduced at 6°C when compared to incubation at 37°C. 
Internalization was also strongly reduced in the presence of 10 μM unlabeled 
octreotide, indicating that this process is highly receptor specific. Furthermore, the 
internalized fraction of [90y‐DOTA0,Tyr3]octreotide was greater than that of [111In‐
DTPA0]octreotide and [111In‐DOTA0,Tyr3]octreotide.
Lukinius et al. [30] and Janson et al. [31] have shown in vivo that, after a diag­
nostic dose of [111In‐DTPA‐D‐Phe1]octreotide, the somatostatin receptor–ligand 
complex is internalized through receptor‐mediated endocytosis to endosomes and 
further into the cell interior. A total of eight patients with midgut carcinoids were 
injected with 160–200 MBq [111In‐DTPA‐D‐Phe1]octreotide 2 days before abdominal 
surgery and during surgery samples of primary and metastatic tumor tissues were 
collected. The radioactive labeled octreotide was demonstrated by silver precipita­
tion in the cell interior in primary tumors as well as in metastases. In the case report 
described by Lukinius et al., which comprised one patient, the amount of silver 
grains (indicating internalization) in the primary tumor was more than that in the 
mesenteric metastasis, possibly indicative of expression of other subtypes of somato­
statin receptors in the primary tumor when compared to metastases, since it is known 
that the somatostatin receptor is internalized differently according to the sst subtype 
of the receptor [32], or due to differences in vascularization of the primary tumor 
compared to the mesenteric metastasis. However, in the seven patients described by 
Janson et al., similar uptake and intracellular processing of 111In‐octreotide in pri­
mary tumors and metastases was found.
Cescato et al. [33] demonstrated that various unlabeled somatostatin analogues 
with a high affinity for sst
2
 induced internalization of sst
2
 and the same held true for 
unlabeled somatostatin analogues with high sst
3
 affinity. In contrast, not all unla­
beled somatostatin agonists with a high affinity for sst
5
 were able to stimulate sst
5
 
receptor endocytosis. The authors postulate that this could be due to the different 
cellular distribution characteristics of sst
5





They found that even in cells that are not exposed to agonists, a distinct intracellular 
perinuclear staining of sst
5
 in addition to cell‐surface sst
5
 was observed. Another 
group [34] showed in COS‐7 cells exogenously expressing rat sst
5
 that functional 
sst
5
 is maintained at the cell surface even in the presence of somatostatin, both 
because of the rapid recycling of the internalized receptor to the cell surface and 
because of massive recruitment of sst
5
 to the cell surface from an intracellular sst
5
 
reserve pool, emphasizing the different features of sst
5
 when compared to the other 
somatostatin receptors.
specific Activity
When using radiolabeled somatostatin analogues for PRRT, high specific activ­
ities are required. At a high specific activity, less unlabeled peptide is present, and 
therefore, there will be less competition between labeled and unlabeled peptides 
for the receptor and a higher percentage of the dose of radioactivity can be inter­
nalized. It is highly plausible that with a higher specific activity, a higher 
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tumoricidal effect can be achieved, as has been shown in vitro by Capello et al. 
[8]. Another study [35] demonstrated that in rats bearing a pancreatic somatostatin 
receptor‐positive tumor, the uptake in the tumor was highest at 0.5 µg injected 
peptide (DOTATOC). With increasing amounts of peptide, tumor uptake decreased. 
This could be the result of a positive effect of increasing amounts of peptide on, 
for example, receptor clustering and a negative effect of receptor saturation when 
increasing this dose further.
In conclusion, for the design of radiolabeled peptides for therapy, attention must 
be paid to biological stability, receptor affinity, receptor specificity, and pharmacoki­
netic characteristics. Internalization plays a pivotal role for therapy with radiometals 
with a short tissue penetration range (like 111In), whereas internalization as such is not 
mandatory for therapy with radiometals with a longer tissue penetration range (like 
90y and 177Lu). However, it remains unclear if compounds that do not internalize have 
a sufficient residence time on the receptor to ensure a radiation dose to the tumor 
high enough to be tumoricidal. Furthermore, for PRRT, high specific activities are 
required. Further animal studies are warranted to elucidate these interesting research 
questions.
clinicAl studies
Table 6.1.2 gives an overview of tumor responses in patients with GEPNETs treated 
with different radiolabeled somatostatin analogues. Chapter 6.3 by L. Bodei et al. 
gives a more detailed overview about the therapeutic use of radiolabeled somato­
statin analogues in patients.
Figure 6.1.3 shows an example of a patient with an insulinoma with liver metas­
tases treated with 29.6 GBq (800 mCi) [177Lu‐DOTA0,Tyr3]octreotate with a partial 
remission (PR) after therapy.
conclusions
For PRRT in patients with GEPNETs, various radiolabeled somatostatin analogues 
are used, which all consist of a cyclic octapeptide, a chelator, and a radionuclide. The 
affinity of these compounds for the five different somatostatin receptors is mostly 
influenced by changes in the peptide used and, to a lesser degree, by metal replacement 
or chelator substitution. Newly developed peptides comprise pansomatostatin ago­
nists, which bind to all five somatostatin receptors. Since some NETs may express 
different somatostatin receptors concomitantly, the use of pansomatostatins may be 
of importance for these tumors.
Internalization of the radiolabeled peptide after specific binding to a tumor cell 
via its receptor is regarded to play a pivotal role for the success of PRRT. Internalization 
is mandatory for radiometals with a short tissue penetration range like 111In. In con­
trast, for radiometals with a longer tissue penetration range like 90y and 177Lu, inter­










































































































































































































































































































































































































































































Figure 6.1.3 Partial remission (PR) in a patient with an insulinoma with liver metastases 
treated with 29.6 GBq (800 mCi) 177Lutetium‐octreotate. (a) CT scan showing multiple liver 
metastases of an insulinoma before treatment with 177Lutetium‐octreotate. (b) CT scan 6 weeks 
after treatment with 177Lutetium‐octreotate, showing regression of liver metastases, consistent 
with a PR. (c) Posttherapy scan of the same patient after the first treatment with 177Lutetium‐
octreotate, showing intense uptake in multiple liver metastases. (d) Posttherapy scan after the 
fourth (and last) treatment with 177Lutetium‐octreotate, showing reduced uptake in liver metas­
tases. ANT, anterior; POST, posterior.
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somatostatin antagonists, which do not internalize, provided that the residence time 
of these compounds at the receptor is sufficient.
Radionuclides used for PRRT are 111In, 90y, and 177Lu. Other radionuclides, as, for 
example, 64Cu, are under investigation. The use of radiolabeled somatostatin ana­
logues in GEPNETs is a very promising treatment, as is shown by the high rate of 
remissions achieved after treatment.
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AbbreviAtions
ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine
AML acute myeloblastic leukemia
BED biologically effective dose
CT computed tomography
GEPNET gastroenteropancreatic neuroendocrine tumor
LQ linear quadratic
MDS myelodysplastic syndrome
MIRD Medical Internal Radiation Dose
MOPP mechlorethamine, vincristine, procarbazine, and prednisone
NCCN National Comprehensive Cancer Network
PET positron emission tomography
PRRT peptide receptor radionuclide therapy
RADAR Radiation Dose Assessment Resource
RT radiotherapy
SPECT single photon emission computed tomography
Prrt Dosimetry
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PePtiDe recePtor rADionucliDe therAPy
Peptide receptor radionuclide therapy (PRRT) is a low‐dose‐rate radiotherapy (RT) 
(as opposed to external beam radiation) developed for treatment of metastasized can-
cer. The radiolabeled peptide contains a DOTA‐chelated radionuclide, Yttrium‐90 
(90Y) or Lutetium‐177 (177Lu). Octreotate binds with high affinity to somatostatin 
receptors that are overexpressed on the cell surface of most neuroendocrine tumors. 
The targeting of radiolabeled somatostatin analogues to tumor cells is the basis of the 
therapeutic effect of these pharmaceuticals.
The radiation toxicity dose estimates used in PRRT are predominately based on the 
experience and knowledge obtained from external beam radiation. In external beam 
RT, the recommended radiation toxicity threshold doses are based on empirical data. 
Over the years, the quality of dosimetry in external beam RT has improved signifi-
cantly, and the combination of clinical experience and information on normal organ 
tolerance doses has resulted in consensus guidelines [1]. Although the recommenda-
tions by Emami contain several limitations and uncertainties, they address a clinical 
need in external beam RT, and consequently, the incidence of radiation toxicity to 
normal organs has been reduced by dosimetry‐based treatment planning [2].
In addition to the large base of empirical knowledge that has been obtained from 
external beam radiation research, there is also more than 60‐year experience in 
radionuclide therapy, in particular with 131I therapy (Iodine‐131 sodium iodide) for 
the treatment of benign and malignant thyroid disorders [3]. The most common 
radiation‐induced toxicity following 131I therapy is bone marrow suppression, 
mainly thrombocytopenia. Limiting the prescribed cumulative administered radio-
activity to a radioactivity level where the bone marrow dose remains below 2 Gy has 
proven to be a successful guideline for preventing hematological side effects [4, 5].
Dosimetry
Patient‐specific dosimetry ideally allows predicting both the risk of radiation‐induced 
organ toxicity and the probability of tumor cure. In PRRT, the emphasis in dosimetry 
research is aimed at assessing absorbed doses to the kidneys and the bone marrow. 
Dosimetry‐guided treatment planning for PRRT is ultimately the aim for an optimal 
treatment with a maximal absorbed dose in the target tumor region together with 
acceptable absorbed doses in normal organs with physiological uptake like kidneys 
and bone marrow. Several problems seriously hamper the development of this ideal 
therapy protocol.
The high‐quality constraints on the dosimetry are set by the steeply sloped dose–
effect limits. Consequentially nonoptimized dosimetry results in the scattered 
response and unproven dose–effect relations. Hardly any PRRT therapy shows severe 
acute toxicity, apart from the late occurring renal toxicity observed years after therapy 
with 90Y‐DOTA‐octreotide [6]. Dose escalation studies have hardly been performed in 
PRRT, and when toxicity is reported, the dosimetry often has not been measured or 
according to a different dosimetry model. By the lack of clear dosimetry‐guided trials 
with toxicity, the dose–effect relations for normal organ toxicity and for tumor cure 
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efficacy are derived from the experience in external beam therapy. Scarcely evidenced 
radiobiology methods are used to relate the RT absorbed dose limits to equivalent 
dose limits for PRRT. In RT, absorbed doses are delivered at high dose rates in frac-
tions of 1–2 Gy and conformal to image‐derived (CT scan) geometry. The absorbed 
doses in PRRT, however, are given with low and exponentially decaying dose rates and 
conformal to physiological, functional, and receptor‐mediated uptake of the radiola-
beled peptide. It is impossible to define one target volume in PRRT, as the therapy is 
aimed at treating metastasized disease, of which only the larger lesions (>1 cm size) are 
visible and thereby evaluable for response. Heterogeneity in the radioactivity uptake 
by variance in receptor expression or on the functional subunit level is also not visible, 
but can seriously influence the absorbed dose distribution, especially for low‐range 
particle emitters.
The aim for dosimetry in PRRT should therefore be to develop a robust, high‐
quality absorbed dose calculation model and to use proven radiobiology models in 
defining the PRRT‐specific dose–effect curves. The high quality is delivered by 
using enough time points appropriate to determine the normal kinetic distribution 
pattern and especially identify patient‐specific deviations; also, the actual volumes 
used in the dose calculations should be patient conform. The secondary aim of 
robustness is necessary when absorbed doses reported by several clinical centers are 
to be compared and can be filled in by developing an omnipotent dosimetry software 
code with hardly any user input or preferably a quickly and easily performed dosim-
etry assessment and calculation model.
Various dosimetry calculation models, practical or more sophisticated, are avail-
able and are being used. Dosimetry data needed are radioactivity measurements of 
blood and urine samples, as well as quantitative scintigraphic images measured at 
least in three time points after administration. Planar imaging is straightforward and 
easily performed to determine the kinetics of the radiopharmaceutical, while SPECT 
and SPECT/CT imaging allows determination of the three‐dimensional organ activity 
distribution with optimal background resolution. Internal dosimetry is usually per-
formed according to the MIRD scheme. Mean absorbed doses in normal organs can 
be derived with dedicated software (like OLINDA/EXM [7]).
The general scheme for calculating radiation dosimetry with radionuclides has 
been defined by the MIRD scheme dosimetry formula [8]:
D r A t dt S r r
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The dose to the target organ (D; kidney or bone marrow) is calculated by the product 
of the number of decays in a source organ (Ã
s
) and the S‐value, which expresses the 
dose rate per radioactivity for a source (r
s
) to target (r
t
) combination. More conve-
niently, the residence time τ is used and is obtained by integrating over the time‐activity 
curve relative to the injected activity A
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of their short β‐particle ranges in tissue. The radioactivity uptake and clearance kinetics 
in the kidneys of the radiolabeled peptide A
s
(t) is needed for calculation of the radiation 
dose to the kidneys, together with the S‐value for the kidney self‐dose. These S‐values 
can be adjusted with the actual patient’s kidney volume, derived from CT imaging; 
both the S‐values and the mass scaling can be performed within the OLINDA/EXM 
code [7]:
D A S A S A Srm rm
h
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There are three contributing sources that account for the radiation dose to the bone 
marrow from radiolabeled peptides: (1) the self‐dose by accumulation in the red marrow 
(Ã
rm
), either by blood flow or by specific uptake in the bone marrow; (2) cross‐dose from 
activity in major source organs and tumors (Ã
h
); and (3) cross‐dose from the remainder 
of the body (Ã
rb
), assuming homogeneous radioactivity distribution. As with the organ 
dosimetry, the calculations of the radiation dose to the bone marrow are highly dependent 
on phantom models, with no possibility for scaling the phantom to patient conformity. 
In case of heterogeneous uptake in the bone marrow, for example, due to bone metas-
tasis involvement, there is currently no accepted model for the dose calculation.
A direct comparison of the radioactivity concentrations in blood and bone marrow 
aspirates in 14 patients treated with 177Lu‐DOTA0‐Tyr3‐octreotate showed that the 
radioactivity concentrations in blood and bone marrow aspirates were nearly equal 
and that there is no specific binding of the peptide to bone marrow precursor cells [9]. 
The contributions to the bone marrow absorbed dose come largely (50% of total) by 
cross‐dose contributions from the remainder of the body, second (34%) by the red 
marrow itself due to circulating blood, and the least (14%) by other source organs 
(liver, spleen, kidney) and tumors. The bone marrow absorbed dose has a high inter-
patient variation.
Pharmacokinetic compartmental models are helpful to identify the ideal time 
points in activity quantification and define numerical solutions in calculating the 
organ cumulated activities (see MIRD pamphlet 16 [10]). The time points depend 
on the number of compartments in the uptake and clearance pattern that are 
needed for accurate residence time determination. For peptides, the uptake and 
initial fast clearance phase are usually neglected due to the longer half‐lives used 
for therapy. For 90Y, the time points used are 4, 24, and 48 h, although when 
measuring by PET imaging using 86Y (with t
1/2
 = 14.74 h) the sensitivity of the last 
measurement is much reduced. With 177Lu, the time points are usually 24, 72, and 
168 h, with optionally a measurement at 1 h to define the 100% whole body 
uptake calibration.
As an example, the pharmacokinetic model for the biodistribution of 177Lu‐
DOTA‐octreotate and the resulting distribution curves are shown in Figures 6.2.1, 
6.2.2, and 6.2.3.
Absorbed dose calculations are generally performed by using dedicated soft-
ware codes with residence times for the source organs τ as input (OLINDA/EXM, 
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RADAR) [7]. These calculations are done for fixed stylized models of the human 
body (e.g., MIRD phantoms) with the possibility to correct for the actual mass 
(M
CT




. More patient 
conformity can be obtained by calculating the absorbed dose in each voxel, either 
by assuming local absorption of all beta‐energy inside the source voxels, or by 
using voxel S‐values (MIRD pamphlet 17 [11]), or by doing a Monte Carlo calcu-
lation of all radiation transport from the source voxels to all surrounding voxels 
and itself.
Absorbed doses in the tumor lesions are estimated by assuming the lesion to be 
spherical in shape and, within the activity, uniformly distributed [12]. The pure 
β‐decay nature of 90Y without any γ‐emission severely hinders direct dosimetry 
for 90Y‐DOTA‐octreotide. Bremsstrahlung images are possible but need exten-
sive reconstruction algorithms and corrections applied [13]. Instead, the imaging 
can be performed using surrogate radionuclides linked to the peptide, either 
with 111In or with 86Y. With its gamma‐emission, 111In‐DOTA‐octreotide is very 
suitable as a surrogate for 90Y‐DOTA‐octreotide dosimetry. The positron emitter 
86Y has yielded good quality dosimetry but is very difficult to make as well as 






































Figure  6.2.1 Generalized compartment model for the biodistribution of 177Lu‐DOTA0‐
Tyr3‐octreotate in humans. Abbreviations: ex1, experimental input function; the time of drug 
administration (defined as T
0
); red dots, sample time points for the indicated compartments 
(organs); ECF, extracellular fraction; q1–9, compartments (or organs) 1–9; k(i,j), kinetic transfer 
components between the indicated compartments i and j (organs).
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111In‐DTPA‐octreotide (OctreoScan) planar or SPECT yields a different biodistri-
bution pattern than 90Y‐DOTA‐octreotide [16]; it did, however, identify the 
patients with high kidney uptake. PET‐based dosimetry with 68Ga‐DOTA‐octreo-
tide is not accurate due to its short physical half‐life (68 min). As 90Y also emits a 
1.71 MeV positron, it has been feasible to image the 90Y renal uptake distribution 
by PET imaging [17]. Imaging of 177Lu‐DOTA‐octreotate with its gamma‐ray 
emissions is much easier to perform and has the advantage of dosimetry 
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Time after administration (h)
Figure 6.2.2 Plasma, urine, kidney, liver, and spleen profiles of 177Lu‐DOTA0‐Tyr3‐octreo-
tate. Curves fit to mean percentages of infused activity (%IA) data using PK compartment 
model after treatment with 1.85 GBq (50 mCi) 177Lu‐DOTA0‐Try3‐octreotate; (a) without 
amino acid coinfusion (N = 5) and (b) with amino acid coinfusion (N = 4) in the same patients.
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evaluation during the actual therapy. Usually, dosimetry is performed during the 
first therapy course with 177Lu‐DOTA‐octreotate.
PRRT using 177Lu‐DOTA0‐Tyr3‐octreotate shows significant similarities to 131I 
therapy. The data in Table 6.2.1 shows that the physical characteristics of 131I and 177Lu 
are similar, except for the high‐energy γ‐rays of 131I, which cause a higher radiation 
dose to nontarget regions. Biodistribution and radiation dosimetry studies have shown 
that the critical organ in both radionuclide therapies (131I and 177Lu‐DOTA0‐Tyr3‐
octreotate) is the bone marrow. In both radionuclide therapies, at the doses shown in 
Table 6.2.2, the absorbed dose in the bone marrow can exceed the toxicity threshold 
dose established with external beam RT (see data in Table 6.2.2). 177Lu‐DOTA0‐Tyr3‐
octreotate treatment results in radiation doses to other organs such as the kidney, 
spleen, and pituitary that may be higher than the doses resulting from 131I therapy. 
However, based on clinical experience, the spleen and pituitary are not critical organs 
in terms of radiation‐related damage from PRRT. The kidneys are generally consid-
ered to be the critical organs for therapy with 177Lu‐DOTA0‐Tyr3‐octreotate. Therefore, 
it is common practice to coadminister amino acids to protect the kidneys [18–35].
bone mArrow toxicity AnD Dosimetry in Prrt
Radiation‐induced bone marrow toxicity results from damage to the hematopoietic 
tissue (the red marrow) where red blood cells, platelets, and white blood cells are 
produced. In PRRT using 177Lu‐DOTA0‐Tyr3‐octreotate or RT using 131I, the radiation 
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Figure 6.2.3 Uptake and clearance of 177Lu‐DOTA0‐Tyr3‐octreotate in kidneys of group 1 
patients. Data, plotted as the mean percentage of radioactivity (%IA), acquired after 
administration of 1.85 GBq (50 mCi, dose level 1); (■) without amino acid coinfusion; and 
(▲) with amino acid coinfusion. Curve fits to data are according to the PK compartmental 
model presented in Figure 6.2.1.
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dose to red bone marrow accumulates from the β‐ray irradiation from 131I or 177Lu 
radioactivity in the blood circulating in the bone and from penetrating γ‐ray radiation 
from activity dispersed throughout the remainder of the body. This “blood circulation” 
bone marrow dosimetry model has been safely employed for decades with 131I therapy 
[3]. It can also be used to determine the maximum dose that can be safely adminis-
tered with 177Lu‐DOTA0‐Tyr3‐octreotate.
KiDney toxicity in Prrt
Radiation‐induced kidney toxicity caused by PRRT is due to damage to the nephrons, 
the basic structural and functional units of the kidney. Nephrons consist of glomeruli 
and tubuli, which are responsible for filtration and reabsorption, respectively. The 
threshold dose for radiation damage to the kidneys by PRRT depends on the radionu-
clide that is used. To date, the radionuclides used for PRRT with somatostatin 
 analogues are Indium‐111 (111In [40, 41]), 90Y ([22, 28–30, 42–47]), and 177Lu 
([9, 20, 31, 33, 34, 44, 46, 48–56]). Tubular reabsorption of 90Y‐labeled peptides 
leads to a uniform radiation field to the kidney parenchyma that is comparable to 
that of external beam RT, despite the lower dose rate of PRRT [28]. A correlation 
was found between the kidney radiation dose and chronic kidney toxicity after 
treatment with 90Y‐DOTA0‐Tyr3‐octreotide, as depicted in Figure 6.2.4. The dose at 
which 50% of the patients will encounter kidney toxicity was established to be 
35 Gy [39], which is 7 Gy higher than the 28 Gy established for external beam RT 
[57]. Because 177Lu has a shorter‐range β‐particle than 90Y, there is less damage to 
nearby nontarget tissue [58, 59]. Moreover, PRRT using a radionuclide with much 
shorter‐range emissions (111In Auger electrons) does not result in kidney damage 
despite higher cumulative doses to the kidney [44]. Therefore, 23 Gy is considered 
to be a conservative value for the radiation toxicity threshold dose for PRRT using 
177Lu‐DOTA0‐Tyr3‐octreotide. A summary of the previously reported kidney and 
bone marrow dosimetry findings in studies using 177Lu‐DOTA0‐Tyr3‐octreotate is 
provided in Table 6.2.3.
tAble 6.2.1 Physical characteristics of 131i, 90y, and 177lu [36]
Characteristic 131I 90Y 177Lu
Decay half‐life (day) 8.0207 day 64.1 h 6.647 day
β‐particle energy  
(keV/decay)
181.9 keV 932.9 keV 133.3 keV
Main γ‐ray energy 
(keV) and abundance 
(%/decay)
364 keV  
(81.7%/decay)
511 keV  
(0.0064%/decay)
113 keV  
(6.4%/decay)
637 keV  
(7.2%/decay)
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KiDney Dosimetry in Prrt
Most dosimetry data analyzed are based on planar measurements. Despite the disad-
vantages of the use of planar image acquisition, it is a widely used and accepted 
technique, and it has been widely used in PRRT [31, 46, 54, 55]. The use of planar 
data based on conjugate view methods is known to be less accurate for determining 
kidney and other normal organ radiation doses. Studies that directly compare SPECT 
and planar imaging show that the planar imaging method consistently overestimates 
organ dosimetry [32–34]. This is primarily due to the occurrence of overlapping 
radioactivity that appears on planar images such as from the overprojection of the 
liver with tumor nodules into the right kidney region of interest and also from 
intestinal radioactivity potentially overlapping the left kidney [31, 55]. For this 
reason, in the study reported here, the organ uptake (abdominal region) was not dif-
ferentiated into separate organs and instead was considered to be a single source 
region. One issue with this approach, however, is that dosimetry models, like the 
OLINDA/EXM code [7], consider separate source organs only and do not facilitate 
dose calculations for dispersed radioactivity by widespread receptor‐positive metas-
tases. Most dosimetry models are based on rigid stylized phantoms with a possibility 



































Figure 6.2.4 Dose–response curve for late radiation‐induced kidney toxicity after external 
beam radiotherapy (XRT, closed dots and solid curve) and after PRRT with 90Y‐DOTA‐
octreotide (open signs and dashed curve). The normal tissue complication probability curve 
for the XRT data (26) is fitted with TD50 = 28 Gy and at slope of m = 0.15. The NTCP curve 
was fitted through 90Y data with TD50 = 35 Gy and m = 0.18 (Curve reproduced with permis-
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the actual patient geometry [60]. The technique has limitations for individual patient 
dosing, because it tends to overestimate organ doses and subsequently leads to con-
servative limits for the total cumulative dose of administered radioactivity. However, 
planar imaging‐based dosimetry with 111In‐DOTA0‐Tyr3‐octreotide has been of value 
in determining threshold doses in population studies for 90Y‐DOTA0‐Tyr3‐octreotide 
therapy [61].
Studies based on planar measurements for dosimetry calculations were performed 
by [31, 46, 55]. In each of these studies, patients were treated with cumulative doses 
of approximately 30 GBq (800 mCi) 177Lu‐DOTA0‐Tyr3‐octreotate given in four sep-
arate administrations, and their findings are in good agreement with other data. Bodei 
and coworkers [46] suggest that for patients without risk factors such as hypertension 
and diabetes, the threshold for kidney damage is set at a biologically effective dose 
(BED) of 40 Gy, which would correspond to a MIRD‐based radiation dose by 177Lu 
of 36 Gy. In the report by Wehrmann, no individual patient doses are given, but with 
a mean kidney dose per radioactivity of 0.9 ± 0.3 Gy GBq−1, the cumulative dose to 
the kidneys will be 27 ± 9 Gy for a cumulative administered radioactivity of 29.6 GBq 
[31]. There was no indication in their publication of any adjustment of the dosing 
scheme. In the study by Swärd et al. [55], the patients were scheduled for four admin-
istrations of 8 GBq each, unless the total radiation dose to the kidneys was more than 
27 Gy. Only 12 out of 26 patients were given the full therapy of four administrations. 
The mean radiation dose to the kidneys was determined to be 24 ± 6 Gy, but no 
individual dosing schemes were provided. The reported patient‐averaged dose per 
radioactivity is in the same order of magnitude: 0.9 ± 0.4 Gy GBq−1. Therefore, while 
these studies show general agreement on the radiation dose per unit of administered 
radioactivity to the kidneys, the lack of long‐term follow‐up data prevents any con-
clusions about long‐term renal toxicity.
Studies comparing the accuracy of radioactivity uptake measurements and dosim-
etry by quantitative SPECT/CT to those obtained with conventional planar imaging 
in patients treated with 177Lu‐DOTA0‐Tyr3‐octreotate were performed by Sandström 
et al. [34, 54], Garkavij et al. [33], and Claringbold et al. [32]. Sandström and 
coworkers [34] showed that planar and SPECT‐based dosimetry results are 
comparable in regions with low tumor density but that planar imaging‐based dosim-
etry in highly neoplastic regions overestimates the dose. The individual patient ratios 
of absorbed dose between the planar and SPECT‐derived kidney dose ranged bet-
ween 0.7 and 5 for the right kidney and between 0.8 and 9 for the left kidney. The 
mean radiation doses to the kidneys in their report are somewhat lower than these 
previously published by others. The observed variations and uncertainties were 
attributed to overlapping radioactivity from organ and tumor lesions. Garkavij and 
coworkers [33] determined that there was a ~30% overestimation of radiation dose 
using planar radioactivity data with background correction outside the abdominal 
cavity in comparison to using SPECT imaging data where all β‐ray energy from 177Lu 
is assumed to be absorbed within each source voxel self (planar, 1.15 ± 0.29 Gy GBq−1; 
SPECT, 0.90 ± 0.21 Gy GBq−1). In their study, the cumulative administered radioac-
tivity was tailored such that the total absorbed dose to the kidneys would remain 
below 27 Gy (based on the planar imaging method), usually by reducing the number 
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of treatments. However, 4 of the 12 evaluated patients were subsequently shown to 
have received planar imaging‐based doses exceeding 30 Gy. But only two patients 
showed radiation doses to the kidneys above 30 Gy (and only slightly) when the 
SPECT method for dosimetry was used. The other two patients with 30 Gy plus 
doses (by planar imaging‐based dosimetry) were found to have doses of about 19 Gy 
using the SPECT method. Furthermore, it was observed that there was an almost 
equal contribution (within 10%) to the total radiation dose to the kidneys from each 
of the treatment cycles.
In the study by Claringbold et al. [32], 33 patients were treated with four times 
7.8 GBq (200 mCi) 177Lu‐DOTA0‐Tyr3‐octreotate. PRRT was followed by treatment 
with capecitabine, which is, given the 14‐day time schedule per treatment, consid-
ered to have no effect on the pharmacokinetics of the peptide. Quantitative SPECT/
CT imaging was used to perform voxel‐based dosimetry using a point kernel to 
model radiation transport. They reported that the cumulative absorbed dose to the 
kidneys for the completed 4 treatments (31.2 GBq cumulative administered dose) is 
10 Gy (range: 4.5–14.6 Gy). This is much lower than the values reported by other 
groups. It is claimed that this difference is due to the use of patient‐specific geometry 
for the dosimetry calculations instead of the stylized MIRD phantom used in the 
OLINDA code [7]. Unfortunately, there was no direct comparison between the out-
comes of both methods.
lineAr QuADrAtic moDel AnD beD
Radiation‐induced damage (cell death) results from the combination of “direct damage,” 
the induction of double‐stranded DNA breaks, and “indirect damage,” the induction of 
multiple single‐stranded DNA breaks that combine to yield a lethal double‐stranded 
break. Dividing the radiation dose for external beam therapy into fractions has shown to 
result in enhanced repair of sublethal damage in normal tissue during the treatment 
intervals compared to the repair in tumor tissue. The repair of sublethal damage dose 
rates is described by the linear quadratic (LQ) model, which when stated in terms of a 
specific biological effect (E) (e.g., toxicity) per fraction (i) of fractional dose (D) can be 
expressed as




 is the radiation dose in Gy, α is the biological effect (per Gy) of the initial 
linear component, and β is the quadratic component of the effect (per Gy2). In terms 
of an observed biological effect such as cell survival, α represents direct, irreparable 
damage (e.g., lethal DNA strand breaks), and β represents lethal combinations of 
indirect, repairable damage (e.g., multiple single‐stranded breaks).
The ratio of both factors (α/β) determines the susceptibility of tissues to different 
dose rates, achieved either by dose fractionation schemes or by using radionuclides 
with different half‐lives. Normal tissue with a low α/β (2–4 Gy) shows less damage 
by a fixed dose delivered at low dose rates, whereas tumor tissue with a high α/β 
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(5–10 Gy) shows relatively constant damage from a fixed dose delivered at varying 
dose rates.
The LQ model can also be used to compare the biological effect to tissue resulting 
from different dose rates due to RT dose fractionation schemes (or different radionu-
clides) by calculating the “BED”. BED comparisons are based on the assumption that 
biological effects at a defined endpoint in specific tissues are equivalent, regardless of 
the dosing scheme. Studies on the induction of chronic kidney disease induced by 
external beam radiation and PRRT with 90Y showed equivalent BEDs [39], as shown in 
Figure 6.2.5. The commonly defined endpoint for chronic kidney disease in these studies 
is a 20% decline in creatinine clearance per year [28, 44], as the clinical endpoint for 
creatinine clearance toxicity is not always reached within the follow‐up after therapy.
The BED (or E/α) is an approximate quantity by which different RT fractionation 
regimens may be intercompared. For instance, for an external beam RT regimen 







At very low dose rates, as is in the case with PRRT, an additional factor must be added 



































Figure 6.2.5 Dose–response curve for correlation between late radiation‐induced kidney 
toxicity and biologically effective dose (BED) to the kidneys after external beam radiotherapy 
(XRT, closed dots and solid curve) and after PRRT with 90Y‐DOTA‐octreotide (open signs 
and dashed curve). The NTCP curve was fitted through 90Y data with TD
50
 = 44 Gy and slope 
m = 0.12 (Figure reproduced with permission from B. Wessels et al. [39]).
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of damage. In this case, as shown in the equation below, BED is determined from the 
cumulative dose (D) that is delivered in i fractions (D
i
), the effective half‐life (T
eff
) of 
the radioactivity in a specific tissue/organ, the repair half‐life (T
μ
), and the ratio bet-
ween direct and combinatorial damage (α/β). The latter values were deduced from 
external RT practice—T
μ










In external beam RT, kidney radiation doses of 23 and 28 Gy are considered to 
result in 5 and 50% probabilities, respectively, of developing radiation nephropathy 
within 5 years after treatment [1]. The 23 Gy dose delivered by fractionated external 
beam RT corresponds to a BED of 34 Gy. A BED of 34 Gy corresponds to a kidney 
radiation dose of 30 Gy for 177Lu‐DOTA0‐Tyr3‐octreotate treatment with a cumulative 
amount of radioactivity of 29.6 GBq given in four administrations (fractions). By 
using radionuclides with long half‐life and by fractionation of the therapy, radiation 
effect in normal tissue will be reduced [39, 63]. Since 177Lu has a longer half‐life than 
90Y (6.65 days vs. 2.67 days), the threshold radiation dose for kidney damage will be 
higher. Bodei et al. [46] calculated that in patients with multiple risk factors for renal 
toxicity, like diabetes and/or high blood pressure, the threshold BED for kidney radi-
ation toxicity with PRRT will be 28 Gy and without risk factors a BED limit of 40 Gy 
is assumed, thereby substantiating dose limits to the risk factors already identified by 
Valkema et al. [44].
bone mArrow Dosimetry consiDerAtions
There are three contributing sources that account for the radiation dose to the bone 
marrow from PRRT: (1) the self‐dose by accumulation in the red marrow, either by 
blood flow or by specific uptake in the bone marrow; (2) cross‐dose from major 
source organs and tumors; and (3) cross‐dose from the remainder of the body, 
assuming homogeneous radioactivity distribution. As with the organ dosimetry, the 
calculations of the radiation dose to the bone marrow are highly dependent on 
phantom models. In case of heterogeneous uptake in the bone marrow, for example, 
due to bone metastasis involvement, there is currently no accepted model for the dose 
calculation.
A direct comparison of the radioactivity concentrations in blood and bone marrow 
aspirates in the 14 patients treated with 177Lu‐DOTA0‐Tyr3‐octreotate showed that the 
radioactivity concentrations in blood and bone marrow aspirates were nearly equal 
and that there is no specific binding of the peptide to bone marrow precursor cells [9]. 
As discussed by Forrer et al., the contributions to the bone marrow absorbed dose 
come largely from cross‐dose from other source organs (liver, spleen, kidney, and 
blood), tumors, and the remainder of the body. The bone marrow absorbed dose has 
a high interpatient variation.
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bone mArrow rADiAtion toxicity literAture
In the study by Forrer, no correlation was found between the radiation dose to the 
bone marrow and the decrease in platelets following treatments (as assessed from 
blood samples taken 6 weeks after the treatment) for patients treated with up to a 
maximum 29.6 GBq (800 mCi) of 177Lu‐DOTA0‐Tyr3‐octreotate [9]. Wehrmann 
and coworkers [31] and Garkavij and coworkers [33] also found no correlation 
between the bone marrow dose and blood parameters after therapy. They report 
mean radiation doses to the bone marrow per administration of 7.4 GBq 177Lu‐
DOTA0‐Tyr3‐octreotate of 0.4 ± 0.1 Gy and 0.5 ± 0.1 Gy, respectively. Walrand and 
coworkers [47] reported that 86Y‐DOTA0‐Tyr3‐octreotide is taken up in the spine at 
later time points. It is not clear whether the observed spinal uptake is unconju-
gated 86Y or the intact radiolabeled peptide. The study of Walrand did show a 
correlation between the bone marrow dose and reduction in platelets after therapy, 
only when the absorbed dose was modulated for the patients with low platelet 
counts before PRRT.
inDuction oF myeloDysPlAstic synDrome  
AnD Acute leuKemiA
Leukemia and myelodysplastic syndromes (MDS), which have the potential to 
evolve into leukemia, are prominent late effects of exposure to radiation. In the gen-
eral population, MDS occurs in 5 per 100,000 people and increases in incidence to 
about 34 per 100,000 among individuals older than age 70 (NCCN, Practice 
Guidelines in Oncology v.4.2006; Myelodysplastic Syndromes). The natural inci-
dence of MDS and acute leukemia in nonradiated GEPNET patients is not known—
the same holds for GEPNET patients treated with chemotherapy. Chemotherapy 
(alkylating agents, nitrosoureas, topoisomerase II inhibitors, e.g., teniposide and eto-
poside), in the presence or absence of external beam radiation, is known to induce 
toxicity to the bone marrow. Various figures for 15‐year cumulative risk of AML 
after chemotherapy have been reported, as high as 10 percent, specifically in Hodgkin 
lymphoma patients treated with mechlorethamine, vincristine, procarbazine, and 
prednisone (MOPP). The 15‐year cumulative risk of AML after doxorubicin, bleo-
mycin, vinblastine, and dacarbazine (ABVD) has been estimated to be less than 1 
percent. This is reflected in a decrease in leukemia risk among those treated for 
Hodgkin lymphoma after 1980 when treatment with MOPP/ABVD largely replaced 
MOPP‐like combinations (2.1 vs. 6.4%) (In UpToDate®, P.M. Mauch, Second malig-
nancies after treatment of classical Hodgkin lymphoma).
The Atlas of Genetics and Cytogenetics in Oncology and Haematology indicates 
that secondary MDS/AML after chemotherapy is diagnosed after lymphoma therapy 
with a percentage of relative risk ranging from 2.2 to 3.3 at 15 years [64]. The inci-
dence rate of leukemia after 131I therapy was reported to be 0.4% and was not dose 




The determination of the radiation dose to organs, including the kidneys, has tradi-
tionally been based on the conjugate view method of planar imaging. The method 
produces generally acceptable results, but not in regions that have widespread 
tumor involvement. In these regions, planar imaging methods fail because images 
have overlapping radioactivity from uptake in the kidney and from metastases and/
or tumor uptake. This leads to an overestimation of the actual kidney radiation 
dose. The use of quantitative SPECT to measure the uptake of 177Lu‐DOTA0‐Tyr3‐
octreotate is less prone to errors caused by this overlapping radioactivity. 
Additionally, CT image can be used to define the actual patient geometry and 
kidney volume, which further improves the quality of the dosimetry. All planar 
imaging‐based dosimetry studies show mean doses per IA of 0.9 Gy GBq−1 with a 
33% variation between patients because of differences in kidney kinetics (see 
Table 6.2.3, planar imaging method). When quantitative SPECT is used, the mean 
radiation dose to the kidneys is calculated to be 0.57 Gy GBq−1 (weighted mean 
from SPECT data in Table 6.2.3) with the same 33% variation induced by difference 
in kinetics. From these data, the cumulative administration of 29.6 GBq 177Lu‐
DOTA0‐Tyr3‐octreotate will result in a kidney radiation dose of 27 ± 9 Gy according 
to the planar imaging method or, more accurately, 16.8 ± 5.7 Gy according to the 
quantitative SPECT method.
KiDney Dosimetry: heterogeneity oF the Dose 
DelivereD to KiDneys
With respect to the biological effect of radiation, the distribution of the dose deliv-
ered to the kidneys by 90Y or 177Lu is different, due to their different β‐energies [59]; 
90Y emits β‐particles with a mean energy of 0.933 MeV, which has a range in tissue 
of 3.5 mm, whereas the β‐particles from 177Lu with a mean energy of 0.133 MeV 
have a range in tissue of only 0.2 mm. The homogeneous radiation exposure of the 
kidneys obtained by 90Y is more similar to the exposures resulting from external RT 
than obtained by the shorter‐range 177Lu. As the radiolabeled peptide is reabsorbed by 
the proximal tubuli, 177Lu will irradiate the tubuli, but because of the limited range of 
177Lu β‐emissions, it will have little effect on the glomeruli. Glomeruli are known to 
be more radiation sensitive and show less repair capacity than tubuli. Glomeruli and 
tubuli may have different repair kinetics and therefore different radiation responses, 
but the actual rates have never been measured. Moreover, in general, dosimetry calcu-
lations are based on the MIRD scheme, with the assumption that radioactivity in the 
kidney is homogeneously distributed. This assumption was investigated by de Jong 
et  al. [58] by determining the distribution of radioactivity in the normal human 
kidney after i.v. injection of 111In‐DTPA0‐octreotide. Three renal cancer patients, 
scheduled for nephrectomy, received i.v. injection of 111In‐DTPA0‐octreotide, and the 
distribution of radioactivity was assessed by SPECT scanning before surgery and by 
ex vivo autoradiography of the kidney after surgery (Fig. 6.2.6).
Figure 6.2.6 Ex vivo autoradiographs and 111In, 90Y, and 177Lu isodose curves for kidney 
sections from 3 patients (a, b, and c) at different time intervals after administration of 111In‐
DTPA‐octreotide (Figure reproduced with permission from M. Konijnenberg et al. [59]). 
(See insert for color representation of the figure.)
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90Y isodose curves (100% = 29 µGy/MBq.s) 
177Lu isodose curves (100% = 3.8 µGy/MBq.s) 
177Lu isodose curves (100% = 4.6 µGy/MBq.s) 
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Based on autoradiography, radioactivity was found to be localized predominantly 
in the cortex of the kidney. In the cortex, radioactivity was not distributed homoge-
neously but formed a striped pattern, with most of the radioactivity centered in the 
inner cortical zone. These findings showed that average dose calculations using the 
MIRD scheme, assuming homogeneous renal radioactivity distribution, are inade-
quate to estimate the radiation dose to various parts of the kidney after radionuclide 
therapy. Different effects due to inhomogeneity can be expected from radionuclide 
therapy using radionuclides emitting particles with short particle ranges, for example, 
Auger electron emitters, alpha‐emitters, and low‐energy beta‐emitters. From the 
aforementioned discussion, it can be seen that the threshold dose constraints deter-
mined from external beam RT are directly applicable to defining the maximum 
treatment dose in PRRT with 90Y‐DOTA0‐Tyr3‐octreotide, but less so with 177Lu‐
DOTA0‐Tyr3‐octreotate where it most likely overestimates toxicity. This distribution 
is not observed in SPECT imaging, and when the dose distributions inside the kidney 
are compared for 111In, 90Y, and 177Lu, based on quantitative SPECT/CT‐based dosim-
etry, no difference between the distribution patterns was observed [66].
111In isodose curves (100% = 2.2 µGy/MBq.s) 
Ex vivo autoradiography,
111In–octreoscan (48 h after injection)
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AbbreviAtions
BED biological effective dose or bioeffective dose
DLT dose‐limiting toxicity
DOTA 1,4,7,10‐tetraazacyclododecane‐N ,N′ ,N″ ,N‴‐ 
tetraacetic acid
GBq gigabecquerel
PRRT peptide receptor radionuclide therapy
PET positron emission tomography
PET/CT positron emission tomography/computed tomography
QoL quality of life
Sqm square meter
SWOG Southwestern Oncology Group
RECIST Response Evaluation Criteria In Solid Tumors
WHO World Health Organization
90Y‐DOTA‐Tyr3‐octreotide or 90Y‐DOTATOC or 90Y‐octreotide
177Lu‐DOTA‐Tyr3‐octreotate or 177Lu‐DOTATATE or 177Lu‐octreotate
PePtide recePtor rAdionuclide 
therAPy (Prrt): clinicAl 
APPlicAtion
Lisa Bodei and Giovanni Paganelli




Neuroendocrine tumors are generally slow growing and are frequently discovered 
when metastatic spread has occurred. This leaves room for multiple treatments, 
 individualized through a multidisciplinary approach that considers tumor type, 
extension, and related symptoms.
The therapeutic choice depends on the aim of the therapy, whether to slow the 
tumor growth and ameliorate the symptoms or to eradicate the disease. Available 
options include surgery, interventional radiology techniques, and medical therapies, 
such as somatostatin analogues, alpha‐interferon, chemotherapy, new biomolecular 
targeted therapies, and peptide receptor radionuclide therapy (PRRT) with radiola-
beled somatostatin analogues [1].
Neuroendocrine tumors overexpress somatostatin receptors on their cell mem-
brane, particularly the subtype 2. This constitutes the biomolecular basis for the use 
of somatostatin analogues in therapy.
“Cold” somatostatin analogues have an important symptomatic effect, and as 
recently demonstrated, they exert an action on tumor growth by limiting its natural 
progression [2]. Nevertheless, the escape from the pharmacologic effect of octreotide 
or lanreotide, the so‐called tachyphylaxis, commonly and early occurs [3].
In the past two decades, a new approach to neuroendocrine tumors based on 
specific receptor targeting with radionuclides was introduced in the clinical practice 
in many European centers (the Netherlands, Switzerland, Italy, Germany, Poland, 
etc.). PRRT consists in the systemic administration of a synthetic analogue, 
 radiolabeled with a suitable beta‐emitting radionuclide. These compounds are able to 
 irradiate tumors and their metastases via the internalization through a specific 
receptor subtype, generally overexpressed on the cell membrane. Preclinical studies 
have indicated many potential receptor candidates for PRRT. To date, the mostly 
exploited system is the somatostatin receptor. After initial experiences with 111In‐
pentetreotide, to date, the most used radiopharmaceuticals are 90Y‐DOTA‐Tyr3‐
octreotide or 90Y‐DOTATOC or 90Y‐octreotide and 177Lu‐DOTA‐Tyr3‐octreotate or 
177Lu‐DOTATATE or 177Lu‐octreotate.
PRRT with either 90Y‐octreotide or 177Lu‐octreotate can deliver consistent radia-
tion doses to lesions, adequate to achieve significant tumor responses.
rAtionAle
The biomolecular basis of PRRT consists in the selective irradiation of tumor cells, 
which derives from the radioactivity transported inside the tumor cell after the inter-
nalization of the receptor–radioanalogue complex. Since newly formed blood vessels 
growing around tumor cells express somatostatin receptors, mainly of subtype 2, 
PRRT can also generate a parallel antiangiogenic response.
First experiences of PRRT began in the early 1990s, when the high‐energy and 
short‐range Auger and conversion emissions of In‐111, normally used in diagnostics, 
began to be exploited for therapeutic purposes. Clinical trials using high activities 
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(~6.7 GBq) of 111In‐pentetreotide in patients affected by neuroendocrine tumors were 
carried out [4].
Despite these premises, objective responses were rare (2.5% partial responses). 
The efficiency of Auger electron emitters is known to be dependent on their incorpo-
ration in the double strand of DNA. The nuclear uptake of 111In‐pentetreotide, in fact, 
is not significant, and this is possibly the cause of the poor results observed in 
patients.
The next logical step was to utilize high‐energy beta‐emitters, such as Yttrium‐90. 
The higher energy (maximum 2.2 MeV) and penetration range (R
95
 5.7 mm) of elec-
trons from 90Y resulted more advantageous, with a direct killing of somatostatin 
receptor‐positive cells and a cross‐fire effect that kills nearby receptor‐negative 
tumor cells.
A new somatostatin analogue, named Tyr3‐octreotide, with receptor affinity 
 similar to that of octreotide, was developed. The 1,4,7,10‐tetraazacyclododecane‐N,
N′,N′′,N′′′‐tetraacetic acid (DOTA) chelated form can be easily labeled with radio-
metals, such as In‐111 and Y‐90. The newly formed molecule is [90Y‐DOTA]0‐Tyr3‐
octreotide or 90Y‐DOTATOC or 90Y‐octreotide.
More recently, a new analogue, named octreotate (chemically a Tyr3,Thr8‐substituted 
octreotide), was synthesized [5]. The new compound has a six‐ to ninefold higher 
affinity for somatostatin receptor subtype 2, the one that is most frequently overex-
pressed by neuroendocrine tumors. Its DOTA chelated form, [DOTA]0‐Tyr3‐octreotate 
or DOTATATE, has been labeled with the beta–gamma‐emitter Lutetium‐177, which 
has a lower energy (maximum 0.49 MeV) and penetration range (maximum 2 mm), a 
longer half‐life (6.7 days), and a gamma photonic emission allowing imaging and 
dosimetry at the same time [6].
clinicAl Protocol
Patients candidate to PRRT with radiolabeled somatostatin analogues are those with 
tumor lesions significantly overexpressing somatostatin receptors. Among the 
inclusion criteria, the presence of functioning receptors, namely, able to internalize 
the receptor–analogue complex and retain the radioactivity inside the cell, is 
 considered of crucial importance for an efficient therapy.
In order to be admitted to the therapeutic phase, in fact, patients must be selected 
according to their OctreoScan scintigraphy (or, more recently, their receptor PET 
with Gallium‐68‐labeled octreotide). These images must show an adequate uptake 
(at least equal to the one of the normal liver), namely, an adequate expression of 
somatostatin receptors, to the lesions in order to plan a high dose to the tumor and a 
low one on normal tissues.
Scintigraphic evaluation is to date the most accurate method to check for the 
overexpression of functioning receptors. Compared to immunohistochemistry, 
which shows that detail at the time of the biopsy, the scintigraphic method allows 
the evaluation of the receptor density and the internalization capacity at present 
time.
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When evaluating receptor scintigraphy for PRRT selection, it is important to 
exclude possible false positives, such as the gallbladder, accessory spleens, recent 
surgical scars, previous radiotherapy, and any other cause of granulomatous‐ lymphoid 
infiltrate that can mimic neuroendocrine tumor tissue.
Potential causes of false negatives must be excluded as well. These are mainly 
represented by small, subcentimetric lesions, under the resolution limit of gamma‐
camera (although this limitation is partially overcome by receptor PET/CT), and 
receptor‐negative lesions due to recent chemotherapy or poorly differentiated 
disease.
PRRT consists in the systemic administration of the radiopeptide. The treatment 
is fractionated in multiple cycles until the maximum cumulative administrable 
activity is reached. This amount is able to efficiently irradiate the tumor, without 
trespassing the conventional 25–27 Gy absorbed dose threshold to the kidneys, which 
are the dose‐limiting organs. Recently, it has been observed that switching from 
absorbed dose to biological effective dose, or BED, this dose threshold value is 
slightly higher.
Therapy cycles are given 6–9 weeks apart, in order to cover from possible hema-
tological toxicity.
In order to reduce renal dose, patients are premedicated with an intravenous infu-
sion of positively charged amino acids, starting from the 2–3  preceding up to the 2–3 
h following PRRT.
Lysine or arginine, 25 g/day, is coinfused with the aim of conveniently hydrating 
the patients and reducing the renal dose by competitive inhibition of the proximal 
tubular reabsorption of the radiopeptide.
Radiopeptide therapy is slowly administered intravenously in about 100 ml of 
saline in about 20 min.
Possible gastrointestinal symptoms, generally a mild nausea, more rarely vomit, 
may occur with the amino acid coadministration.
efficAcy
In almost 15 years of academic phase II trials, despite the lack of homogeneity 
among studies, PRRT with either 90Y‐octreotide or 177Lu‐octreotate proved to be 
efficient, with tumor responses in more than 30% of patients, symptom relief and 
quality of life (QoL) improvement, biomarker reduction, and, ultimately, an impact 
on survival.
The most used radiopeptide in the first 8–10 years of experience is 90Y‐octreotide. 
All the published results derive from different phase I–II studies, inhomogeneous as 
to inclusion criteria and treatment schemes. Hence, a direct comparison is virtually 
impossible to date. Nevertheless, even with these limitations, objective responses are 
registered in 10–34% of patients [7–12].
Figure 6.3.1 reports an example of objective response in a patient affected by a 
well‐differentiated neuroendocrine carcinoma from unknown primary with diffuse 
bone marrow metastases.
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In a study carried out at Basel university, 39 patients with neuroendocrine tumors, 
mostly of gastroenteropancreatic (GEP) origin, were treated with 4 cycles of 90Y‐
octreotide, with a cumulative activity of 7.4 GBq/sqm. Objective responses, according 
to WHO criteria, were described in 23%, with a complete remission in 2 patients, 
partial in 7, and a disease stabilization in 27. Pancreatic neuroendocrine tumors (13 
patients) showed a better objective response (38% partial + complete) than the other 
classes did. A significant amelioration of related symptoms occurred in the majority 
of patients [10].
In another multicenter phase I study, carried out at Rotterdam, Louvain, and 
Tampa universities, 60 patients affected by GEP neuroendocrine tumors were treated 
with 4 cycles of 0.9, 1.8, 2.8, 3.7, 4.6, and 5.5 GBq/sqm administered 6–9 weeks 
apart. In a first evaluation of the results, published in 2002 in 32 evaluable patients, 
objective responses, according to SWOG criteria, consisted in about 9% of partial 
responses and 9% of minor responses [13]. In a subsequent analysis of the same 
patient population, published in 2006 on 58 assessable patients who were treated 
with cumulative activities of 1.7–32.8 GBq, a 57% clinical benefit, including stabili-
zation and minor responses, was observed, according to SWOG criteria. A true 
objective response was described in 5% of the patients. The most relevant finding of 





figure 6.3.1 Morphologic response in a patient affected by bone marrow metastases and 
previous liver metastases from a well‐differentiated neuroendocrine carcinoma, Ki‐67 10% 
with an unknown primary. The patient underwent a right liver hepatectomy with a homolateral 
adrenalectomy. After surgery, the patient was treated with 177Lu‐DOTATATE (24.6 GBq 
cumulative activity). The evaluation of the status at baseline by means of 68Ga‐DOTATOC 
PET/CT (a, fusion sagittal image; b, MIP image) shows diffuse bone marrow involvement, 
particularly in the axial skeleton. The evaluation performed after the end of PRRT by means of 
68Ga‐DOTATOC PET/CT (c, fusion sagittal image; d, MIP image) shows the almost complete 
disappearance of the lesions. Please note the hypertrophy of the left liver lobe, as a consequence 
of the right lobe resection. (See insert for color representation of the figure.)
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and a median progression‐free survival (PFS) of about 29 months. These results 
 compared well with the 12‐month overall survival of the historical group treated with 
111In‐pentetreotide. The median PFS was 29 months [11].
The results of two phase I–II studies and a retrospective evaluation in 141 patients 
were published by the Milano group in 2004. Patients were affected mainly by 
 neuroendocrine tumors and were treated with a cumulative activity of 7.4–26.4 GBq of 
90Y‐octreotide, divided into 2–16 cycles, administered 4–6 weeks apart. Objective 
response rate was 26%, including partial and complete responses, according to SWOG 
criteria. Disease stabilization was observed in 55% of the patients and disease progres-
sion in 18%. The mean duration of response ranged between 2 and 59 months (median 
18). The majority of the patients who responded had GEP neuroendocrine tumors. The 
study showed that, by dividing the objective response according to the basal status, 
stable patients at baseline had better outcome (partial and complete responses in 32%) 
than did progressive ones (partial and complete responses in 24%) [9].
Recently, a multicenter study aimed at studying the role of 90Y‐octreotide in 90 
patients with symptomatic, metastatic “carcinoids,” namely, neuroendocrine tumors 
originating from the small intestines, was published. This study showed that PRRT 
with 90Y‐octreotide was able to induce stabilization or tumor response, according to 
SWOG criteria, in 74% of patients as well as a durable amelioration of all the symp-
toms related to the tumor mass and the hypersecretion of bioactive amines. 
Interestingly, the symptomatic response had an impact on survival, since PFS was 
significantly longer in those who had durable diarrhea improvement [14].
More recently, the Basel group published the results of their open‐label phase II 
trial in 1109 patients treated with 90Y‐octreotide, divided in multiple cycles of 
3.7 GBq/m2 each. Objective morphologic responses, according to RECIST criteria, 
were observed in 378 (34.1%), biochemical response in 172 (15.5%), and symptom-
atic in 329 (29.7%). Longer survival was correlated with tumor and symptomatic 
response. The best predictor of survival was the tumor uptake at baseline [12].
Since its introduction in clinical trials in 2000, the new radiopeptide DOTATATE 
labeled with Lutetium‐177, 177Lu‐DOTATATE or 177Lu‐octreotate, has gained a great 
popularity, due to its higher affinity for sst
2
, its easier manageability, and the possi-
bility of imaging. Nowadays, it is the mostly used radiopeptide.
The first clinical trials were carried out at Rotterdam university. In a preliminary 
report, 35 patients with GEP neuroendocrine tumors were treated with 3.7, 5.6, or 
7.4 GBq of 177Lu‐octreotate, up to a final cumulative dose of 22.2–29.6 GBq, with 
complete and partial responses in 38%, according to WHO criteria. No serious side 
effects were observed [15].
In a subsequent series enlargement, 131 patients with somatostatin receptor‐
positive GEP neuroendocrine tumors were treated with cumulative activities of 177Lu‐
octreotate ranging from 22.2 to 29.6 GBq. In the 125 evaluated patients, according to 
SWOG criteria, complete remissions were observed in 3 patients (2%), partial 
 remission in 32 (26%), minor response in 24 (19%), and stable disease in 44 patients 
(35%), while 22 patients (18%) progressed. Better responses were more frequent in 
case of a high uptake on baseline octreotide scintigraphy and in case of limited 
liver  involvement. On the other hand, progression was significantly more frequent in 
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patients with a low performance score and extensive disease at enrolment. Median 
time to progression (TTP) was more than 36 months, comparing favorably to chemo-
therapy [16].
In addition, 177Lu‐octreotate significantly improved the global health/QoL and 
various symptom scales, particularly fatigue, insomnia, pain, as well as role, 
 emotional, and social functions, in patients with metastatic GEP tumors. The effect 
was more frequent in patients obtaining tumor regression, but surprisingly, it was 
also observed in progressing patients [17].
Recently, an evaluation of the enlarged series of 504 patients treated with 177Lu‐
octreotate, 310 of which evaluated for efficacy, confirmed the occurrence of complete 
and partial remissions in 2 and 28% of cases, with minor responses in 16% and sta-
bility in 35%, according to SWOG criteria. However, the most precious information 
of this study was the impact of PRRT on survival, with a median overall survival 
>48 months and a median PFS of 33 months. A direct comparison with literature data 
obtained from similar patients showed an important 40–72‐month survival benefit. 
Although these data are not derived from proper randomized phase III trials, the huge 
difference in survival is most likely to be caused by a real impact of PRRT. These 
data compare favorably to other treatments, such as chemotherapy, from the cost/
benefit and tolerability point of view [18].
A categorization of objective response showed once more that pancreatic tumors 
tended to respond better than other GEP tumors, although pancreatic gastrinomas 
tended to relapse in a shorter interval (median TTP 20 months vs. >36 in the remain-
ing GEP tumors) [16].
A number of phase II studies, mostly retrospective, oriented at defining the 
objective response in specific classes of diseases, were published in the past years.
A phase II study included traditionally considered “poor responding” tumors, 
such as bronchial and gastric neuroendocrine carcinomas. Patients were treated 
with standard 22.2–29.6 GBq activities. Despite the limited number of patients 
studied, the observed objective response, according to SWOG criteria, was 
comparable to the one observed in GEP tumors: in bronchial 5/9 partial responses, 
1 minor and 2 stabilizations, and in gastric tumors 1/5 complete response, 1 minor 
and 2 stabilizations. In thymic tumors, the patient series was too small to draw any 
conclusions [19].
Another phase II study with 177Lu‐octreotate administered at standard activities in 
a small series of patients with “nontypical” neuroendocrine tumors or simply sst
2
‐
positive neoplasms, such as paragangliomas (12 patients), meningiomas (5 patients), 
small cell lung carcinomas (3 patients), and eye melanomas (2 patients), demon-
strated that PRRT is able to yield tumor responses, evaluated according to SWOG 
criteria, in paragangliomas and meningiomas, although with lower rates compared to 
“typical” neuroendocrine tumors. In small cell lung carcinomas and in melanomas, 
PRRT with 177Lu‐octreotate did not produce any antitumor effect. The limited number 
of patients may have hampered the study results, particularly for meningiomas, and 
the need of further studies is suggested by the authors [20].
As regards meningiomas, a dedicated study of PRRT with 90Y‐octreotide on 
a  series of 29 patients, 14 with benign forms, 9 atypical, and 6 malignant, was 
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published in 2009 by the Milano group. Patients received cumulative activities of 
5–15 GBq divided in 2–6 cycles. According to SWOG criteria, disease stabilization 
occurred in 19/29 patients (66%), while progression was observed in the other 10 
(34%). Better results occurred in patients with low‐grade meningiomas, with a 
median PFS of 61 months, compared to atypical and malignant forms, with a median 
PFS of 13 months. These data point out the need of treating patients with an adjuvant 
approach, shortly after surgery, particularly in high‐grade meningiomas, where 
lesions tend to be large and multiple [21].
177Lu‐octreotate has also been tested in a small group of 5 patients with iodo‐ 
negative or resistant differentiated thyroid carcinomas, among which 3 patients with 
Hürthle cell carcinoma. According to SWOG criteria, 1 patient with Hürthle cell 
carcinoma had a partial response, 1 patient with Hürthle cell carcinoma had a minor 
response, and 2 patients, one with a Hürthle and the other with a papillary form, had 
disease stabilization. These data outline the importance of PRRT with 177Lu‐ octreotate 
in a category of endocrine tumors, especially Hürthle cell carcinomas, that has no 
valuable therapeutic options [22].
Finally, PRRT has also been administered in children and young adults with 
somatostatin receptor‐positive tumors. A phase I study involved 17 subjects (2–24 
years old) affected by neuroblastomas, MEN2b, gliomas, and neuroendocrine 
tumors. Patients were treated with 90Y‐octreotide with activities ranging from 1.1 to 
1.85 GBq/m2/cycle for a total of 3 cycles, administered 6 weeks apart. According to 
the Pediatric Oncology Group criteria, 12% of partial responses and 29% of minor 
responses were observed. Improved QoL during the treatment was a major advantage 
of the therapy. Therefore, PRRT proved to be efficient and tolerated also in young 
patients [23].
Recently, the Rotterdam group published the results of the salvage protocol with 
177Lu‐octreotate. Patients were enrolled in progression after an initial response to 
PRRT with 177Lu‐octreotate, administered with standard cumulative activities (22.2–
29.6 GBq). As a consequence, 32 patients with bronchial or GEP neuroendocrine 
tumors received 2 additional cycles of 177Lu‐octreotate, with a cumulative activity of 
15 GBq. A new objective response was obtained in 8 patients (2 partial and 6 minor 
responses), while stabilization was registered in another 8. Median TTP was 17 
months. Both response rate and duration over time appear, therefore, lower than 
the one obtained with the primary treatment. Nevertheless, salvage therapy was well 
 tolerated by the majority of patients and is, therefore, a valuable option in this 
 category [24].
Presently, following recent tendencies in oncology, PRRT experiences are direct-
ing toward combination therapies. Studies of 177Lu‐octreotate combined with the 
radiosensitizer chemotherapy agent capecitabine have been published in the past 
years. The first study showing encouraging results was carried out in a small group 
of 7 patients with progressing GEP neuroendocrine tumors. Patients were treated 
with 4 cycles of standard activities of 177Lu‐octreotate plus capecitabine (1650 mg/
sqm) for the following 2 weeks. The evaluation showed the absence of severe tox-
icity, particularly hand–foot syndrome or hematological or renal toxicity. Objective 
responses were indeed observed [25].
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A recent phase II study was completed in 35 patients with progressing neuroendo-
crine tumors. Patients were treated with 4 cycles of 7.8 GBq of 177Lu‐octreotate plus 
capecitabine, 1650 mg/m2, for the following 2 weeks. According to RECIST criteria, 
a 24% objective response was observed, with a 70% stable disease and 6% progres-
sion, without adjunctive toxicity [26].
tolerAbility
After 15 years of experience, we can state that, from the safety point of view, PRRT 
is generally well tolerated. Acute side effects are usually mild: some of them are 
related to the coadministration of amino acids, such as nausea (or more rarely vomit). 
Others are related to the radiopeptide, such as fatigue (commonly), a modest alopecia 
(possible after 177Lu‐octreotate), or the exacerbation of an endocrine syndrome, 
which rarely occurs in functioning tumors. Chronic and permanent effects on target 
organs, particularly the kidneys and the bone marrow, are generally mild if the 
necessary precautions are taken.
Dosimetric studies indicated that it is possible to deliver elevated absorbed doses 
to the tumor, with a relative sparing of normal organs, especially kidneys and bone 
marrow.
While hematological toxicity mainly occurs immediately after PRRT and is 
 usually mild and transient, permanent and severe bone marrow toxicity is a rare event 
after PRRT, being the resulting bone marrow absorbed doses usually well below the 
threshold of toxicity [27, 28]. In contrast, delayed renal toxicity that may occur if the 
dose threshold is exceeded is permanent. The kidney is, in fact, the critical organ at 
the doses that are normally reached with PRRT. Commonly accepted data, from 
external beam radiotherapy experience, indicate threshold values for toxicity of 
about 25–27 Gy. Recently, radiobiology concepts applied to nuclear medicine therapy 
indicated that bioeffective doses (BED) are more accurate in predicting toxicity and 
40 Gy was indicated as a more likely threshold for renal toxicity [29, 30]. 
Nephrotoxicity derives from the proximal tubular reabsorption of the radiopeptide. 
The strategy of coinfusing positively charged amino acids, such as lysine or arginine, 
competitively inhibiting the radiopeptide reabsorption, leads to a 9–53% reduction of 
the renal doses [31].
Despite renal protection, a loss of renal function of variable degree (generally 
mild) may appear months after the end of PRRT. Cases of severe, end‐stage renal 
damage are nowadays rare and mainly occurred at the beginning of PRRT 
 experience, when renal protection was not in use and very high activities were 
administered [32].
Nevertheless, independently of the development of a clinically evident renal 
damage, renal function is “consumed” to some extent after PRRT, and a decline in 
creatinine clearance occurs with time. This loss is more pronounced for 90Y‐ octreotide 
(median 7.3% per year) than for 177Lu‐octreotate (median 3.8% per year) [33].
Studies demonstrated that a higher and more persistent decline in creatinine 
clearance and the subsequent development of renal toxicity occurred in those 
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patients with risk factors for delayed renal toxicity, particularly long‐standing and 
poorly controlled diabetes and hypertension. In these patients, the renal BED 
threshold results about 28 Gy, lower than the one of patients without risk factors. 
Therefore, a preliminary screening of the candidate patients before PRRT appears 
essential [34].
From a hematological point of view, PRRT is generally well tolerated. Severe, 
WHO grade 3 or 4, toxicity does not occur in more than 13% of cases after 90Y‐
octreotide and 2–3% after 177Lu‐octreotate [8, 12].
Previous dose‐finding phase I studies demonstrated that maximum cumulative 
administrable activity per cycle of 90Y‐octreotide, with renal protection, is 5.18 GBq 
[35]. No dose‐finding studies have been conducted for 177Lu‐octreotate, and studies 
employing the dose‐limiting toxicity (DLT) method were abandoned, since  literature 
data showed the possibility to safely use 7.4 GBq as a maximum activity per cycle 
and dosimetric studies showed the advantage of hyperfractionation in lowering 
the  renal and bone marrow dose (L. Bodei, EANM’10 Annual Congress of the 
European Association of Nuclear Medicine, Vienna, Personal communication, 
2010; [28, 16, 34]).
177Lu‐octreotate demonstrated a higher tolerability compared to 90Y‐octreotide, 
largely due to the physical characteristics of the two radioisotopes.
Phase I–II studies have demonstrated that absorbed and bioeffective doses 
 delivered to kidneys and bone marrow remain within the thresholds (L. Bodei, 
EANM’10 Annual Congress of the European Association of Nuclear Medicine, 
Vienna, Personal communication, 2010).
Finally, the possibility of exacerbation of endocrine syndromes, such as carcinoid, 
hypoglycemic, or Zollinger–Ellison syndrome, must be taken into account, although 
quite rare. This appears to be related to the massive cell lysis and hormonal  stimulation 
occurring after PRRT that must be prevented and treated accordingly [36, 37].
conclusions
PRRT, either with 90Y‐octreotide or 177Lu‐octreotate, demonstrated to be efficient and 
relatively safe up to the known thresholds of absorbed and bioeffective dose. Toxicity 
profile is acceptable from a renal and hematological point of view, if necessary 
protective measures are taken.
PRRT proved to induce a significant improvement of the QoL and of all the symp-
toms related to the disease in more than 70% of treated patients. Differently from 
other treatments applied in neuroendocrine tumors, PRRT with either 90Y‐octreotide 
or 177Lu‐octreotate showed a median TTP of at least 30 months. Moreover, patients 
responding to PRRT with a stabilization or a tumor reduction (accounting for about 
75% of treated population) obtain a significant impact on survival (40–72 months 
from diagnosis). For these reasons, despite the absence of randomized controlled 
trials, PRRT is considered as a standard of care in the treatment of neuroendocrine 
tumors, and it is rightfully inserted in many therapeutic algorithms and considered by 
scientific societies dedicated to neuroendocrine tumors [38–40].
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MRI magnetic resonance imaging
NET neuroendocrine tumors
PET positron emission tomography
pNET pancreatic NET
PR partial remission
PRRT peptide receptor radionuclide therapy
SMS somatostatin
SSTR somatostatin receptors
SUV standardized uptake value
TER tubular extraction rate
introDuction
The heterogeneous nature of neuroendocrine tumors (NETs) and their indolent 
course together with lack of optimal conventional therapy for the management of 
advanced cases pose a challenge for the oncologists. The overexpression of 
somatostatin receptors (SSTRs) on their cell surface enables the effective treatment 
of NETs with peptide receptor radionuclide therapy (PRRT) using radiolabeled 
somatostatin (SMS) analogues. The previous authors have already discussed the 
concepts and clinical application of PRRT. In this chapter, we would focus on 
Duo‐PRRT.
rADionucliDes
The most frequently used radionuclides in PRRT are Yttrium‐90 (90Y) and 
Lutetium‐177 (177Lu). These radionuclides have different physical characteristics, for 
example, beta‐particles are emitted at different energies, resulting in various tissue 
penetration ranges. A pronounced “cross‐fire effect” is found when using 90Y, since 
the beta‐particles are emitted with a relatively high energy, resulting in a tissue pen­
etration range of up to 12 mm, which may be preferable for larger tumors. While this 
cross‐fire effect is beneficial to overcome the inhomogeneity of receptor expression 
in cancer cells, allowing irradiation of tumor cells that are not directly targeted by the 
radiopharmaceutical, the long range of the 90Y beta‐particles appears to increase the 
potential for kidney toxicity [1]. 177Lu, on the other hand, emits intermediate‐energy 
beta‐particles, resulting in a tissue penetration range of up to 2 mm, which may be 
preferable for smaller tumors. In addition, 177Lu has two gamma peaks at 113 and 208 
keV, which makes it suitable for imaging with a gamma‐camera for posttherapeutic 
dosimetry. Another difference between these radionuclides is their physical half‐life. 
Although the influence of the physical half‐life is not yet fully understood, it is very 
likely that it influences the therapeutic as well as the secondary effects. For 90Y, it is 
2.7 days, whereas the physical half‐life of 177Lu is more than double (6.7 days). 
These differences in characteristics in turn influence the decision on the choice of 
 radionuclide (Table 6.4.1) to be used for PRRT.
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concePt of combineD Prrt
Pragmatically, during PRRT, the presence of different sizes of tumors with inho­
mogeneous distribution of SSTR in a particular NET patient should be taken into 
consideration to ensure that most of the beta‐energy from the radioisotope is 
absorbed and the radiation dose to the tumor is optimized [2]. A conceivable solu­
tion to take this heterogeneity into account is the use of a combination of the radio­
nuclides 177Lu and 90Y, with considerably different energies and tissue penetration 
ranges of the emitted beta‐particles. Sequential administration of 90Y‐ and 177Lu‐
labeled analogues also is helpful for the treatment of larger tumors, followed by 
treatment of smaller metastases respectively in further treatment cycles. This con­
cept of Duo‐PRRT refers to the use of 90Y‐ and 177Lu‐labeled SMS analogues 
(DOTATATE or DOTATOC) in sequence, that is, in two different settings, 3–6 
months apart from each other. Tandem‐PRRT, on the other hand, specifically refers 
to the concurrent use of these radioisotopes, that is, in the same setting. There has 
been some difference in opinion about the nomenclature. Where some groups have 
used the term Tandem‐PRRT, in our opinion, it was rather Duo‐PRRT that was 
being investigated [3]. In a study by de Jong et al., favorable results were achieved 
using a combination of 177Lu‐ and 90Y‐labeled SMS analogues when compared with 
either 90Y‐ or 177Lu‐labeled analogue alone, in animals bearing tumors of various 
sizes [4]. The results of a recent study by Kunikowska et al. indicated that Tandem‐
PRRT (with 90Y/177Lu‐DOTATATE) provided longer overall survival than with a 
single radioisotope (90Y‐DOTATATE) and the safety of both methods was 
comparable [5].
tAble 6.4.1 factors taken into consideration for deciding upon the Prrt  
dose/schedule and regime 177lu versus 90Y
Tumor related Non‐tumor related
SSTR expression on the tumor cells Age
Size of the metastatic lesions Long‐standing diabetes mellitus
Number of lesions Uncontrolled arterial hypertension
Presence of necrosis in the metastatic 
lesions
Nephrotoxic chemotherapy
Proliferation Rate (Ki‐67/MiB1) Radiation therapy with kidney in the field of 
radiation
Neoadjuvant setting primary as in 
inoperable NET
Single kidney
Possibility/necessity of combined internal 
radionuclide therapy with external 
radiation therapy
Preexisting myelosuppression
Tumor‐related cachexia (BMI <18.5)




The PRRT regimen should take into account all clinical aspects and molecular fea­
tures of NET in a particular patient [6]. Many groups have resorted to schematic 
treatment with fixed schedules and doses. The administration of PRRT in over 1300 
patients to date at the Bad Berka neuroendocrine tumor center (BBNETC) has been 
individualized and based on the evaluation of Bad Berka score based on specific 
selection criteria (Table  6.4.2). Apart from the size of the tumor, an important 
consideration on the choice of radionuclide for PRRT is the localization of metas­
tases of NET. Bone metastases have been demonstrated to be effectively controlled 
by PRRT using 177Lu with long progression‐free and overall survival [7].
The BBNETC group in 2003 since the availability of 177Lu pioneered the 
systematic use of Duo‐ as well as Tandem‐PRRT in a large patient group of progres­
sive NETs, nonresponsive to octreotide/interferon treatment or chemotherapy 
(Figs. 6.4.1, 6.4.2, and 6.4.3). More than 450 patients have been treated with Duo‐
PRRT. Frequent therapy cycles (4–6 and up to 10) applying low or intermediate 
doses of radioactivity are suitable for these relatively slow‐growing tumors (long‐
term low‐dose, not short‐term high‐dose concept). Despite the documentation of 
clinical value of PRRT in NETs, the potential renal toxicity must be kept in mind.
Due to the small size, radiopeptides are filtered through the glomerular capillaries 
in the kidneys and subsequently reabsorbed by and retained in the proximal tubular 
cells. Hence, kidneys are the dose‐limiting organs [1, 8]. Given the high kidney 
retention of radiopeptides, positively charged molecules, such as l‐lysine and/or l‐
arginine, are used to competitively inhibit the proximal tubular reabsorption of the 
radiopeptide [8]. In addition, the patients should be well hydrated. Based on the 
tAble 6.4.2 bad berka score of patient selection for Prrt is based on specific 
molecular and clinical features of net
Molecular features Clinical features
SUV on receptor PET/CT (for referrals: 
Krenning’s score on OctreoScan) for 
determining SMS receptor density
Renal function (GFR measured by Tc‐99m 
DTPA and TER measured by Tc‐99m 
MAG3 as well as serum creatinine and 
BUN) and elimination kinetics
Ki‐67 index/tumor grade Hematological status (blood counts)
FDG status (glucose hypermetabolism of 
tumors/metastases)
Liver involvement
Tumor dynamics (doubling time, new 
lesions)
Extrahepatic tumor burden
Functional activity of tumor Karnofsky’s performance score (KPS) or 
ECOG scale
Weight loss






figure  6.4.1 Partial remission after Tandem‐PRRT demonstrated by 68Ga‐DOTATOC 
PET/CT (a, b, c, before; d, e, f, after Tandem‐PRRT using 4000 MBq 177Lu‐DOTATOC and 
4500 MBq 90Y‐DOTATOC) of a very large, partially necrotic nonfunctional well‐differenti­
ated neuroendocrine neoplasm in the pancreas tail and body, with intense somatostatin receptor 
expression. The tumor was infiltrating the neighboring structures and caused life‐threatening 
recurrent bleedings which stopped after PRRT. SUV
max
 dropped from 39.9 to 35.3, molecular 
tumor volume dropped from 542 to 214 ml, and the size overall diminished (a and d, coronal 
fused PET/CT images; b and e, CT images in transverse view; c and f, fused PET/CT images 
in transverse view). (See insert for color representation of the figure.)
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animal experiments of the groups in Rotterdam and Amsterdam, our group has pio­
neered the clinical use of gelofusine in addition to amino acids for kidney protection. 
Cumulative and per‐cycle renal absorbed dose, age, hypertension, and diabetes are 
considered as contributing factors to the decline of renal function after PRRT [1]. At 
the BBNETC, renal function is serially determined by 99mTc‐MAG3/tubular extrac­
tion rate (TER) and by 99mTc‐DTPA/GFR measurements. All data is entered in a pro­









figure 6.4.2 A 52‐year‐old patient had nonfunctioning, well‐differentiated neuroendo­
crine tumor of the pancreatic tail with local extension into the stomach and neighboring 
organs, lymph node metastases, as well as extensive bilobar liver metastases and few bone 
metastases and underwent Tandem‐PRRT with 5.5 GBq of 177Lu and 3.5 GBq of 90Y. 68Ga‐
DOTATOC PET showed good molecular response in the lesion in segment S8 of the liver 
(white arrow). There was 47% fall in the SUV from 70.8 to 37.7. T1‐weighted MRI with con­
trast showed posttherapy increase in the size of the lesion but with progressive necrosis (long 
arrow) and hypervascularity in the rim (short bold arrow) indicating a favorable therapeutic 
response. The left panel (a–d) shows pretherapy and middle panel (e–h) shows posttherapy 
images in transverse view (a and e, PET; b and f, CT; c and G‐PET/CT fused; d and h, MRI). 
The whole body planar scan (i) acquired 44 h posttherapy (177Lu gamma‐energy window) 
showed good uptake and long retention in the metastases. (See insert for color representation 
of the figure.)
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Before each new treatment cycle, restaging should be performed by morphologic 
(CT/MRI) and molecular imaging (68Ga‐DOTA‐SMS PET/CT; in selected cases, 18F‐
FDG or 18F‐fluoride PET/CT studies should be additionally performed), blood chem­
istry, and tumor markers (CgA, serotonin, specific hormones). Another very important 
aspect of personalized medicine and THERANOSTICS is dosimetry. Estimation of 
tumor and normal organ doses (MIRD/OLINDA) performed after PRRT (using 
Lu‐177‐labeled SMS analogues DOTATATE or DOTATOC) is important to ensure 
that maximum dose is delivered to the tumors and therefore optimizing an individu­
alized treatment protocol [9].
Besides renal toxicity, bone marrow involvement must be considered although it 
appears not to be a principal dose‐limiting factor. Acute hematological toxicity is not 
uncommon, especially after 90Y‐labeled peptide therapy, and the possibility of a mild 
but progressive impoverishment in bone marrow reserves has to be considered in 
repeated cycles. In addition, myelodysplastic syndrome (MDS) or overt leukemia 
may develop in patients receiving high bone marrow doses, especially in those previ­
ously treated with alkylating agents [10].
177Lu‐DOTATATE was predominantly used for small metastases or in patients 
with impaired renal or hematological function. A recent analysis of 416 patients (all 
NET subtypes) treated at the BBNETC showed a median overall survival from the 
time of first diagnosis of 210 months and a median survival after first PRRT of 59 
months (Fig. 6.4.4). This experience confirms an earlier report about overall survival 
benefit [11]. Long‐term follow‐up of up to 7 years after Duo‐PRRT showed no 
significant grade 3 or grade 4 nephrotoxicity attributed to concurrent or sequential 
Duo‐PRRT. The median fall in TER was lesser in patients undergoing Duo‐PRRT 
than in those undergoing PRRT with 177Lu or 90Y alone.
In patients with progressive disease (PD) with NET of nonpancreatic origin and 
pancreatic NET (pNET), tumor response after a mean follow‐up of 2 years was as 
follows: after 3 PRRT cycles, complete remission (CR), partial remission (PR), and 
(a) (b)
figure  6.4.3 Fused PET/MRI images in transverse view in the same patient (a, using 
68Ga‐DOTATOC; b, using 18F‐FDG) show mismatch of the uptake of the 2 tracers (68Ga‐
DOTATOC >18F‐FDG) in the lesion in segment S8 of the liver, demonstrating good 
differentiation and high somatostatin receptor density. (See insert for color representation of 
the figure.)
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minor responses (MR) were seen in 52% of patients with pNET (and in 48% in non‐
pNET); disease was stabilized in 39% with pNET and in 45% of patients with non‐
pNET. Thirty‐six patients with advanced disease died of PD. Objective tumor 
responses (including improvement of clinical symptoms) were seen in 93% (91% 
pNET) of the patients. Significant hematological toxicity (mainly erythrocytopenia, 
rarely neutropenia, and thrombocytopenia) occurred in less than 15% of all patients. 
MDS developed in five patients (all of whom had also received chemotherapy 
before). End‐stage renal insufficiency was not observed in any of the patients with 
normal kidney function before PRRT. In most patients receiving 177Lu‐DOTATATE 
alone (n = 417 cycles), serum creatinine and TER/GFR did not change significantly. 
Therefore, the probability and magnitude of renal toxicity can be significantly 
reduced (or completely avoided) when PRRT is administered in fractionated doses in 
patients without any preexisting risk factors and under appropriate nephroprotection 
[12]. Chemotherapy, diabetes mellitus, hypertension, Hedinger’s syndrome, and 
cachexia were identified as the risk factors for nephrotoxicity after PRRT.
We also have treated patients with progressive metastases of NET and with a 
single functional kidney (24 patients). None of these patients showed grade 3 or 4 
nephrotoxicity. PRRT resulted in PR in 36% and stable disease in 36% of the pts; 
28% had PD. Fourteen had grade 1 erythrocytopenia, three had grade 1 leukocytope­
nia, and three had grade 1 thrombocytopenia. In 2009, we have given fractionated 
low‐dose PRRT to two patients on hemodialysis due to end‐stage renal insufficiency 
(to the best of our knowledge, this was the first ever worldwide experience with such 
a condition). No significant hematotoxicity was observed in the two patients on 
 dialyses, and both showed a good clinical and objective therapy response [13].
Combined Y-90 / Lu-177 DOTA-TATE PRRNT
Survival function



















Results ZKL Bad Berka
Analysis of 415 NET Patients
figure  6.4.4 Survival curve depicting the overall survival of patients undergoing 
Duo‐PRRT at the BBNETC.
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summArY
Duo‐PRRT using concurrent and sequential administration of 90Y‐ and 177Lu‐labeled 
SMS analogues is highly effective in the management of NETs, even in advanced 
cases, and may be more effective in progressive NETs than using either radionuclide 
alone. Apart from a benefit in overall survival from time of diagnosis of several 
years, significant improvement in clinical symptoms and excellent palliation can be 
achieved. In patients with progressive NET, fractionated, personalized PRRT with 
lower doses of radioactivity given over a longer period of time results in good 
therapeutic responses. By this concept, severe hematological and/or renal toxicity 
can be avoided, and the quality of life can be improved. PRRT should only be 
 performed at specialized centers for individualized interdisciplinary treatment and 
long‐term care.
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RfA radiofrequency ablation
RILD radiation‐induced liver disease
sIRT selective internal radiation therapy
sPECT single photon emission computed tomography
TACE transarterial chemoembolization
Us ultrasound
srfa stereotactic radiofrequency ablation
TAME transarterial mechanical embolizations
trAnsArteriAL PePtide recePtor rAdionucLide therAPy
This approach is based on the idea of intra‐arterial (i.a.) administration of DOTA‐(0)‐
Phe(1)‐Tyr(3)‐octreotide (DOTATOC), resulting in regionally intensified peptide 
receptor radionuclide therapy (PRRT) [1]. Mcstay et al. showed that hepatic i.a. 
injection of 90Y‐DOTA‐lanreotide is a safe and effective palliative treatment for 
patients with progressive large‐volume somatostatin receptor‐positive liver metas-
tases from neuroendocrine tumors (NETs) [2].
The selective binding process of ssT analogues to the ssT receptor on the NET 
cell surface is the underlying principle for this new treatment, which offers the pos-
sibility of combining the effect of a transarterial therapy with selective internal radi-
ation [3]. This makes transarterial PRRT an attractive approach for patients with 
disseminated liver metastases and patients who are not eligible to radiofrequency 
ablation (RfA) or TACE.
Requirements can be evaluated before treatment planning and include a normal 
renal function, which can be confirmed by renal scintigraphy, as well as knowledge 
on the arterial perfusion of the liver metastases to be treated. However, patients with 
high tumor burden to the liver should be given special attention, as these patients 
have an increased risk of developing radiation‐induced liver disease (RILD) [4].
DOTATOC is radiolabeled using 68Ga to evaluate the tumor uptake in vivo, 
performing positron emission tomography/computed tomography (PET/CT) 
imaging. High uptake values have been proven for radiopharmaceuticals applied 
intra‐arterially, leading to lower radiation exposure in healthy tissue. first studies 
report on differences in uptake of DOTATOC when comparing intravenous (i.v.) 
injection to i.a. injection [3].
Angiographic intervention forms the basis in this interdisciplinary treatment 
approach and requires the access to the celiac axis via a transfemoral access. A 
microcatheter is then inserted coaxially and advanced to the common hepatic artery, 
proper hepatic artery, taking into consideration possible anatomic variations.
Due to the fact that tissue distribution 72 h after i.a. application equals distribution 
second to i.v. application, isotopes with shorter half‐life periods are of interest for 
this procedure. 177Lu has some disadvantages when applied intra‐arterially in 
comparison to 90Y, due to a lower binding affinity to the peptide and a longer half‐
life period. Using less peptide during synthesis is supposed to lead to improved 
results of i.a. therapy [5].
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National radiation protection regulations are of high relevance when considering 
i.a. application of PRRT, taking into consideration the risk of contamination during 
the application process as well as the risk of postinterventional complications such 
as bleeding. furthermore, the transport of the radioactive substance from the radio-
pharmaceutical laboratory to the angiographic intervention center as well as the 
application has to be done according to national regulations [6]. Available treatment 
results up to now are comparable to results from i.v. PRRT [5, 7].
rfA
In percutaneous image‐guided RfA, probes are inserted into the tumor using ultra-
sound (Us), CT, or magnetic resonance imaging (MRI) [8]. The tumor is subse-
quently devitalized by thermal ablation avoiding surgical resection. Microwave 
ablation and electrovaporization are less frequently applied ablation technologies of 
local tumor destruction. The basic principle of electrovaporization is destruction of 
cell membranes by an electrical current, not by heat.
When comparing surgical resection to RfA, surgery is associated with a mor-
bidity of 15–45% and mortality of 1–5% [9, 10]. RfA represents a low‐risk procedure 
[11]. Major complications requiring intervention such as intraperitoneal bleeding, 
liver abscess, intestinal perforation, pneumothorax and hemothorax, or bile duct 
injury are in the range of 2–3% and may often be treated by minor radiological inter-
ventions such as drainage or coil embolization [12, 13]. The procedure‐related 
mortality rate is below 1%. Minor complications amount to 5–9% and include the 
postablation syndrome (fever up to 38.5°C, weakness, fatigue, and leukocytosis). 
Blood loss, prolonged postoperative intensive care stay, and abdominal wall insuffi-
ciency are not associated with RfA. A large prospective study by Mazzaglia et al. of 
RfA with Us guidance included 63 patients with unresectable hepatic metastases 
from NETs. The median survival after the first ablation was 3.9 years. A significant 
difference was noted between patients whose largest metastasis exceeded 3 cm in 
size (median survival <3 years) and those whose dominant lesion was smaller than 
3 cm (median survival not reached by study closure). In over 90%, symptomatic 
improvement was reported posttherapeutically, and the median duration of symptom 
control was 11 months [14].
Gillams et al. treated 19 patients with 36 percutaneous RfA procedures. During a 
median follow‐up of 21 months, the authors found a complete response (CR) in 6 
patients, a partial response (PR) in 7, and stable disease (sD) in 1. symptomatic dis-
ease was reduced in nine (69%) of the 14 patients suffering from hormone overpro-
duction. One patient passed away due to carcinoid crisis. The median postablation 
survival was 29 months [15].
The feasibility and success of RfA depend on the size and location of the liver 
lesion. Lesions sized larger than 1 cm usually require more than one probe or sev-
eral probe positions in order to treat the tumor with overlapping ellipsoidal (single 
straight electrodes) or spherical (single expandable electrodes) ablation zones, 
respectively [16]. Incomplete RfA and as a consequence local recurrence 
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are generally related to large size of tumors (>3–5 cm), poor tumor visibility and 
unfavorable distribution of probes, as well as imprecise probe positioning and 
cooling effects by larger vessels. The technical limitations of conventional single‐
needle in‐plane techniques using Us or CT have been largely overcome by recent 
multineedle approaches using CT‐based 3D treatment planning and stereotactic 
needle guidance (sRfA) [17]. sRfA allows effective and safe treatment of large‐
volume disease [18]. In analogy to surgical R0 resection, A0 ablation including a 3D 
safety margin of at least 5 mm can be objectively verified and documented, by 
fusion of postablation and preablation images. The use of multimodal fused images 
from PET/CT during sRfA may permit selective treatment of active metastasis as 
determined by 68Ga‐DOTATOC uptake.
In selected patients, optimized RfA technique can provide comparable oncologic 
results to resection. Therefore, feasibility of RfA should be discussed in interdisci-
plinary oncologic boards.
seLective internAL rAdiAtion therAPy
selective internal radiation therapy (sIRT) is a promising new treatment approach 
for tumors of various entities, such as hepatocellular carcinoma, colorectal cancer, 
and NETs [19] (fig. 6.5.1 and Table 6.5.1).
Compared with transarterial mechanical embolizations (TAME) and chemoembo-
lization (TACE), sIRT combines the therapeutic principles of embolization and 
internal radiation. selective treatment of unresectable liver metastases is extending 
the treatment options. High local radiation doses can be selectively targeted to the 
tumor due to the fact that metastatic hepatic tumors derive 80–100% of their blood 
supply from the arterial rather than the portal hepatic circulation, while the normal 
liver tissue is supplied by the portal vein (60–70%).
Patients considered for sIRT are characterized by unresectable hepatic primary or 
metastatic cancer, liver‐dominant tumor burden, and a life expectancy of at least 3 
months [20]. Before patients are selected for sIRT, the arterial blood supply has to be 
investigated; patency of the portal vein is not mandatory for treatment. However, 
intrahepatic arteriovenous shunts need to be excluded.
90Y is a β‐emitter, resulting from neutron bombardment of 89Y in a reactor, with 
a tissue penetration of mean, 2.5 mm, and max, 11 mm, and short half‐life (64 h), 
which makes it attractive for i.a. treatment. The emitter is loaded to microspheres in 
the range of 20–40 µm, enabling delivery to the tumors via the hepatic artery. 
Therasphere consists of insoluble glass microspheres where 90Y is an integral 
constituent of the glass. On the other hand, resin 90Y microspheres have received 
fDA premarket approval for hepatic metastases from colorectal cancer, concurrent 
with fluorodeoxyuridine. The microspheres are trapped within the tumor vessels, 
whereas the lower size limit prevents the microspheres from proceeding into the 
venous circulation. The mean tissue penetration of 2.5 mm spares normal liver 
parenchyma. Therefore, sIRT can provide high local tumor doses ranging from 50 
to 150 Gy, in contrast to the traditional whole‐liver external beam radiation where 
radiation doses have to be limited to 30 Gy [20].
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The combination of morphological imaging (CT and MRI) with functional 
imaging, by using combined imaging modalities (PET/CT, sPECT/CT), provides the 
most reliable information for determining the region of interest. According to the 
tumor spread in the liver, selective treatment of one or both liver lobes is performed. 
sequential treatments may be safer than a whole‐liver treatment in 1 session. 
sequential treatments allow for a safer approach, maintaining a 30‐ to 45‐day interval 
between the therapies [19, 21].
selective application of 99mTc‐MAA is done in the right and left hepatic arteries. 
Planar scintigraphic images are performed for dosimetric measurements. Direct 
(a) (b)
(c) (d)
figure 6.5.1 A 67‐year‐old male patient suffering from an adenocarcinoma of the colon 
sigmoideum, stage pT3 N1b M1 R0 (K‐ras mutation not present), and UICC stage 4. The patient 
had undergone resection of the primary in 10/2010. He then underwent multiple palliative che-
motherapeutic treatments until february 2013, when CT showed progressive liver metastases to 
the right liver lobe (a). Pulmonary shunt scintigraphy using 150 MBq Tc‐99m‐MAA on 8/4/2013 
revealed faint uptake over both lungs, reaching a pulmonary shunt rate of 14% in the semiquan-
titative analysis. The scan showed increased liver uptake in the right liver lobe (b). Embolization 
of the gastroduodenal and right gastric artery was performed using coils (c). Application of 1400 
MBq Y‐90‐sIR‐spheres was performed on 18/4/2013. 0.3 GBq was applied in segment IV and 
1.11 GBq was applied in the right liver lobe, selectively. Posttherapeutic bremsstrahlung scan 
revealed increased uptake in the right liver lobe on sPECT/CT imaging, showing no extrahepatic 
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tracking of microsphere distribution during application is not feasible and usually not 
required while using glass microspheres, but is mandatory for resin microspheres 
because of the relatively high embolic tendency.
Bremsstrahlung scintigraphy up to 24 h after application of the microspheres 
assists in documenting the distribution of microspheres within the liver.
Extrahepatic distribution of microspheres to visceral sites such as the stomach, 
duodenum, gallbladder, or pancreas may be associated with the risk of severe radia-
tion damage leading to pain, ulceration, and possibly perforation [22–24]. This com-
plication is to be avoided by obligatory embolization of the relevant sidebranches of 
the hepatic artery prior to sIRT. successful embolization of dangerous sidebranches 
can be assessed by the pretreatment 99mTc‐MAA scan. Absolute contraindications 
for sIRT are excessive shunting to the lungs as quantified by the 99mTc‐MAA scan 
that would result in 30 Gy lung dose on a single administration, a high tumor burden 
with limited hepatic reserve or signs of reduced liver function as potentially indicated 
by elevated levels of bilirubin, highly elevated liver enzymes (aspartate transaminase 
or alanine transaminase (ALT), significantly altered international normalized ratio or 
partial thromboplastin time, or reduced serum albumin.
Patients who have undergone prior radiotherapy involving the liver should be 
evaluated on a case‐by‐case basis. Low ECOG performance score, history of infec-
tions to the bile system, and portal hypertension are risk factors.
Posttherapeutic complications have been described, including liver failure. 
Postinterventional pain has to be considered. Postembolization syndrome includes 
fatigue, nausea, and abdominal pain. On a regular basis, patients receive a gastroin-
testinal ulcer prophylaxis and antinausea prophylaxis.
Radiation‐induced pneumonitis and elevation of liver function tests, RILD and 
development of anicteric ascites and increased abdominal girth, as well as rapid 
weight gain with hypoalbuminemia have been observed posttherapeutically. Bile 
duct complications include radiation‐induced necrosis. first imaging as routine 
follow‐up consisting of abdominal MRI and a metabolic imaging, normally PET/CT, 
is performed 4 weeks posttherapeutically. The next series of imaging are performed 
3, 6, 9, and 12 months after treatment.
cLinicAL resuLts of the sirt in PrimAry And secondAry 
hePAtic mALignAncies
Gray et al. [25] reported on 29 consecutive patients with advanced liver metastases 
from colorectal cancer, showing response rate of 89%. Mean and median survival for 
patients with metastases confined to the liver was 14.5 and 13.5 months.
In a randomized trial, Van Hazel et al. [26] compared the response rate and time 
to progression disease in a regimen of systemic fluorouracil/leucovorin chemo-
therapy versus the same chemotherapy along with a single administration of sIR‐
spheres in patients with advanced colorectal liver metastases. The time to progressive 
disease and median survival were significantly longer for patients receiving the 
combination treatment.
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Rhee et al. in a study with 42 patients who underwent sIRT using glass or resin 
microspheres demonstrated that 92% of glass and 94% of resin patients were classi-
fied as PR or sD at 6 months after treatment [27].
King et al. treated 34 patients who had unresectable NET [28]. symptomatic 
responses were observed in 18 of 33 patients (55%) at 3 months and in 16 of 32 
patients (50%) at 6 months. Radiological liver responses were observed in 50% of 
patients and included 6 (18%) CR and 11 (32%) PR, and both had a mean overall 
survival of 29.4 ± 3.4 months. In patients who had evaluable CgA marker levels, there 
was a decrease in CgA marker levels after RE.
concLusion
In confined liver metastasis from NET, RfA and more recently sRfA are powerful 
local curative treatment options. selective i.a. administration of DOTATOC and 
sIRT are promising new approaches towards a regionally intensified treatment reg-
imen in large bilobar and disseminated liver disease [29–32]. Whether i.a. 
administration of PRRT results in a higher tumor uptake or intensified therapeutic 
efficacy in comparison to i.v. PRRT still has to be investigated. However, sIRT has 
already proven to be a feasible therapeutic option. All available therapeutic approaches 
have to be inserted in an inter‐ and multidisciplinary treatment approach for meta-
static NET patients.
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The high expression of somatostatin receptors (SSTRs) is the molecular basis for 
imaging and radionuclide therapy of neuroendocrine neoplasms. The receptor density 
and homogeneity are important factors for diagnostic and therapeutic effectiveness 
of the radiolabeled somatostatin analogues [1, 2]. Gastroenteropancreatic neuroen-
docrine tumors (GEP‐NETs) are not the only neoplasms with high density of SSTRs. 
Similar density and incidence of SSTRs have been identified in other neuroendocrine 
tumors such as pheochromocytomas, paragangliomas, and pituitary adenomas but 
also in tumors of the nervous system such as neuroblastomas, medulloblastomas, and 
meningiomas [1–12]. Data on the expression of SSTR on glial tumors are conflicting 
[8, 12–14]. Detection of glial tumors by somatostatin receptor scintigraphy (SRS) 
depends not only on the expression of SSTR but also on the integrity of the blood–
brain barrier [8, 15]. There is limited information on the expression of SSTR in 
 ependymomas—the level of expression is variable and generally lower than that seen 
in embryonal tumors [8, 16]. The expression of SSTRs, but at lower incidence and 
density, is also observed on the plasma membrane of the cells of medullary thyroid 
cancer, small cell lung cancer (SCLC), and melanoma [1, 2, 17, 18]. However, as 
opposed to neuroendocrine tumors with the homogeneous distribution of the SSTRs, 
the SSTR expression in those tumors might be heterogeneous [1, 2].
The abovementioned facts are important for the use of radiolabeled somatostatin 
analogues as the therapeutic agents in case of neoplasms other than gastroenteropan-
creatic tumors. However, the use of peptide receptor radionuclide therapy (PRRT) in 
tumors other than GEP‐NETs is limited. Most of presented beneath results of clinical 
trials are promising, but to prove the efficacy and safety of PRRT, more numerous 
groups of patients should be included.
Paragangliomas are neuroendocrine tumors derived from extra‐adrenal autonomic 
parasympathetic ganglia [19]. Visualization of paragangliomas is possible with the 
use of metaiodobenzylguanidine (MIBG), which is structurally similar to noradrena-
line and is transported into the chromaffin cells and subsequently stored in the secre-
tory vesicles [19]. This allows imaging with 123I‐ or 131I‐metaiodobenzylguanidine 
(131I‐MIBG), and 131I‐MIBG can be used as a therapy [19–21]. Most  paragangliomas 
express also SSTRs [1, 2, 17, 19]. SRS detects more than 90% of known lesions 
[19, 22]. SRS can be useful also in staging patients with metastatic pheochromocy-
toma because imaging with labeled MIBG is less sensitive in this group [19, 23]. But 
in case of primary pheochromocytomas, SRS is less sensitive than 123I‐MIBG, partially 
because of interference from the high physiologic uptake of labeled somatostatin ana-
logue by the kidneys nearby [19]. Radiolabeled somatostatin analogues might be con-
sidered as an alternate therapeutic option in paragangliomas and also malignant 
disseminated pheochromocytomas [19, 24]. Van Essen et al. studied twelve patients 
with paragangliomas with positive SRS treated with 177Lu‐octreotate [19]. Tumor 
regression was observed in two and disease stabilization in one of four patients with 
progressive paragangliomas [19]. The authors used also PRRT in five patients with 
meningioma (results in this group will be discussed in the following), in three patients 
with SCLC, and two patients with melanoma [19]. The authors concluded that 177Lu‐
octreotate can have therapeutic effects in paraganglioma and may play a role in the 
management of this disease, particularly in case of progressive disease with 131I‐ or 
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123I‐MIBG‐negative lesions, and confirmed expression of the SSTRs [19]. 177Lu‐
octreotate does not seem to have clinical effects in SCLC and melanoma [19].
In case of the pituitary tumors, treatment depends on the size and hormonal 
activity of the lesions. Except the prolactin‐secreting tumors, for which dopamine 
agonists are the first‐line therapy, the treatment of choice is usually surgery [25–28]. 
However, prior to the invasive intervention, patients with functioning pituitary ade-
nomas need to be usually prepared with medical therapy. In vitro and in vivo studies 
confirmed expression of SSTRs in pituitary tumors [1, 2, 25, 29–31]. Long‐acting 
somatostatin analogues such as octreotide and lanreotide have an established place in 
the treatment of growth hormone (GH) secreting pituitary adenomas, both in pre‐ and 
postsurgical management [32]. There is also novel promising multireceptor ligand 
somatostatin analogue with affinity for SSTR subtypes 1–3 and 5 used in case of 
pituitary adenomas causing acromegaly [33]. Somatostatin analogues in combination 
with dopamine agonists might be used also in case of ACTH‐secreting pituitary ade-
nomas [34, 35]. Also, in case of TSH‐secreting tumors, medical treatment includes 
dopaminergic agonists and/or somatostatin analogues [36]. In case of  prolactin‐
secreting tumors resistant to medical treatment and/or with tumor growth‐induced 
visual field impairment, surgery is indicated [25, 28]. Radiotherapy might be also 
considered; however, the efficacy is delayed and treatment of huge masses causes 
extensive irradiation of the brain [25, 28]. Similarly, as in case of pheochromocy-
tomas and paragangliomas, there are pituitary tumors resistant to established 
therapeutic schemes. Therefore, there is a need to search for novel therapies. Baldari 
et al. reported the effectiveness of radiolabeled somatostatin analogues in case of 
giant cabergoline‐ and octreotide‐resistant prolactinoma, which caused neurological 
symptoms [25]. The administration of PRRT led to remarkable tumor shrinkage and 
a significant improvement in clinical condition [25].
Neuroblastomas derive from the neural crest and synthesize neurotransmitters, 
including somatostatin [6]. SSTRs (particularly subtype 2) are expressed on the 
 surface of some neuroblastomas, which enables the use of PRRT [4–6]. Neuroblastoma 
is a typical example of an embryonal tumor of childhood [6, 7, 37, 38]. Neuroblastomas 
show heterogeneity of behavior ranging from spontaneous regression and 
differentiation into benign neoplasms in infants to potentially aggressive dissemina-
tion in older children [6, 8]. Current treatment for high‐risk disease involves an 
intensive regime with induction chemotherapy, surgery, myeloablative chemotherapy 
with stem cell rescue, radiotherapy, and continuing therapy with 13‐cis‐retinoic acid 
and immunotherapy [6, 39–41]. Despite advances in the management of neuroblas-
toma, the long‐term survival rate remains under 40% [6, 39–41]. For patients with 
relapsed or refractory neuroblastoma, treatment options include further  chemotherapy 
or therapy with 131I‐MIBG [6]. The use of radiolabeled somatostatin analogues in 
neuroblastoma involves a distinct and separate cell‐surface molecular target different 
from the norepinephrine transporter molecule that takes up 131I‐MIBG [6]. Menda 
et al. have conducted phase I trial with the use of 90y‐DOTATOC in children and 
young adults with refractory solid tumors (neuroblastomas but also paragangliomas 
and other embryonal and astrocytic brain tumors) expressing SSTRs [7]. PRRT dem-
onstrated a favorable safety profile with no dose‐limiting toxicities observed [7]. 
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Gains et al. using data on six children with neuroblastoma who were imaged with 
68Ga‐DOTATATE PET/CT and subsequently received molecular radiotherapy using 
177Lu‐DOTATATE provided proof of principle that children with relapsed or primary 
refractory high‐risk neuroblastoma who have SSTR‐positive disease can be imaged 
and treated with SSTR‐targeted agents [6].
Medulloblastoma is the most frequent embryonal tumor of the central nervous 
system [42, 43]. The therapeutic approach for primary medulloblastoma consists of 
surgery, chemotherapy, and radiotherapy of the craniospinal axis [42]. The recur-
rence rate for medulloblastoma is observed in more than one third of cases, and 
recurrences are located either on the primary tumor site or along the cerebrospinal 
fluid pathways [42]. Based on the fact that medulloblastomas express high levels of 
SSTR2, Beutler et al. have used targeted radiotherapy (intrathecal administration of 
90y‐DOTATOC) to treat tumor remnants, which persisted despite conventional and 
high‐dose chemotherapy and intercurrent resection of the lesion [3, 42]. According 
to the authors, targeted radiopeptide brachytherapy may represent a promising 
 additional treatment modality for recurrent medulloblastoma when combined with 
surgery,  conventional chemotherapy, and high‐dose chemotherapy [42].
Meningiomas arise from cap cells of the arachnoid membrane [44]. In contrast to 
embryonal tumors such as neuroblastoma and medulloblastoma, the incidence of 
meningiomas increases with age, but in children, those tumors are more often 
 malignant [44]. Meningiomas are usually benign tumors (WHO grade I), but 6% are 
atypical (grade II) and 2% malignant (grade III) [44, 45]. Surgery is the treatment of 
choice and is usually curative [44, 46]. However, recurrence is not uncommon 
 specially for grades II and III [44, 46, 47]. External beam radiation therapy (EBRT) 
is usually given as a second‐line treatment in case of recurrent or inoperable 
 meningiomas [44, 48–53]. But there are still patients left for whom both surgery and 
radiotherapy are not effective [44]. Therefore, there is a need to search for other new 
therapeutic modalities [44]. As it was mentioned earlier, meningioma cells express 
SSTRs usually at high density, which enables both visualization of those tumors by 
the use of SRS and also is the basis for targeted radionuclide therapy [1, 2, 17, 44, 54, 
55]. Bartolomei et al. submit promising results of the therapeutic use of 90y‐
DOTATOC in case of 29 patients with recurrent or progressive meningioma after 
surgery, radiotherapy, and chemotherapy [44]. As the authors concluded, the adju-
vant role of radioisotope therapy, soon after surgery, particularly in atypical and 
malignant meningiomas deserves further investigation [44]. Van Essen et al. 
 confirmed also the efficacy of 177Lu‐DOTATATE in case of five patients with 
 meningioma tumors, among them three very large and exophytic tumors; however, 
response rates in this group of patients were lower than observed in patients with 
GEP‐NETs [19]. Kreissl et al. have also presented results of therapy of 10 patients 
with unresectable meningioma treated with PRRT (177Lu‐DOTATATE or 177Lu‐
DOTATOC) followed by EBRT [56]. According to the authors, PRRT of meningi-
omas may be safely used in combination with EBRT [56]. This approach represents 
an attractive strategy for the treatment of unresectable locally recurring, progressive, 
or symptomatic meningioma in order to either increase the dose delivered to the 
tumor or to reduce the dose for organs at risk [56].
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SCLC express neuroendocrine markers, among them SSTRs [1, 2, 17, 18]. 
Therefore, radiolabeled somatostatin analogues can be used for diagnostic scintig-
raphy and might be considered for therapeutic use [18]. Pless et al. presented report 
of somatostatin receptor‐targeted radiotherapy for SCLC [18]. The authors have 
treated six patients with SCLC and positive SRS [18]. Each patient received 60mCi/
m2 90y‐DOTATOC intravenously every 3 weeks, for a total of three cycles [18]. All 
six patients had tumor progression, median progression‐free survival (PFS) was 
37.5 days (28–52), and median overall survival (OS) was 103.5 days (28–269) [18]. 
The authors concluded that in contrast to well‐differentiated neuroendocrine tumors, 
90y‐DOTATOC seems to be inactive in SCLC [18]. As it was presented earlier, van 
Essen et al. have used 177Lu‐octreotate in case of three patients with SCLC and also 
concluded that this radiopeptide does not seem to have clinical effects in SCLC [19]. 
Edelman et al. presented results of a phase I trial, in which patients with metastatic 
or recurrent SCLC that could not be treated surgically and that were demonstrated to 
have SSTRs by positive 99mTc‐P2045 (11‐amino acid somatostatin analogue) imaging 
results were treated with escalating doses of 188Re‐P2045 [57, 58]. There were no 
objective responses; however, five of eight patients with progressive disease at 
 baseline remained stable at 8 weeks after therapy [57, 58]. The authors concluded 
that although responses were not seen, survival for these heavily pretreated patients 
is interesting and merits further research [57]. Presented results demonstrate that 
despite the proven expression of SSTRs at the cells of SCLC, PRRT does not seem 
to be effective in this type of tumor.
Medullary thyroid cancer (MTC) is neuroendocrine neoplasm derived from the 
parafollicular cells or C cells of the thyroid and accounts for nearly 5–10% of thyroid 
malignancies [59–61]. Overall, the prognosis for patients with MTC is good. The 
10‐year survival rate for patients with MTC is 75–85% [62]. Approximately half of 
the patients with MTC present with disease limited to the thyroid gland [62]. One 
third of patients present with locally invasive tumors or clinically apparent spread to 
the regional lymph nodes [62]. Patients with regional disease have a 5‐year OS rate 
of 75.5% [62]. Distant metastases portend a poor prognosis, with a 10‐year survival 
rate of only 40% [62]. Recurrent disease develops in approximately 50% of patients 
with MTC [62]. The primary treatment for MTC is extensive and meticulous surgical 
resection. Total thyroidectomy with complete resection of lymph nodes in the central 
neck, paratracheal, and upper mediastinal region is frequently needed. At present, 
surgical excision is the only effective treatment for MTC. Patients who have clini-
cally evident disease are best treated with a minimum of total thyroidectomy and 
bilateral central neck dissection [63, 64]. EBRT does not currently play a significant 
role in the treatment of patients with MTC [63, 64]. However, radiation therapy has 
been applied to help palliate local disease when surgery is not a feasible option [62, 
64]. Follow‐up should start 2–3 months postoperatively by obtaining new baseline 
calcitonin levels [59–61]. An undetectable basal serum calcitonin level is a strong 
predictor of complete remission [59–61]. Complete remission may be further 
 confirmed after a provocative test [59–61]. Serum calcitonin should be repeated 
every 6 months for the first 2–3 years and annually thereafter [59–61]. When the 
postoperative calcitonin level is elevated, a careful metastatic evaluation must be 
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performed prior to proceeding with operative exploration [59–61]. In some MTC 
patients despite of the elevated postoperative calcitonin levels and/or abnormal 
results of the pentagastrin test, there is no evidence of the disease in available imaging 
techniques. Moreover, these patients are left with few therapeutic choices. 
Conventional chemotherapy has shown limited efficacy in patients with MTC [65]. 
Complete responses are very rare and partial responses have been seen in less than 
one third of patients [65]. Based on the expression of the SSTRs on the surface of the 
medullary thyroid cancer cells, there is a possibility of the use of the targeted 
 radionuclide therapy [1, 2, 66–69]. Patients with metastatic disease can have 
significant symptoms from calcitonin excess and those may benefit from treatment 
with somatostatin analogues [66]. So far, treatment of MTC patients with labeled 
somatostatin analogues revealed moderate responses, which might be connected 
with heterogeneous expression of SSTR in these neoplasms [1, 2, 67–69]. It is worth 
to mention here that medullary thyroid cancer cells overexpress also gastrin and 
 cholecystokinin 2 (CCK‐2) receptors [1, 2, 70, 71]. The ability of the medullary thy-
roid cancers to take up the labeled analogues of gastrin has been demonstrated in the 
clinical studies [70, 71]. The gastrin and CCK‐2 receptors are potential and prom-
ising targets for the radionuclide therapies, as their ligands have been successfully 
labeled with β‐emitting radioisotopes [70, 71].
There are other peptide receptors, such as the glucagon‐like peptide 1 (GLP‐1) 
receptor in insulinoma, gastrinoma, pheochromocytoma, paraganglioma, and 
medullary thyroid cancer, being taken into consideration as the promising targets for 
diagnostic approach and in the future probably also for radionuclide therapy [1, 2, 
17, 71].
Presented examples prove that the use of radiolabeled somatostatin analogues is 
not limited to gastroenteropancreatic neoplasms. PRRT might be an alternate 
therapeutic option for patients with other tumors expressing SSTRs, particularly in 
case of recurrent neoplasms or disease resistant to standard therapeutic procedures. 
However, treatment with radiolabeled somatostatin analogues in those other neo-
plasms is usually not as efficient as in case of GEP‐NETs. Therefore, there is still a 
need to search for other more specific peptide receptors, which might become targets 
for novel therapeutic strategies.
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KE108 pansomatostatin synthetic nonapeptide
MAPK mitogen-activated protein kinase
mRNA messenger ribonucleic acid
NET neuroendocrine tumor
NHEs Na+/H+ exchangers








vIP vasoactive intestinal polypeptide
nAtive Hormones
Somatostatin (SS) was first isolated from ovine hypothalamic extracts and was 
 characterized as a tetradecapeptide. It was identified as part of the releasing 
 hormone family for its property to inhibit the secretion of growth hormone (GH) 
from pituitary cells by Brazeau and colleagues in 1973 [1]. There are two naturally 
bioactive SS products, somatostatin-28 (SS-28) and somatostatin-14 (SS-14). SS-28 
contains the entire sequence of SS-14 at its carboxy terminal, immediately preceded 
by a double pair of basic amino acids [2]. SS-28 was first isolated from ovine [3] 
and then from porcine [4] and rat [5] brain tissues. Both forms of mammalian SS 
are derived from a larger inactive precursor molecule, preprosomatostatin (PPSST), 
that is processed by posttranslational enzymatic cleavage to yield the active poly-
peptides (Fig. 7.1). Isolation and cloning of human and rat cDNAs encoding PPSST 
revealed the sequence and structure of a polypeptide consisting of 116 amino acids 
[6–9]. SS-14 is generated by dibasic cleavage at an Arg101-Lys102 residue, whereas 
endoproteolysis of a monobasic Arg88 site produces SS-28 [10, 11]. A secondary 
monobasic site was determined in PSST, the cleavage of which results in the gener-
ation of a 10-amino-acid peptide termed antrin (PSST
1–10
) [12–14]. various mixtures 
of SS-14 and SS-28 are produced in mammalian tissues [15] because of the 
differential processing of PSST. SS-14 and SS-28 are the only known biologically 
active forms of PSST. Other products have also been identified in circulation 
 following processing whose biological function remains uncertain as they are 
 lacking of any known activity [10, 15].
SS-producing cells are typically neurons or endocrine-like cells and are found 
in high density in the central and peripheral nervous systems and in the endocrine 
 pancreas and in the gut and in small numbers in the thyroid, adrenals, submandibular 
glands, kidneys, prostate, placenta blood vessel walls, and immune cells [16–22]. 
The major role of hypothalamic SS is the inhibition of GH from anterior pituitary 



































Figure 7.1 Sequence of PPSST and its derivatives. The bioactive peptide hormones SS-28 and SS-14 are derived 
from parent PSST (92 aa, 25–116), which is generated from a larger inactive precursor molecule PPSST (1–116). 
Endoproteolysis of monobasic Arg88 produces SS-28, and cleavage at a dibasic Arg101-Lys102 produces SS-14.
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pituitary and indirectly through suppression of growth hormone-releasing hormone 
(GHRH) release [24, 25]. These pathways both interact with each other at their point 
of convergence at the level of the pituitary and through direct neural connections 
within the hypothalamus [26]. There are two secretory feedback loops that modulate 
SS release—the short loop, where SS is negatively regulated by GHRH [24] and 
 subject to positive feedback by GH [27], and the long loop, where insulin growth 
factor type 1 (IGF-I), produced by GH acting on the liver, provides a positive influence 
for SS release [28] (Fig. 7.2). In addition, secretion of hypothalamic SS can be further 
promoted by dopamine, substance P, neurotensin, glucagon, hypoglycemia, various 
amino acids, acetylcholine, α
2
-adrenergic agonists, vasoactive intestinal polypeptide 
(vIP), and cholecystokinin and can be inhibited by glucose [29, 30]. Similar mecha-
nisms also exist in the hypothalamic control of thyroid-stimulating hormone (TSH) 
secretion [31–35].
Moreover, SS functions as a neurotransmitter in the brain with effects on 
cognitive, locomotor, sensory, and autonomic functions [20, 32–34, 36]. SS inhibits 
the release of dopamine from the midbrain and the secretions of norepinephrine, 
thyroid-releasing hormone, and corticotrophin-releasing hormone including its own 











Figure 7.2 GH regulation by SS. Growth hormone-releasing hormone (GHRH) and 
somatostatin (SS) are produced in the hypothalamus. GHRH stimulates synthesis and secretion 
of growth hormone (GH) (right upper arrow) and SS inhibits GH (left upper descending arrow). 
GH feeds back positively for SS (left upper ascending arrow). There is a second positive 
feedback for hypothalamic SS from liver IGF-1 (left large ascending arrow). IGF-1 is produced 
in the liver after stimulation of pituitary GH (right lower descending arrow).
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luteinizing hormone, follicle-stimulating hormone, prolactin, or adrenal corticotrophin 
hormone under normal physiological conditions. SS has direct effects on the thyroid 
by inhibiting the release of T4, T3, and calcitonin from thyroid parafollicular cells 
stimulated by TSH.
Within the gastrointestinal tract, virtually every gut hormone has been shown to 
be inhibited by SS, including gastric acid, pepsin, bile, and colonic fluid. In the pan-
creas, SS is an endogenous islet hormone. Its actions on the pancreas were first noted 
within the year of its discovery by two groups, following infusion in humans and 
baboons [37].
SS regulates the secretion of hormones from several tissues, including neurotrans-
mission. When synthesized and released from δ cells of pancreatic islets, SS causes 
suppression of the synthesis and secretion of both insulin and glucagon, including the 
inhibition of pancreatic polypeptide [38–42]. Moreover, a downregulation in SS and 
sst expression has been associated with Alzheimer’s disease [43]. Although the role 
of SS in Huntington’s disease is controversial, it is believed that SS-positive neurons 
are selectively spared from disease [44].
Regulation of SS can be achieved by a broad array of secretagogues—from ions 
and nutrients to neuropeptides, neurotransmitters, hormones, growth factors, and 
cytokines—as it interacts with various bodily systems [20, 32, 33, 36]. Almost every 
neurotransmitter or neuropeptide tested has been shown to exert some sort of effect 
on SS secretion with a certain degree of tissue specificity. Potent stimulators of SS 
secretion are glucagon, GHRH, neurotensin, corticotrophin-releasing hormone, 
 calcitonin gene-related peptide, and bombesin [20, 22, 45]. Thyroid, GH, IGF-I, and 
insulin trigger SS release from the hypothalamus [20, 22, 36], while insulin, leptin, 
and epinephrine inhibit its release from the pancreas and hypothalamus, respectively 
[20, 22, 36].
ss recePtor subtyPes
The physiological actions of SS-14 are mediated by high-affinity plasma membrane 
receptors. Five SS receptor subtypes (sst
1–5
) have been identified by gene cloning 
techniques, and they belong to the superfamily of G-protein-coupled receptors 
(GPCRs). Yamada and coworkers in Bell’s laboratory cloned the first 2 ssts in early 




 [46]. This success was 
followed by the cloning of rat sst
1
 [47]; mouse, rat, and human sst
3
 [48–51]; rat and 
human sst
4
 [52–54]; and rat and human sst
5




 lack classical 
introns in the coding segment. One of the receptors (sst
2
) is expressed in two alterna-
tively spliced forms [57], a long sst
2A






 differ only 
in the length of the cytoplasmic C-tail [21]. So, there are six putative sst subtypes of 
closely related size, each displaying seven helical transmembrane segments (TMS) 
typical of GPCRs. The five human sst genes segregate on separate chromosomes 
[22]. The five human sst sequences range in size from 356- to 391-amino-acid  residues 
and show the greatest similarity in the putative TMS (55–70% sequence  identity). 










 (69%) [21, 58, 59]. All sst receptor isoforms that have 
been cloned so far not only from humans but also from other species have a highly 
conserved sequence motif, YANSCANPI/vLY, in the seventh TMS, which is a signa-
ture sequence for this receptor family. The hsst
1–5
 display one or multiple sites for 
N-linked glycosylation within the amino-terminal segment and second extracellular 
loop (ECL). All of the hsst
1–5
 have three to eight putative recognition motifs for pro-
tein phosphorylation by protein kinase A, protein kinase C, and calmodulin kinase II 









 display a conserved cysteine residue 12 amino acids 
downstream from the seventh TMS, which may be the site of a potential palmitoyl 
membrane anchor as observed in several other members of the GPCR superfamily 
[22]. On the other hand, hsst
3
 lacks the cysteine palmitoylation membrane anchor 
and displays a longer C-tail than the other hssts. Interestingly, sst
1–5
 subtypes exhibit 
a remarkable degree of structural conservation across species [21, 59]. Particularly, 
there is 94–99% sequence identity among the human, rat, and mouse isoforms of sst
1
; 
93–96% sequence identity among the human, rat, mouse, porcine, and bovine isoforms 
of sst
2







 are somewhat less conserved, showing 82–83% sequence 
 identity between the human and the rodent homologs [22]. All sst
1–5
 bind SS-14 with 








 bind SS-14 
with a 2–3-fold higher affinity than SS-28 [46, 51, 53, 54, 60, 61]. In contrast, hsst
5
 
binds SS-28 with a 10–30-fold higher affinity than SS-14 and can be considered 
SS-28 selective [56, 60, 61]. Based on these sequence homologies, the receptor sub-











 belong to the second group [62]. The five sst
1–5
 display 









 internalizes after ligand binding 
but can also assemble the sst
5
 receptors from intracellular stores to the membrane 
[64]. The activation of G-proteins actuates the signal transduction pathway of ssts. 
The G-protein consists of three subunits: the α (Gα), the β, and the γ(Gβγ) subunits. 
After the activation of the G-protein group, the nucleotide exchange of GDP for 
GTP results in the dissociation of the complex, and the Gα and Gβγ are free to spread 
their signal. Binding of SS ligands to the ssts is transduced to several key enzymes, 
such as adenylate cyclase, phosphotyrosine phosphatases (PTPases), and mitogen- 
activated protein kinase (MAPK), along with changes in the intracellular levels of 
calcium and potassium ions [19, 21, 36, 58, 59, 62, 65, 66]. Sst subtype, signaling 
elements, sst internalization, desensitization, and receptor crosstalk are a few of the 
factors that will determine which signal will eventually prevail.
The first effector enzyme to be identified and regulated by ssts was adenylate 
cyclase, and all five sst subtypes negatively couple to the enzyme [60]. Ssts are 
 coupled to several types of potassium channels such as the delayed rectifier, inward 
rectifier, ATP-sensitive potassium channels, and large conductance calcium-activated 
BK channels [67–71]. Ssts have also been shown to directly modulate high-voltage-
dependent calcium channels [72] and may also inhibit calcium currents by activation 
of cGMP protein kinase [73]. Moreover, ssts have also been shown to couple to Na+/
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H+ exchangers (NHEs) [74–76] to modulate such features as cell adhesion, migration, 
and proliferation [77]. Sst
1
 was the first subtype to specifically regulate NHE-1 









[76]. Ssts activate a number of phosphatases that have been implicated in cell 
growth. Tyrosine phosphatase and also serine and threonine phosphatase activation 
has been demonstrated to be recruited by ssts [19, 62, 65, 66]. According to recent 
studies, ssts can function as dimers and/or oligomers [78]. Homo- and heterodi-
merization was first demonstrated for the hsst
5
 subtype [79, 80]. Hsst
5
 can form 
heterodimeric association with hsst
1
 but not with hsst
4
, indicating that SS receptor 
heterodimerization is restricted to specific subtype combinations [80]. Western 





form homodimers when expressed alone and heterodimers when coexpressed in 
HEK293 cells [81].
exPression oF sst1–5 in normAl tissues And tumors
The expression of sst subtypes has been examined in human and rodent tissues using 
different procedures including Northern blot, reverse transcriptase-polymerase chain 
reaction (RT-PCR) amplification of cellular RNA, ribonuclease protection assay, and 
in situ hybridization [21, 22, 53, 58, 59, 66, 82]. In rat, mRNA for sst
1–5
 has been 
localized in the cerebral cortex, striatum, hippocampus, amygdale, olfactory bulb, 
and preoptic area [82]. In particular, sst
1
 mRNA in rat is expressed in the brain, 
pituitary, islets, jejunum, stomach, heart, spleen, and adrenals [46]; rsst
2
 mRNA is 
abundantly expressed in the brain as well as in the pituitary, pancreatic islets, and 
adrenals [57, 83]; and rsst
3
 mRNA is densely expressed in the cerebellum and in 
moderate amounts in the amygdala, cortex, and striatum and in the spleen, liver, and 
pituitary [50]. Rsst
4
 mRNA is poorly expressed in the brain, cerebral cortex, hippo-
campus, and olfactory bulb [53], and rsst
5
 mRNA is expressed in the brain, in high 
levels in the hypothalamus and preoptic area and in a moderate extent in cortical and 
subcortical regions [56, 84].
In human, ssts are expressed in the brain [65] as well as in numerous peripheral 
 tissues, including the pituitary, pancreas, gut, thyroid, adrenal, and kidney, and the 
immune system. Most studies are based on mRNA measurements. In contrast to 




 mRNA is expressed in 
high levels in the brain and kidney and in moderate levels in the jejunum, colon, 
and liver [46, 57]. Hsst
3
 mRNA has been detected in brain pituitary and islets 
[50], and hsst
4
 mRNA has been detected in moderate levels in the brain, stomach, 
and lung and other tissues in lesser amounts [54]. Hsst
5
 mRNA shows limited 
expression in man including the pituitary gland in adults and the pituitary and 
hypothalamus in the fetus [56, 84]. Interestingly, the liver, kidneys, cerebellum, 
and lungs, which are atypical target organs with negative or low SS binding, show 
high expression of sst mRNAs [21]. Sst
1–5
 are often coexpressed in various 
amounts and combinations in different tissues and cell types [19, 21, 36, 58, 59, 




 is found in GHRH-producing arcuate 









 are expressed in the adult human 
pituitary, whereas in the pituitary of rats, all five rssts are expressed [82, 
87–89].
Of particular interest is the fact that sst
1–5
 are expressed alone or in various com-
binations in many human tumors (Table 7.1) where they show higher densities than 
in normal tissues. Ssts are often highly expressed in neuroendocrine tumors (NETs) 











Neuroblastomas ne hd ne ne ne
Meningiomas ne hd ne ne ne
Medulloblastomas ne hd ne ne ne




Lymphomas ne 7/7 hd ne ne 3/7 ld




Paragangliomas 2/10 hd 8/10 hd 2/10 ld ne ne
Small cell lung cancers ne 2/2 hd ne ne ne







































ne ne 1/19ld2/19md 2/19md
Gastric carcinomas
2/5hd
1/5hd ne ne 2/5hd1/5ld
Ependymomas 1/2hd ne ne ne 1/2hd
x = cases per pattern, y = total cases, hd = high density, md = medium density, ld = low density, and ne = no 
expression.
including GH-secreting pituitary adenomas and gastroenteropancreatic tumors. 
Furthermore, ssts are expressed as well in many other tumors including neoplasias 
of the brain, breast carcinomas, lymphomas, renal cell cancers, mesenchymal tumors, 
and prostatic, ovarian, gastric, hepatocellular, and nasopharyngeal carcinomas. The 
most frequently detected subtype is sst
2
 and is expressed in neuroblastomas, medul-
loblastomas, breast carcinomas, meningiomas, paragangliomas, lymphomas, small 
cell lung cancers, hepatomas, and renal cell carcinomas. Moreover, sst
2
 seems to play 
an important role in tumor growth inhibition in agreement with reports by Buscail 
et al., suggesting that the absence of sst
2
 subtype may be responsible for the rapid 
growth of pancreatic and colonic cancers [90]. A few tumors with clear predomi-
nance of sst
1
 have been identified such as prostate carcinomas and sarcoma. 
Nevertheless, several other tumors may also have moderate expression of sst
1
, 
including gastroenteropancreatic tumors, pheochromocytomas, gastric carci-





 [91]. No tumor expression for sst
3
 was identified except for inactive 
pituitary adenomas where sst
3
 are often present. A possible explanation that sst
3
 
are not often detected may be that this receptor is expressed intracellularly in 
some tumors and not on the cell membrane. Moreover, sst
4
 proteins and also 
sst
4
 mRNA were found to be frequently expressed in tumors. Sst
4
 expression in 
moderate levels was documented only in one sarcoma, suggesting that membrane-
bound sst
4
 does not play a significant role in human cancer [91]. Sst
5
 are often 
expressed in pituitary adenomas and in moderate levels in sarcomas, prostate 
 cancer, gastroenteropancreatic tumors, gastric carcinomas, and ependymomas. 





frequently expressed, often together, in GH-secreting pituitary adenomas [84, 91]. 




 is expressed in neuroendocrine gastroenteropancreatic 
tumors and pheochromocytomas [91].
Thus, despite the predominance of sst
2
 expression in many human tumors, coex-
pression of sst
2
 with other sst
1–5
 subtypes is frequent enough. Furthermore, tumors 
devoid of sst
2
 may express one of the other sst
1–5
. These two findings have clinical 
implications for sst-targeted diagnosis and therapy, so far attempted mainly with sst
2
-
preferring peptide analogs (vide infra). It is reasonable to assume that pansomatostatin-
like peptides, that is, analogs binding with high affinity to all five human sst
1–5
, will 
broaden the clinical indications of their sst
2
-selective counterparts, as they will localize 
and treat a wider range of human tumors. Furthermore, the use of  pansomatostatin-like 
analogs will enhance the diagnostic sensitivity and/or therapeutic efficacy in such 
cases where sst
1–5
 coexpression occurs given that localization at the tumor is expected 
to increase. Due to the poor metabolic stability of native SS-14, synthetic and sst
2
-
preferring analogs have been clinically applied so far in diagnosis and therapy. 
However, interest in the development of new metabolically stable pansomatostatins 
for clinical use has been increasing recently due to their inherent potential to fully 
exploit the molecular (co)existence of more than one sst
1–5
 in human cancers. 
Furthermore, such analogs will provide excellent molecular tools to deeper explore 
and understand the pharmacology and function of sst
1–5
 in vitro and in vivo.
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From sst2 PreFerring to PAnsomAtostAtin rAdioligAnds
New SS derivatives have been synthesized with receptor subtype selectivity, higher 
 stability, and improved pharmacokinetics compared to the native peptide. Octreotide, 
 lanreotide, vapreotide, and the hexapeptide MK678 are such analogs (Fig.  7.3). 
However, these reduced-size SS analogs do not bind with high affinity to all five 
presently known SS receptor subtypes [19]. They showed high-affinity binding to 
sst
2








 [92]. Although 
these analogs are available for clinical use, none of them can detect the tumors 
expressing preferentially sst
1
, such as sarcomas and prostate cancer, or sst
3
, such as 
inactive pituitary adenomas [91].
Moreover, many neuroendocrine tumors are resistant to SS sst
2
-selective analog 
therapy because they often express several SS receptor subtypes other than sst
2
. As a 
result, drug development has recently been focused on stable SS analogs with high 
affinity to all five receptors subtypes (pansomatostatins) to imitate the broad actions 
of the native hormones. Some SS analogs, such as In- and Y-DOTA-lanreotide, have 
been claimed to bind with high affinity to all five sst
1–5
. However, binding studies 
with sst
1–5





 receptor subtypes [93].
The multi-SS analog SOM230 (pasireotide) and the true pansomatostatin synthetic 
nonapeptide KE108 are both reduced-size analogs of SS-14 (Fig. 7.3). SOM230 has 
affinity for the four of the five SS subtypes, with IC
50
 values of 9.3 nM (sst
1
), 1.0 nM 
(sst
2
), 1.5 nM (sst
3
), >1000 nM (sst
4
), and 0.16 nM (sst
5
) [94]. Although SOM230 has 
comparable sst
2
 affinity with octreotide, it shows incapacity to stimulate sst
2
 internali-
zation in vitro and in vivo [95]. In addition, SOM230 is more potent than octreotide in 
inducing internalization and signaling of the sst
3





recycle faster to the plasma membrane in SOM230 than in octreotide-treated cells and 
may counteract homologous desensitization in sst
2
-expressing cells [96]. SOM230 has 
also potent inhibitory effects on GH and IGF-I release and very high metabolic stability 
in vivo. SOM230 primarily targets the sst
5
, and accordingly, it is a promising candidate 
for the treatment of ACTH adenomas, octreotide-resistant GH adenomas, and octreo-
tide-resistant carcinoid tumors. Early phase I clinical trials have started with SOM230 
to fully explore its therapeutic potential in man [97].
KE108 has high affinity to all five SS receptors, with IC
50
 values of 2.6 ± 0.4 nM 
(sst
1
), 0.9 ± 0.1 nM (sst
2
), 1.5 ± 0.2 nM (sst
3
), 1.6 ± 0.1 nM (sst
4
), and 0.65 ± 0.1 nM 
(sst
5
) [98]. Both KE108 and SOM230 are full agonists for adenylyl cyclase inhibition 
but antagonize the actions of SS-14 to stimulate calcium and ERK phosphorylation 
[99]. KE119 is the 3-I-Tyr0 analog of KE108 and has also pansomatostatin properties 
and could be used as radiotracer in vitro and in vivo to identify tissues expressing all 
five SS receptor subtypes [98].
KE88 is an analog of KE108 modified by coupling DOTA to the N-terminus, and 
it retains a high affinity to all five sst
1–5
. The KE88-based radioligands may be inter-
esting and suitable for imaging sst
2
-expressing tumors at early time points (68Ga) and 
sst
3
-expressing tumors at later imaging time points using a longer-lived radionuclide 
(64Cu, 86Y) [100]. Coupling of acyclic tetraamines to KE108 and des-Tyr0-KE108 
resulted in Demopan 1 and Demopan 2, respectively, both able to bind 99mTc in good 
Figure 7.3 Molecular structures of SS-14 and smaller-ring synthetic  analogs. Molecular 
structure of native 12-AA ring tetradecapeptide SS-14 (top), followed by the cyclic octapep-
tide octreotide, the cyclic hexapeptide MK678 and the nonapeptide KE108; the lower structure 
represents SOM230. Coupling of DOTA, NOTA, N4 chelators and their  derivatives for stable 
labeling with medically useful radiometals has been performed at the positions indicated by 
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yields. These analogs, despite their true in vitro pansomatostatin profile, exhibited 
suboptimal pharmacokinetics in animal models [101].
In the late 1970s, the Merck group has synthesized the first bicyclic peptides to 
increase the metabolic stability of the native hormones. Some years later, veber et al. 
[102–104] performed structure–activity relationships studies with these analogs to 
elucidate the structural parameters implicated in SS function. Following these results, 
Maecke et al. synthesized AM3 [DOTA-Tyr-cyclo(Dab-Arg-cyclo(Cys-Phe-D-Trp-
Lys-Thr-Cys)] wherein the DOTA chelator is coupled for trivalent radiometal binding 









, as shown by immunofluorescence-based 
internalization assays and by Ca2+ flux studies. AM3 seems to be comparable with 
similar broad sst binding analogs, such as DOTANOC [106, 107].68Ga-AM3showed 
pharmacokinetics similar to 177Lu-AM3, including clear tumor delineation and recep-
tor-mediated uptake. This radiopeptide may be good a candidate for PET/CT studies 
of sst-expressing tumors [105].
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rsst rat sst‐expressing tumors
SPECT single‐photon emission computed tomography
sst somatostatin receptor subtype
introduction
Somatostatin receptors belong to the large family of G‐protein‐coupled receptors 
(GPCRs) also called seven‐transmembrane receptors (7TMR). This receptor class 
is  the largest and most ubiquitous plasma membrane receptors and encompasses 
the most successfully used druggable targets in the market. The receptors transfer 
extracellular stimuli—exerted by light, odor, or agonistic ligands—into intracellular 
signals [1, 2].
Typically, GPCR activation by agonists results in activating many signaling path-
ways, which for most receptors are mediated by G proteins and β‐arrestins. Distinct 
biological responses are often linked to these pathways. Usually, full agonists acti-
vate the full range of receptors signaling network (full spectrum of signaling path-
ways), whereas antagonists inactivate the signaling network, and they block the 
signaling action of agonists. However, biased ligands selectively activate some sig-
naling pathways while inactivating others mediated by the same receptor. This 
enhanced functional selectivity allows developing agents with increased efficacy 
(e.g., effective internalization and retention) and/or decreased adverse effects. 
Ligands developed in this field are mainly focused on the cardiovascular and central 
nervous system (CNS) diseases.
Aberrant expression and activity of GPCRs are also considered important in 
tumorigenesis [3, 4]. In a deep sequencing study, O’Hayre et al. found that about 
20% of human tumors harbor mutations in GPCRs [3]. Long before these studies, 
Reubi et al. showed that GPCRs are overexpressed on a variety of human tumors 
and therefore found to be important targets in cancer imaging and targeted radio-
nuclide therapy [5]. The prototypes of these cancers are neuroendocrine tumors 
overexpressing somatostatin receptors as shown by autoradiography [6]. Five 
somatostatin receptor subtypes (sst1–sst5) are known, and they are all overex-
pressed to some extent in these tumors; the most important one is sst2 for reasons 
not known at present. As discussed in Chapters 8 and 10, radiolabeled somato-
statin‐based peptides were developed for imaging (SPECT and PET) and for tar-
geted radionuclide therapy [6–8]. They are successfully used in the clinic and are 
the only radiolabeled peptides having an impact in patient care. These radioligands 
are all potent agonists that internalize into tumor cells upon binding to the receptor. 
This mechanism was considered to be essential (mandatory) for active and high 
accumulation of the radioligand in the tumor along with long tumor retention. This 
paradigm was supported by data from the Anderson and our own group. Lewis 
et al. showed that the rate of internalization correlated with the tumor uptake in a 
group of four 64Cu‐labeled somatostatin‐based octapeptides [9]. In a series of 
99mTc‐labeled HYNIC/EDDA‐octreotide (HYNIC/EDDA‐TOC, where HYNIC 
refers hydrazinonicotinamide and EDDA to ethylenediamine‐N,N′‐diacetic acid), 
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compared with 111In‐DOTA‐TOC (DOTA: 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐
tetraacetic acid) and OctreoScan, Storch et al. have shown a strong linear correlation 
between the uptake in the tumor and in the pancreas (sst2‐positive organ) and the 
rate of internalization in cell culture [10]. In addition, Ginj et al. [11] described a 
family of carbocyclic octapeptides with pansomatostatin properties (high affinity 
for all five receptor subtypes). When these peptides were tested for their agonist 
properties using a cAMP assay (inhibition of forskolin‐stimulated cAMP produc-
tion), they showed potent agonistic properties at all five receptor subtypes. On the 
contrary, they did not internalize in sst2 nor did they show any Ca2+ release when 
incubated with human embryonic kidney (HEK)293‐human sst2 (hsst2) cells. They 
antagonize somatostatin stimulation of intracellular Ca2+ flux. Interestingly, they 
showed rapid internalization in HEK293‐hsst3 cells. Consequently, in a dual tumor 
model xenografted with HEK293‐hsst2 and HEK293‐hsst3, a fast washout was 
found from the sst2 tumor, but high tumor uptake and long retention were found in 
the hsst3 tumor. These peptides were later shown to be biased ligands on sst2 and 
true agonists on sst3 [12]. These data argued for the use of radiolabeled somato-
statin‐based agonists as internalization indeed appears to be of high importance for 
high and long‐lasting tumor uptake.
However, a number of recent observations have challenged this strategy. 
Antagonists may have characteristics other than those related to internalization that 
may make their radiolabeled derivatives suitable tools for in vivo receptor targeting. 
Most relevant is the in vitro evidence that, in certain circumstances, antagonist radio-
ligands may recognize a higher number of receptor‐binding sites than agonist radio-
ligands [13, 14]. A higher number of receptor‐binding sites may result in higher 
uptake than agonist radioligands, and the lack of internalization may compensate for 
a faster washout, which can nicely be combined with short‐lived radionuclides such 
as 68Ga and 18 F for PET or 213Bi for therapy. This was the hypothesis to start a project 
on somatostatin‐based radiolabeled antagonists along with the University of Berne 
(Jean Claude Reubi) and the Salk Institute (Jean Rivier).
rAdiolAbeled AntAgonists
chemistry
The first somatostatin‐based antagonists were published by Bass et al. in 1996 
[15]. They found that in the octapeptide series (disulfide cyclized, hexapeptide 
core), the inversion of chirality at positions 1 and 2 of the octapeptide (octreotide 
family) converted an agonist into a potent antagonist. Later structure–activity rela-
tionship studies by the Coy group afforded new structures.  The most potent of 





 (Pal = 3‐pyridyl‐alanine) 
[16]. Based on these findings, the antagonists were used as leads for further modi-
fications as well as DOTA coupling for radiometal labeling by Cescato et al. [17] 
and Ginj et al. [18].
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preclinical studies
The first preclinical studies with radiolabeled somatostatin antagonists were per-
formed by Ginj et al. targeting rat sst2‐ and sst3‐overexpressing transfected HEK293 
[18] cells. It was shown that the potent sst2 and sst3 antagonists are superior to radio-
labeled agonists of similar or even higher receptor affinity with regard to in vivo 
tumor uptake as well as tumor‐to‐normal tissue ratios.
An impressively high uptake of the antagonist sst3‐ODN‐8 radioligand (Table 8.1) 
in HEK293‐sst3 tumors (60%IA/g, 1 h p.i.) has been reported, which actually has 
indeed never been achieved by any somatostatin receptor agonist ligand. Not only the 
uptake at the peak time point was very high, but also the long‐lasting accumulation 
of the antagonist radioligand up to 72 h after injection was a remarkable result and 
represents a considerable advantage over targeting with established agonists. The 
same observation was obtained in HEK293‐sst2 tumors with the sst2 antagonist 111In‐
DOTA‐sst2‐ANT (Table  8.1). In this study, 111In‐DOTA‐sst2‐ANT has been com-
pared with 111In‐DTPA‐TATE (DTPA: diethylenetriaminepentaacetic acid), and 
knowing the outstanding targeting abilities of 111In‐DTPA‐TATE [19], it is striking to 
see that the in vivo uptake at 4 and 24 h for the sst2 antagonist is twice as high, despite 
the fact that the antagonist is not internalized into the tumor cells and that its sst2‐
binding affinity is lower than for the agonist [18].
Explanations for these excellent in vivo targeting properties of antagonists may be 
found, at least in part, in the higher number of binding sites recognized by antago-
nists, compared to agonists, as shown using the HEK293‐sst2 and HEK293‐sst3 
tAble 8.1 somatostatin‐based antagonists that have been developed as potential 
radiotracers
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transfected cell lines [18]. It appears that in an in vivo situation, an agonist that triggers 
a strong internalization but binds to a limited number of high‐affinity receptors is a 
less efficient targeting agent than an antagonist lacking internalization capabilities 
but binding to a larger variety of receptor conformations.
In another study, the antagonist sst2‐ANT was compared with the powerful ago-
nist TATE, both conjugated to 4,11‐bis(carboxymethyl)‐1,4,8,11‐tetraazabicy-
clo[6.6.2]hexadecane (CB‐TE2A) and labeled with 64Cu, employing the frequently 
used rat pancreatic cell line AR42J [20]. Interestingly, this study did not show the 
superiority of the antagonist in vivo, despite the fact that a 14‐fold higher number of 
binding sites for the antagonist were found, similar to what was found with the trans-
fected cell line HEK293‐sst2 for 111In‐DOTA‐sst2‐ANT compared to TATE [18]. 
These data indicated that the in vitro and in vivo properties of radiolabeled GPCR 
antagonists are not understood well yet and need further studies.
Relatively little is known in regard to structural parameters determining the phar-
macological properties of radiolabeled somatostatin‐based antagonists. A recent 
study demonstrates that the chelate makes the difference on the affinity and also 
pharmacokinetics of these antagonists [21]. In this study, the sst2 antagonist LM3 
(Table 8.1) was coupled to three different macrocyclic chelators, namely, CB‐TE2A, 
1,4,7‐triazacyclononane,1‐glutaric acid‐4,7‐acetic acid (NODAGA), and DOTA. The 
NODAGA and CB‐TE2A conjugates were labeled with 64Cu, while the NODAGA 
and DOTA conjugates with 68Ga. In vitro and in vivo studies showed the strong 
dependence of the affinity and pharmacokinetics on the chelator and radiometal. For 
instance, 68Ga‐NODAGA‐LM3 has a 10‐fold higher sst2 affinity than the 
corresponding DOTA conjugate (68Ga‐DOTA‐LM3) and a 5‐fold higher sst2 affinity 
than the corresponding 64Cu complex (64Cu‐NODAGA‐LM3), indicating that there is 
a much stronger influence of the appended chelate than found in somatostatin‐based 
agonists [22]. Significant differences were observed in the in vivo behavior of the two 
64Cu‐labeled peptides, namely, 64Cu‐NODAGA‐LM3 and 64Cu‐CB‐TE2A‐LM3. 
Even though 64Cu‐CB‐TE2A‐LM3 has 1.6‐fold better affinity than 64Cu‐NODAGA‐
LM3, this is not reflected in a higher tumor uptake. On the contrary, 64Cu‐NODAGA‐
LM3 shows a distinctly higher uptake than 64Cu‐CB‐TE2A‐LM3 at 1 h (35.5 vs. 19.3 
%IA/g) and 4 h (37.9 vs. 26.9 %IA/g). Significant amount of radioactivity is accumu-
lating in the kidneys for both radiolabeled antagonists but 2‐ to 9‐fold higher for 
64Cu‐CB‐TE2A‐LM3, depending on the time point, probably due to the positive 
charge of 64Cu‐CB‐TE2A‐LM3 versus the neutral charge of 64Cu‐NODAGA‐LM3.
An important issue in tumor targeting, especially concerning therapeutic applica-
tions, is the retention of the radioligand in the tumor. As mentioned previously, 
studies indicated that low or absent internalization correlates with very short tumor 
retention [11, 23]. Concerning 64Cu‐NODAGA‐LM3 and 64Cu‐CB‐TE2A‐LM3, both 
showed low internalization. Therefore, it is remarkable that 64Cu‐NODAGA‐LM3 
has a (relatively) slow but distinctly faster washout from the tumor (~15 %IA/g, 24 h 
p.i.) compared to 64Cu‐CB‐TE2A‐LM3, which shows almost no washout between 4 h 
(26.9 %IA/g) and 24 h p.i. (21.6 %IA/g). This may be of high importance if therapy 
is considered with the beta emitter 67Cu (t
1/2
 = 64 h) as the area under the curve may 
be larger for the 64/67Cu‐CB‐TE2A conjugate. Despite the negligible washout 
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of 64Cu‐CB‐TE2A‐LM3 from the tumor, the tumor‐to‐normal tissue ratios are 
remarkably higher for 64Cu‐NODAGA‐LM3 compared to 64Cu‐CB‐TE2A‐LM3 
(Fig. 8.1a; e.g., tumor‐to‐kidney, 12.8 vs. 1.7, and tumor‐to‐muscles, 1342 vs. 75.2, 
at 24 h), an important parameter for good image contrast. These differences were 
especially impressive for the tumor‐to‐kidney ratios, which strongly increase with 
time and are much higher than usually seen with somatostatin‐based radiolabeled 
agonists. MicroPET imaging shows clear tumor localization and very high image 
contrast, especially for 64Cu‐NODAGA‐LM3 (Fig. 8.1b).
It has been shown that the chelated somatostatin agonists are sensitive to N‐
terminal radiometal modifications, with Ga‐DOTA agonists having signifi-
cantly higher binding affinity than their Lu‐, In‐, and Y‐DOTA correlates [24]. For 
instance, Ga(III)‐DOTA‐OC has three times higher affinity for sst2 than Y(III)‐
DOTA‐OC, Ga(III)‐DOTA‐TOC has six times higher affinity than Y(III)‐DOTA‐TOC, 
and Ga(III)‐DOTA‐TATE has eight times higher affinity than Y(III)‐DOTA‐TATE 
[24]. These improved binding affinities also translated into improved internalization 
rates and concomitantly higher tumor uptake [25]. In those studies, it appeared ade-
quate to generalize that 67/68Ga is a radiometal that systematically improved the sst2 
affinity of somatostatin agonists as well as their pharmacokinetics. It was further 
confirmed in vivo in patients with neuroendocrine tumors that 68Ga‐DOTA‐NOC 
(NOC: [1‐Nal3]octreotide), 68Ga‐DOTA‐TOC, and 68Ga‐DOTA‐TATE were better 
imaging agents than the 111In‐DOTA congeners [25–29].
Recently, a study was published on whether chelated somatostatin antagonists are 
also sensitive to radiometal modifications. In this study, three different somatostatin 
antagonists, namely, JR10, JR11, and LM3 (Table 8.1), were conjugated to the che-
lators DOTA and NODAGA, and various (radio)metals including In(III), Y(III), 
Lu(III), Cu(II), and Ga(III) were added [30]. Surprisingly, in all three resulting antag-
onists, the Ga‐DOTA analogs were the least affine radioligands, with an sst2‐binding 
affinity up to 60 times lower than the respective Y(III)‐DOTA, Lu(III)‐DOTA, and 
In(III)‐DOTA compounds (Table 8.2). Interestingly, however, substitution of DOTA 
by the NODAGA chelator in the antagonist conjugate was able to increase massively 
its binding affinity in contrast to the Ga(III)‐DOTA analog.
An important finding in this study is the 8‐fold difference between In(III)‐DOTA‐
JR11 (IC
50
 = 3.8 ± 0.7 nM) and Y(III)‐DOTA‐JR11 (IC
50
 = 0.47 ± 0.05 nM). 111In is 
commonly used as a surrogate for 90Y for imaging the biodistribution of 90Y‐labeled 
tracers and for dosimetry (e.g., 111In/90Y‐DOTA‐TOC). The recent results indicate 
that 111In may not be a suitable surrogate of 90Y and therefore not very reliable for 
dosimetric studies of the therapeutic radiolabeled peptide based on somatostatin 
antagonists. Moreover, this may be the case for other peptide families and has to be 
investigated.
A striking finding from these studies is the comparison of the antagonists with 
clinically used agonists. The side‐by‐side in vivo comparison between 68Ga‐
DOTA‐TATE and 68Ga‐DOTA‐JR11 illustrates the great potential of the antago-
nists. 68Ga‐DOTA‐JR11, having a dramatically lower affinity for the sst2 
(~150‐fold) compared to 68Ga‐DOTA‐TATE (Table 8.2), showed a 1.3‐fold higher 
tumor uptake (23.8 vs. 17.8 %IA/g, 1 h p.i.), while 68Ga‐NODAGA‐JR11, with a 
64 Cu-NODAGA-LM3 64 Cu-CB-TE2A-LM3
0 20
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Figure  8.1 (a) Tumor‐to‐normal tissue ratios of the radiolabeled antagonists 64Cu‐
NODAGA‐LM3 (grey bars) and 64Cu‐CB‐TE2A‐LM3 (black bars) in biodistribution studies 
in HEK293‐sst2 tumor xenografts at 1, 4, and 24 h p.i. are significantly higher for the NODAGA 
conjugate than for the CB‐TE2A conjugate (**P < 0.01 and ***P < 0.001). (b) MicroPET images 
of 64Cu‐NODAGA‐LM3 and 64Cu‐CB‐TE2A‐LM3 at 4 and 24 h p.i. (coronal sections) showed 
the potential of these radiopeptides for in vivo imaging of sst2‐expressing tumors and high-
lighted the improved tumor‐to‐background contrast of 64Cu‐NODAGA‐LM3, especially tumor 
to kidney [21].
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tAble 8.2 chemical structures of three sst2 antagonists based on the Jr10, Jr11, 
and lm3 family and their metallated conjugates and ic50 values for sst2 (mean ± sem, 
n ≥ 3) [30]
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6‐fold lower affinity (Table 8.2), showed an up to 1.7‐fold higher tumor uptake 
(30.7 vs. 17.8 %IA/g, 1 h p.i.) [30]. The low‐affinity antagonist is slightly superior, 
which again may be explained by the higher number of binding sites for antago-
nists versus agonists [18], outweighing the affinity differences. This was also 
impressively demonstrated with in vitro autoradiographic studies of human tumor 
specimens [31], discussed afterward. PET images highlighted the higher uptake of 
the antagonists compared to agonist (Fig.  8.2) and the excellent background 
clearance already at 1 and 2 h p.i.
There are already two studies in animal tumor models where a side‐by‐side 
comparison of somatostatin receptor antagonist versus agonist showed that the antago-
nists bind to sst2‐ and sst3‐expressing tumors in vivo better than agonists with comparable 
or even higher affinity [18, 30]. This was proven also to be the case in a side‐by‐side in 
vitro binding studies on several different, well‐characterized human tumor samples of 













Figure  8.2 Small‐animal PET images (coronal sections) of HEK‐hsst2 tumor‐bearing 
mice injected with 68Ga‐DOTA‐TATE, 68Ga‐DOTA‐JR11, and 68Ga‐NODAGA‐JR11, 1 and 2 h 
p.i., show the potentiality of the radiolabeled antagonists 68Ga‐DOTA‐JR11 and 68Ga‐
NODAGA‐JR11 to image sst2‐expressing tumors in vivo. They also illustrate the higher tumor 
uptake of the radiolabeled antagonists compared to agonist, and they confirm the specificity of 
all radiotracers as no tumor is visualized in the blocking experiments [30].
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About 50 sst2‐positive human tumor tissue samples were analyzed by in vitro 
receptor autoradiography for the expression of sst2, comparing the binding capacity 
of 177Lu‐DOTA‐BASS and 177Lu‐DOTA‐TATE in successive tissue sections. Both 
radioligands efficiently bind to the sst2 receptor on the different tumor tissues. 
However, in all cases, the radiolabeled antagonist 177Lu‐DOTA‐BASS bound to more 
sst2‐receptor sites in the tumors than did the agonist 177Lu‐DOTA‐TATE. 
Autoradiograms of representative examples for all tumor types analyzed are shown 
in Figure 8.3a. The mean ratios of the antagonist 177Lu‐DOTA‐BASS to the agonist 
177Lu‐DOTA‐TATE ranged from 4.2 up to 12.3 (Fig.  8.3b). This significantly 
increased binding may increase the localization accuracy for tumors and metastases 
but also increase the efficacy of radiotherapeutic intervention with such antagonist 
radiotracers. Of particular interest is the fact that tumors other than neuroendocrine, 
such as tumors that normally express a low density of receptors, for example, breast 
carcinomas, renal cell cancers, or non‐Hodgkin lymphomas, showed the same results. 
Those tumors are not currently among those being routinely investigated with 
somatostatin receptor imaging. It is therefore impressive to see that by using the 
antagonist radioligand, it is possible to increase, at least in vitro, the number of 
binding sites in breast carcinomas and renal cell cancers 11.4‐ and 5.1‐fold, respec-
tively (Fig. 8.3b). As well, the case of non‐Hodgkin lymphomas normally expressing 
a low amount of sst2 showed a 4.8‐fold increase in receptor number with the antag-
onist radioligand, reaching levels that may be detected more easily in vivo than with 
current agonists. These in vitro human data, together with the in vivo animal tumor 
data, are strong arguments indicating that sst2 antagonists may be worth testing in 
patients in a wide range of tumors including nonneuroendocrine tumors. Such sst2 
antagonist radioligands should be useful not only for diagnostic tumor imaging but 
also for targeted tumor radiotherapy.
clinical studies
The first pilot study of radiolabeled somatostatin‐based antagonist demonstrates 
their feasibility of imaging sst2‐expressing tumors in patients [32]. This pilot study 
provides the first clinical evidence that radiolabeled sst2 antagonists not only 
detect sst2‐expressing neuroendocrine tumors but also may even be superior to 
agonists for imaging and therapy of neuroendocrine tumors. The studied antagonist 
111In‐DOTA‐BASS had a favorable biodistribution profile (higher tumor uptake and 
lower organ uptake) than the agonist 111In‐DTPA‐OC, resulting in a higher tumor 
detection rate.
The two radiotracers, 111In‐DOTA‐BASS and 111In‐DTPA‐OC, were compared in 
5 patients with metastatic thyroid carcinoma or neuroendocrine tumors. 111In‐DOTA‐
BASS detected 25 of 28 lesions, whereas 111In‐DTPA‐OC detected only 17 of 28 
lesions. All lesions visible on 111In‐DTPA‐OC scans were also detected by 111In‐
DOTA‐BASS, whereas there were 8 lesions on 111In‐DOTA‐BASS that were not 
visible on 111In‐DTPA‐OC. There were additionally 3 bone lesions that were negative 
on both 111In‐DOTA‐BASS and 111In‐DTPA‐OC scans, but bone metastases were 
confirmed by serial CT. Figure 8.4a shows representative images of the same patient 
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Figure 8.3 (a) Comparison of 177Lu‐DOTA‐TATE and 177Lu‐DOTA‐BASS receptor auto-
radiographic binding in successive sections of various types of human cancers (ileal carcinoid, 
pheochromocytoma, breast carcinoma, renal cell carcinoma, and non‐Hodgkin lymphoma) 
expressing sst2. Columns from left to right represent hematoxylin and eosin staining, total and 
nonspecific binding of 177Lu‐DOTA‐TATE, and total and nonspecific binding of 177Lu‐DOTA‐
BASS. Binding is markedly stronger with the antagonist 177Lu‐DOTA‐BASS. HE, hematox-
ylin and eosin; NHL, non‐Hodgkin lymphoma; NS, nonspecific; Pheo, pheochromocytoma; 
RCC, renal cell carcinoma. (See insert for color representation of the figure.) (b) Quantitation 
of in vitro receptor autoradiography experiments with various types of human cancers (ileal 
carcinoid, pheochromocytoma, breast carcinoma, renal cell carcinoma, and non‐Hodgkin lym-
phoma) using 177Lu‐DOTA‐TATE and 177Lu‐DOTA‐BASS as radioligands. Shown are bar 
graphs of specific binding (counts/h) of radioligands to tumor sections after quantitation using 
InstantImager. For all tested human tumor types, the antagonist 177Lu‐DOTA‐BASS exhibited 
markedly better binding behavior. NHL, non‐Hodgkin lymphoma; Pheo, pheochromocytoma; 




































































Figure 8.4 (a) 111In‐DOTA‐BASS (4, 24, and 72 h p.i. left) and 111In‐DTPA‐OC (4 and 24 h 
p.i. right) planar anterior whole‐body scans from patient with neuroendocrine carcinoma. The 
images illustrate the better tumor‐to‐background uptake ratio of 111In‐DOTA‐BASS (e.g., 
tumor‐to‐liver uptake ratio of 6.7 at 4 h p.i. and 3.5 at 24 h p.i.) compared to 111In‐DTPA‐OC 
(1.2 at both time points). In this patient, 111In‐DOTA‐BASS detected 16 metastases, whereas 
111In‐DTPA‐OC detected only 11 metastases. (b) Comparison of 111In‐DOTA‐BASS and 111In‐
DTPA‐octreotide uptake in the kidneys, spleen, and tumors. Values are expressed as mean ± SD 
of 5 patients. OC = octreotide; p.i. = after injection [32].
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scanned with both radiotracers. The longest residence times of 111In‐DOTA‐BASS 
were observed in the tumor and kidneys.
The quantitative analysis showed relevant differences in the biodistribution bet-
ween the antagonist 111In‐DOTA‐BASS and agonist 111In‐DTPA‐OC (Fig. 8.4b). The 
antagonist showed up to 4.1 times higher uptake in the tumor (3.5 ± 2.8 %IA vs. 
1.0 ± 0.99 %IA) 4 h after injection. At the same time, the uptake in the kidneys was 
lower for the antagonist (1.5 vs. 2.3 %IA), resulting in up to 5.2 times higher tumor‐
to‐kidney uptake ratio in favor of the antagonist. The antagonist also showed lower 
uptake than the agonist in organs such as the liver (1.4 ± 0.2 vs. 1.7 ± 0.6 %IA) and 
spleen (1.0 ± 0.2 vs. 2.3 ± 1.0 %IA) 4 h after injection.
With respect to radionuclide therapy, it is particularly encouraging that tumor‐to‐
kidney ratios were up to 5.2 times higher for the antagonist than for the agonist as the 
kidneys are the major dose‐limiting organ in peptide receptor radionuclide therapy. 
The several-fold higher tumor‐to‐kidney uptake ratio could significantly improve the 
efficacy and toxicity profile of radionuclide therapy. In an attempt to further evaluate 
the potential of somatostatin receptor antagonists for radionuclide therapy, the organ 
doses of 90Y‐DOTA‐BASS were calculated based on the assumption that 90Y‐DOTA‐
BASS shows the same biodistribution as 111In‐DOTA‐BASS. Compared with litera-
ture data for 90Y‐DOTA‐TOC [33, 34], 90Y‐DOTA‐BASS showed lower renal, 
hepatic, and splenic radiation doses [32].
some interesting Aspects
The pharmacokinetics of the first radiolabeled antagonist in humans, 111In‐DOTA‐
BASS, has been studied more thoroughly in order to investigate the potency of these 
new radiolabeled antagonists as therapeutic radiopharmaceuticals. The same antago-
nist was studied with 177Lu to clarify if the radiometal has an influence on the phar-
macokinetics [35]. The tumor uptake was almost identical for the two radiolabeled 
peptides 111In‐DOTA‐BASS and 177Lu‐DOTA‐BASS (30–35%IA/g, 4 h p.i.), and the 
washout is relatively slow for both; about 50% still remains in the tumor 48 h p.i. This 
indicates no radiometal influence of this DOTA‐conjugated antagonist, rendering 
177Lu‐DOTA‐BASS a promising radiotherapeutic agent. This result is somewhat con-
trary to what was shown with the somatostatin‐based radiolabeled antagonist LM3 
[21] as discussed previously, where distinct differences in pharmacology depending 
on radiometal and chelator were found. Attempts to block the tubular cell‐mediated 
kidney uptake of antagonistic radiopeptides with agents, which are successful in the 
clinical use of corresponding radiolabeled agonists, showed that lysine and Gelofusine 
were both effective in kidney blocking of 111In‐DOTA‐BASS. Both agents did not 
block tumor uptake but blocked about 50% of kidney uptake, increasing the tumor‐
to‐kidney ratio about 2‐fold. Last but not least, this study excluded species differ-
ences as the biodistribution results of 111In‐DOTA‐BASS in mice bearing 
hsst2‐expressing tumors (hsst2) in comparison to mice bearing rat sst2‐expressing 
tumors (rsst2) were found to be very similar. This study indicated the relevance of 
radiolabeled somatostatin‐based antagonist not only in diagnostic imaging but also in 
targeted radionuclide therapy of somatostatin receptor‐positive tumors.
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All the previously mentioned metallated peptides demonstrated antagonist 
potency in immunofluorescence microscopy‐based internalization experiments [18, 
21, 30, 35]. They did not trigger sst2 receptor internalization and antagonized the 
receptor internalization mediated by an agonist. However, in the radioligand internal-
ization experiments, the corresponding radiotracers, for example, 68Ga‐NODAGA‐
LM3, 68Ga‐DOTA‐LM3, or 111In‐DOTA‐BASS, but also other radiolabeled 
antagonists, such as 64Cu‐CB‐TE2A‐BASS [20, 36], showed significant levels of 
internalization in sst2‐positive cell lines, albeit much lower than the internalization 
of corresponding radiolabeled agonists. Internalization studies of 111In‐DOTA‐BASS 
in cells not expressing sst2 showed no internalization of the radioligand, while pre-
treatment of the sst2‐expressing cells with hypertonic sucrose, known to prevent 
receptor endocytosis by preventing clathrin‐coated pit formation [37], distinctly 
reduced radioligand internalization. These findings are strong indications of a 
specific receptor‐mediated internalization process of the radioligands. It is still an 
open question why these antagonists internalize in a radioligand experiment but are 
not able to stimulate sst2 internalization. It should be considered that in the immuno-
fluorescence microscopy experiments, the sst2 receptor trafficking itself is moni-
tored where ligand trafficking is monitored in the radioligand experiment. Moreover, 
the ligand is used in high excess in the immunofluorescence microscopy experi-
ments, while in the radioligand internalization experiments, the concentration of the 
radioligand is far below tumor saturation. As far as in vivo concerns, the first in vivo 
data indicate receptor internalization triggered by agonists but apparently not by 
antagonists [38].
conclusion
The recent developments indicate the change of paradigm for in vivo targeting of 
somatostatin receptors using radiolabeled somatostatin‐based antagonists than ago-
nists, as this may considerably improve the sensitivity of diagnostic procedures and 
the efficacy of targeted radionuclide therapy of somatostatin receptor‐positive tumors.
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Somatostatin (SRIF) is a widespread neuropeptide with mainly inhibitory function on 
hormone release in the anterior pituitary and the gastrointestinal tract, as well as with 
antiangiogenic, antiproliferative, and analgesic properties [1–3]. Within the  nervous 
system, SRIF acts as a neuromodulator with physiological effects on neuroendocrine, 
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motor, and cognitive functions [4]. SRIF displays antiproliferative activities triggering 
different intracellular pathways, at least in vitro, involved in the control of cell growth 
as well as apoptosis [1–4]. The effects of SRIF are mediated by five different SRIF 
receptors (SSTRs), heterogeneously distributed on target cells [1–4].
Recently, the complexity of the somatostatinergic system has been extended by 
two new important findings: the discovery of cortistatin (CST) as well as the evi-
dence of cross interaction between the same SSTRs and between these and other 
membrane receptors, in particular dopamine receptors (DRs). These new challenging 
discoveries have led the research toward finding potential new drugs and to the 
opportunity to capitalize on these new pathophysiological acquisitions.
Cst
The cDNA of this new neuropeptide, displaying strong structural similarities with 
SRIF, has been discovered and cloned in 1996 by De Lecea et al., who identified for 
the first time CST in rat cortex [5].
CST is a cyclic peptide derived from a prepropeptide of 114 residues, and 
comparable to SRIF‐14 and SRIF‐28, proteolytic processing of procortistatin results 
in the production of two isoforms in rat, CST‐14 and CST‐29, and in human, CST‐17 
and CST‐29 [5–7]. In analogy with SRIF, CST contains the four amino acids Phe7, 
Trp8, Lys9, and Thr10 [5], which are essential for binding to the five SSTR subtypes 
(sst) [8]. Because of its high structural resemblance to SRIF, CST binds with high 
affinity to the five known sst; however, despite these analogies, these neuropeptides 
are products of different genes [7].
CST shares several functional properties with SRIF; however, some biological 
activities of CST are unique. Indeed, many differences in the direct effects of SRIF 
and CST have been described. Among these are the induction of slow‐wave sleep, the 
reduction of locomotor activity, and the activation of cation‐selective currents not 
responsive to SRIF [9]. Most of the actions of CST have been designated to the 
 regulation of behavior, sleep, and memory mechanisms localized in the brain. Both 
compounds seem to depress neuronal activity in the hippocampus [5] and reduce 
development of seizures [10] and can deteriorate memory consolidation [11], whereas 
CST‐treated rats showed a clear hypoactive behavior, and the electroencephalogram 
(EEG) showed a dramatic increase in cortical slow waves [5]. Subsequently, after 
administration of CST, rats spent more time in slow‐wave sleep and less time in rapid 
eye movement (REM) sleep. On the other hand, the administration of SRIF results in 
sleep periods dominated by REM sleep, without significantly affecting the other 
phases of sleep [5, 7, 12]. Moreover, it has been demonstrated that CST expression is 
upregulated during sleep deprivation in rats. In this phase, also upregulation of SRIF 
has been demonstrated in the brain [13, 14]. This suggests that both SRIF and CST 
may have sleep regulatory functions and probably interplay in the regulation of sleep 
in their own specific way. Summarizing, in behavior and sleep regulation, either 
SRIF or CST play important roles, whereas the clinical significance of these peptides 
in regulating these processes needs to be more extensively investigated [15].
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As already mentioned, CST was initially found to be selectively expressed in the 
brain cortex and hippocampus; however, further studies revealed its expression in the 
human kidney, stomach, testes, as well as leukocytes [16]. The functional  significance 
of CST in peripheral tissues is currently under investigation. Since SRIF plays 
 important roles in regulating various processes in humans through its SSTRs and 
CST may act via these G‐protein‐coupled receptors as well, we could expect that 
CST might have comparable effects in the body with respect to regulation of cell 
proliferation and secretion. However, as previously stated, in the human brain, differ-
ences in effects of CST and SRIF have been described [9]. Indeed, these differences 
may be explained by different postreceptor signaling pathways or by the existence of 
a specific CST receptor. In fact, recently, a novel MrgX2 receptor has been cloned. 
CST binds this receptor with a relative higher affinity of over 2500 peptides tested, 
including SRIF [17]. These findings suggest that CST acts via either the SSTRs or 
MrgX2, which may explain some differences in effects between SRIF and CST. 
Although further studies are warranted to support this hypothesis, MrgX2 could 
 represent the putative CST receptor; however, CST has been more recently shown to 
bind, with lower affinity, the type 1a growth hormone secretagogue receptor (GHS‐
R1a) as well [18].
Focus on the immune system
A significant anti‐inflammatory effect of SRIF has been demonstrated in different 
experimental animal models displaying an inflammatory state. CST has also been 
shown to inhibit the production of proinflammatory cytokines and nitric oxide by 
activated macrophages and to stimulate the secretion of the anti‐inflammatory 
 cytokine interleukin (IL)‐10, affecting circulating levels of these molecules and strik-
ingly improving survival and clinical outcomes in mouse models of sepsis, Crohn’s 
disease, and rheumatoid arthritis [19–21]. In fact, very recently, the role of CST in 
immune cells during inflammatory processes in rodent models has been deeply 
investigated. Firstly, Gonzalez‐Rey et al. demonstrated in murine models of lethal 
endotoxemia that CST prevented the septic shock‐associated histopathology, 
including inflammatory cell infiltration and multiorgan intravascular disseminated 
coagulation [19]. It was suggested that the main action of CST in regulation of septic 
shock was the deactivation of resident and infiltrating macrophages. Similarly, in a 
mouse model of inflammatory bowel disease, it was found that CST was able to 
reduce disease severity, also by decreasing the levels of proinflammatory/cytotoxic 
cytokines, chemokines, and acute‐phase proteins during inflammation [20]. Finally, 
the effects of CST were investigated in a murine model of rheumatoid arthritis [21]. 
In this setting, CST treatment significantly reduced the grade of collagen‐induced 
arthritis, completely abrogating swelling of joints and destruction of cartilage and 
bone [21]. These recent findings in murine models imply an important regulatory 
role for CST in immune‐mediated diseases and potential implications for future 
clinical use. As SSTRs are also widely expressed in affected tissues in patients 
suffering from immune disease, such as rheumatoid arthritis, as well as granuloma-
tous disease and inflammatory bowel disease, CST may have comparable inhibitory 
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effects in humans [22–24]. It may therefore be hypothesized that CST may have 
future clinical implications in controlling immune cell‐mediated disease. However, it 
should be noted that many differences in sst expression between rodents and humans 
have been described [25, 26]. Differences in sst expression may account for differ-
ences in effects between both organisms. However, future in vitro and in vivo studies 
will be necessary in order to evaluate the functional significance of CST in human 
immune disease [15].
Therefore, two different ligands (SRIF and CST) can activate SSTRs to dampen 
inflammation, but CST anti‐inflammatory action appears to be stronger than that of 
SRIF, possibly because of CST binding to GHS‐R1a and, hypothetically, to MrgX2 
as well. In animals, cyclosomatostatin, an SSTR‐antagonist, fully blocked the anti‐
inflammatory effect of SRIF, but not of CST, while a GHS‐R antagonist partially 
antagonized CST activity [19–21, 27]. In addition, only CST inhibited basal and 
IL‐1β‐stimulated release of prostaglandin E2 by primary rat microglia, a population 
of CNS‐resident macrophage‐like cells [28]: thus, CST action on innate immunity 
cells might also be broader than that of SRIF.
As is known, the wide expression of ssts in the human immune system has 
 suggested a potential functional significance of SRIF and its receptors in immune 
cell function. The thymus plays a pivotal role in the control of the immune system 
and for the establishment of immunocompetence. Apart from the local production of 
SRIF, three receptor subtypes, sst1, sst2A, and sst3, have been found in the thymic 
tissue [29]. However, SSTR expression in the human thymus is age dependent, and 
the expression of the three SSTR subtypes is heterogeneously distributed within the 
different cell subsets forming the complex architecture of this organ [29, 30]. A 
selective expression of sst1 and sst2A has been detected in cultured thymic epithelial 
cells (TEC), whereas the whole population of isolated thymocytes express sst2A and 
sst3 [31, 32]. In fact, sst2A seems selectively expressed in very early thymocytes; 
however, while this latter SSTR is downregulated during thymocyte maturation, sst3 
is upregulated and appears predominantly, or even selectively, expressed in the 
mature subsets [32]. Conversely, thymic macrophages and dendritic cells maintain 
the selective expression of sst2A [31–33]. Interestingly, in other human lymphoid 
tissues, such as the spleen, SSTRs are heterogeneously expressed, again maintaining 
a preferential localization of sst2 in cells of the monocyte–macrophage lineage and 
of sst3 in resting and activated lymphocytes [4, 25, 34]. In support of this concept, it 
is intriguing that peripheral human T lymphocytes (derived from thymocytes) seem 
to selectively express sst3 [34].
In an interesting paper of 2003, the authors investigated mRNA expression of 
SRIF and CST (isoforms) by RT‐PCR in different immune tissues, such as the 
thymus, spleen, and bone marrow [35]. SRIF was only detected in the whole thymic 
tissue and TEC, but not in thymocytes, whereas no SRIF mRNA was recorded in the 
human spleen and bone marrow. CST mRNA, however, was clearly expressed in all 
tissues tested. Moreover, by ligand‐binding studies, it has been also demonstrated 
that CST can displace [125I‐Tyr3]octreotide binding with relatively high affinity on 
human thymic tissue and sst2‐expressing cells [35]. Then, in preliminary studies, it 
has been demonstrated that CST inhibits proliferation of isolated human 
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thymocytes, suggesting that also CST may contribute to the development of mature 
T lymphocytes [36].
Interestingly, differences in CST mRNA expression levels were observed between 
monocytes and their functionally derived cells, that is, macrophages and dendritic 
cells: in fact, when monocytes differentiated into mature macrophages in vitro, CST 
mRNA levels increased approximately 60‐fold [35], pointing to an upregulatory 
mechanism for CST mRNA expression during differentiation and maturation of 
monocytes into both macrophages and dendritic cells and, possibly, a more important 
role for CST in the mature immune system.
Moreover, because no SRIF mRNA but only CST mRNA was detected in the 
 samples tested, in view of the presence of ssts in these tissues, and on the basis of 
both the expression of CST and the observation that CST is able to bind to human 
sst2 receptors, it has been hypothesized that CST, rather than SRIF, may act via 
SSTRs in the human immune system in an autocrine and/or paracrine manner [35]. 
Noteworthy, CST, but not SRIF, mRNA can be detected in human monocytes– 
macrophages and can be upregulated upon activation in parallel with sst2 mRNA, 
suggesting the existence of an autocrine CST–sst2 loop [27].
Focus on the pituitary
In a number of recent either in vivo or in vitro studies, it has been found that SRIF 
and CST may exert inhibitory effects on prolactin secretion by prolactinomas [37, 
38]. Indeed, in a series of cultured prolactinomas, CST significantly inhibited 
 prolactin secretion, similarly to the effects induced by the sst5‐selective agonist 
BIM23206, while the sst2‐selective agonist BIM23210 only exerted significant 
effects in one case [38]. In an in vivo study, a significant, comparable reduction in 
prolactin levels was obtained after infusion with either SRIF or CST [37]. These 
effects may be explained by their high binding affinities to both sst2 and sst5, mainly 
by acting via the predominantly expressed sst5, while on the other hand, sst2‐selective 
agonists were found to have limited effects on prolactin levels [39]. The clinical 
importance of sst analog therapy in prolactinomas remains uncertain as their effects 
seem not to be additive to the effects of the widely used dopamine (DA) agonist 
treatment regimens. CST has been tested also in clinically nonfunctioning pituitary 
adenomas (NFPAs), where there is effectively reduced cell viability in 6 out of 13 
NFPAs. However, CST resulted as less potent in reducing cell viability in these 
tumors compared with either SRIF or sst‐selective analogs [40]. Interestingly, recent 
evidence shows a growing number of spliced variants of SSTRs, particularly sst5, in 
other species, such as pig, as well as in humans. In particular, truncated isoforms of 
five and four transmembrane domains (TMDs), named sst5TMD5 and sst5TMD4, 
respectively, have been recorded in pituitary adenomas of diverse etiology, including 
NFPAs, corticotropinomas, somatotropinomas, and prolactinomas [41]. In contrast 
to the predominant membrane localization of full‐length sst5, both sst5TMD5 and 
sst5TMD4 show a preferentially intracellular localization. Despite their truncated 
nature, both receptors seem to be functional. However, whereas sst5TMD5 is selec-
tivity activated by SRIF compared with CST, cells transfected with sst5TMD4 almost 
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exclusively respond to CST and not to SRIF [41]. In summary, the available data 
suggests that CST substantially may partially reproduce the in vitro effects of SRIF 
on pituitary secretions of human and animal models. Conversely, the functions of 
CST in the majority of peripheral endocrine (and nonendocrine) tissues are almost 
unknown. Despite this last observation, the differential tissue expression of SRIF, 
CST, and their receptors suggests that CST may act as a sort of natural SRIF analog 
in a number of tissues, whereas in specific endocrine tissues, it may play a predomi-
nant, unique regulatory role, although the challenge is now to find the differences 
between these neuroendocrine peptides [42].
dopAstAtin
In addition to the discovery of the CST, in recent years, the somatostatinergic system 
has been studied for its interactions with another complex but similar system, the 
dopaminergic one.
DA is the predominant catecholaminergic neuropeptide in human central nervous 
system where it controls a variety of functions including cognition, emotion, 
locomotor activity, and regulation of the endocrine system. DA plays multiple roles 
also in the periphery, as a modulator of cardiovascular and renal function, gastroin-
testinal motility, as well as hormone synthesis and secretion.
The various actions of DA in the endocrine system are mediated by specific 
 receptors (DRs) that can be differentially expressed on both endocrine and neuroen-
docrine cells. SSTRs and DRs share some similarities: they are both G‐protein‐cou-
pled receptors (GPCRs) and belong to two distinct receptor superfamilies, each 
consisting of 5 subtypes. Two isoforms of the D2 have been also found and charac-
terized, the long (D2long) and short (D2short) isoforms. These two forms are gener-
ated via alternative splicing and differ only for a small amino acidic fraction at 
intracellular level. However, the D2short seems more important and deeply involved 
in the control of cell activities, at least in neuroendocrine cells [43, 44].
Similarly to SSTRs, also DRs are linked to different intracellular pathways, 
leading mainly to the negative control of hormonal secretion and/or of cell cycle or 
to induction of apoptosis through different signaling transduction mechanisms [45]. 
Indeed, particular interest is rising in the potential role of these regulatory neuropep-
tides in the control of cell cycle. In pituitary tumor cells, SRIF and its analogs exert 
an antiproliferative effect by acting on the phosphatidylinositol 3‐kinase (PI3K)/
AKT signaling pathway, whereas apoptosis has been observed upon binding of SRIF 
and SRIF analogs to sst3 and possibly to sst2 as well [46]. Also, both isoforms of D2 
receptor play a relevant role in the signaling pathways involved in the proliferation 
and cell death of pituitary tumor cells, possibly through p38 mitogen‐activated 
 protein kinase (MAPK) and ERK activation [47].
Until recently, it was believed that a single dominant SSTR or DR subtype could 
control a single biologic function. Consequently, ligands with high affinity for 
specific receptor subtypes were developed and introduced in the clinical practice, 
including the SRIF analogs octreotide and lanreotide and their slow‐release (SR) 
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depot formulations, octreotide LAR and SR lanreotide first and Autogel later, all of 
which bind preferentially sst2. On the other side, DA agonists such as bromocrip-
tine, quinagolide, and cabergoline, which bind predominantly D2 receptor, have 
been largely used in the treatment of endocrine and neurological disorders. Indeed, 
several studies have demonstrated a close positive correlation between the presence 
of each receptor and the clinical response to the analog targeting that specific 
receptor [48, 49]. However, a lack of clinical response to SRIF and DA analogs has 
been observed in a rather high percentage of patients despite the presence of 
functional sst2 or D2 receptors. To overcome the resistance to single‐agent treatment, 
the use of a combined SRIF analog and DA agonist treatment has also been explored 
with modest success [50].
More recently, further studies on the characterization of the receptor profile have 
definitively shown that the concept of a single dominant SSTR or DR subtype 
controlling a specific biological function is too simplistic and does not account for 
the lack of efficacy expected for the corresponding medical therapy.
In the past years, the knowledge about SSTRs physiopathology has been extended 
by the discovery that SSTRs can interact on cell membrane forming receptor dimers 
[51]. A series of studies, carried out on transfected cell lines, have shown that dimers 
can consist of two identical SSTR subtypes (homodimers) or two different subtypes 
(heterodimers), with a range of possible combinations depending on the specific sub-
type and, probably, on the specific SSTR‐expressing cell population. SSTR dimeriza-
tion can be a ligand‐dependent phenomenon, since natural SRIF and subtype‐specific 
SRIF agonists have different effects on dimerization, leading to formation or, on the 
contrary, dissociation of SSTR dimers [51–56]. SSTR homo‐ and heterodimerization 
also involve cellular events beyond the membrane, since it modifies SSTR internaliza-
tion and trafficking, as well as signal transduction [57, 58]. More interestingly, SSTRs 
can also form functional dimers interacting at membrane level with DRs [51]. Indeed, 
in a recent study, the dimerization between SSTRs and between SSTRs and D2 
receptor has been finally observed also on prostate and non‐small cell lung cancer 
lines that, in contrast to previous studies, were not transfected with the specific 
GPCRs, but expressed constitutively both families of receptor subtypes [59].
However, few studies have been conducted so far to assess the final consequences 
of receptor dimerization on cellular function [43, 56], and the clinical relevance of 
heterodimerization between SSTRs and DR must be proven [59].
The combination of all these basic research observations, concerning the interac-
tions of SSTRs and DRs, and the clinical reports of enhanced efficacy of combined 
SRIF and DA analog treatment lead to the concept of creating chimeric molecules 
combining structural features of both compound classes [60, 61]. These hybrid 
 products indeed combine structural elements of both SRIF and DA in the same mol-
ecule and simultaneously recognize, with high‐affinity binding activity, and activate 
both SSTRs and DRs. Generally, these new intriguing products may display greatly 
enhanced potency and efficacy, as compared with that of individual SSTR or DR 
agonists [60]. Among the new classes of chimeric compounds, two have been more 
largely explored, BIM‐23A387, targeting simultaneously sst2 and D2 receptors, and 
BIM‐23A760, targeting sst2, sst5, and D2, and have been named dopastatins.
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preclinical experience
In primary cultures of human GH‐secreting pituitary adenoma cells, it was observed 
that individual SRIF and DA analogs interacting with either sst2 or D2 receptors both 
suppress GH secretion in a dose‐dependent manner. The combination of individual 
sst2 and D2 agonists achieves no greater suppression of GH than the single agonist 
alone. In contrast, when the dopastatin sst2–D2 was tested, a greater than 100‐fold 
increase in potency was observed in terms of suppressing GH, and similar potency 
was observed in suppressing prolactin levels from mixed GH‐/prolactin‐secreting 
human pituitary adenoma cells [60, 62]. In a recent paper, a small series of thyro-
tropin‐secreting pituitary adenomas were evaluated for SSTR and DR expression and 
the relationships between receptor expression, in vitro antiproliferative response, and 
clinical data [63]. In this study, tumor cell proliferation was tested in vitro using 
octreotide, cabergoline, and two chimeric compounds, BIM‐23A760 and 
BIM‐23A387. BIM‐23A760 caused the highest antiproliferative effect among all the 
compounds tested, while combined treatment with octreotide and cabergoline 
 displayed an additive effect of magnitude comparable to that of the other chimeric 
compound, BIM‐23A387. Moreover, octreotide resistance in one case could be 
 overcome by treatment with the chimeric compounds. From this study, it can be 
extrapolated that a high sst5/sst2 ratio might be predictive of a positive outcome to 
long‐term treatment with SRIF analogs in this type of pituitary adenoma. However, 
combined SSTR and D2 receptor targeting might be considered as a potential tool to 
improve the response rate in SRIF analog‐resistant tumors [63].
Even more intriguing is the evidence that these chimeric compounds appear to be 
more effective than traditional molecules also in inhibiting cell proliferation. Data 
derived from a preclinical study on tumor cells, in which the GPCR profile of a well‐
established human non‐small lung cancer cell line, CALU‐6, was characterized, 
 displayed a more potent inhibitory effects on cell proliferation of two new chimeras, 
BIM‐23A387 and BIM‐23A370, compared with monomeric receptor activators and 
also with combination of specific SRIF analogs and DA agonists [43]. This evidence 
was lately confirmed in a multicenter study by Florio et al. in NFPAs unresponsive to 
conventional analogs [64]. In this setting, the chimeric compound BIM‐23A760 was 
able to achieve a better control of cell growth, measured by 3H‐thymidine incorpora-
tion in cell cultures, when compared with the individual DA and/or SRIF analogs, 
alone or in combination [64]. In the study by Ferone et al., both BIM‐23A387 and 
BIM‐23A370 were significantly more potent in inhibiting CALU‐6 cell proliferation 
compared with classical and new experimental SRIF analogs and DA agonists, tested 
either alone or in combination [43]. Moreover, in another study, an increased inhibi-
tion of proliferation in either prostate cancer or non‐small lung cell lines has been 
observed, which was more evident with those ligands stimulating the formation of 
receptor dimers [59].
The most effective antisecretory and antiproliferative activity of chimeric 
 compounds is not yet fully elucidated, and currently, a definitive explanation for the 
peculiar properties of these new hybrid molecules has not been found yet. Definitively, 
possible explanations for the increased efficacy in suppressing hormone production 
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include their ability to bind and activate multiple receptors, resulting in the activation 
of multiple signal transduction pathways or even alternative pathways, and/or the 
possibility that the interaction between receptor ligands allows a stabilization of the 
receptor in its active conformation or reduces the rate of internalization and, finally, 
that the chimeras make rapid passage of the ligand, released from the receptor, to 
another receptor [65].
Moreover, the receptor distribution on tumor cells is certainly one of the key 
 elements in regulating the cellular response to both SRIF analogs and DA agonists 
[45]. Recent evidence indicates that the chimeric molecules can act differently 
in various tissues tested and that their effect may vary depending on the cell type. 
In fact, a different degree of cytotoxicity of chimeric compounds, for example, in 
 neuroendocrine bronchopulmonary cell lines and in cells lines resembling the neuro-
endocrine tumors (NETs) of the small intestine, was observed [58]. The responses of 
each cell line suggest that the NETs of the various districts, resulting from different 
neuroendocrine cells, may require cell‐specific antiproliferative agents on the basis 
of the uniqueness of receptor profile of individual lesions [58].
Having molecules with multiple receptor affinity and being able to modulate the 
activity on the various receptors, obtaining a product with maximum effectiveness 
and minimal side effects was attempted. Interestingly, when the activity was strong 
either on sst2, sst5, or D2, the compound has no greater efficacy than one of currently 
available clinical analogs of ssts [65]. Since it is known that the sst5 directly 
 suppresses insulin secretion from pancreatic beta cells, with potential side effect on 
glycemic balance, the ideal activity ratio for a chimeric molecule to be used clinically 
would seem to be potent sst2 and D2 activity, with moderate activity at sst5 level [60, 
66]. This condition has been developed with the chimeric compound BIM‐23A760.
In Vivo experience
BIM‐23A760 has also been tested in vivo in normal cynomolgus monkeys and found 
to induce a significant dose‐related suppression of both GH and prolactin. A consen-
sual and expected reduction in the levels of IGF‐I was observed after 24 hours of 
treatment with this dopastatin. No effect was observed on either insulin secretion or 
circulating glucose at any time or dose of BIM‐23A760 during the whole study [60]. 
In a phase I study in normal individuals, BIM‐23A760 was observed to dramatically 
suppress prolactin levels for prolonged periods of time (>8 days) from single subcuta-
neous injections without significant side effects [67]. Further, in a phase II study, 
single subcutaneous administration of BIM‐23A760 to acromegalic patients resulted 
in a significant, prolonged suppression of circulating GH levels [68]. Unexpectedly, 
however, when tested in a phase IIb study examining chronic administration of 
BIM‐23A760 in acromegalic patients, the suppressive effect on GH was unimpres-
sive, while prolactin was profoundly suppressed. Follow‐up study of the clinical blood 
sample and supporting basic experimentation revealed that, in human, BIM‐23A760 
produces a metabolite with potent dopaminergic activity that interferes with the 
activity of the parent molecule. However, a new experimental phase is still ongoing to 
modify the compound structure to avoid production of interfering metabolites while 
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maintaining the potent, enhanced activity [60, 61]. The new products will be soon 
available for exploring their clinical properties in different sectors of endocrine and 
nonendocrine diseases.
ConClusions
In conclusion, due to the strong evidence that SSTR and D2 receptors are widely 
coexpressed in pituitary adenomas, as well as in a large variety of well‐differentiated 
NET, originating from different tissues such as the gastrointestinal tract, pancreas, 
lung, adrenal, and thymus, the perspective for the use of dopastatins is wide and 
 challenging. Indeed, the new findings in the pathophysiology of SSTRs and DRs, 
together with the availability of new universal and subtype‐specific SRIF and D2‐
selective analogs, may offer in the near future new weapons to clinicians facing these 
complex endocrine disorders and to patients for improving their survival and reducing 
the high morbidity associated with these diseases.
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AADC, see Aromatic amino acids 
decarboxylase
Acromegaly, 173–9, see also 
Somatotropinoma
ACTH, see Adrenocorticotropic hormone
Adenylate cyclase, 7–11, 13, 219, 296
Adrenocorticotropic hormone, 99,  
171, 180
AIP, see Aryl hydrocarbon receptor 
interacting protein
Amine precursors uptake and 
decarboxylation, 56
AN-162, 204, 205
Angiography, 94, 98, 274
Apoptosis, 9, 10, 12, 13, 15, 193
APUD, see Amine precursors uptake and 
decarboxylation
Aromatic amino acids decarboxylase,  
77–9, 115(Fig.)
Aryl hydrocarbon receptor interacting 
protein, 12
Auger electrons, 209, 220, 237, 253, 254
BED, see Biologically effective dose
Benzylothienyl-alanine octreotide, see 
DOTABOC
Bevacizumab, 195
Bifunctional metal chelating agent, see Chelator
BIM-23A760, 167, 179, 181, 182, 328–30
somatostatin receptors binding affinity, 
167, 328, 330
BIM-23A387, 328–30




Biologically effective dose, 241–4, 260
Bleeding, gastric tract, 167, 199–200








11C-epinephrine, 58(Tab.), 114, 115(Fig.)
11C-hydroxyepinephrine, 114, 115(Fig.)
11C-hydroxytryptophan, 58(Tab.), 77(Fig.), 
79, 81–4, 94, 96, 101, 107
Cabergoline, 178, 181–3, 284, 328, 329
Calcitonin, 93, 128, 130, 286, 287
cAMP, see Cyclic adenosine monophosphate
Cancer, hepatocellular, 145, 204
Capecitabine, 242, 259
Carbidopa, 79, 81
Carcinoid, see Neuroendocrine neoplasm(s)
Carcinoid crisis, 79




Chelator, 33, 40–44, 43(Fig.), 45, 215, 216, 310
macrocyclic, 310
organometallic carbonyl complexes, 42
tetraamines, 42
tetradentate, 42




Chromogranin A, 66, 92, 96, 101–3, 106, 
183, 270, 280
Corticotrophin, see Adrenocorticotropic 
hormone






mRNA tissue expression, 325–6
pituitary function regulation, 326
receptors, 323
somatostatin receptors binding, 323, 326
structure, 323
synthesis, 323
tissue and organ distribution, 323–4
Contrast-enhanced ultrasonography (CEU), 95
Copper-64, 221–2, 300, 307, 309(Tab.), 310
Corticotropinoma 326, see also Cushing’s 
disease








64Cu-TETA-octreotide, 58(Tab.), 63, 221
[64Cu-TETA-Tyr3]-octreotate, 221–2
Cumulative administered radioactivity, 231
Cushing’s disease, 179–81, see also 
Corticotropinoma
Cushing’s syndrome, 96
Cyclic adenosine monophosphate, 7, 8, 10, 





Diethylenetriaminepentaacetic acid (DTPA), 
40, 215, 215(Fig.)
l-3,4-Dihydroxyphenylalanine, 77
DLT, see Dose limiting toxicity
L-DOPA, see l-3,4-Dihydroxyphenylalanine
Dopamine, 77, 327
Dopamine agonist, 170, 174, 178–9, 181–3, 
328, see also Bromocriptine; 
Cabergoline; Quinagolide
Dopamine beta hydroxylase, 115(Fig.)
Dopamine receptor, 27, 179, 196, 327, 328
cell proliferation control, 327
functional dimerization with somatostatin 
receptors, 328
hormones secretion control, 327
isoforms, 327
subtype D2, 27, 181, 182, 196, 327–30
subtypes, 327





Dose, bioeffective, see Biologically effective 
dose









DOTATOC, 216, 217(Fig.), 224, 274
[DOTA]0-Tyr3-octreotate, see DOTATATE
[DOTA]0-Tyr3-octreotide, see DOTATOC
EBRT, see External beam radiation therapy
EDDA, see Ethylenediamine-N,N’-diacetic acid
Endoscopy, 92–4
colonoscopy, 103, 106
tumor endoscopic excision, 106
upper gastrointestinal endoscopy, 92–4




EUS, see Endoscopic ultrasonography
Everolimus, 195







138, 140–142(Tab.), 146, 147
medullary thyroid cancer, 128, 130, 131
neuroendocrine neoplasms, 66, 68, 76, 83, 
96, 100, 102, 103, 107, 108, 270
paraganglioma and pheochromocytoma, 
114, 115(Fig.), 119–21, 121 
(Tab.), 122(Fig.), 123
6-18F-fluorodopamine, 77(Fig.), 78, 114, 




67, 77–80, 83, 84
medullary thyroid cancer, 128, 130, 131
neuroendocrine neoplasms, 94, 96, 101–2, 107
paraganglioma and pheochromocytoma, 










68Ga-DOTANOC, 58(Tab.), 59–71, 107, 114, 
115(Fig.), 119, 131, 311
somatostatin receptors binding affinity, 
59, 119, 131
68Ga-DOTATATE, 58(Tab.), 60–71, 107, 
114, 119, 131, 138, 146, 147, 216, 
285, 311, 312, 313(Tab.)
somatostatin receptors binding affinity, 
131, 218(Tab.)
68Ga-DOTATOC, 58(Tab.), 59–71, 107, 114, 
115(Fig.), 119, 138, 143, 145, 216, 
235, 274, 276, 311
somatostatin receptors binding affinity, 





Gallium-68, 41, 59, 208, 308, 309(Tab.), 310
Gastrin, 92, 93, 287
Gastrinoma, 91, 94, 95, 98, see also 
Zollinger–Ellison syndrome
Gastrointestinal stromal tumor, 144
GCC, see Goblet cell carcinoma
GH, see Growth hormone
GIST, see Gastrointestinal stromal tumor
Glial tumor, see Glioma
Glioma, 137, 283
Glomus tumor, 58(Tab.), 113
GLP-1, see Glucagon-like peptide 1
Glucagon-like peptide 1, 98, 284
Glucagonoma, 95, 99
Goblet cell carcinoma, 103
Graves’ ophtalmopathy, 155, 157–8, 203
Growth hormone, 171, 173–5(Tab.), 176–9
Growth hormone secretagogue receptor type 
1a, 324, 325
HCC, see Cancer, hepatocellular
Head and neck tumors, 137
5-HIAA, see 5-Hydroxyindoleacetic acid
5-Hydroxyindoleacetic acid, 66, 81, 83, 101
N-Hydroxysuccinimidyl 
hydrazinonicotinamine, 42–3
HYNIC, see N-Hydroxysuccinimidyl 
hydrazinonicotinamine
Hyperinsulinism, congenital, 80, 204
338 INDEx
IGF-1, see Insulin-like growth factor-1
125I-lanreotide, 143–4
123/131I-metaiodobenzylguanidine, 40, 79, 
129, 130, 145–6, 284
 paraganglioma and pheochromocytoma, 
114, 116, 117, 119–21, 121(Tab.), 




111In-DOTA-BASS, 47, 59, 219, 309, 






111In-DOTA-LAN, 145, 147, 300






111In-DOTATOC, 46, 61, 115(Fig.), 220, 











111In-octreotide, 16, 33, 37, 40, 44, 61, 67, 
114, 115(Fig.), 116, 117, 119, 122, 
122(Fig.), 136–8, 140, 142–7, 155, 
157–8, 207–9, 215–17(Fig.), 219, 
222, 223, 235, 246, 253, 254, 300, 
308, 315, 318
neuroendocrine neoplasms, 47, 48, 57, 59, 
60, 62, 79




Insulin-like growth factor-1, 14, 173–5(Tab.), 
176–9, 193





Iodine-131, 207, 236, 237, 237(Tab.), 
238(Tab.), 245
IOU, see Ultrasound, intraoperative
123I-Tyr3-octreotide, 37, 116, 129, 136,  
138, 146
125I-Tyr3-octreotide, 325
JR10, 309(Tab.), 311, 313(Tab.)
JR11, 309(Tab.), 311, 313(Tab.)
Ketokonazole, 181
Ki-67, 95, 107
Lanreotide, 3, 37, 165, 166, 191, 192, 194, 
215, 300, 327
acromegaly 174–7
autogel formulation, 167, 171, 176, 
179, 181, 328
slow release formulation, 174, 328
somatostatin receptors binding affinity, 
131, 165, 167(Tab.), 171, 173, 300
Large amino acids transporter, 77, 78, 81
Large cell neuroendocrine cancer, 100
LAT, see Large amino acids transporter
LCNEC, see Large cell neuroendocrine 
cancer
LET, see Linear energy transfer
Leukemia, 245, 270
Linear energy transfer, 222
Linear quadratic model, 242–4
LM3, 309(Tab.), 310, 311, 313(Tab.)
177Lu-AM3, 302
177Lu-DOTA-BASS, 314, 315, 318
177Lu-DOTATATE, 144, 210, 211, 216, 221, 
233, 235–8(Tab.), 240(Tab.), 241, 
242, 244, 246, 254, 255, 257–8, 
259–61, 266, 270, 271, 283, 284, 
314, 315
somatostatin receptors binding affinity, 
218(Tab.)
177Lu-DOTATOC, 270, 284





Lung tumors, 137–43, see also 
Neuroendocrine neoplasm(s), 
appendiceal NENs, Bronchial 
NENs; 99mTc-depreotide
somatostatin receptors expression, 137, 138
Lutetium-177, 33, 40, 41, 209, 219–22, 224, 
233, 236, 237, 237(Tab.), 244, 246, 
248, 254, 265–7, 270, 274, 309(Tab.)
Lymphoma, 146–7, 298(Tab.)
Hodgkin’s disease, 147, 245
MALT lymphoma, 147
non-Hodgkin’s lymphoma, 147, 315
MALT, see Mucosa associated lymphoid tissue
Mammalian target of rapamycin, 12, 195
MANEC, see Mixed adenoneuroendocrine 
carcinoma
MAPK, see Mitogen-activated protein kinase
MAx, see MYC-associated factor x
Medullary thyroid cancer, 49, 98, 128–31, 
208, 212, 283, 286–7
somatostatin receptors expression, 49, 
129, 287
therapy, 128, 131, 212
Medulloblastoma, 285, 298(Tab.)
Melanoma, 283
MEN, see Multiple endocrine neoplasia 
syndrome
Meningioma, 136, 137, 205, 283, 285, 
298(Tab.)
Merkel cell carcinoma, 146
mIBG, see 123/131I-Metaiodobenzylguanidine
MicroPET, 311
MIRD, 232–4, 242, 246, 270
Mitogen-activated protein kinase, 9–14,  
296, 327
Mixed adenoneuroendocrine carcinoma, 
56(Tab.), 103, see also Goblet cell 
carcinoma
MK678, see Seglitide
Molecular response parameter, 66
Monte Carlo calculation, 234
MORE, see Molecular response parameter
Mrgx2 receptor, 324, 325
mTOR, see Mammalian target of rapamycin
Mucosa associated lymphoid tissue, 147
Multiple endocrine neoplasia syndrome(s), 
47, 48, 93, 95, 121, 128, 133
MYC-associated factor x, 113
Myelodysplastic syndrome, 245, 270, 271
1-NaI3-octreotide, see DOTANOC
1-NaI3Thr8-octreotide, see DOTA-NOC-ATE
NEC, see Neuroendocrine cancer
NET, see Neuroendocrine neoplasm(s)
NEN, see Neuroendocrine neoplasm(s)
Neuroblastoma, 58(Tab.), 145, 212, 284, 
298(Tab.)
Neuroendocrine cancer, 91
Neuroendocrine neoplasm(s), 46, 48, 49, 
56–7, 58(Tab.), 75–84, 208, 221, 
245, 267–72, see also 
Neuroendocrine cancer
appendiceal NENs, 102–3, 103(Fig.)
bronchial carcinoid, 100, 137, 138
bronchial NENs, 100, 137, 138
colorectal NENs, 105–6, 106(Fig.)
duodenal NENs, 93–4, 94(Fig.)
gastric NENs, 91–2, 91(Fig.), 92(Fig.)
jejunoileal NENs, 100–102, fig 102
lung carcinoid, 100, 137, 138
pancreatic NENs, 91, 94–100,  
97(Fig.), 167
functioning pancreatic NENs, 96–100
non-functioning pancreatic NENs, 
94–6
PET/CT, 55–71, 92–4, 99–103, 106, 107, 
see also Positron emission 
tomography
somatostatin receptors expression, 24, 
32, 95, 107, 167, 190, 266, 283, 
284, 298(Tab.)
unknown primary tumor, 63–5, 107, 255
WHO classification, 56, 211
Neuroendocrine tumor(s), see 
Neuroendocrine neoplasm(s)
Neurofibromatosis type 1, 113
Neuron specific enolase, 68
NF1, see Neurofibromatosis type 1
NHS-HYNIC, see N-Hydroxysuccinimidyl 
hydrazinonicotinamine
Nitric oxide synthase, 9, 14
NODAGA, see 1,4,7-Triazacyclononane, 
1-glutaric acid-4,7-acetic acid
Non-small cell lung cancer, 137, 140–141, 
205, 329
Norepinephrine transporter, 115(Fig.)




Octreotate, 215, 218, 254
somatostatin receptors affinity, 218(Tab.), 254
Octreotide acetate, 3, 11, 37, 129, 165, 166, 
190–192, 205, 209, 215, 222, 284, 
327, 329
acromegaly treatment, 174–7
long acting release formulation, 166, 171, 
174, 178–9, 181–2, 192, 328
pituitary tumor treatment, 174–7, 180, 
183, 202–3
non-oncological treatment indications, 
199–204
oral formulation, see Octreolin
PROMID study, 193–4, 196
somatostatin receptors binding affinity, 
131, 165, 167(Tab.), 171, 
173(Tab.), 191, 218(Tab.)
Octreotide pamoate (Onco-LAR), 167
OLINDA/ExM, 232, 233, 239, 242, 270
Onco-LAR, see Octreotide pamoate
Pansomatostatin(s), 47, 167, 218–19, 
291–302, 308, see also Pasireotide
AM3, 302
depoman, 300
KE88, 47, 218, 300
KE108, 47, 218, 300
KE119, 300
radiolabeled, 218–19
Paraganglioma, 58(Tab.), 112–24, 208, 212, 
283, 284
somatostatin receptors expression, 
114–16, 283, 298(Tab.)
Parathyroid related peptide, 192
α-Particle emitters, 222




long acting release formulation, 167
neuroendocrine neoplasms, 167
pituitary tumors, 167, 180–181, 183
somatostatin receptors binding affinity, 
167(Tab.), 171–2, 196, 218, 300
Pegvisomant, 179
Peptide receptor radionuclide therapy, 61, 
65, 66, 68, 70, 80, 92, 96, 101, 
131, 144, 207–12, 219, 224, 227, 
253–62, 275, 282–7
acute toxicity, 231
amino acids and gelofusine 
co-administration, see Peptide 
receptor radionuclide therapy, 
intraarterial PRRT, kidney protection
bone marrow toxicity, 236–7, 244–5, 260, 
270, 271
combined PRRT, 210, 221, 266–72
critical organ, 236, 267
cross-fire effect, 220, 222, 265
dosimetry, 65, 211, 220, 230–248, 270
duo PRRT, 266, 270
efficacy, see Peptide receptor radionuclide 
therapy, regimen choice, response
gastroenteropancreatic neuroendocrine 
tumor(s), see Neuroendocrine 
neoplasm(s)
GEP NET, see Neuroendocrine 
neoplasm(s)
haematological toxicity, see Peptide 
receptor radionuclide therapy, 
bone marrow toxicity
individualized PRRT, 267–71
intraarterial PRRT, 65, 275
intratumoral injections, 137
kidney protection, 236, 240(Tab.), 255, 
260, 267–9, 318
kidney toxicity, see Peptide receptor 
radionuclide therapy, 
nephrotoxicity
NET, see Neuroendocrine neoplasm(s)
neuroendocrine neoplasm(s), 215, 221, 
224, 255–9, 267, 274
nephrotoxicity, 209, 237–43, 246–8, 260, 
267, 270, 271
nephrotoxicity risk factors, 271
overall survival, 270–271
patient qualification, 101, 267(Tab.)









response, 66–70, 210–211, 225 (Tab.), 
254–60, 270–271
salvage protocol, 259





side effects, 260–261, see also Peptide 
receptor radionuclide therapy, bone 
marrow toxicity; Peptide receptor 
radionuclide therapy, nephrotoxicity
transarterial PRRT, see also Peptide 
receptor radionuclide therapy, 
intraarterial PRRT
tumors other than NENs, 282–7
Peroxisome proliferator-activated receptor 
gamma, 180
Pharmacokinetic compartmental models, 233
Phenylethanolamine-N-methyltransferase, 
115(Fig.)
Pheochromocytoma, 58(Tab.), 112–24, 208, 
212, 283
somatostatin receptors expression, 
114–16, 283, 298(Tab.)
Phosphatidyl inositol 3 kinase, 10, 11, 327
Phospholipase, 13
PI3K, see Phosphatidyl inositol 3 kinase
Pituitary tumors, 136, 170–183
non-functioning, 182–3, 202–3, 326
somatostatin receptors expression, 171, 
172(Tab.), 174, 180–183, 284, 
298(Tab.)




PPAR gamma, see Peroxisome proliferator-
activated receptor gamma
Preprosomatostatin, 190, 292, 293(Fig.)
Prolactinoma, 182, 326
Prosomatostatin, 7, 190, 292, 293(Fig.)
Prostate cancer, 204, 298(Tab.), 329
Protein kinase, 8, 11, 13, 296
Protein tyrosine phosphatase(s), 9, 296
PRRT, see Peptide receptor radionuclide therapy
PTHrp, see Parathyroid related peptide
Quinagolide, 328
Radiation dose, 224, 233, 239, 242, 244–6, 
248, 266, 276
absorbed dose, 232, 233, 236, 241, 244, 
260, 266
cumulative absorbed dose, 237, 241, 242
Radiation-induced cell damage, 242
Radiation-induced liver disease, 274, 279
Radiofrequency ablation, 274–6
stereotactic needle guidance, 276
Radioguided surgery, 104–5, 143–4






internalization, 36, 47, 222–4, 310, 319
kit(s), 44–5






radionuclide(s), 40–41, 215, 217
residence time, 224
somatostatin receptors binding  





RECIST criteria, 66, 68, 211, 257
Renal cell carcinoma, 145, 298(Tab.), 315
Retinopathy, 202–3
RFA, see Radiofrequency ablation
Rheumatoid arthritis, 26, 155, 159–61
RILD, see Radiation-induced liver disease
Sandostatin, see Octreotide acetate
Sarcoidosis, 158
SCLC, see Small cell lung cancer
SDH, see Succinate dehydrogenase
Seglitide, 166, 300
Selective internal radiation therapy, 276–80
complications, 279
contraindications, 279




SIRT, see Selective internal radiation therapy
Sjögren syndrome, 155
SMS201-995, see Octreotide acetate
SOM230, see Pasireotide
342 INDEx
Somatostatin, 7–9, 13, 21, 57, 190, 322–3
antiproliferative effect, 9, 327
receptor binding affinity, 32, 167(Tab.), 
171–2, 218
anti-secretory effect, 8, 294, 295
degradation, 32, 36
discovery, 1–3, 190, 292
function, 8
neutrotransmission, 294
pituitary hormones secretion regulation, 
8, 170–171, 292, 294, 294(Fig.)
posttranslational processing, 190
secretion, 7–9, 295
somatostatin-14, 7, 32, 219, 222, 292, 
293(Fig.), 296, 298, 323
somatostatin-28, 7, 32, 292, , 218, 
218(Tab.), 293(Fig.), 296, 323
structure, 191(Fig.), 293(Fig.)
tissue and organ distribution, 32,  
164, 292
tumor, secretion by, 93
Somatostatin analogue(s), 166–7, 190–191, 274
acromegaly treatment, 173–9
adverse effects, 178, 192–3, 201
antiproliferative effect, 167, 193–5, 202
bicyclic, 46




hypersecretion syndromes treatment, 
191–2, 167
hypoglycaemia treatment, 203–4




other neuroendocrine neoplasms 
treatment, 131,
pharmacotherapy, 164–5
pituitary tumors treatment, 170–183, 
202–3, see also Acromegaly 
treatment
selective agonists, 326
somatostatin receptors binding affinity, 




Somatostatin receptor(s), 3, 274, 323
antiangiogenic effect, 14, 26, 193
apoptosis, 9, 12, 13
autoradiography, 22, 22(Tab.), 114, 
116, 315
cell proliferation control, 9–14, 193, 297
cell, tissue and organ distribution 
13–15, 146, 154, 190, 202, 203, 
297–8, 325
coding gene(s), 7, 22
cortistatins, 323, 324
functional dimerization with dopamine 
receptor, 167, 329
gene transmission regulation, 8–9
growth factors, 9, 14, 193
heterodimerization, 179, 182, 297, 328
homodimerization, 297, 328
immune system, 154–5, 324–6
immunohistochemistry, 22(Tab.), 23–4
inflammation, 26, 155, 159–61
internalization, 219, 222–3, 307, 308
methods of identification, 22–4
mRNA tissue expression 22–3, 
table 22, 115–16, 119, 143, 146, 
297, 299, 325–6
neoplasm(s), expression in 24–6, 
26(Tab.), 32, 57, 107, 114–16, 
136, 144, 283, 284, 298–9
physiology, 7–15, 296–7
secretory suppression, 8
signaling, 8–14, 10(Fig.), 193
splicing, 7
sst5TDM4, 7, 171, 326
sst5TDM5, 7, 171, 326
structure, 7, 171, 190, 295–6, 307
subtype 1, 7–11, 13–15, 24, 26(Tab.), 32, 
58, 59, 173(Tab.), 199, 218 (Tab.), 
295–300, 325
subtype 2, 7–9, 11–15, 24–6(Tab.), 27, 32, 
58–60, 66, 173(Tab.), 193, 199, 
202–5, 218(Tab.), 295–300, 302, 
308–13, 318, 319, 325–30
subtype 2A, 7, 11, 23, 58, 66, 219,  
295, 325
subtype 2B, 7, 11, 58, 295
subtype 3, 7–9, 13–15, 24, 26(Tab.), 32, 
58, 59, 171, 173 (Tab.), 193, 202, 
203, 218(Tab.), 295–9, 300, 302, 
308, 309, 312, 325, 327,
INDEx 343
subtype 4, 7–9, 13–15, 24, 26(Tab.), 32, 58, 
59, 173(Tab.), 218(Tab.), 295–300
subtype 5, 7–9, 13–15, 24, 26(Tab.), 32, 
58, 59, 173(Tab.), 199, 203, 
218(Tab.), 295–300, 326, 328–30
subtypes, 7–15, 23–6, 32, 46, 57–9, 60, 
92, 115–16, 166, 171–4, 
172(Tab.), 173(Tab.), 183, 190, 
192, 218(Tab.), 295–9
truncated isoforms, 7, 171, 326
Somatostatin receptor(s) antagonist(s) 47, 
59, 219–20, 307–19
cyclosomatostatin, 325
radiolabelled antagonists, 219–20, 307–19
Somatostatin receptor PET/CT, 58(Tab.), 
59–71, 79, 80, 83, 94, 95, 128, 
130, 131, 274
diagnosis, in, 60–63
68Ga-labeled somatostatin analogues 80, 








therapy response evaluation, 66–70
Somatostatin receptor scintigraphy
gastro-entero-pancreatic neuroendocrine 
neoplasm(s), 48, 79, 83, see also 
Neuoendocrine neoplasm(s)
inflammation and infection imaging, 
154–61
medullary thyroid cancer, 128–31
negative scans causes, 32
neuroendocrine neoplasm(s), 32, 47, 48, 
82, 83, 90–108
neuroendocrine tumor(s), see 
Neuroendocrine neoplasm(s)
non-neuroendocrine neoplasm(s), 32, 33, 
136–47
procedure, 96
protocol, see Somatostatin receptor 
scintigraphy, procedure
radiopharmaceuticals, 36–9, see also 
Radiopeptides
single photon emission computed 
tomography (SPECT), 36–49, 157
Somatostatinoma 95, 99, 100
Somatotropinoma 326, 329, see also 
Acromegaly
mixed GH/prolactin secreting tumor, 329
Somatuline, see Lanreotide
Small cell lung cancer, 100, 138–40,  
283, 286
somatostatin receptors expression, 286, 
298(Tab.)
SRS, see Somatostatin receptor scintigraphy
Sst3-ODN-8, 309, 309(Tab.)
Succinate dehydrogenase, 113, 115(Fig.), 
119–22, 122(Fig.), 123
SWOG criteria, 256–9
TACE, see Transarterial chemoembolization
Tallium-201 chloride, 141




99mTc-depreotide, 33, 38–9, 136, 138, 140, 
143, 144, 147, 155, 158
solitary pulmonary nodule, 33, 141, 
142(Tab.), 143
somatostatin receptors binding affinity, 33
structure, 38(Fig.)













99mTc-tektrotyd, 39, 44, 46, 48, 49, 59, 114, 











N, N’, N”, N”’-tetraacetic acid
1,4,7,10,Tetraazacyclododecane-N, N’, N”, 
N”’-tetraacetic acid, 40, 41, 209, 
215, 215(Fig.), 254, 310, 311
1,4,8,11,Tetraazacyclotetradecane- 




Transarterial chemoembolization, 70, 274, 276
Transarterial mechanical embolization, 276
Transhepatic portal venous sampling, 94, 98
Tricine, 43–4
1,4,7-Triazacyclononane, 1-glutaric 
acid-4,7-acetic acid, 310, 311
Tumor induced osteomalacia, 147
[Tyr3]-octreotate, see [Tyr3,Tyr8]-octreotide
Tyr3-octreotide, 39, 215, 216, 218, 218(Tab.)
[Tyr3,Tyr8]-octreotide, 45, 215, 310
Tyrosine kinase inhibitor(s), 128, 131, 144
Ultrasonography, endoscopic, 57, 61, 92–5, 
98, 99, 106
EUS-guided fine needle aspiration biopsy 
95, 99
Ultrasound, intraoperative, 98
Vapreotide, 3, 33, 37, 199–200, 215, 300
somatostatin receptors binding affinity, 
33, 300
Vascular endothelial growth factor, 14
VEGF, see Vascular endothelial growth factor
Vesicular monoamine transporter, 77, 81, 
113, 119
VHL, see Von Hippel–Lindau syndrome
VIP-oma, 100
VMAT, see Vesicular monoamine transporter













90Y-DOTATATE, 209, 210, 221, 266
86Y-DOTATOC, 209, 245
90Y-DOTATOC, 33, 209, 210, 216, 220–223, 
231, 234, 235, 237, 238(Tab.), 
241, 244, 248, 254–7, 258–61, 
284, 285, 311, 318




Yttrium-86, 211, 220, 233, 234, 245, 300
Yttrium-90, 33, 40, 41, 209, 219–22, 224, 
233–5, 237, 237(Tab.), 243, 244, 
248, 254, 265, 266, 270, 274, 
309(Tab.)
ZES, see Zollinger–Ellison syndrome
Zollinger–Ellison syndrome, 91, 93, 94, 
see also Gastrinoma
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(a) (b)
Figure 3.1 SSTR type 2A determination in a cellblock preparation from a liver metastasis 
of a well‐differentiated neuroendocrine carcinoma of unknown primary. (a) Hematoxylin and 
eosin; (b) immunoperoxidase; (a and b) original magnification 400×.






Figure 4.2.1 68Ga‐DOTATATE PET/CT (maximum intensity projection image on extreme 
left) shows multiple primary neuroendocrine tumors in pancreatic tail with an SUVmax of 15.4 
(a); in both adrenals, massive enlargement and partial necrosis in the left adrenal with an 
SUVmax of 29.7 (b) and comparatively smaller and less dense SSTR expression in the right 
adrenal with an SUVmax of 10.3 (c); and right ovary with an SUVmax of 11.6 (d). There was 
also widespread metastasis in the liver, multiple abdominal/extra‐abdominal lymph nodes, and 
possibly the pituitary gland (SUVmax of 5.4) (a, b, c, d—images in transverse view; CT on the 





Figure 4.2.2 Identification of rare metastases of neuroendocrine tumors with high‐sensitivity 
on 68Ga‐SSTR PET/CT: not only were myocardial metastases, which were otherwise difficult to 
appreciate on CT (a), localized on 68Ga‐DOTA‐SSTR PET/CT (b) but also pericardial metastases 





Figure 4.2.3 In this case of CUP syndrome, 68Ga‐DOTATOC PET/CT (MIP image on 
extreme left) revealed somatostatin receptor‐positive primary tumor in the jejunum with SUVmax 
of 13.8 (a), along with multiple metastases in the liver (b), bone (c), lymph nodes (d), and a 
metastasis in the left adrenal. (a, b, c, d—images in transverse view; CT on the left and fused 
PET/CT on the right.)
(a) (b)
(c) (d)
Figure 4.2.4 Nonfunctional, well‐differentiated neuroendocrine neoplasm of the 
 pancreas head with hepatic and abdominal lymph node metastases and proliferation rate 
(Ki‐67) of 7%. 18F‐FDG PET/CT (a, b) demonstrated no increased glucose metabolism in 
the metastases. 68Ga‐DOTATOC PET/CT (c, d), on the other hand, demonstrated intense 
expression of somatostatin receptors. This mismatch is a sign of good prognosis and an 







Figure 4.2.5 68Ga‐DOTATATE PET/CT (a, MIP image pretherapy; d, MIP image post-
therapy) demonstrated significant therapeutic response in the same patient (described in 
Fig. 4.2.4) (partial response according to molecular imaging criteria) after PRRT with 2700 
MBq 90Y‐DOTATOC. Hepatic metastasis in segment S5 inferoventral segment of the liver 
(b, fused PET/CT image in transverse view pretherapy; e, fused PET/CT image in transverse 
view posttherapy) showed an SUV fall of 68% from 61.1 to 19.4 posttherapy. Preaortic lymph 
node metastasis (c, fused PET/CT image in transverse view pretherapy; f, fused PET/CT image 





Figure 4.2.6 Neuroendocrine neoplasm of the pancreatic tail with hepatic and skeletal 
metastases: 68Ga‐DOTATATE PET/CT (pretherapy images—a, MIP; b, coronal PET/CT fused; 
c, transverse PET/CT fused) demonstrated excellent response in the liver metastases after two 
cycles of PRRT with a cumulative administered activity of 8000 MBq of 177Lu (posttherapy 
images—d, MIP; e, coronal PET/CT fused; f, transverse PET/CT fused).
Figure 4.3.2 18F‐DOPA PET/CT. Images of a 73‐year‐old female with a serotonin‐ 
producing metastasized well‐differentiated NET of the small bowel (carcinoid). On the left, a 
maximum intensity projection (MIP) image is depicted; in the middle, a coronal slice; and on 
the right, a coronal fusion slice of PET and low‐dose CT. Physiological uptake of 18F‐DOPA is 
visible in the striata and excretion via kidneys with physiological activity in the ureters and 
urinary bladder. Metastases are visible in the liver and mesenteric tissue/lymph nodes. 
18FDOPA, 6‐18F‐l‐3,4‐dihydroxyphenylalanine; PET/CT, positron emission tomography/
computed tomography.
Figure 4.3.3 11C‐5‐HTP PET/CT. Images of a 62‐year‐old female with a gastrinoma. In 
 contrary to 18F‐DOPA PET, the striata are not visualized. On the left, an MIP is depicted; in the 
 middle, a coronal slice; and on the right, a coronal fusion slice of PET and low‐dose CT. 
Physiological excretion of 11C‐5‐HTP metabolites is via kidneys with physiological activity in the 
ureters and urinary bladder. Tumor is visible in the head of the pancreas and metastases in the liver. 
11C‐5‐HTP, β‐[11C]‐5‐hydroxy‐l‐tryptophan; 18F‐DOPA, 6‐18F‐l‐3,4‐dihydroxyphenylalanine; 
PET/CT, positron emission tomography/computed tomography.
(a) (b)
(c)
Figure 4.4.1.4 PET/CT with radiolabeled somatostatin analogue (68Ga‐DOTATOC) in 
patient with disseminated pancreatic neuroendocrine tumor. Arrows indicate liver (a, b) and 
lymph node metastases (a, c).
(a) (b)
Figure 4.4.1.7 A 60‐year‐old man with recurrence of pancreatic glucagonoma. 
Somatostatin receptor scintigraphy with 99mTc‐EDDA/HYNIC‐TOC showing a recur-
rence of the disease in the head of the pancreas. Arrows indicate the lesion in the head of 
the pancreas (a - SPECT/CT image; b - CT image).
Figure 4.4.2.3 (a) 99mTc‐EDDA/HYNIC‐TOC SRS in a 37‐year‐old woman with multiple 
paragangliomas with prevalent expression of SSTR4 (80% of cells). (A) Axial, (B) sagittal, 
(C) coronal views, (D) whole body scan. (b) Immunohistochemical staining for SSTR subtype 
4 (magn. × 400). Courtesy of Prof. R. Tomaszewska, Dept. of Pathology, Jagiellonian 







Figure 4.4.4.1 99mTc‐tectrotide scintigraphy in bronchial carcinoid (SPECT/CT) (Nuclear 
Medicine Unit, Department of Endocrinology, University Hospital in Krakow, Poland).
Figure 6.2.6 Ex vivo autoradiographs and 111In, 90Y, and 177Lu isodose curves for kidney sections 
from 3 patients (a, b, and c) at different time intervals after administration of 111In‐DTPA‐octreotide 
(Figure reproduced with permission from M. Konijnenberg et al. [59]).
Ex vivo autoradiography,




111In–octreoscan (72 h after injection)
111In isodose curves (100% = 1.4 µGy/MBq.s) 
111In isodose curves (100% = 1.7 µGy/MBq.s) 












































90Y isodose curves (100% = 29 µGy/MBq.s) 
177Lu isodose curves (100% = 3.8 µGy/MBq.s) 





Figure 6.3.1 Morphologic response in a patient affected by bone marrow metastases and 
previous liver metastases from a well‐differentiated neuroendocrine carcinoma, Ki‐67 10% 
with an unknown primary. The patient underwent a right liver hepatectomy with a homolateral 
adrenalectomy. After surgery, the patient was treated with 177Lu‐DOTATATE (24.6 GBq 
cumulative activity). The evaluation of the status at baseline by means of 68Ga‐DOTATOC 
PET/CT (a, fusion sagittal image; b, MIP image) shows diffuse bone marrow involvement, 
particularly in the axial skeleton. The evaluation performed after the end of PRRT by means of 
68Ga‐DOTATOC PET/CT (c, fusion sagittal image; d, MIP image) shows the almost complete 
disappearance of the lesions. Please note the hypertrophy of the left liver lobe, as a consequence 
of the right lobe resection.
111In isodose curves (100% = 2.2 µGy/MBq.s) 
Ex vivo autoradiography,
111In–octreoscan (48 h after injection)
(c)





























Figure 6.4.1 Partial remission after Tandem‐PRRT demonstrated by 68Ga‐DOTATOC 
PET/CT (a, b, c, before; d, e, f, after Tandem‐PRRT using 4000 MBq 177Lu‐DOTATOC and 
4500 MBq 90Y‐DOTATOC) of a very large, partially necrotic nonfunctional well‐differentiated 
neuroendocrine neoplasm in the pancreas tail and body, with intense somatostatin receptor 
expression. The tumor was infiltrating the neighboring structures and caused life‐threatening 
recurrent bleedings which stopped after PRRT. SUVmax dropped from 39.9 to 35.3, molecular 
tumor volume dropped from 542 to 214 ml, and the size overall diminished (a and d, coronal 









Figure 6.4.2 A 52‐year‐old patient had nonfunctioning, well‐differentiated neuroendo-
crine tumor of the pancreatic tail with local extension into the stomach and neighboring 
organs, lymph node metastases, as well as extensive bilobar liver metastases and few bone 
metastases and underwent Tandem‐PRRT with 5.5 GBq of 177Lu and 3.5 GBq of 90Y. 68Ga‐ 
DOTATOC PET showed good molecular response in the lesion in segment S8 of the liver 
(white arrow). There was 47% fall in the SUV from 70.8 to 37.7. T1‐weighted MRI with con-
trast showed posttherapy increase in the size of the lesion but with progressive necrosis (long 
arrow) and hypervascularity in the rim (short bold arrow) indicating a favorable therapeutic 
response. The left panel (a, b, c, d) shows pretherapy and middle panel (e, f, g, h) shows post-
therapy images in transverse view (a and e, PET; b and f, CT; c and g, PET/CT fused; d and h, 
MRI). The whole body planar scan (i) acquired 44 h posttherapy (177Lu gamma‐energy 
window) showed good uptake and long retention in the metastases.
(a) (b)
Figure 6.4.3 Fused PET/MRI images in transverse view in the same patient (A, using 
68Ga‐DOTATOC; B, using 18F‐FDG) show mismatch of the uptake of the 2 tracers (68Ga‐
DOTATOC >18F‐FDG) in the lesion in segment S8 of the liver, demonstrating good 
differentiation and high somatostatin receptor density.
(a) (b)
(c) (d)
Figure 6.5.1 A 67‐year‐old male patient suffering from an adenocarcinoma of the colon 
sigmoideum, stage pT3 N1b M1 R0 (K‐ras mutation not present), and UICC stage 4. The 
patient had undergone resection of the primary in 10/2010. He then underwent multiple 
 palliative chemotherapeutic treatments until February 2013, when CT showed progressive 
liver metastases to the right liver lobe (a). Pulmonary shunt scintigraphy using 150 MBq 
Tc‐99m‐MAA on 8/4/2013 revealed faint uptake over both lungs, reaching a pulmonary shunt 
rate of 14% in the semiquantitative analysis. The scan showed increased liver uptake in the 
right liver lobe (b). Embolization of the gastroduodenal and right gastric artery was performed 
using coils (c). Application of 1400 MBq Y‐90‐SIR‐spheres was performed on 18/4/2013. 0.3 
GBq was applied in segment IV and 1.11 GBq was applied in the right liver lobe, selectively. 
Posttherapeutic bremsstrahlung scan revealed increased uptake in the right liver lobe on 
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Figure 8.3a Comparison of 177Lu‐DOTA‐TATE and 177Lu‐DOTA‐BASS receptor 
 autoradiographic binding in successive sections of various types of human cancers (ileal 
 carcinoid, pheochromocytoma, breast carcinoma, renal cell carcinoma, and non‐Hodgkin 
lymphoma) expressing sst2. Columns from left to right represent hematoxylin and eosin 
staining, total and  nonspecific binding of 177Lu‐DOTA‐TATE, and total and nonspecific 
binding of 177Lu‐DOTABASS. Binding is markedly stronger with the antagonist 177Lu‐DOTA‐
BASS. HE, hematoxylin and eosin; NHL, non‐Hodgkin lymphoma; NS, nonspecific; Pheo, 
 pheochromocytoma; RCC, renal cell carcinoma.
